IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
US008062640B2
(») United States Patent
Sleeman et al.
(io) Patent No.: US 8)062)640 $2
(45) Date of Patent: Noy. 22, 2011
(54) HH'H AI'FIVITY HUOI AN AlVTIBODIBS TO
PCSK9
(56) References Cited
U.S. I'Kl FNT DO('UMENTS
(75) lilvciitoi's: Mark W. Sleeman, Mahopac, NY (US),
Joel H. Martin. Futnam Valley. VY
(US): Tammy T Huang, Cioldens
Bridge. NY (IJS): Douglas Macnonald,
New York, NY (US)
(
' Notice: Subject to nny disclaimer. the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.
(73) Assignee Rcgeneron Pharmaceuticals, Inc..
lorrytovvn. NY (US)
7,029.895 BI
7,129.338 Bl
7,300.754 B2
7,482,147 B2
2006 0147945 Al
2007'0082345 .Vt
2007'0224663 At
2008:0008697 Al*
2009'0142352 At
2009:0232795 Al
2009&0246192 At
2009 026')350 Al
4'2006 Glucksmann ct si
10,2006 Oiaet sl.
I I'2007 Abi Fadcl ct al
1'2009 Glucksinsnn ei si
7'i006 Fchuondsetal
4'2007 C)ta et al
9,'2007 Rosen et sl.
L 2008 Minticr ct al
6,'2009 Jackson ei al
9,2009 Condra et at
10 2009 C'ondra et ai
10,2009 Glucksmsnn et sl
(Continued)
424 94 63
(21) Appl. Nou 12/637,942
(22) I'iled: Dec. 15, 2009
FOREIGN PATl iNT DOC(JMI:.NTS
1067ltl2 A2 1 2001
(C:ontinucd)
(65) Prior Publication Data
US 2010/0166768 Al Jul. I, 2010
Related U.S. Application Data
OTHBR I'UBLICKJIONS
LsGsce et al (J Flin lavevi Am Soc Clin Invest. Vov 1,
2006,116(1 1) 2995-3005) "
(Contimied)
(60) Provisional application No. 61/122,482. filed on Dec.
15. 2008, provisional applicntiim No. 61/210.566,
filed on Mar. 18. 2009, pmvisional application No.
61/168,753, filed on Apr. 13, 2009, provisional
applicatiiin No. 61/218.136, liled on Jun 18, 2009,
provisional application No. 61/249,135, filed on Oct.
6. 2009. provisional application No. 61/261.77/i, filed
on Nov 17. 2009.
(51) Int. Cl.
d61K 19/195 (2006.01)
C07K16/00 (2006.01)
C12P 21/0// (200Cxol)
(52) U.S. CL ............. 424/158.1; 530/387.1: 530/387.9
(58) I'ield of Classitication Search ........................ None
Sec application file for complete search history
Priniun Erviiiiner C bene M Woodward
(74) .Jiivrnei..ixeni, vr Firm Valets Gre: Friudc R.
('ottingham
(57) ABSTRACT
An hummi antibody or antigen-binding fragment of a humnn
antibcxly that specifimilly binds and inhibits human pmpro-
tein convertase subtilisin/kexin type 9 (h)sCSK9) character-
ised by thc ability to rcxfucc serum I.DI, cluilcsterol by
40-80/n over a 24, 60 or 90 day period relative to predose
levels, with little or no rcxjuction in senun HDL cholesterol
and/or with little or no measumble effect on liver function. as
determined by ALT and AST measurements.
3 Claims, 14 Drawing Sheets
1QOQ.GG
400.00
10.00 1
E
1.OO -I
c) 0,10
336 604 672 840 1QGO 1176 1344
US 8,062,640 $2
Page 2
U.S. PATL'NT DOCUMENTS
2009 0326202 Al
2010 0040(i la Al
2010 0040611 Al
2010 0041102 Al
2010 0068199 Al
Is )009
2 '2010
2 2010
2 '2010
3'2010
Jackson ct al
Sitlani et al
Sp;urow et sl
.Siitlani et al
Liang et at
EP
F,P
V'0
%0
%'0
%0
%'0
WO
%0
WO
%0
%0
%0
%0
WO
%0
%0
%0
1514933 Al
1618212 Bl
Ol 57081 A2
2008'057457 42
200'8'057458 A2
2008'057459 A2
200%0()33tl2 A2
%0 2008057457 A2 "
%0 2008057458 A2 s
19020080)7459 A2 e
WO 20080(i3382 A2 "
2008'125623 A2
WO 2008125623 A2 "
2008'll)ti47 A2
2009 026558 Al
2009'055783 62
2009'100297 Al
2009 100318 Al
3 20os
11 '2007
8 2001
52OOS
5 200li
5 '2008
5 2008
5 Joas
5 2008
5 goag
5 2008
10 2008
Ia 2008
II 2008
2 2009
4 2009
8 2009
8 2009
FORk 1(iN PAT)',N f DO('U MEN I'
OTHER PLIBLJOATIONS
Bcn)annct S, et al (2006) "Thc Piopiotcm Comertase (PC) PCSK9
Is Inactnated by Funn anitor P('5 6A*' Biol (hem 2)ti(4U
)0561-30572
Grozdanov. PN. et al (2006) "Expression and localization of
PCSK9 rn iat hepatic cells.** Biochem. Cell Biol. 84. 80-92.
Maxi)oil K V ot al (2004) '*Adcnoviral-mediated exprossion of
Pc sk9 in mice results in a low-density lipoprotein receptor knockout
phenotype" PEAS 101(18). 7100-7105
Rashid. S., et al. (2005) **Decreased plasnn cholesterol and hyper-
sensitimty to statins in mice lacking Pcsk9y PVAS 102(15) 5374-
5379
Lagacc, T A, et al (2006) '*Semeted PCSK9 decasses the number of
LDL receplois m hepalocytes and m I)vers of parabiotic micey J
Clin. Inicst 116(ll). 29))5-3005.
Annex to 1orm PC'I ISA)206 Communication gelatin ~ to the
Results of the Partial International Search for PCT US2009 068013,
mailed Mar la. 2010
Chan. Joyce (', et al (2009) "A pioprotein convertase subtibsini
kexin iype 9 neuuahnng antibody )educed sei nm cholesterol in nuce
and nonhiunan pumatcs " PEAS 106(24) 9820-9825
" cited by examiner
U.S. Patent Nov. 22, 2011 Sheet I of 14 US S,062,640 B2
COE
Cl
O
N N
N N
y, IL
0 LO
Z N
Ol-N
IU Q.
LU LU
LQ LQ
A Q.
N I-
Ct Q.
N I/I
LQ A
Q. Q.
CQ N
et cf
I- I-
Q 0
CO
O C'l
oo
Z Z
g g
oo
w LLI
Ol N
ZZ
Q Z
LO O0
CO
Z Z
00
Z
g g
00
w LLI
CO N
Z Z
Q Z.
(O O
O
z 2
CO
O N
00
Z Z
g 0
0 0
w LU
N N
Z Z
Q Z
O
O
z 2
Z Z
CO
00
Z Z
gg
0 0
w
N
Q„Z
CO Cl0
CO
Z Z
CO
Ol CC
Ol
0 0
Z
g g
00
w w
CO M
y. y
Z
CO 0
O
CO CO
Z 2
Z Z
CO
Ol
Ol OI
oo
Z
g g
oo
w LU
Ol N
LL Z
Cl
O
CO
z 2
Z Z
U.S. Patent Nov. 22,2011 Sheet 2 of 14 US S,062,640 B2
U.S. Patent Nov. 22,2011 Sheet 3 of 14 US S,062,640 B2
Ct Ct Cl
~oJI)ooQ 381108 )o %
U.S. Patent Nov. 22,2011 Sheet 4 of 14 US S,062,640 B2
Cl
Cl N
(0J)UOQ Aojjott jo %
U.S. Patent Nov. 22,2011 Sheet 5 of 14 US S,062,640 B2
U.S. Patent Nov. 22,2011 Sheet 6 of 14 US S,062,640 B2
U.S. Patent Nov. 22,2011 Sheet 7 of 14 US S,062,640 B2
U.S. Patent Nov. 22,2011 Sheet 8 of 14 US S,062,640 B2
U.S. Patent Nov. 22,2011 Sheet 9 of 14 US S,062,640 B2
U.S. Patent Nov. 22,2011 Sheet 10 of 14 US S,062,640 B2
U.S. Patent Nov. 22,2011 Sheet 11 of 14 US S,062,640 B2
U.S. Patent Nov. 22,2011 Sheet 12 of 14 US S,062,640 B2
O
C)
C)
C)
C)
C)
((UJ/FLU) UGI)Bj/U80LIOQ
U.S. Patent Nov. 22,2011 Sheet 13 of 14 US S,062,640 B2
8 T
((LU/RLU) LIOI)BJ/UBDUOJ
U.S. Patent Nov. 22,2011 Sheet 14 of 14 US S,062,640 B2
US 8,062,640 B2
1
HIC".H AFFINITY HUMAN h&NTIBOHIF)S TO
PCSK9
C:ROSS-RFFERFNC'E, TO RFLATFD
APPI,IC'TIONS
This application ciauns the benefit under 35 USC ss H 9(e)
of U.S Provisional 61/261.776 filed 17 Nov. 2009. 61/249,
135 tiled 6 Oct 2009, 61/218,136 filcxt 18.1un 2009, 61(168,
753 filed 13 Apr. 2009, 61!210,566 tiled 18 Mar. 2009 and
61/1229,482 filed IS Dec. 2008. which applications are
lmrein specifically incorporated by refercncc in tlmir entirety
I'IFI.D OF THF, INVFNTION
111e present im:ention is related to human antibodies and
anu en-binding fragile&its of human antibodies that specifi-
cally bind human proproteui converts se subtilisin/kex&n type
9 (VCSK9), and therapeutic methods ofusing those antibod-
ies. "o
SEQULNCE LISTING
An ASCII compi rant text file of the s&cquence listing is tiled
concurrently auth the present specdicat&on (37 CI&R
as 1.52(e)-"'md
37 CFR ss I 821). The contonts of tlm text tile are herein
incorporated by reference The text file contauiing the
sequence hating &s named "PCSK9 SeqList*', was created on
11 Dcsx 2009, 'md contaii)s appmximatcly 418 kilobytes
"o
STATFMFNT OF RFI ATFD ART
Proprotein convcrtase subtilisin/kexin type 9) (VCSK9) is a
proprotein co&hverhase belonging lo tlm proteillasc K subfam-
ily of the secretory subulase family. The encoded proteus is ""
synthesized as a soluble zymogen that undergoes mitocata-
lytic intrainoleculsr processing in tlm cndoplasmic reticulum
Evidence suggest tlmt VCSK9 increases plasma LDL choles-
terol by promoting dcgm&Lstio&h of the I,DI. receptor( which
med&ates LDL endocytosis hn the liver, the ma)or route of sa
LDL clearance from circulation. 'I'he stnlcture of P('SK9
protein shows that it has a signal scqumlce, foflo&vcd by a
prodonlain. a catalytic domain that contains a conserved tnad
of residues (D186. H226 and S386), and a (xtenninal
donlain. It is syhhthes&zed as a soluble 74-kDa precursor tlmt ss
undergoes autocatalytic cleavage in the ER. generating a
14-kDa prodomain and 60-kDa catalytic I'ragment The auto-
catalishc activity has been shov, n io be required for secretion.
After cleavage the prod orna in remains tightly associated with
thc catalytic domain. (1
Antibodies to PCSK9 are described in. for example, WO
2008/057457, WO 2008/057458, WO 2008/057459, WO
2008/063382, WO 2008/125623, and US 2008/0008697.
BRIEF SUMMARY OF TI IE INVENTION
In a first aspect, tim invention provides Iiully humml mono-
clonal antibodies (mAbs) and mtigerebuidhng frag&then&a
thereof that specifically bind and neutralize lnunan V( SK9
(hPC'SK9) activity. Rl
In one embodiment. the invention comprises an antibody or
mhtigen-binding fragnwnt uf an antibody that specitlcally
binds 11PCSK9 mid is characterized by at least one of:
(i) capable of reducing senun total cholesterol at least
about 25-35% and sustaining the reduction over at least a 24 &
day penod relative to a predose level, preferably the reduction
in serum total cholesterol &s at least about 30-40%;
(ii) capable of reducing serum I J)I. cholesterol at least
about 65-80% and sustainin the reduction over at least a 24
day period relative to a predose level;
(iii) capable of red&icing serum triglyceride at least about
25-40% relative to predose level;
(iv) does not reduce senun HDL cholesterol or reduces
serum I IDL cholesterol no more than 5% relative to predose
level.
In onc embodiment, tlm invention comprises an antibody or
amigen-bindulg frl ment of an mlubody that specflically
binds hPCSK9 and is characterized by at least one of:
(i) capable ol'ekicing scnim I,DI cholesterol at least
about 40-70% and sustaimng the reduction over at least a 60
or 90 day period relative to a predose level,
(ii) capable of'educing serum tnglyceride ut least about
25-40/'s relative to predose level;
(iii) docs not reduce serum HDL cholesmrol or reduces
serum I IDI, cholesterol no more than 5% relative to prado se
level.
In one mnbodimenL the antib&xiy or miligcn-binding I'rag-
ment is chamctenzed as b&nduig an ephtope compri sin amino
acid residue 238 of hp('SK9 (SEQ ID NO:755). In a more
specific embodiment, the antibody or mlth en-b&nduig frag-
ment binds an epitope composing one or more ofamuio acid
residue 238. I 53. 159 and 343 ofhP( SK9 (SEQ ID NO:755)
.j. In a more specific embodiment, the antibody or frag&theat
thereof is clmractenzed as binding an epitope which does &lot
compnse an mnino mid residue at position 192. 194, 197
and/or 237 of SEQ ID NO:755.
In one embodilllc&1L tlm alltib&xiy or antigen-binding I'rag-
mmhtischaractenzedasb&nduigmlepitopccompnsing un&no
acid residue 366 of ld'CSK9 (SL1Q ID NO:755). In a more
specific embodiment, the &mtibody or mlthgcn-binding I'rag-
&lie&It hillis all op i tope coluprlslilg 0&le oh incr'e of &1&lllllo &le&&i
residue at position 147, 366 mhd 380 of SFQ ID NO:755 In a
morc specific mnboduuent, the antibody or antigen-bindmg
fragment of an anubody is chamcterized as bhndmg an
cpitope which docs not comprise an amino acid residue at
position 215 or 238 ol'SFQ ID NO 755
In one embodiment, the antibody or antigen-binduivg frag-
nwnt is characterizcxi as exhibiting an enhanced binding
afhmty (Kn) for hPCSK9 at plf 5.5 relative to the Kr, at pH
7.4. as measured by plasmon surface resonance. In a specific
embodiment, thc antibody or fragment tfhercx(f cxlfibits at
least a 20-fold, at least a 40-fold or at least a 50-fold enhanced
affinity for V('8K9 at an acidic pH relative to a neutral pH, as
measured by surface pl eamon resonance.
In one embodiment, the antibody or antigen-binding frag-
ment is characterized as not exhibiting an enhmlced bindmg
aflimty for PCS K 9 at an acidic pl I relative to a neutral pi i. as
measured by surface plasmon resonance. In a specific
embodunenL the antibody or 1'ragment thereof exhibits a
decreased binding aflin&ty at an acidic pl i.
In anotimr embodiment thc antibody or mltigcn-binding
frs ment binds human. human CiOF mutation D374Y. cyno-
molgus monkey, rhesus monkey. mouse. rat and Immster
PCSK9
In one embodunent, the ultibody or ultigen-binding frag-
ment binds human and monkey P('SK9, but does not bind
mouse, rat or hamster PCSK9
I'he niflbs can be full-length (e.g., an ISGI or Ig(14 anti-
body) or may comprise only an antigen-binding portion (e g.,
a I'ab. I'(ab'), or scl'v fnsgment), and may be modified to
afl'ect functionality. e.g., to eliminate residual effector func-
tions (Reddy ct al. (2000) .I Immunol 164:1925-1933)
In one enibodkment, the invention compnses an antibody or
antigen-binding fragment of an antibody comprising a heavy
US 8,062,640 B2
chain variable region (HC'i&R) selected from tlm group con-
sisting of SLIQ ID NO: 2, 18, 22, 26, 42, 46, 50, 66, 70, 74, 90,
94.98,114.118,122,138.142.146.162,166,170,186.190,
194, 210, 214i 218, 234. 238. 242, 258. 262. 26&i. 282. 286,
290, 306. 310. 314, 330, 334. 33R 354. 358. 362, 378. 382,
386. 402. 406, 410. 42G. 430. 434, 450. 454. 458. 474, 478.
482. 498. 502. 506. &22. 526. 530. 54Cu 550. 5&4. 570. 574.
578, 594, &RR 602, 618. 622. 626. 642. 646,(i50. 666. 670,
674, C&90. 694, 698. 714, 718, 722, 738 and 742, or a subsfan-
t&ally s&nular sequence thereof hav&ng ai least 90%. at least
95%, at least 98% or at least 99% sequence identity. In one
cmbodimcnt, the IK"1'R composes an amino acid sequence
selected ffom the group cons&stu&g of SLQ ID NO:50, 66. 70,
74. 90, 94. 122, 138, 142. 218, 234. 238, 242. 258, 262. 314,
330 and 334 In a more specific embodiiuent, the HCVR
comprises Sk'Q ID NO:90 or 218.
In one embodimalt, the nntibody or fragment ther(mf filr-
ther comprises a hght chain venable region (J.C VR) selected
from the group consisting of Sl)Q ID NO:10, 20. 24, 34, 44.
48. 58, 68. 72, 82. 92, 96. 106, 116. 120. 130, 140, 144. 1&4,
164, 168, 178. 188, 192. 202. 212. 21Ci. 226, 23&i, 240. 250,
260, 2t&4, 274, 284. 288, 298. 308. 312. 322. 332. 336, 346,
356. 360. 370. 380. 384. 394. 404. 408. 418. 428. 432. 442,
452. 456. 466. 476, 480. 490. 500. 504. 514. 524, 528, 538,
548, 552, &62. 572, 576. 586. 596, 600. 610. 620. G24. 634,
644. 648. 658. 66'8, 672, 682. 692. 696. 706. 716. 720. 730,
740 and 744. or a substantially similar sequence thereof hav-
u&g nl least 90%. at least 95%, at leusl 98% or al least 99%
sequence &dent&ty. In one embodiment, the LCVR composes
&ill anlunl ac ltl sLquc ace scfccfcsf floe& lfic group co osis I elg of
Sl;Q ID NO: 58, 68. 72. 82, 92. 96, 130. 140, 144. 226, 236,
240. 250, 260, 264, 322, 332 and 336. In a more specific
embodiment, thc I.C'VR comprises SFQ ID N(F92 or 22C&
In specific embodiments. the antibody or fragment thereof
comprises a H(.'VR and LC VR JHC'VR/1.('VR) SL&fucncc
pair sclectal f)om the group consistin of'SFQ ID NO. 2/10.
18/20, 22/24. 26134, 4 2 i4 4, 46i4 S, 50i58. 66i68. 70/72. 74/82,
90/92, 94!96. 98/106i 114/1) t&. 118/120, 122/130. 1 381 J40,
142/144, 146/154, 162/ I C&4. 166,'1 6S, 170/178. 186/I 88, 190/
192. 194/202, 210/212, 2141216. 218i226, 234/23&i, 238/240,
242/250, 258/260, 262/264. 266/274, 282/284, 286/288, 2901
298, 30G/308, 310/312, 314/322. 330/332, 334/336, 338/346,
35413&6, 358/360, 3Ci2/370. 3781380, 382i384. 386/3(94, 4021
404. 406/408, 410/418, 426/428. 430/432, 434/442, 450/452.
454i 456, 458/46CC 474/476. 478/480, 482/490, 498/500, 5021
504 506&&14 522/&24 526/528, 530/53S, 54&i/54S. 550!552,
554/562, 570/572. 574/576. 578/586, 594/596. 59S/600. 602/
610. 61S/620, 6221Ci24, 626/634, 642i644, Cid(i/648, 650/658,
666'668, 670'672„674/682. 690'692, 694 '696. 698 '706, 714/
716, 718/720. 722/730, 738/740 and 742i744. In one embod&-
ment, the HCVR and LCVR sequence pair composes one of
SFQ ID NO 50/58, 66/68. 70/72. 74i82, 90/92, 94/96. 122/
130. 138/140, 142/144, 218/226, 234/236, 238/240. 242/250.
258/2&if, 262/264, 314/322, 330/332 nnd 334(33(i In a morc
spec&fic embodunenu the JICVR/I CVR par composes SRQ
ID NO 90/92 or 218/22(i.
In a second aspect„ the invcntimi fi.'aturcs an lmtibody or
ant& en-bmdulg fragment ofan ant&body compr&sing a heavy
chain ('1 )R3 (H(.'DR3) domain selected from the group con-
slsllligof'SFQ IDNO 8, 32 56, 80, 104. 128, 152, 176. 200,
224, 248. 272. 29)6. 320, 344. 3G8, 392. 41(i. 440. 464. 488,
512. 53t&, 5CiO, 584, 60S, &i32, 65&i, 680, 704 and 728, or a
substantially s&nular sequence thereof laving at least 90%, at
least 95%, at least 98% or at least 99% sequence identity; and
a light chain(.'DR3 (L( DR3) domain sclcctcd from the group
consisting of SLIQ ID NO:16, 40, 64, 88. 112, 136, 1&if. 184.
208, 232, 25&). 280, 304. 328, 352. 376. 400. 424. 448. 472,
496, 520, 544, 5&i8, 592, 616, ti40, &i64. 688, 712 and 73&i, or
substa&t&ally similar sequences thereoflaving at least 90%, at
least 95%, at least 98 ib or at least 99 is sequence identitv. Jn
onc embodiment, the HCDR3/I,( DR3 sequence pair is
s selected from the gmup cons&stu&g of SEQ ID NO:56/64,
80/88. 128/136, 224/232, 248/25&i and 320/32S. In a more
specific emboduuenu the IICDR3'I,CDR3 sequence p ur
compr&ses SL'Q ID NO:SO/88 or 224/232.
In a furt her embodiincnu the invention am&posing wi m&fi-
ul body or fulpueut thereof further compnsu&g a heavy clmu&
CDRI JIKDRJ) domain selected from the group consist&ng
of'SFQ JD NO 4, 28. 52, 76, 100. 124, 148, 172. 196. 220,
244. 268, 292. 316. 340, 364. 388. 412, 436, 460, 484, 50S,
532. 556. 580. 604, 628, 652, 676, 700 and 724. or a substan-
tuilly similar sc(JilCOCC fhclCof hllving al lc'IS& 90/6, at least
95%. at least 98% or at least 99% sequence ida&tity; a 1&ea&y
chain ( DR2 (HC'DR2) domain selected from thc group con-
sistu&g of SFQ JD NO 6. 30. 54, 78. 102, 126, 150. 174, 198,
222, 246, 270, 294, 318, 342. 366, 39)0, 414, 43S, 462, 48&i,
6 510 534 558. 582. fifiti, 630, 654, 67S, 702 and 726, or a
substa&tially similar sequence thereof hav&ng at least 90%, at
least 95%. at least 98% or at least 99i8 sequence identity; a
1&ght cha&n CDRI JLCDRJ) dome&n selected from the group
consisting of SL'Q ID NO: 12, 36. 60, 84. 108, 132. 156. 180,
204. 228, 252. 276, 300, 324. 348. 372, 396, 420, 444, 468,
492. 516, 540. 564, 5S8. 612. 636, 660, 684, 708 and 732, or
a substant&ally similar sequence thereof having at least 90%,
at faust 95%. al least 98'io or at least 99'/ sequence identity,
and a hght chain CDR2 (LCDR2) domau& selected from the
so group amsisting ofSFQ ID NO 14, 38, 62. 86, 110. 134. 158,
182. 206. 230. 254. 278, 302. 326, 350, 374, 398, 422, 446,
470,494,51R 542,566,590,614.638,G62,68G.710and734.
or a substantially similar sequa&cc tiara&f having at lt:ast
90'/v. at least 95%. at least 98% or at least 99% sequence
"» idaitity. In one embodimait. the heavy and light chain CDR
scqutulct&s con&priss a scqucnce si:Iccti:0 flonl the glt&ilp coll-
sist&ng ofSLQ ID NO: 52. 54, 56, 60, 62, 64, 76. 7 S. 80. 84. 86,
88, 124. 126, 128, 132, 134, 136, 220. 222, 224, 228, 230,
232, 244. 246. 248, 252. 254, 256: und 316, 318. 320. 324,
46 326 328. Jn more specific embodiments, the CJM sequences
comprise SF Q II) NO: 76, 78. SO, 84. 86, 88, or 220, 222. 224,
228. 230, 232.
In a related embodiment, the invention comprises an anti-
bodv or nntigcn-binding fragment of an antibody ((hich spe-
cifically binds hf'CSK9, u herein the ant&body or fragnlent
comprises heavy and light chain C'DR donmins contained
uitlun heavy and hght cia&n sequence pairs selected fromthe
gmup consisting of SHQ ID NO: 2i10. 18/20, 22/24, 26134,
42/44. 46!48, 50/58. 66/68, 70/72. 74/82, 90/92. 94/96.
o 98/106. 114/116, 118'120, 122/130, 138/140, 142/144. 146/
1&4 162i164, 166/168 170/178. )86/JSS, 190/192. 19)41202,
210/212. 214!21Cu 218!226, 234/236, 238,'240. 242!250,2&8,'60
262/264, 266/274. 282!284. 286i288, 290/29R 306i)08,
310/312. 314/322. 330!332, 334/R36, 338/34CL 354/356, 358/
s 360. 362/370, 378/380. 382!384. 386/394, 402/404. 406/408,
410/418, 426/428. 430/432, 434/442, 4 &0/452, 454/45(i, 458('
6C&. 474476, 478/480. 482/490. 498/500, 502/504, 5OC& '514,
522/524. 526i&28. 530/538, 546/54K 550/552. 554/562, 570/
572, 574/57(i, 578/&86. 594/59&i, 598/Ci00, (102/&i)0, 618/620,
6(1 C&22/624. 626!634. 642/644, 646/648, 650,'(i58. 666!668,67,'i72.
G74&fi82, 690i692. Ci94/696. 698i706,714/716 7)gi720,
722/730. 738/740 and 7421744. In one anb odin&ant, the ('IM
sequences are conte&ned a&tlun HCVR m&d LCVR selected
from the amino acid sequence pairs of SkQ ID NO: 50/&8,
6 66/68. 70/72. 74182. 90192. 94196. 1221130, 138/140. 142/
144. 2181226, 234/236. 238'240. 242i250, 258/260. 2621264.
314/322. 330i332 and 334/33&i. In more spsv:ific embodi-
US 8,062,640 B2
5
ment% the ('DR sequences arc cumprised within H( VR/
LCVR sequences selected from SL&Q ID NO: 90/92 or 218i
226.
In (me en&bodiment, tlm inventio&i provides fully human
monoclonal antibody or ant&gen-bu&ding fraynent thereof s
that specifically bind hp(. SK9 and neutralize PCSK9 activity.
where&n the u&t&body or frigment thereof exhibits one or
more of the fo1 low u&g charac ten sties: (& ) capable of reduc&ng
serum totnl choleatcriil at lmist nbout 25-3&% and sustmning
the reduction over at least a 24 day penod relative to a predose n&
level, preferably the reduction in serum total cholesterol is at
least about 30-40'/o, (n) capable oi relumng scnim I Di
cholesteml at least about 65-80% u&d sustaunng the reduc-
tion over at least a 24 day period relative to a prcdosc level,
(ii&) capable ol'educing seru&u triglyceride at least nboul
25-40%o relative to predose level: (iv) does not i&ace serum
HDI, clx&lcsterol or reduces serum HDI, cholesterol no morc
than 5% relative to predose level, (v) b&nds an ep&tope com-
prising amino acid residue 238 of hPCSK9 (SI)Q ID
NO 755), (vi) exhibits an enhanced binding afiinity (K„) for o
hPCSK9atp115.5relat&vetotheK„atpl17 4,asmeasuredby
plasmon surface resonance, wherein the enhanced aflinity is
at least about a 20- to 50-fold increase &n affinity, (vn) binds
luunan. human l &OF mutat&on D374Y. cynomolyis monkey,
rhesus monkey, mouse, rat and hamstir PCSK9, (viii) com- "
prises heavy and light chau& CDR3 sequences compris&n
SL'Q ID NO:80 and 88; and (ix) comprises CDR sequences
I'rom SEQ ID NO 90 and 92.
In one embod&ment, the invent&on pmvides fully human
monoclonal antibody or antigi:n-binding fray&mnt therwif &o
thai specifically hind human PCSK9 (hPCSK9) and neutral-
ize PCS K9 activ&ty, where&othe antibody or fragment thereof
exhibits one or more of lhc fiiflowing charactcnstics: (i)
capable of reducuig serum LDL cholesterol at least about
40-70%& and sustaining the reduction over at least a 60 or 90 "»
day period rclativc to a prcdosc leiml, (&i) capable of rnluc&ng
serum twglyceride at least about 25-40% relative to predose
level; (iii) docs not reduce scnm& HDL cholesterol or reduces
serum HDI, cholesteml no more tluin &% relative to predosc
level; (iv) binds an epitope comprising amino ac&d residue &o
366 of hPCSK9 (SFQ ID NO 755), (v) does not exhibit an
enhanced bind&ng aifinity for PCSK9 at an ac&d&c pH relative
to a neutral pH. as measured by surface plasmon resonance;
(vi) binds ln&mnn and n&o&fey P( SK9, but does not bind
mouse, rat or hamster PCSK9; (vi&) comprises hea&0 and 1& Jo&t 4.
chain CIM3 sequences comprising Sk Q ID NO 224 and 232;
and (viu) composes CDR sequences from SEQ ID NO 218
and 226.
In a third nspeck lhe invent&on provides nucleic ac&d mol-
ecules encodu&gant&-PCSK9 annbod&es or fraynents thereof. o
Recombinant expression vectors carrying the nucleic acids of
lhe u&vent&m&, and host cells into ~hick such sectors have
been u&troduced. are also encompassed by the invent&on, as
are nmthod& ofproducing tlm antibodies by culn&ring thc host
cells iu&der cond&t&ons penn&tting producuon of lhe mtibod- s
ies, and recovering the antibodies produced.
In one cmbodimcnl. thc invention provides an antibody or
fragment thereof compnsiog a HCVR encoded by a micleic
acid sequence ad ected from the group consisting of SI.Q ID
NO 1,17,21,25.41.45.49,65,69 73.89 93.97 113,117, w&
121, 137. 141. 145. 16&l, IG5. IG9o 185. Iyg 193. 209). 213,
217. 233. 237. 241, 257. 261. 265. 281, 285. 289o 305. 309,
313, 329. 333. 337. 353. 357. 3(il. 377. 381. 385. 401. 405,
409, 425. 429, 433. 449, 453, 457. 473. 477. 481. 497. S01,
505. 521, 525. 529. 545. 549. 553, 56&), 573, 577. 593. 597. r
601. 617. 621. 625. 641. 645. Gi49. 665. 669. 673, 689. 693.
697, 713, 717. 721, 737 and 741, or a substantially identical
sequence having at least 90%, at least 9S'/o, at least 98%, or at
least 99% homology thereof. In one embodiment. the I ICVR
is encoded by a nucleic acid sequence selected from the youp
consistin of SFQ ID NO 49, 65, 69. 73, 89. 93, 121. 137,
141. 217. 233. 237. 241, 257, 261, 313, 329 and 333. In more
specific embodiments, the HCVR is encoded by a nucleic
acid sequence selected fmm the group cons&st&ng of SEQ ID
NO: 89 and 217.
In onc cmbodimenl, thc antibody or 1'ragnmnt therm&f 1'ur-
ther composes a LCVR encoded by a nucle&c acid sequence
selected from the gmup cons&stu&g of SEQ ID NO: 9, 19, 23,
33 43 47 57 67 71.81 91.95,105.115,119.129,139.143,
153. 163, 167. 177. i87, 191. 201. 211, 215, 225, 235, 239,
249. 25&), 2(i3, 273. 283. 287. 297, 307, 311, 321, 331, 335,
345. 3«. 359. 369. 379, 383. 393, 403, 407, 417, 427, 431,
441. 451, 4SS. 465. 475, 479. 489. 499, 503, S13. 523, 527,
537. 547, 551, 561, 571, 575. 585. 595, 599, 609, 619, 623,
633. 643. 647. 657. 667, 671. 681, 691, 695, 705, 715, 719,
729, 739 and 743, ore substantially identical sequence having
at lenst 90/'o, al loast 9&%, al leasl 98%. &1& ill 8:Jsl 99%
homology thereof. In one embodiment. the LCVR &s encoded
by a nucleic acid sequence selected from the group consisting
ofSEQ ID NO: 57, 67. 71, 81. 91, 95. 129, 1 39. 143, 225. 235,
23&7, 249. 259, 2(i3o 321, 331 and 335. In more spec&iic
embodiments, the LCVR is encoded by a nucleic acid
sequence selected from the group cons&st&n of SEQ ID NO;
91 and 225.
In one embodiment. &he u&van&ion limlures an mt&body or
amigen-hindu&g fragment of an anubody compnsu&g a
H(.DR3 domain encoded by a miclwitide s&xiuencc &ulcc&cd
from the group cons&sun of SEQ ID NO 7, 31, 55. 79. 103,
127, 151. 175. I9&R 223, 247. 271, 295, 319, 343, 367, 391.
415, 439, 463. 487. 511, 535. 55'), 583, 607, 631, 655, 679,
703 and 727, or a substant&ally ident&cal sequence havu&g at
least 90"/o, at least 95%. at least 98%, or nt least 99 "/o honlol-
ogy tlmrcof, and a I,(:DR3 &km&sin encodcdi by a nnclwilide
sequence selected from the group cons&st&ng of SEQ ID NO
15. 39, ti3, 87, ill, 13&, 159, 183, 207, 231, 255, 279, 303,
327. 3&1, 375. 3i)9. 423, 447. 471, 495, 519, 543, 567, 591,
(i15. 639, 663, 687, 711 and 735. or a substantially identical
sequcncc having at least 90/'o, at least 95'/o, at least 98%o. or at
least 99'/o homology thereof; ln one embod&ment, the
H('IM3 and I.('DR3 comprise a scxiuence pair encoded by
the nucleic acid scqumice of SFQ ID NO: 5$63, 79/87,
127i135. 223/231, 247i255 and 319/327, respectively. In
more specific embodiments. the HCDR3 and LCDR3 com-
prise a sequence pa&r encoded by the nuc le&c acid sequence of
SL'Q ID NO: 79/87 and 223/231.
In a further cmbodimenl. the antibody or 1'ragmenltherei'urther
composes, a I IC DR I dome u& encoded by a nucleat&de
sequence selected from the group consisting of SL'Q ID NO:
3,27,51,75,99,123.147.171.195.219,243.267,291,315,
339. 363. 387. 411. 435, 459. 483, 507, S31, SSS, S79, 603,
627. ti51. 675, 6&)i) and 723, or a substantially identical
sequence hav&ng at least 90%. at least 95%. nt least 98%, or al
least 99% homology thereof; a H('IM2 domain encoded by a
nucleotide &equence selected from the group consistingoi'IIQ
ID NO.5. 29. 53, 77. 101. 12 &, 149, 173. 197. 221. 245,
2(i9. 293, 317. 341. 3(&5, 389. 413. 437, 4(il, 485, 509, 533,
557. 581, 605. 629, 653, 677. 701 and 723. or a substantmfly
identical sequence hav&ng at least 90'/o, at least 95%, at least
98%o or at least 99% homology thereof, a I/CORI dumain
encoded by a nucleoude sequence selected from the youp
consisting ofSEQ ID NO: 11, 35, 59. 83. 107. 131. 155, 179,
203. 227. 251. 275. 299, 323. 347, 371, 3&)5, 419, 443, 467,
491. 515, 539. 563, 587, 611. 635, 659, 683, 707 and 731. or
a substantially identical sequence having at least 9)0%, at least
US 8,062,640 B2
95%, at least 98%. Ilr at ILdst 99% htinlill(igv thcrt'.Cf, Bnd a
LCDR2 domain encoded by a nucleotide sequence selected
from the group consisting of SHQ ID NO: 13, 37, 61, 85. 109,
133, 157. 181, 208 229. 253. 277, 301. 325. 349. 373. 397,
421, 445. 469. 493, 517, 541. 565. 589. 613. 637, 661. 685, s
709 and 733, or B substantially identical sequence having at
least 90%. at least 95%. Bt least 98'/v. or at least 99% homol-
ogy thereof. In one embodiment. the heavy and light chain
('DR stlqucnccs itic cncildLil lii'hc nucleic acid scqucnces'l
QIDNO 51,53 55,59,61 63 75 77,79,83 85„87;123, lo
125. 127. 131, 133, 135: 219. 221. 223. 227. 229, 231: 243,
245.247,251,253,255,nnd 315,317,319,323.325.327 In
more specific embodiments. the heavy and hght chain CDR
scqumlces are cncodcd by tlm nucleic acid sequences ofSFQ
ID NO: 75. 77. 79, 83, 85. 87, and 219, 221. 223, 227. 229.
231.
In a fourth aspect. Ihe imvntion fcaturcs an ISOIBILVI anti-
body or antigen-binding fragment there»If that specifically
binds hPCSK9, comprising a HCDR3 and a I,('DR3, wherein
HCDR3 comprises ml amino acid scxlumlce ol'hc filntlula SoX'S Xd X's Xs X's X''" X"
X'1 X" X" X" X's X" X" X'v X" (SFQ
IDNO 747). whereinX'sAlmX'IsAI orLys,X'IsAsp.X's
Ser or lie, X's Asn or Val, X's Leu or Trp, X" Is Gly or
Met. X'isAsnorVal,X" isPheor Tyr,X'oisAsp, X" is Leu "
or Met. X" Is Asp or absent, X's Tyr or absent, X'" Is Tyr
or absent. X" is Tyr or absent, X" is Tyr or absent. X' is Cily
or absent, X" is Met or ahsenh X" is Asp or absenh and X "
Is Val or absent; and LCDR3 comprises ml amino acid
svqiwncc ol'he formula X's Xs X X''o
X
'" Xv (SI Q ID NO 750), it herein X's Ciln or Met,
X Is Gin,X's Tyror Tlu;X is TyrorLeu.X'is Thror(iln,
X's Thr, X's Pro, X" is Tyr or I cu, and Xa is Thr.
In a further embodiment. the antibody or fragment thereof
further comprise a HCDRI sequence of the fiinnula "»X''' X's X's (SFQ ID NO 745).
whereuiX'isGly,X isPhe,Xs is Tlu;X Is Phe.X'Is Seror
Asn. X'is ScrorAsn, X is Tyror His, and X" isAlaor Trp;
a HCDR2 sequence of ihe fomiula X' X'''''"
(Sl QIDNO 746).whereinX'is lie,X is do
Ser or Asn. X's (ily or (i in. X" is Asp or Ser, X's (ily. X" is
Ser or Lily, X's Thr or Glu. and X" is Thr or Lys; a LCDRI
sequence of the formula X' X X''"X''o X" X'SFQ ID NO 748) wherein
X's GIB, Xl is Ser, X'sVal orLeu. X is Leo, X'is liisor 4.
Tyr, X's Arg or Ser, X 's Ser or Asn. X's Asn or (ily. XV ls
Asn. X Is Arg orAsn. X Is Asu ol Tvl'. Bud X" Is Phe or
absent: a LCDR2 sequence of the formula X''s
(SI1QIDNO 749) wherein X'is Trpor leo,X'isAlaorfily.
and X's Ser I'IG. I shows the sequence ahpuuent ofheavy u
and light chain varmble regions for 316P and 300N uxdtbs.
In a lifih aspect. the uneutiml features a hunian uiti-
PCSK9 antibody or anti en-bindulg fragment ofan antibody
lxmlprising a lit'.dvv chain variable region (H('v'R) cnc(ldcd
by nuchxitide SLxluence Be@nants deuved from Via D„and.l„s
germline sequences, and a light chain variable region
(i.('VR) encoded by nucILxitidc BLquLncc si:gnicnls tlcilvcil
from V». and IB germline sequences, ~herein the germlule
sequences are (a) VB gene segment 3-23, DB gene segment
7-27, J„gene segment 2, V» gene seglucnt 4-1 lmd J» gene ci
segntent 2; or (b) V„gene segment 3-7. D„gene segment 2-8.
IB gene segment (i, V». gene segment 2-28 and J». gene seg-
ment 4.
In a sixth aspect, the invention features an antibody or
mitigen-binding fragment thereof that binds to a P( SK9 pro- r
tein of SLIQ ID NO:755. Vi herein the binding of the antibody
or fragment thereof to a variant PCSK9 protein is less than
5(F/tt of the binding bcnvcen the antibody or fragment thereof
and the P('SK9 protein of SLQ ID NO:755. In specific
embodiment, the antibody or fragment thereof bulds to the
variant P('SK9 protein with a binding aflinlty (K„) which is
less than about 50'/n. less than about (10%, less thmi about
70'/w less than about 80%, fess than about 90% or less than
about 95% compared lo the bulding to PCSK9 (SLQ ID
NO:755).
In one mnbodimenb the variant P('SK9 protein cmupriscs
at least one mutation Bt position 238 of SHQ ID NO 7 5 5. In a
nxire speciiic embodiment. the nuitation Is D238R. In one
cnibtlduucnt, the anbbody or mtibody fragnicnt binding
aflinity for the variant I'( SK9 protein is at least 90/tt less
relative to the wildtype protein of SL'Q II& NO: 755, wherein
the variant protein compn sea a mutation at residue 238. In one
cmbodinwnt, thc antibody or antibody fragnwnt binding
aflinity for the variant P('SK9 protein i ~ at least 80% less
relative to the wildtype protein of SI.'Q ID NO:755, wherein
Ihc v'u'laill prolclli c(linpl'lscs a lililtauon Bl onc ol Biol'e. (11
residue 153, 159, 238 and 343. hl a more specific emlxidi-
ment, the mutation is one of S153R, L'159R, D238R and
D343R.
In one embodunent, the variant PCSK9 protem compnses
at least onc mutation at position 366 o I'SFQ ID NO 755 In a
nxire spccilic embodiment, thc mutation is F366K In one
embodiment, the antibody or antibody fragment binding
aflimly lor the variant P('SK9 proteul is at least 95% less
relaiive to the wildlype proteus ol'SIIQ ID NO:755, ulwreln
the wa riant protein comprises a nnuati on at residue 3(i(i. In one
embodiment, the antibody or antibody fragment binding
ailimty for the variant PCSK9 proteul Is at least 9(F/v less
rclativc to thc wildtypc protein ol'SFQ ID NO:755, v herein
the variant protein comprises B nmtation at one or more of
residue 147, 366 and 380. In a more specific embodiment, the
mutau on Is one ofS14 7 IL F 366K and V3 80M. In one
embodime-
ntnt. dw. antibody or antibody fragnwnt binding atlinity for
the variant P('SK9 protein is at lmist 80% less relative to tlm
wddtype protein of SFQ ID NO:755. wherein the vanant
pmteiu comprises a mutation at olm or nuire ol'esidue 147,
36(i and 380 In a morc specific mubodimcnt, the mutation is
one of 8147F. kxli6K Bnd V380M.
The invention encompasses anti-P('SK9 antibodies having
a modified glycoaylation pattern. In some ap pi cat ions, modi-
tication to remove iuidesirable glycosyfation sites may be
useful. or e.g., removal of a fiicose moiety to Increase anti-
body dependent cellular cytotoxicity (ADC(q fmlction (see
Shield et al (2002) .IHC 277 26733) In other apphcauons.
modification of galactosylauon can be made ui order to
modify complement dependent cytotoxicity (CDC).
In a seventh aspect. the invention features a phanuac cut i eel
composition compnsin a recombulant human antibody or
frBgnlcnt thercol'vhich speciFically binds hPCSK9 afltl ti
pharmaceulimilly acceptable carrier In one embodiment, the
invention features a composition wlfi ch is a combination ofan
antibody or antigen-binding fragment of an mltibody ol'the
lnveutioix and a second themipeutic agenu The second thera-
peutic agent may be any agent that is advmitagcously com-
bined with the antibody or I'ragment thereof of thc invention,
for example, an agent capable of Inducing a cellular depletion
of cholesterol synthesis by inhibiting 3-hydioX----methy-
glutaryl (I IM(i)-coenzyme A (CoA) reductase. such as. for
example. cerovastatin, atorvastatin, simvastatin, pitavastin,
rosuvastatin. fluvasmtin, Iovasuitin, pmvastatin, ctc; capable
of inlubiting cholesterol uptake and or bile acid re-absorp-
tion: capable of increasing lipoprotein catabolism (such as
tjS 8,062,640 B2
10
nincin): and/or act ivators of the I )CR transcription factor tlhat
plays a role in cholesterol eliminntion such as 22-hydroxyc-
holesteml.
In m& eighth aspect, the unvntion I'ca&urn& methods for
inhibiting hPCSK9 activity using the anti-P&. SK9 antibody or
ant&gen-binding portion of the antibody of the invention,
where&a the thempeunc methods compose admuusteru&g a
thempeuticatty effect&ve amoum ol'a phanuaceuucal comp&a
sition comprising an antibody or antigen-binding fmgment of
&O
an anubody of the invent&on. The d&sorder treated is any
disease or comit&on v;hich is improved, ameliorated, inhib-
ited or presented by removal, ud&ibition or reduction ol'C'SK9
activity. Specihc populations treamble by the them-
peut&c matin&ds of the invention include subjects indicated for „
LDL spheres&s. subtects v,ith PCSK9-acuvat&ng nu&tations
(gain ol'I'unction muustions. "GOF"), subjects with hctcrozy-
gous Familial Hypcrcholesterolemia (lmFH); subjects with
primary hypercholesterolemia who are statin &na&lerant or
stat&nuncommlled:and subjects atnskfordevefopinghyper- o
clmlesterolemia wlm may be preventably treated. Other ind&-
cations include dyslipidmnia associated with secondary
causes such as Type 2 d&abates mell&tus, cholestat&c liver
d&seases (prunary bil&ary c&rrhosis), nepluonc syndrome,
hypothyroidism. obesity. m&d thc prevention m&d treatnmnt ot'-'tlmrosclorosisnnd cardiovasculm diseases.
In specific embodunents of the method of the invention, the
ant&-hPCSK9 antibody or antibody fragment of the u&vent&on
&s useful to reduce elevated total clu&lcsterol, non-HDL eh&a
lesterol. Ll&L cholesterol. and/or apolipoprotein B (apolipo-
protein B100).
The ant&body or antigen-bu&d&ng fragment of the invent&on
may be used alone or in combination w ith a second agent, for
example,anHMC&-CoAreductaseinhibitorand/orotherl&pid „
lowenng dnigs.
Other embodiments w &11 become apparent lyom a rev&ew of
tlm ensuing dctailcd description
BRIEI'ESCRIPTION OI'I IE I'IGURL'ICi.
1 Sequence comparison tables oflmavy chain (A) and
light clmsu& (B) variable regions and CDRs of antibodies
H111316P and I I IM300N.
Flti 2. Antibody concentmtim&s in serum over fin&c 316P 4-
5 mg!kg ( ); 300N s mglkg (C))& 316P 15 mg!kg (5): 300N
15 mg!1&g (~ )
FIG. 3. Serum total cholesterol level as a percentage of
chm&ge over bulfer control Buffi.r control (a), 3! 6P 5 n&g/kg
(~ ): 300N5&ug/kg(A): 316P 15mg/kg( ) 300N15 &ng/kg Su
(A).
FIG 4. Serum I.DL cholesterol hwel as a percenuige ot
change over bufti:r control Bufli:r C'ontrol (', 316P 5 mg/kg
(~ ): 300N 5 mg/kg (Ak 316P 15 mg/kg ( ); 3()0N 15 mg!kg
(6).
FIG. 5. Serum LDL cholesterol level nom&al&zed to buffer
control Bufli.rem&trot ("), 316P 5 mg/kg (~), 300N 5 mg/kg
(i): 316P 15 mg!1&g ( ); 300N 15 mg/I'g (6).
FIG. 6. Serum HDL cholesterol level as a percentage of &,so
change over bulTer control BulTer cm&tml (a), 316P 5 mg/kg
(~ ): 300N 5 mg/kg (A): 316P 15 n&g/kg ( ): 300N15 mg/kg
(A)
11G. 7. Sen&m triglycende le~el expressed as a percentage
of change over bulfer control. ButTer control (*); 316P 5
mg/kg (8). 300N 5 mg/kg (A), 31C&P 15 mg/kg ( ). 300N 15
mglkg (6).
Fiti. 8 Sennn I.DI cholesterol level expressed as a per-
centage ofchange over baseliim following a single dose sub-
cutaneous adnunistrat&on. 316P 5 mg/kg (5); 300N 5 mg/k
(0)
I'ICi. 9. Antibody concentrat&ons n& serum over time fi&l-
lowing a single dose subcutaneous a&hninistmtion. 316P 5
mg/kg (~), 300N 5 mg/kg (A)
FICi. 10. We&&em blot for mouse LDL receptor of total liver
homogenates. Samples were taken 24 hours after PBS (lanes
1-3), 5 mg/kg 316P (lanes 4-6). or 5 n&g&kg of non-hPC'SK9
spec&lic mAb (lanes 7-8) adnunistnsuon and 4 hours alter 1.2
mg/kg hP( SK9-mmh (nil lanes)
FIG.11 Iit'fectsof316PonsvnuuI.DLcbolesterollcvelin
I'I:SK9'""'" mice. Buffer control gt 3161' mg/kg (H): 316P
5 mg/kg (tttt); 316P 10 n&g/kg ( )
FICi. 12 Anti-hPC:SK9 mAb senim phannacokineuc pro-
file in I 57BI.!6 mice Single dose of I'ontrol I mAb (~ ) at 10
mg/kg. 316P (A) at 10 mg/kg and 300N (E) at 10 mg/kg
FIC&. 13. Anti-hPCSK9 na&&b serum pham&acokinetic pro-
file in hl'C'SK9 heterozygous mice. Single dose of C'ontrol I
nuAb (~ ) at 10 mg/kg, 31 6P (A ) at 10 mg/kg and 300N (E) at
10 mg kg.
FICi. 14. Effect of316P on senun LDL cholesterol levels in
Syrian I is mater fed a normal d&et. Bufibr c out mt (~ ): 316P I
mg/kg (I); 31C!P 3 mg/kg (A); 316P 5 &ugvl g (4).
DEIAILFD DESI'RIP fION
Before the present methods are described. it & s to be under-
&to&xi that this invention is not limiu:d to pnrticular nmtho&ks,
and expenmenu&l condit&ons descnbed. as such inetlu&ds and
cond&tions may vary. It &s also to be understood that the
tcnninology usvd herein is li&r thc purpose. of describing
part&cuter embodunents only. and is not u&tended to be l&mit-
ing, since the scope of the present invm&tion will be limited
onlv by the appcndcxt claims
Unless defined other&v&se. all techmcal m&d sc&entitic terms
used herein have the same meaning as conunonly understood
by one of ordu&an skill in the art to &vhich this invcnti&m
belongs. Although any methods and materials similar or
equivalm&t to those described herein can be used in the pmc-
nce or testu&g of the present invent&on. preferred methods and
materials are now described. All publications mentioned
herein are incorporated lmrein by refcrcnce in their cntiroty
Defuutlons
The tern& "human proprotein convertase subtilisin!1 cain
type 9" or "hPCSK9". as used here&n, relers to hPCSK9
having the nucleic acid sequence shown in SLQ ID NO:754
and tlm nmino acid sequence ol'EQ 113 NO 755, or a bio-
log&cally acta e frarguent thereof
The term "antibody", as used herein. is u&tended to refer to
in»uunoglobulin molecules comprised of I'our potypc7&tide
chains. &wo hea&y (H) clmu&s and two h ht (L) cha&ns u&ter-
conncccted by disulfide bonds Fach lmavy chain is comprised
of a heavy chau& variable reg&on ('*HCVR'* or yVH") and a
heavy chain constant region (comprised of domains I'Hl,
CH2 and C.'H3). Fach li it cfrain is comprised of a light clmin
varu&ble region ("I.C'VR or '*L I,") mul a light chain constant
region (C.'I,). The VH m&d VL regions can be further subdi-
&'idcd into regions ol'hypervnriabiliiy. termed complmncnta-
rity determining regions (I:DR). mterspersed w&th reg&ons
that are morc conserved. tanned framework regions (FR).
Each VH m&d VL &s composed of tluee CDRs and four FRs,
arranged from amino-tern&inus to carboxy-term&nus in the
followeing order: FR I, I DR I, I'R2. I DR2, FR3. CDR3, FR4.
Subst&tution of one or more CDR residues or omiss&on of
one or more CDRs is also possible. Antibodies lmve been
US 8,062,640 B2
12
described in tlm scientific literature in which one or twn I DRs
can be dispensed with for binding. I'adlan stol (1995 FASL'B
J. 9;133-139) analyzed the contact re iona betw(een m&tibod-
ies m&d their antigens. based nn published crystnl stnicturcs,
and concluded tlmt only about onc fiflh to one third oi'('DR
residues actually contact the antigen. Pa dian also found mmiy
ant&bodies &n u.hich one or two CDRs had no anuno ac&ds ill
coll&&Ic & wltll oil Silt&'&I (see also. Mal dos e1 al. 2002 I Mo1 B&ol
320: 41 5-428).
CDR residues not contacting ant&gen con be ident&fied
based on prev&ous studies (for example res&dues 1160-065 &n
CORI 12 ai'c of&co in11 Inquired). from reg&ons of Kabat CDRs
lying outside Chothia CI&RS, by molecular modeling anChor
emp&rically. If a CITR or residue(s) thereof is omitted, &t is
usually subst&tuted u&th an amino ac&d occupyin the corre-
spm&ding position in another human antibody sequence or a
coflsc&Is&is of s1&ch scqilcl&ccs Pool&1ons fol substlt&It&nfl
w&thin CDRs and mnino acids to substitute can also be
selected empincufly I',mp&meal subst&tutions can be conser-
vative or non-conservati(u subst&tutions.
ll&e term "lmmon antibody*l os used herein, is intended to
include antibod&es hav&ng vrmable and constant re iona
derived from human germline inununoglobul&n sequences.
The human mAbs of thc invention may include nmino acid
res&dues not encoded by hummi germline &mmunoglobul&n
sequences (e.g.. mutations introduced by random or site-
spec&lic mutagenesis in vitm or by soniatic mutution ui vivo).
for example &n the CDRs ond ui particular CDR3. However,
Ihc term "human mitibody'2 as uscxl hcrcin, is not intcndcd to
u&elude nuAbs ui uhich CDR sequences derived from the
gennl&ne of another mmnmal&an spec&es (e.g., mouse), have
been graficd onto luunan FR seqummes
The term '*specdically buids." or the hke. mern&a tlmt an
antibody or antigen-binding fragnwnt thereof fonna a com-
plex with an antigen ilrnt &s relatively stable under phys&ologic
cond&t&ons. Spec&fic binduig can be characterized by an equ&-
librium dissociation constant of nt Iemst about 1 x10 ' or
less (e.g, a snuiller K» denotes a tighter binding). Methods
for determining whether two molecules speci tically bind are
well known in tlm art rmd include, for example. equilibrium
d&olys& s, surface pl eamon resonance. and the like An isolated
antibody that specifically binds 1&PCSK9 may. however,
exhibit cross-reactivity to other ant igcns such as PCSK9 mol-
ecules from other species. Moreover, nn&lti-specific antibod-
ies (e.g.. bispecifics) that bind to hPCSK9 and one or more
add&t&onal ant&gens ue nonetheless considered antibod&es
that "spec&ficolly b&nd" hV(:SK9, as used herein.
The tenn 'high afliuity" antibody rei'ers tn those mAbs
having a buiduig afliruty to hPCSK9 of at least 10 '"
M;
preferablv 10 "
M; even more preferably 10 '. as meo-
swcxf by surfiice plasmon reson u&ce., e.g.. BIACORFr" or
solut&on-affimty LL)SA.
By the tenn 'slow off mtc". "Koft" or "kd" is meant on
ant&body tlra& dissociates f'rom hPCSK9 (vith a rate constant
oflxl0 's 'orless,preferably lx10 s 'orless,osdeter-
mined by surf'oce plasmon rcsonancc. c g, BIAC'ORFr"
The tenn *'anugen-binduig poruon" of mi nntibody (or
simply "antibody fraynenf*), as used herein, refers to one or
morc fragments oi'an antibody that retnin the ability to spc-
citically bind to hVCSK9. An antibody fmgment may include
a I'ob 1'ragment. a F(ab')s fragment, a Fv fragn&ent, a (LAb
fragment. a fmgment contaitung o CDR. or an isolated CDR.
'Il&e specific embodiments, antibody or antibody fragments
of the invention n&ay be conjugated to a tlmrapeutic moiety
("immtuioconiugate"), such as a cytotoxin, a chemothempeu-
tic drug, an immunosuppressant or a radioisotope.
An "isolated antibody", os used herein, is intcndkxf to refer
to mi antibody that is substanua fly free ofother mAb s hav&n
different antigenic specific&ties (e g.. an isolated antibody that
speciticafly binds hPCSK9 is substantially free of mAbs d&nt
s specifically b&nd ontigens other than hPCSK9). An isolated
antibody that specifically binds hPI.'SK9 may, however. have
cross-react&vity to other antigens. such os PCSK9 molecules
fbom other species
A "neutralizing antibody", as used hwcin (or an "antibody
0& that neutmlizes PCSK9 acuvity"). is intended to refer to an
ant&body whose binding to hl'CSK9 results in udubition of at
lmist one biological activuy of P&. SK9. Tins inlubition of'the
b&Clog&cal act&v&ty of PCSK9 can be assessed by measunn
one or more indi cntors ofPCSK9 biological activity by one or
more of several standard in vitro or &n vivo assuys kn(mn ui
the art (see examples below).
Thc term "surface plasmon rcsonancc", as used herein,
ref'ers to an
opt &col
phenomenon that el km s Ior the m&sly si s of
real-time biospecific interactions by detection of alterations
in in protein concm&trotio&IS wiIhin o bioscnsor matrix li&r
example usu&g the BIACORFO" system (Vham&acia B&osen-
sor AB. Uppsala, Swsxfen mid Piscataway, N.J.).
The term "Ki,". Ss used here&n. is intended to refer to the
equihbrium dissociation constant of a particuLar antibody-
antigen intemction.
The tenn "ep&tope" is a reg&on of an ant&gen that &s bound
by an antibody. Epitopes may be defined as structural or
funct&onal. Functional ep&topee ore generally a subset of the
structural ep&topes and have those res&dues that directly con-
&a tribute to the affinity of Ihc interaction. Epitopcs nlay also bc
conformatioiud. that &s. composed of n(m-l&near umno ac&ds.
hi certain embod&ments. ep&topes may include determinants
that arc chmnically active surface groupmgs of molcculcs
such as am&no acids. sugar side chains, phosphoryl groups, or
"» sulfonyi gmups, and, in certain mnbodiments. may have spe-
cific three-dimensional structural characteristic~. Snd/or spe-
cific charge characterist&cs.
Thc tern& '*substantial identity" or *'substnntially identical,*'he
referring ro a nucleic acid or fragment therm&f. indicates
sn that. when optimafly aligned with appropriate nucleotide
insertions or deletions with another nucleic ncid (or its
complementary strand). there &s nucleotide sequence identity
in at leo st about 90%, and more preferably at least about 95'!n,
96%. 97%, 98% or 99% of thc luiclcotide bases, as measured
by any well-known algoritlun of sequence &dent&ty, such as
FAS'IIA. BI,AST or GAV, as discussed below.
As applied to polypept&des. the term "substantial s&mdar-
ity" or "substantially similar*'eans that tv;o peptide
sequences„v hen optim oily afigned, such os by the programs
n GAP or BFSTI'IT using default gap we&its. slmre at least
90'!s sequence identity. even more preferably at least 95"!s,
98% or 99% sequence identity Preferably, residue posit&mis
wh&ch are not Identical differ by conservative amino ac&d
subst&IUI&o&is A cur&servo&1vca&111&ioacidwlbstltutlofl Isolm
s &n wh&ch an amino acid res&due is substituted by another
amino acid residue having a side chain (R group) with similar
clmmical propcrtics (e g, charge or hydrophobicity) ln gen-
eral. a conservat&ve amuio acid subst&tut&on w&fl not substan-
tially change the functional prope&ties of a protein ln cases
o& ulmre tuo or morc amino acid sequences differ from each
other by conservat&ve substituuons, the percent or degree of
similarity may be adjusted upwards to correct for tlm c(mser-
vat&ve nature of the substitunon. Means for mak&n this
adjustment are (veil know n to those of sk&11 in the art. See. e g.,
Pcnrson (1994) Methods Mol Biol. 24: 307-331, which is
here&n &ncorpomnted by reference. I'xamples of groups of
amino acids that have side chains with similar chemical prop-
13
US 8,062,640 B2
14
erties include I) aliphatic side chnins'lycinc, alanine,
valine, leucine and isoleuclne; 2) aliphatlc-hydroxyl side
clmins: serine and threonine: 3) amide-containing side
chains: asparagine and glutaniine, 4) aromatic side chains
phenylalanine, tymsine. nnd tryptoplmn; 5) basic side chains: s
lysins. arginine, and histidine: 6) acidic side chains: asparmte
and glutamate, and 7) sulfiu-contaimng side chains: cysteule
and metluonule. Preferred conservative mnino acids substi-
tution groups alc: valine-leucini-isolcucine. phcnylalmluie-
tyrosine. Iysute-argo«ac. alatune-vahne„glutamate-aspar- «1
tate. and asparagine-glut«mine. Alternatively, a conservative
replacenlcnt is any change I«ising a positive value in the
PAM250 log-likelihood matnx disclosed in Gonnet et al.
(1992) Science 256 1443 45, herein incorporated by rcfi.r-
ance.A'*inoderatelyixmservative'*replacementisanychan e
having a noonegative value in the I'AIVI250 log-likelihood
matrix
Sequence sunilarity for polypept ides is typically measured
using sequence analysis sofuvare. I'mtein analysis software
«latches sunlldl sLqucllccs iii111g nlLilsur'es (lf silllildiltv ss
a«styled to various substinitions. deletions and other modiTi-
cations, including conservative amino acid substitutions For
ulstance, CJCG software cont uns progmms such as CJAP and
BL'ST IT f wlfich can be used with default parameters to deter-
mine sequence homology or sequence identity between "
closely related polypeptides. such as homolo ous polypep-
tides from different species of organisms or be«veen a wild
type pmtem and a nnitein thereol'ee, e.g, CJC'Ci Version 6.1.
Polypeptide sequences also can be compared usul FASTA
with delinult or recommended parnnmtcrs; a program in Ci('(i ln
Version 6.1 FASTA (e,g.. I'ASTA2 and I'ASTA3) provides
ally«vents and percent sequence idetltlty of the regions of the
best overlap between tlm query and search scquenccs (Pear-
son (2000) supra). Another preferred algontluu when com-
paring a sexi«ence nf thc invmltion to a database contnining a "»
large number ol'equences from dil'li:rent organisms is thc
conlputer progmm BLAST, especially BLASTP or
TBLASTN, using dcfmiit paramctcrs. See, e g.. Aitsclml ct al
(1990) J Mol B«ll. 215 403410«ad (1997) Nucleic Acids
Res. 25:3389 402, each of wluch is herein incorpomted by 4«
refute«CL.
In specific embodiments, the antibody or antibody fmg-
ment for use in the metlxld of the invention may be monospe-
cilic, bispivitic. or multispccific Multispecific antibodies
mny be specific for difTerent epitopes of one target polypep- 4.
tide or may contain mltigen-binding domains specific for
epltopes of more than one target pol)qrepude. An exemplary
bi-speci tie antibody format that can be used in the context of
Ihc present invention involves Ihe ure ol'a Iirst mununoglo-
bulin(1 ) CH3 domaul and a second I CH3 domain, v'herein o
the first and second Ig CID domains differ fmm one another
by at leasi one amino acid, and wherein ut lmist mle mnulo
acid difference reduces buldin of the bispecitic antibody to
Protein A as compared to a bi-spimific antibody lacking tlm
amour acid dilference. In one embodnnent, the Iirst I CH3 s
domain binds Protein A and the second lg ('H3 domain con-
Iains a mutation that reduces or abolishes Protein A binding
such as an H95R modilicatlon (by IMCJT exon numbenng,
H435R by FU numbering). The second ('H3 may further
comprise mi Y96F modilication (by IMCiT: Y436F by FIJ) al
Further modifications that may be found within the second
( H3 include: Dltll'2 I.JSM, N44S. K52N, V57M, end VII21
(by IMGT; D356E. L35SM, N3g4S, K392N. V397M. and
V4221 by EU) in the case of lgGJ nlhbs: N44S. K52N, and
VS21 (IM(JT, N334S, K392N, and V4221 by FI1) in thc case r
of IgCi2 nlkbs; and Q15R. N44S. K52N, V57M, R69K.
E79Q, and VS21 (by IMCr'I'I Q355R. N384S. K3112N,
V397M, R409K, 11419Q, and V4221 by FI J) in the case of
IgCr4 mAbs. Variations on the bi-specilic mltibody fomiat
described above are contemplated within the scope of the
present invention.
By the pluase "therapeutically effective mnount" is meant
an amount that produces the desired effiect for which it is
admlrustered. The exact amount will depend on the purpose
ofthe treatment. nnd will be use ertaulab le by one skilled ul the
art usuig knoll n techniques (sec, fiir example I,loyd (1999)
The An, Science and Teclulology ol Pharmaceutical ( om-
pounding).
Preparation oflhuna«Antibodies
Methods for enemtuig human anubodies in t«lnsgenic
mice are known (see filr exmnpli, IJ.S. Pnt No 6.511(1.541,
Raga«aron Pharmaceuumils. VEI,OCIMMIJNE™) The
VFI.OCIMMUNE1" timlulology involves genemtion of n
trmisgcnic mouse hnving a gcnoitic comprising huillan heavy
and hght chuul venable regions operably lucked to eiulog-
enous mouse constant region loci such that the mouse pro-
duces nn mtibody comprising a luminn variable region and a
mouse constant region ln response to anti eruc stimulation.
The DNA encoding the variable regions ofthe heavy mid light
chains of the antibody are isolated and operably linked to
DNA encoding the human heavy and light chain constant
regions Thc l&NA is then expressed in a cell capable of
expressing the fully lou«an antibody. In specific embodiment,
the cell ls a CHO cell.
Antibodies may be therapeutically uset'ul ui blocking a
llgand-receptor interaction or i«I«biting receptor component
internction, rather than by killing cells through fixation of
complement and partlmpntion in coinplement-dependent
cytotoxicity (CDC). or killing cells through antibody-depen-
deni evil-medi«teil cytotoxicity (ADC( ) The constant region
ofan mtibody is thus important m the abihty of an anubody
to hx implement and nwdiatc cell-dependmlt cytotoxicity.
Thun tlm i so type of an antibody may be selected on the basis
ofwhether it is desirable for the antibody to medulte cytotox-
Ic I IV
Iluman antibodies can exist in two fimns that arc associ-
ated with lunge heterogeneity. In one foun. an antibody mol-
ecule comprises a stable four-chain constmct of approxi-
mately 150-160 kDa ln which the dimers are held together by
an interchnin heavy chain disulfide bond. In a second filrm,
the dimers rme not lirficcd via inter-clrdin disulfidc bonds and a
molecule of about 75-50 kDa is formed composed of a
covalently couple«I light and heavy cliain (half-antibody).
These forms have been extremely dlfiicult to separate. even
after affinity purification.
Thc frequmlcy el'appar«ance of the second form in various
ultact IgCJ isotypes is due to, but not hmited to. structuml
differences associated with the hinge region isotype of the
antibody A sui le amino acid substitution in the hinge region
of the bun«in IgG4 hinge can s igni licmltly reduce the
appeara-
ncee of thc second form (Angel et al (1993) Molecular
Imnuuiology 30:10&) to levels typically observe«I using a
human ig(11 hinge. The instant invention encompasses mlti-
boibcs lrdving one or morc mutations in tlm hinge C'H2 or
CI D region lvlfich may be desirable, for exmnple, ul produc-
tion. tn improve the yield of the desired antibody form.
Cicnerally, a VFI,OC'IMlvRJNFr" mouse is challenged
with the antigen of interest. and lympliatic cells (such as
B-cells) are recoverixl f«ml the niicc that express antibodies.
The 1ymphanc cells may be fused with a myeloma cell line to
prepare inmlortal hybndoma cell lines, and such hybridoma
cell linis are scrcmwd mid selected to identify hybridoma cell
lines tlmt pmduce antibodies specific to the antigen of ulter-
est. DNA encoding the variable regions of the heavy chain
15
US 8,062,640 B2
16
mid light chain may be isolated mid linked to desirable iso-
typic constant regions of the heavy chain and hght chain.
Such an antibody protein may be pmducad in a cell. such as a
('HO cell. Alternatively, DNA encoding thc amigcn-specific
clumeric antibodies or the vanable donmins of the hght and s
heavy chains may be isolated dirccctly from antigen-specific
lymphocytes.
Initially. Iugh afhnity chimeric antibodies are isolated hav-
ing a human varinblc region and a mou&u cmistani region. As
descnbed below, the antibodies are characterized and ui
selected for desirable chamcteristics. including atfinity,
scleciiviiy. cpiiope. etc Thc nloilse collsialu I egiolls are.
replacot withe desired human const mt region to generate the
fully human antibody of the inventiim, for example wild type
or moditied IgGI or Ig(14 (lilr example. SEQ ID NO 7&1.
752. 753). W'hite the constant region selected may vary
according ul specific use, high affinity antigen-binding and
target spew ficity charactenstics ress!e iu thc vannble rcy'on.
kpitope Mapping and Related Teclmologies
To scrcvn filr antibodies that bind to a particular cpiiopc c
(e.g., those wluch block binding of IgL'o its high alhnity
receptor). a mutine cross-blocking assay such as tliat
descnbed.tari/Iuriiex. Ilarlow and Lane (Cold Spria Ilarbor
Press, Cold Spring Harb., N.Y.) can be performed. Other
methods include alanine scanning nuitantw peptide blots "
(Reineke (2004) Methods Mol Biol 248.443-63) (herein spe-
citically incorpomted by reference in its entirety), or peptide
cleavage analysis. In addition. methods such as epitope exci-
sion. epitope extraction and chemical niodification of ann-
gcns can bc mnploycd (Tomcr (20(N) Protein Science 9 lc
487-496) (herein specflically uicorporated by reference in its
entirety).
The term "epi tope*'e I'era to a site mi mi antigen in w hie h B
andior T cells respond B-cell epitopes can be formed both
from contiguous amino acids or noncontiguous amino acids "»
jilxtapiisid by tertiary folding ol'a protein Fpiuipes formed
from contiguous amino acids are typically retauied on expo-
sure to denaturing solvents, wlmrcas epitopes fonnixl by ter-
linry folding arc typically lost on treatment with denaturing
solimnts. An epitope typicafly includes at least 3, and more sn
usually, at least 5 or 8-10 muino acids in a unique spatial
Collforlnatloil.
Moditication-Assisted Protiling (MAP). also knoivn as
Antigen Structure-based Antibody Protiling (ASAP) is a
method tlmt categorizes large numbers of monoclonal anti- &5
bodies (ntkbs) directed against the same antigen according to
the similanties of the binding protile of each antibody to
chenucally or enzymatically modified antigen surfaces (IJS
2004/0101920. herein spcmificat ty incorporated by reti'rance
in its entirety). Each cate ory may rellect a unique epitope o
either distinctly difTerent from or partially overlapping with
epiiope represented by another cate ory Tins technology
allows rapid tiltenng ofgenetically identical ntkbs. such tlmt
characterization can bc filcu sad on genetically distinct mAbs
When appficxt to hybridoma screening. IvLAP may fncilitate s
identification of rare liybridoma clones tliat produce nifibs
luiving thc desired characteristics MAP may bc uvud til soll
the anti-PCSK9 mAbs of the invention uito gmups ol'mAbs
binding different epitopes
In various cmbodimcnt&, the anti-hP('SK9 imtibody or ai
antigen-binding fragment of an antibody binds an epitope
within the camlytic domain, wlfich is about 153 to 425 of SVQ
ID NO:755); more specifically. an epitope from about 153 to
about 250 or from about 250 to about 42S: more specifically,
the mitibody or antibody fmgment of thc invention binds an r
epitope witlun the fragment from about 153 to about 208.
from about 200 to abom 260. from about 250 to about 300,
from about 275 to about 325. fmm about 3(N to about 3(ifl,
from about 350 to about 400, and/or from about 375 to about
425.
In various embodinwnts, thc anti-hP(.SK9 antibody or
anugen-binding fragment of an antibody binds an epitope
witliin the propeptide domain (residues 31 to 152 of SL'Q ID
NO;755k. more specitically, mi epitope from about residue 31
al about residue 90 or from about residue 90 to about residue
152, more spccilically. the mitibody or antibody I'ragment of
the invention buids an epi tope wiilun the iragmeni from about
residue 31 to about residue 60. from about residue 60 to about
resiihie 90, 1'rom about residue 85 fii abmit residue 110, I'rom
about residue 100 to about residue 130. from about residue
125 to abour residue 150. from about residue 135 to shorn
residue 152. and/or I'rom about residue 140 io about residue
152
In annie embodiments, thc anti-hPCSK9 antibody or anti-
gen-binding fragment oI'mi antibody binds an epitope witlun
the (tterminal domain, (residues 426 to 692 of Sk'Q lt&
NO 7«): more spccitically, mi epiuipe fium about residue
426 to about residue S70 or from about residue 570 to about
residue 692: more specifically, the antibody or antihodv frag-
ment of flie invention buids an epitope within the fragment
from about residue 450 to about residue S00, from about
residue &00 to alxlut residue 550. from about residue 550 to
about residue 600, andior from about residue 600 to about
residue 692.
In some embodiments, the mtibody or uitibody fragiuent
buids an epitope wluch includes more than one of the enu-
merated epiiopes within tlm catalytic. propc7iide or (ttcnui-
nal domain, and'or within iivo or threw different domauis (for
example, epitopes witlun the cataty&tc and C-ternunal
dommns, or iviihin thc propcpiidc mid catalytic Ikimmna Or
u itlun the propeptide, catalytic and C-tennuml domauis.
In some embodiments, tlm antibody or mitigen-binding
fragment binds an epitopc on hP(.'SK9 romprisuig mnmo
acid residue 238 of hPCSK9 (SEQ ID NO 755) Experimen-
tal results (Table 27) shov, that w hcn 0238 was mutated, the
Ki, of inAb 316P exhibited &400-1'old reduction in binihng
aflinity (-I x10 M to -410x10 M) and 'I,
1 decreased &30-
fold (from -37 to -I niin) In a specific mnbodinient, tlm
mutation v;ls D238R. In specific embodiments. the antibody
or antigen-binding fragment of the invention binds an epi tope
of hPCSK9 comprising two or nxlre of mnino acid residues at
positions 153. 159, 238 and 343.
As shown below, a mutation in amino acid residue 153, 159
or 343 resulted in about a 5- to 10-fold decrease in altinity or
similar shortening in'I', In specific embodiments, themuta-
tion ivas S153R. F.159R mid/or D343R
In some embodiments, the antibody or anti en-binding
fragment binds an epitope on hP('SK9 comprising amino
acid residue 366 of hPCSK9 (SI',Q ID NO 755). Fxpeerimen-
tal results (I'able 27) show that i&hen L366 v.as mutated. the
afiinity of niAb 300N exhibited about 50-fold dccrmisc
(-0 7x10
'
to -36x10 ') atid a sunilarshorienitig in T, s
(fmm -120 to -2 min). In a spccitic embodiment the muta-
tion is FS66K
The present inv eauon uicludes anti-PCS K 9 mitiho dies that
bind to the sanw. epitope as miy of the specific exemplary
antibodies described herein. I.ikc« i ac. I he present invi:ntmn
also includes anti-PCSK9 antibodies tlmt compete for bind-
ing to P('SK9 or a P( SKI) fragnwnt with any of the specitic
exemplary antibodies described herein.
One can easily determine whether an antibody binds to the
same cpitope as, or competes for binding will, a refi:rance
anti-PCS K9 antibody by usuig routine methods known in the
art. For example, to detemune if a test antibody binds to the
17
()S 8,062,640 B2
sanw. epitope as a rcfcrcitcc anti-P( SK9 antibody of the
invention, the reference antibody is allovved to bind to a
PCSK9 protein or peptide under saturating conditions. Next,
the ability ofa test antibody to bind to the P( SK9 molecule is
assesscxl. If the test anubody is able to bind to PCSK9 fol- I
lowing saturation binding with the reference anti-I'('SK9
antibody. It can be concluded that the test antibody binds to a
different epitope than the reference anti-PCSK') antibody. On
the other hand. if'Ihc test antibody is imt able to bind to thc
PCSK9 molecule following saturation binduig with the ref- io
erence anti-PCSK9 antibody, then the test antibody may bind
to tbc sane cpitope as ibc epitope bound by the rcl'erencc
anti-PCSK9 antibody of the invention.
To detenninc if an antibody conipetcs liir binding with a
refcrence anti-PCSK9 mtibody, tlie above-described binding i.
lllctllodolclgv Is per(on'lied ill two ollcirtutiolls: ill a first ori-
entation. tlm refi rene c antibody is allowed to bind to n P( SK9
molecule under saturatin conditions fol lowed by assessment
of binding of the test antibody to the P('SK9 molecule In a
second orientmion, the test antibody is allowed to bind to a o
PCSK9 molecule under saturating conditions followed by
as sea ament of binding of the reference antibody to the P('SK9
molecule. If. in both onentations. only the first (saturatuig)
antibody is capable ofbinding to the P('SK9 Oui le cu le. then it
is concluded that the test antibody and the rcfermicc mitibody "
compete for binding to PCSK9. As will be appreciated by a
person of ordinary skill in the art, an antibody that competes
I'or buiduig with a rel'erence antibody may not nimessanly
bind to the identical epitope as the reference antibody. but
may stcrically block binding of the relbrencc antibody by io
bnuling ut overlapping or adjacent epuope
7 vo antibodies bind to the same or overlapping epitope If
each competitively inhibi(s (blocks) bindin ol'the other ki
the antigen. That is, a I-, 5-, 10-. 20- or 100-Ibid excess of one
antibody inhibits binding of tlm other by at least 50% but
prcli:rably 75%, 90'/n or evcli 99% Bs llicasurcxi in a compeli-
uve bind uig assay (see. e g.. Junghans et al . Cancer Res. 1990
50.1495-1502). Alternatively, two antibodies have the same
epitopc Il cssentiully all 'Illlillo BIclrl lnutatlolls us tlic aatigcil
that reduce or eliminate binding of one antibody reduce or So
eliminate binding of tlm other. Tv'o antibodies have overlap-
ping epitopes if some amino acid nnitations that reduce or
eliminate binding of one antibody reduce or eliminate bind-
ing of thc other.
Additional routine experimentation (e.vg., peptide mutation 4.
and binding mialyses) can then be carried out to confirm
whether the observed lack ofbinding of the test ann body Is in
fact due to binding to the same epitope as the reference
antibody or il'teric blocking (or another phenomenon) is
responsible for the lack of observed binduig. Expenments of o
this sort can be performed using ELISA. RIA. surface plas-
mon resonnnce. 1)ow cytometry or miy other qunnutative or
quahtative antibody-binduig assay available in the art.
In a specific embodiment. the invention comprises an miti-
P( SK9 antibody or uitigen buiding fr i ment ol'an antibody I
that binds an PCS K9 protein of SL'Q ID NO:755, wherein the
binding bctwccn thc uitibody or fragnwnt thcreol'Io P('SK9
and a vanant PCSK9 proteus Is less than 50% of the buidutg
between the mitibody or fragment mid the PCSKI9 protein of
SFQ ID NO'755 In onc spceiiic mnbodiment, Ihc varinnt ci
PCSK9 protein composes at least one nuitation of a residue at
apositionsclcctcdfmmthe~voupconsistingofl53, 159,23g
and 343. In a more specific embodiment, the at least one
mutation is S153R, E159R, D23gk, and/or D343k. In
miother specitic cmbodimcnt, thc vmiant P('SK9 protein (
comprises at least one nnitation of a residue at a position
selected from the group consisting of 366. In one specific
embodiment, thc variant P('SK9 protein comprises at least
onemutationofaresidueatapositionselected fromthegroup
consisting of 147. 366 and 330. In a more specific embodi-
ment. the mutation is S147F. F366K and V330M.
Intitninocmijugatcs
The invention encompasses a lnmian anti-PCSK9 mono-
clonal antibody coil)ugated to a therapeutic moiety ('tuuu-
noconiugate'*). such as a cytotoxin. a chemothemipeutic dnig.
Bn llllltlililosiipprcasaitt ol a faifiolsot(ipc ( 1'totol" ill Bgciits
include any agent that is detnmental to cells. Examples of
suitable cytotoxin agents and chemothempeutic agents for
I'onning unmunoconjugutes are known in the art, see for
example. WO 05/1030g I.
Hispecifics
The antibodies of the present utvenuon may be monospe-
cific. bispecificb or multispeciiic. Multispccilic mAbs niay be
specific for dif1'erent epitopes of one target polypcptidc or
may contain antigen-binding domains speciiic for more than
one target polypeptide. Sew, e.g., Tutt et al (1991) J. Immu-
nol 147:60-69. The human anti-PCSK9 mAbs can be linked
to or co-expressed with another functional molecule, e.g.,
another pepude or protein. For example, an antibody or frag-
ment thereof can be fiuictionally linked (e.g., by chemical
coupling, genetic fusion, noncovalcnt association or otlmr-
w ise) to one or more other molecular entities, such as another
antibody or antibody fmgment, to produce a bispecific or a
nudtispecilic mtibody with a second buidin specilicity.
An exemplary bi-specihc antibody format that can be used
in thc cmitext of tlm premnt immntion involves tlm usc ol'a
iirst Immunoglobuhn (Ig) CI 13 domain and a second Ig CH3
domain. wherein the first and second Ig CH3 domains differ
I'rom onc anothi r by at least one nmino acid. mid wherein at
least one mnino acid dilTerence reduces binding of the bispe-
cilic antibody to Pmtein A as compared to a bi-spcciiic miti-
body lacking tfm mniim acid dilfermice. In onc mnboduucnt„
the first Ig CII3 domain binds Proteus A and the second Ig
('Hi domain contains a mutation that reduces or abolishes
Prou:in A buiding such ms un H95R modification (by IM(iT
exon numbering; H435R by EU numbering). The second
(.Hi may lhrthcr cimiprise a Y96F nmdification (by IM(iT,
Y4361'y LIU). I'urther modifications that may be found
witlfin the second (.'H3 include: l&l fil'2 LISM, N44S, K52N,
V57M, mid VS21 (by IM()T, D356F,. L35SM, N3114S,
K392N. V397M. and V4221 by LIU) in the case of lg(il
antibodies; N44S. K52N, and VS21 (IM(il': N334S. K392N,
and V4221 by LU) in the case of IgG2 antibodies: and Q15R,
N44S, K52N. V57M, k69K, L'79Q, and VS21 (by IM(il;
Q355R, N334S. K392N. V397M, R409K. E419Q, and V4221
by EU) ui the case of IgG4 antibodies. Variations on the
bi-speciiic antibody format described above are contem-
plated within the scope of the present invention.
Bioequn alents
Tlm anti-p(.SK9 antibodies and antibody fragnients of tlm
present invention encompass proteins havuig amino ncid
sequences that vary from those of the described mAbs, but
that retain tlm ability to hind human P('SK9 Such variant
niAbs mid antibody fi Igiuents compose mie or more BMi-
tions, deletiona or substitutions of amino acids when com-
pared to parent sequmtcc, but exhibit bio lotpcal activitv that is
essentially equivalent to tlmt of the described mAbs. Like-
wise, the miti-P('SK9 antibody-encoding l)NA sequmices of
the present mvention encompass sequences that compose one
or more additions, deletions, or substinuions of nucleotides
when compared to thc disclosed sequence, but tlmt encode an
anti-PCS K9 antibody or antibody fragment that is essentially
bioeqmvalent to an anti-PCSK9 mitibody or antibody frag-
19
US 8,062,640 B2
20
file&it &if tlm invention I,xamples of such variant mnino acid
and DNA sequences are discussed above.
Two antigen-binding pmte&ns. or antibodies, are consid-
ered b&oequivalent if, for example, they arc phnnnaceutical
eqiuvalents or pharmaceuncal alternutnes whose mte and s
extent of absorption do not slxiw a signiticant difference
when admnustered at the same &uotar dose under sinular
experimental condinons, either single does or multiple dose.
Smnc antibodies will bc considerext cqmvalents or phanna-
ceuncal aliernatives il they are equivalent in the extent of their ui
absorption but not ui their rate of absorption and yet may be
considered biocqui& alcnt becmisv. such differcnccs in tfm rate
ofabsorption are intennonal and are retlected &n the labeluig,
are not essential to the attainment ol'fective body drug
concemrntions on. c g, chronic usc. mxl arc considercxt medi-
cally insignificant for the particular drug product studied. In
onc mnbodinmnt, nvo antigen-binding proteins nrc
bniequivalent il'thereareno climcallymennuigful differences
in their safety, purity, and potency.
In onc mnbodimcnt, two antigen-binding proteins arc c
bioequivalent &f a patient cmi be switched one or more times
between the reference pmduct and the biological product
without an expected increase in the nsk of adverse etfectw
ll&CI&&tllilg a Cllll&CBIIV Siglllf&CBI&t CllallgC ill 11111111&ilogC&1&C&tvc
or diminished effectivmiess, as compared to continued "
tllei'Bpv'ltlioilt sucll sultcllillg.
In one embodunent, two antigen-binding proteins are
biocquivalcnt &f they both act by a coimmon macha&siam or
mecharusms of acnon for the condition or conditions of use,
to ilm cxtcnt that such mechanisms are known "&1
Bioequ&valence may be demonstrated by &n vivo md ui
vitro methods. Bioequivalence measures include, e.g., (a) an
in vivo test in humans or other mamnrals, in which ihc con-
ceimation ol the anubody or its metabolites &s measured in
blood, plasma, senim.orothcrbiologicaltluidasafimctionof "»
time, (b) an in vitro test that 1&as bc&'.n co&rclBtcd uith and is
reasonably predictive of luunan in vivo b&oavailability data;
(c) an in vivo test in lnmians or other man&mals in which the
appropnate acute pluimumological clfect of the antibody (or
its target) is measurcxt as a function of time; and (d) in a sa
well-controlled clinical trial that establislms safety, ctficacy,
or bioavailab&hty or bioequivalence of mi antibody.
Bioequivalent variants of anti-V('SK9 antibodies of the
invention may bo constructed by, f&ir cxaniple, making vari-
ous substitutions of residues or sequences or deleting temu- 4.
nal or internal residues or sequences not needed f&ir biological
activity. For example. cysteine residues not essential for bio-
logical activity can be deleted or replaced with other mnino
acids to prevent lormation of umiecessary or incorrect
intmmolecular d&sultide bnd es upon renatumstion. &i
Treatment Population
The in&cation provides therapeutic methods I'or treatuig a
hummi pauent in need of a composition of the uivention.
While modihcations in lifi.style and comentional dn&g treat-
ment are often successli&l ui reducing cholesterol levels, not s
all patients are able to achieve the reconunended target clm-
Icsterol les cia with such approaclms Various cmiditions, such
as tiunilial hypercholesterolemu& (I'l). appear to be resistmit
to lovvering of LDI,-('evels in spite of aggressive use of
COIIVCO&i&)liat tl'&claps'ol&loaug&&US Slid l&CICI'Oaygoua f'tilt&i" 60
ial hypercholesterolemia (hol'll, hept lj is a condition asso-
ciated u ith prenu&ture athemsclerotic vascular disease. How-
ever. patients diagnosed v;ith hol'I I are lar ely unresponsive
to conventional dn&g therapy and have limited treatment
options. Specifically, treatmenr v,ith statins. which reduce r
LDL-(.'y &nlubiting cholesterol synthesis and upregulat&ng
the hepatic LDL receptor, may have little effect in patients
whuse I.DI receptors arc non-existent or defective A mean
I.DI,-('eduction of only less than about 20% has been
recently reported in patients with genot)pe-confirmed hoFII
treated with thc maximal dose ol'tauns The addiumi of
erctimibc 10 &ugrday to this rcguncn resulted in a total rntnc-
tion of LDL-C levels of 27%. which is still far from optimal.
Likeiv&se. niany patients me stat&a non-responsive. poorly
comrof led with status therapy, or cannot tolerate stat&n
tlmnpy: in gmieral, these patients nrc unablc to achieve. cho-
lesterol control with alternative treatments. There is a large
unmet medical need for new treatments thut can address the
short-cmuings ol'current treatment opti&ms
Specific populations treatable by the therapeutic methods
of the invention include patients indicated for LDL spheres is,
subjects with PCSK9-activating (C&OF) mutations. heterozy-
gous Fmnilial Hypcrcfxilestcrolcmin (hcl H), subjects v;i&h
primary hypercholesterulemia who are statin intoler&nt or
statin uncontrolled; and sub lee ts at nsk for developing hyper-
cholesterolenua u ho may be preventably treated
Therapeutic Admuiistration and Formulations
The invention provides therapeutic compositions compris-
uig the anti-PCSK9 antibodies or mitigen-binding frag&Beats
thereof ol the present invennon. The admirustrat&on of thens-
peutic compositions in accordance with thc invention will bc
administered ivith suitable m&rrier:, excipicnts, and other
agents that are incorporated into tiirmulations to provide
improved transfer, delivery, tolerance, and Q&e like A muhi-
tude of appropriate formulations min be fouixl in the formu-
lary I nown to all phamiaceutical chemists: Kensington's
Plmrmaceutical Sciences, Mack Publislung Compnny, Eas-
ton. Pa. These formulations include, for exumple. powders,
pasteu ointments. jellies, waxes. oils. Iipids, lipid (cationic or
anionic) containing vesicles (suet& as LIVOFBCTIN'"). DNA
conjugates, anhydrous absorption pastes, oil-in-water and
water-ui-oil ennilsions. emulsions carbo&vax (polyethylene
glycols of various rnolccultm umights). semi-solid gals, and
semi-solid mixturn containing carbowax. Scen also Powdl et
al. "Compendium of excipients for parenteral fomn&lations"
PDA (199g) .I Phann Sci Teclmol 52:238-311.
Thc dose may vary depending upon ihc age and thc sixr ol'
subject to be administered, target disease. conditions, route
of administration, and die like When ilm antibody of the
present invention &s used fiir treating various conditions and
diseases associated with V('SK9, including hypercholester-
olenu«. disorders associated u.ith LDL and apolipoproteui B,
and lipid metabolism disorders, and the like. in an adult
patient. &t is advmtageous to intravenously administer the
amibody of the present in~ention normally at a suigle dose of
about 0.01 to about 20 mJokg body weight, more preferably
about 0 02 to abm&t 7, about 0 03 to about 5, or about 0.0& to
about 3 mg'kg body weight. Depending on the seventy of the
condition, the frequency and tlm duration of the treatment cmi
be adlusted
Various delivery systems are known and can be used to
administer thc phannaccutical composition of tlm imvntion,
e.g, encapsulation in hposomes. micropart&cles, microcap-
sules, recombinant cells capable of expressing Cie nnuant
&'iruses, receptor &ncdiatcxt endocytosis (ser. e.g, Wu et al.
(1987) J. Biol. Chem. 262:4429-4432). Methods of introduc-
tion include, but are nor limited to, intradcnnnl. intnnn&scu-
lar, intraperitoneal, intnsvenous, subcutaneous. uitnnasal,
epidural, and oral routes. The composition may be adminis-
tered by any convenient room, for cxnmple by infusion or
bolus intection. by absorpuon tluough epithelial or mucocu-
tancx&us lininvgs (e.g., oral mucosa. rectal and intestinal
21
(jS 8,062,640 B2
22
mucosa, ctc ) an&1 nuiy be administered togetlmr v ith other
biologically active agents. Adnunistmtion can be systemic or
local.
The phnmmceutical con&position can bc also dclivcrcd in a
vesicle. in particular a hposome (see Laager (1990) Science s
249:1527-1533; Treat et al. (1989) in Liposomes in the
Thenipy ol'Inlhctious Disease and Cancer, I.opez Berestem
and Fidler (eds.). Liss. Neiv York, pp. 353-365; Lopez-Ber-
estein, ibid., pp 317-327, scc gcncrally ibid ).
In certaui situations. the pharill'iceililctll colilposltliiil call l(1
be delivered in a controlled release system. In one embodi-
nicn( a pump may bc usexi (sei: I anger, suprm Scfton (1987)
CRC Cnt Ref. Biomed. Fng. 14:201). In another embodi-
nwnt, polymeric materials can bc uvmd, scc. Medical Appli-
mitions of C'ontrolled Release, I anger and Wise (eds ).('RC'res,
Boca Raton. Fla. (1974). In yet another embodiment. a
controlled release system can bc placed in proximity of thc
composition's target. linis requiring only a fraction of the
systemic dose (see. e.g., Cioodson, in Medical Applications of
Coturollcxi Relmism. supra. vol 2. pp 115-138, 1984) c
The mjectable prepm stions may include dosage forms for
intravenous. subcutaneous. intmcuts ncv&us and intramuscular
ugecuons. dnp inliisions, etc. These in)actable preparations
may be prepared by methods publicly known. For example,
the injcctable preparations may be prcparcxI, e.g, by dissolv- "
ui . suspending or emulsifyuig the antibody or its salt
described above in a sterile aqueous medimn or an oily
mad&un& comuntionally used lier injections. As the aquas&us
medium for injections, there are, for example. physiolo ical
saliim, an isotonic solution contnining glucose and other aux- ia
dian agents, etc., i& luch inay be used in combination i& ith an
appropnate sofubilizing agent such as an alcohol (e.g.. etha-
nol), a polyalcohol (c.g, propylene glycol, polycthylenc gly-
col), a nonionic surfactant [e.g.. polysorbate 80, IICO-50
(polyoxyethylene (50 moll adduct of hydrogenated castor "»
oil)j, ctc As thc oily tucxliutn, there arc employed, e.g.
sesame oil, soybean oil, etc., wluch may be used in combina-
tionn
with a sulu b il izing agent such as bmizy I ben&nate, bcnzy1
alcohol. ctc Thc injection thus prcparcd is preferably filled in
an appmpriate ampoule. A pharmaceutical composition of sc
the present invention can bc ddivered subcutaneously or
intravenously with a standard needle and synnge. In addition,
with respect to subcutmieous delivery. a pen delivery device
readily has applications in delivering a phamiacoutical com-
position of the present invention. Such a pen delivery device 45
can be reusable or disposable. A reusable pen delivery device
genemlly utdizes a replaceable cartridge that contains a phar-
maceutical composition. Once all of the pharmaceutical com-
position within the cartriilge hav been admimsterexi and the
cartridge is empty, the empty cartndge can readily be dis- c
carded and replaced vvith a new cartridge thar contains the
pharmaceutimal composition Thc pen debvery decvice can
then be reused. )ca disposable pen delivery device, there is no
replaceable cartridge. Rather, the disposablc pcn deli&wry
device comes preiilled ivith the phamiaceutical composition s
held in a reservoir within the device. Once the reservoir is
mnpiicd of the plmrmaceutical composition. the entire dev icc
is discarded
Numerous reusable pmi and autoittjector delivery devices
have applications in tlm subcutaneous dclivcry of a pbarma- ui
ceutical composition of the present mvention. L'xamples
include, but cenainly arc not liniitcd to AUTOPFNi" (Ow en
Mumford, Inc.. Woodstock, UK). DISETRONIC™ pen (Dis-
etronic Medical Systems. Burghdori', Switzerland), HUivlA-
I,O(i MIX 75/25'™ pen. Hl JMAI,O(ir" pen. HUMAI.IN (
70i30'i'i pen (Lih Lilly and Co., Indianapolis, Ind.).
NOVO PL'Nvu I, 11 and ill (Novo N ordisk, ('openhagen, Den-
mark), NOVOPFN.JIJNIOR™(Novo Nordisk,(.'openhagen,
Demnark), BD'w pen (Becton Dickinson. Franklin I.akes,
N J) OPTIPL&I&FM OPIIPLN PROru OI&TII&LN STAR
I,FT'", and OPTICLIK&" (smmli-aventig Frank('imt. Cicr-
nimiy), ui usmc only a li:w Fxmnples of disposabic pcn
delivery devices having applications ui subcutaneous deliv-
ery of a plmimiaceutical composition of the present in~ention
include. but ci:rtiunly are not hmitcd io thc SOI,OSTAR™
pen (sanofi-avetitis). the FLBXPLN™ (Novo Nordisk), and
tlm KWIKPFNrw (Fli I illy)
Advantageously, the pharmaceutical compos iumis I'r oral
or parmiteral use described above are prepared into dosage
forms in a unit dose suited to fit a dose of thc active ingredi-
ents. Such dosage fonna ui a unit dose include, liir ex unple,
tablets, pills, capsules, injections (mnpoules), suppositories,
ctc. Thc amount of the aforesaid mitibody contained is gen-
emlly about 5 to about 500 mg per dosage form in a unit dose;
especially in the form of injection, it is preferred that the
aforesaid antibody is contained in about 5 to about 100 mg
and in about 10 to about 250 mg for tire other dosage fonna.
I'he invention provides therapeutic nmthods in which the
annbody or antibody fragment of the invention is useful to
treat hypercholesterolemia associated with a variety of con-
diiions involvmg hPCSK9 The uui-PC'SK9 untibixhes or
annbody fragments of the invention are particularly use ii&1 for
the trmitmont of hypercholcsterolemia and tlm like I'ombi-
nation therapies may uiclude the mui-PCSK9 antibody of the
lllvelltioil wltll. for exailllple, olla ol'lloi'e ofall&'&guilt tllat (I )
induces a cellular depletion ol'cholesterol symhcsis by inhib-
iting 3-hydroxy-3-methylgluuiryl (IIMCJ)-coenzyme A
(C oA) rixiuctase. such as cerivastatin, atorvastatin, simvasta-
un. piiavastatin, n&suvastniin, Iluvaitatin. Iovastatin, pravav-
tatin: (2) ialubits cholesteml uptake and or bde acid re-ab-
sorption; (3) increase lipoprotein catabolism (such as niacin);
and activmors ol'the I XR transcnption factor ihat plays n role
in cholesterol elimination such as 22-hydroxycholesterol or
fixed combinations such as crctiniibe plus simvastatin, a sta-
tin with a bile resui (e.g.. cholestymnune. colestipol,
col asevelam), a lixed combination ofniacin plus a sta tin (e g.,
niacin with lovastatin), or with other lipid lowering agents
such as omega-3-fatty acid ethyl eaters (for example, oma-
cor).
BXAMI'LHS
The fo1 low invg examples are put forth so as to provide those
oi'ordiniuy skill in the an wuh a cmnplcic disclosure aixl
description of how to make and use the methods and compo-
sitions of the invention, and are not intended to linut the scope
ol'what the inventors regard as their invenuon. Ffliir(v have
been made to ensure accuracy with respect to numbers used
but sonw. experimental em&ra mid deviations should bc
accounted for. IJnless indicated otherwisc, nx&lunular weiglu
is average molecular weight, temperature is in degrees Cen-
tigrade.. mul pressure is at or near atmosphi:ric
Fxmnplc I
Cieneration of Human Antibodies to Human P('SK9
VBLOCIMMUNInu mice were unmunized with human
P('SK9. and tlm antibody inuuune response monitored by
ami en-spec&lie inununoassay usuig serum obtauied from
these mice. Anti-l&PCSK9 expressing B cells were harvested
from thc splcens of inmiunized mice shown to have elevated
anti-hPCSK9 antibody titers were fused with mouse
myeloma cells to form hybridomas. The hybridomas w ere
23
US 8,062,640 B2
24
Example 2
Ciene I)tiitzaunn Analysis
To analyze the structure of the mAbs pmduced. the nucleic
acids encoding antibody variable regions v;ere cloned and
sequenced. I'he predicted amino acid sequences of the van-
able regions werc confirmed by N-tcimuial amino acid
sequencin . I'rom the nucleic acid sequence and predicted
an&inn acid sequence of the n&Abs, gene usage was idcntitied
I'or each antibody chain.
'IABLli I
H &( Ct).un Llvdlt t.h (n(
Vni&blc Kccon
screened mid selectucd to identify cell lines expressing
hPC'SK9-specific antibodies using essays as described below
The assays identified several cell lmes that pmduced chuneric
miu-hPCSK9 mitibodies designated ms HIM300. IIIM504,
HJM505, HJM500. H I M497, HJM49g, HI M494, HI M309.
0 I M312. HJM499. HJM493. HJM496, HIM503, HIM502,
HIM50g. HIM495 and HIM492.
Iiuman PC'SK9-specific antibodies werc also isolated
directly from antigen-immuiuzed B cells lvithnut fiision to
myeloma cells, as described in HS 2007/0230945AJ,
hereby incorporated by refi.rance in its entirety i leavy aml
light chain vanable regions were cloned to generate fiilly
humnn anti-hPC.'SK9 antibodies designated as HIH313.
HJH314. HJII315. 11111316, HHD17, H11131g. HJIL320,
HJH321 mid HJH334. Stable recombinant antibody-express-
ing C'HO cell lines expressing thcsc antibodies were estab-
lished.
37
cunt)body Kn T,, Kr, T&
HJM300
HIM&U9
HIM)l
kl I M493
"0
HIM494
HIM4(Js
lll M496
HI M49,
0 I M498
H I M499
H I vis(s)
HIM.
u'IM
01
"0
HIM. 04
HI VISO
HI M su 8
0 I M. 1(i
lm
9J
0"
46 .
870
440
2 4
20 I
64(lu
106
14(ln
78 3
3470
2740
I i8
1070
17&(
7461
l. 68
49 I
114
1
Snl
3i(
20
91
9.'lb
118
72
1510 '!2
7 6
4'12 392
2. 341
7510 19
4 I lib
48(l 29((
7. 00 14
8. 316
601(l
411 151
1889 10
11200 6
9 ou 6
442 110
3960 lu
T100) Fach antibody was captured at a flov rate of 4 pl/niin
for 90 scc on a goat miti-mouse IgCi polyclonnl antibody
surface created thn&ago direct chenucal coupling to a BIA-
CORFT&'hip K& form a captured antibody burl&ace lhiman
PCSK9-myc-myc-his (hPC'SK9-mmh) at 0 c&mcentrationl0
nM or 12.5 HM was Injected over the captured antibody
surfaces at a flowmte of 50 pl/min for 300 sec, and mitigen-
antibody dissociatinn w ns moiutored lbr 15 mui at either2'0
CL or 37'L (Kr&=pM, T, a=min)
TABLL'
.'Unihod& VH D HI vK JK
3-13 I- 6
3 3-3
.'-. 3 3-3
.13 .')7
.'-13 1-26
4-59 3-lu
1-18 2-2
7-5 1-7
2-5 6-6
3-7 2-8
3-3(J 2-8
3-30 2-8
H313
HIH'14
HIH31
HIH316
01031"
010318
HIH lzu
HIH'1st
HIH&3'l
Minn
HIM 04
HIM 0
HIM (Jn
HI I 1497
III lv1498
HI M4'l4
Hi lvllnu
III lvl I I ."
HI M499
HI M493
H I lv1496
Huvl (J
Hll mu&
HIM(nfl
HI M49
HH1492
1-18
3 11
613
321 613
3-21 6.1&
.21 6-13
-13 6-19
1-18
.I 6-13
.'-ll 6-13
3-9 4.11
.1-23 3-3
3-15
I-&
4-1
4-1
16
19
- (( I
1.
7.
15
3 20
I-
I-
i-is
3-15
3-1.
1-9
3
Example 3
Antigen Binding Affinity Determination
Equilibrium dissociation constants (K„) for hi'I'SK9 bind-
ing, to mAbs genemted by hybridomn cell lines described
abnve were deternuned by surface lonetics in 0 real-time
biosensor surface plasmon resonance assay (BIAC'ORE'u
TABLE 3
snnhod&
60
HIH3131'111714P
Hlllll&P
HIH316P
Hlu'117P
HIH318P
HIH'2UP
HIH 21P
HIH" 4P
Pv T( Kv T
&
244
3990 65
129 151
377 I
30406 137
771 28
Sb& lub
37 0 46
(w)
3560
luau
I I'660
169U
1930
36U
159no
6(J
43
:)
70
28
8
2'issociation
mate (kd) of selected nu«bs for tagged rhesus
monkey (,Maraca ma/a/a) PCSK9 (nunPCSK9: SEQ JD
NO 756) (mnlPC'SK9-lilillh) dt 25 C was di:Iclmlllud ms
described above.
I'iquilibrium dissociation constants (Kn) for hPC'SK9 bind-
ing to nukbs genemited via direct isolation of splenocytes
v'ere dctemiincd by surfncc kinetics in a rmd-time binscnsor
surface plasmon resonance assay (BIAC:ORETC T100) Fdch
4()
selected antibody was captured at a flowmte of 2 )d)min for 6
llllll oil 8 godt &itltl-llillllatl I' pol)'cloll'll iulllbo&13'urface
created timon/I direct chemical coupluig to a BIACOREnu
chip tn fi&mi a captured antibody surl'acc Hunmn PCSK9-
45 mnth at a concentration of 50 nM or 12.5 OM was inlected
over the capnired antibody surface at a flow rate of 70 ul/min
Iior 5 niin, and antigen-nntibody dissnciatimi was ninnitored
for 15 min at either 25'L or 37''Km=PM; Ti:I'llhl).
25
TABLLI 4
(jS 8,062,640 B2
26
TABLL'
Anil hod
'IH
I P
HIH lt!P
HIH334P
H)031 P
HIH316P
HI H."AP
H1(vl'll 0
HI Mi()4
H)M497
H)M(li"
Il I M496
bt (I l)
. 9' 10
3 69 x 10
tl A6 x 10
'(n
, 9,1(n ')71(i"
I (2 x 10 "
i()4x 10
6 6)i x In-'
7'I x 10
44 Hn
T,,(m n)
'26
3
I
51
51
36
76
17(
147
26(
olin enn
hPCSK9-mmh
10 nn)PCSKJ nil)i)In
hPCSK9(D )47Y)-mmh
in)P('SK9-nnnh
nniaPCSK9-ti
(PCSK9-inn))8
0 I'Iten(:il '. C
I "60
446(n
249il
1420
m(A
410(n
16 27
1(J 6"
15 166
4) 8
tl
8'49
3(i(JN
Kr, 'I
UJ KJJ
316P
'lv
ll
13
Fxnmplc 4
Effect of pl I on Anti en Binding Affinity
Tbe elTamts of pH on Imtigen binding affinity fir CHO
cell-produced fully inmlan anti-hVCSK9 nLAbs was assessed
as described above. The mAbs tested are fully human ver-
sions of 1110316P ('316P") (HCYR/LCYR SEQ ID NO:
90/92: C:DR sequcnccs SFQ ID NO'6/78/80 and 84!86/88)
and Ei I M300N ('300N") (I ICYR/LCYR SL'Q ID NO: 218i
22(i: CI)R sequences Sl Q ID NO 220/222/224 and 228/230/
232). Ihululn PCSK9-myc-myc-his (hPC'.SK9-mmh) i(as
capnired on an anti-myc mAb surface either at a high density
(about 35 to 45 resonance units) (RU) or at a low density
(about 5 to i 4 I&U). Loch antibody. At 50 nM in I IB ST (pl I 7.4
or pH 5.5) v'as intjamtcd over thc captured hPC'SK9 surface ot
a flow mtc of 100 ul/nil liir 1.5 min at 25''nd antigcn-
antlbody dissociation was monitored for 10 min. I'ontrol E
anu-hPCSK9 BLAb SEQ ID NO: 79/101 (WO 2008i063382)
(Ko pM: Tn olin),
TABLE 5
hPt:(Ke mmh
mPC'(K.) mmh
hPt (Kvlm)47Y) mmh
nntPCSK9) nnnh
nniaP( (Kv.ln
(PC"SK9-mnih
"0
tiPCSK9-lnnnh
ni)PCSK9.)ill)it)
hPt (Kv(D347Y) mmh
liltPC SKA in(ill)
nnaPCSK9-ti
(P& SK9 mmh
hPCSK9-nnnh
mPCSK9-mmh"0
hPCSKU(D347(') inmh
nnfPCSK9-mnnh
nniaP(. SK9-ln
i'P ( S K 9 i)i)i)1)
1)0(n
NB
13)nl
17))
NB
NB
76
XB NB
46 W)IU
ll ')8(0(n
NB NB
NB NB
Contin) I
NB
04
NB
NB
3')fan
NB
7100)l
36200)n
NB
NB
14 174)
NB NB
Il 73 U
ln 2 67 A(n
NB NB
ma NB
Con(no) 0
.'
NB
30
3
NB
NB
143 66
; (xl I I
191 Ll5
lf)2 6.
6 fal 3
24( nl 2
212
3" I
4(J 56
12 6.
ND:VD
10(
TABE.I/ 7
H L'tram at IT C
)tish hPCSK9 Lo) hPCSK9
Den)ann'I Sin(ra('n IT„K», T, J
Antihodv Kn T,J Ko T,J Ko T,i Kn T,a
316 P 191 74 144 83 ".9 45 188 8
30nN 6 ()7 1180 26 31)n IJ(J I'!SA 13
ronnoll zl)000 29 ND ND ND ND ND ND
Thc antigen binding properties of31 6P mid 300N at pH 7 4
or pH 5.5 were determined by a modified BIACORE'm assay (J
as described above. Bnetly. nLAbs w ere lmmoblhzed onto
BIACORET"CM5 sensor chips vio omule couplulg. Muying
concentrations of myc-myc-lus tagged hPCSK9. mouse
PC'SK9 (mPC'SK9. SFQ ID NO 757), hPCSK9 with a uain of
function (CiOI') point nnitation ofD374Y(hPCSK9(D374Y), 5
cynomolgus monkey (fhfaca(a fasciml/aris) VCSK9 (mf-
PC'SK9, SFQ ID NC3:761) (mlPC'SK9), rat (Rartar narvegn-
«us) PCSK9 (rPCSK9. SI',Q ID NO 763), aud lui-tagged
Syrian golden hamster (Mcsacricctur (iiiratas) VC SK9
(maPC'SK9, SFQ ID NO:762) (nmPCSK9), rmlgulg Irom 11 m)
to 100 BM, were Injected over the antibody surface at the flov;
rote of 100 pl/ml fi)r 1.5 min mid antigen-antibody dissocin-
uon was momtored In real time for 5 nun at either 25'.
(I'able 6) or 37" C. (Table 7). Control IE anti hpt'SK9 nLAbs
Si Q ID NO:67/12 (WO 2009!026558) (NB: no binding was 0
observed under the expenmental condition) (K„pM:
T, 2
—min).
hPCSK9-nnmh
nn)PCSK9.)linn))i
hPt SK9(D347Y)inmh
m(PC.SKAJ mmh
nnaPC.'(K'J h
(P&.SK9 nanh
hPCSKJ-nmih
)))Pc S K9.)flin)In
hPCSK9(D347Y)-faint(
)AIPCSK J inn)f1)n
nn(aPC)K9 h
)PCSKU-inn)ilk
hPCSK9 mmh
nim:SK9-nnnh
hPCSK9(D347Y)-(nmh
nn)IPCSK9.)inn)i)i
nnnaPCSK9-tn
(PCSK9
hPCSKA mmh
inPC (K9 nnnh
hP('SK9(D)47Yi-nnnh
mtPC SKA-nnmh
4(JA)n
11200
666n
3770
17GI)
5'(100
3169
9 142
3 1360(n
4 1560
Il
XD
399
3A(JN
ll
3
ND
I
2470
NB
261()
48)(n
NB
NB
I
NB
I
U. I
NB
NB
4 90)l
NB
169Ufifl
((J(JA(n
NB
NB
(n I 11'100
NB NB
nl 4 „,(loin
li 6 (36)n
NB NB
NB NB
Control 0
NB
XB
84 87
86tlo 3
2(1 (7
ISA I 7
zfn
m 3
48" 26
I-I 6(
1190(n
NB NB
14 280(n(n
8 6
813 NB
NB NB
('on(in) I
27
US 8,062,640 B2
28
in&PCSK9-t&
IPC'5K90-In(ah
TABLL'-l:oirtltllied
it Et'teer.n
&7''o
'I Ko 'I
8830 0.5 t D VD
0 00 I 33 1
Fx&itnp le 5
using BIACORE™3000. Briefiy, nnti-hP('SK9 mAbs were
captured on an anti-hl'c surface created tlu ough direct chemi-
calcouplingtoaBIACORE "chip.fh&rifiedtaggedlfl'CSK9,
hP( SK9(D374Y), mmPCSK9, mfPCSK9, mPCSK9,
5 maPCSK9. or rPCSK9, each at 1.56 nM to 50 nM. was
in)ected over the antibody surface at either 25" (2 or 37" (2
Bindu&g between 316P. 300N, Control I. Control II. or Con-
trol III and the PCSK9 prote&ns was determined (Ko pM;
T, & mm) (ND &mt dctermu&cd).
10
TABLE 9
316P mAh
Anti-hP('SK9 mAbs Binding to hp('SK9 with Point
Mutation D374Y 5
11&e binding affinity of selected anti-hP( SK9 mAbs to
hP('SK9 with a gain of function ((iOF) point mutation of
D374Y &hp('SK9(D374Y)-nunh) was determined as
dcscribcd above. Each antibody was captured at a Ilowrate of
40 pl/min for 8-30 sec on 0 goat anti-human Ig(i polyclonal
antibody surface created through direct chemicnl coupling to
a BIA('ORLv" chip to form a captured antibody surface.
hP( SK9(D374Y)-mmh at varying concentrations of I 7g nM
to 100 nM was injected over thc captured antibody surface at
a flo&vram of 50 ul/min fi&r 5 n&in, and tlm dissociation of
hP('SK9(D374Y)-nunh and antibody was mnnitored for 15
min at 25" C. ('.ontrol lib anti-ld'CSK&J nhAbs SFQ ID
NO.49/23 (WO 2009/02055K) (Kn=pM; T, a=min)
Ant Set&
hPCSK9 mrnh
hPt 500)i m&74Y) mmh
&nmPCSK9 mtnh
mfPC')K9 tomh
mP( SK9-nnnh
m&PCSK9-h
&PCSK't-nnnh
Ko Ti, Kr T,e
lt&00 9 58(l &6
420() 4 169(t
18&lf& I I& 9
18(&I 11 5 "0 60
47tio 23&m 11
19000 I 6810
500 I &4&0()
TABI,F, 10
30(IV It) &h
7'C
TABLL& g "0
At&t'I en Ko I, Eo I,,
&ritihnd)
16P
I (1 &N
Coon ni I
Contr ni II
Cont(a) I I I
Ko
17ul
lli6(&
236(l)
66
10
14
49
2(
2&6
126
hP('SK9-nnnh
hP('SE9tD 74Yprmnh
mn&PCSK9-n&mh
mfP('SK9-nnnh
tt&PCSK9.&&III&h
rn&!'CSK9-h
IPCSK9-nnnh
24flt& 2 740 ll(l
ron 14 9oc 65
16oc 26 610 7)
&8oa 11 I (n& 45
N13 NB VB VB
NB Nli Nu VB
VB NB VB VB
Fxample 6
Binding Specificity ofAnti-hPCSK9 mAbs
31tiP. 300N. and ('ontrol I anti-hP('SK9 n&Abs uvre cap-
t()roti otl 0&1& amine-coupled anti-l&pc ('M5 chip on BIA-
('ORE&u2000 faggix) (myc-myc-his) lnunan P(.'SK9,
luunan PCS K I
(1&P('SKI 
) (SFQ ID NO:759)). human PCSK7
(hP(.SK7)(SI)QIDNO:760).ormouse P('SK9 were injcctcd
(100 nM) over the captured mAb surface and allowed to bind
at 25' fiir 5 min ('hm&gcs in RIJ ivere recorded. Results
300N and Control I boiu&d only to hP(.:SK9, and 31&ip bound
bod& hPCSK9 and mp('SK9
ll&e binding speciticities of m&ti-hP('SK9 mAbs were
dctermincd by FI.ISA Brieflyr alai-hp('SK9 antibody was
coated on a 9&&-well plate. Human PCSK9-mmh, mPCSK9-
nuuh, maP('SK9-h. hPCSK l-mmh, or hP('SK7 mmh. at I 2
nM, were added to antibody-coated plates and incubated at
RT I'or I hr Plate-hound PCSK protein was then detected by
HRP-conjugated anti-His antibody Results show that 31(&P
binds human. n&ouse, and hamster P( SK9, whereas 300N and
( ontrol I imly bound hP( SK9 None of the m&ti-hp( SK9
mAbs exhibited significam binding to hPCSK I or hP(. SK7
L'xample 7
Cross-Reactivity ofAnti-hl'('SK9 nukbs
Cross-react&vity of ant&-hPCSK9 n&Abs with mmPCSK9.
mfl'CSKB), ml'CSK9,maPCSK9, orrP('SK9was determined
Atn&se &
hPt:SK9-rrnnh
hPt:SK9(nn&4YI-rnmh
tt&tnPCSK9.Intr&h
rr&ll'CSK9-rrnnh
tnPt SK9 mmh
m&PCSK9 h
rPCBK9 mmh
&0
An't Sen
hPCSK9 mmh
hP('SK9(D3 4Y) mmh
m (PC SKsr nnnh
mPt SK9 rnmh
&n&P('SK9 h
6 IPCSK9-nin&h
TABI/E 11
0 ontrol I mAh
&7 C
Kr, To Kt
72600(&
VD
4 tx&of&
14)fio
NR
NR
NR
27 fio 16
VD 13600
9&of)0
ill 49flf& 14
VR NB VR
NB VR
VR NB NR
TABLL'2
t.ornrol II rt&Ah
&7'
Ko T&, Ko T&,
91 16. 6&
93 90 66 2&6
&3 'lir 54(
47(&) & 2&00 i)
60stio 0 4 210&m 2
14&t&0 1 6900
US 8,062,640 B2
hnt( ett
hPCsK9 )tltlth
hPCSK9(D37491-nunit
)I) IPi 5 K 9 -)tt)trit
mPC'5 K9-mmh
maPC"SK')-h
iPCBK9-mmh
29
TABLL 13
0 el)( t ) I HI fr( it
37'
Kn 'I,,
380 378
130 660
11)) 750
3300 I
780 lf)7
iau HB
490
I AA(l
'40
109(X)
Alia)
450
126
10
67
5''
Kn 'I,)
30
pre-mixed with varied mnounts of antibody, ranging from 0 ro
—50 nM in serial dilutionx followixI by I hr incubation at
mom temperature (RT) to ulfoiv antibody-antigen bindin to
reach cquilibriiun The equilibrated santple solutimis were
tcuthsferrLXI to rcccT)tor or rcvcptor fragment coated plates.
After I hour of binding. the plates were washed and boiuid
hPCSK9-mnih detected using I IRP con)ugated anti-myc anti-
body 1(.,„values (in pM) were dctemiitted as ihe amount of
mtibody required t(i achieve 50% relhicuon ol'PCSK9-
nunh bound to the plate-coated recepuir or receptor fragment.
The results show that specitic mAbs functionally block
PCSK9 I'rom binding the three reccptors at both neutral pH
(7.2) and acidic pH (5.5).
TABI,F, 14
pit
'I „ pkl 5.5
Plate ('oatut surface
hh hLDI K- cto I C I-X BOP-XB hl DLK-ecto hok-.h POP9XB
316 P
),AH
Control I
( o)tt)ol u
t:ontml ul
I.
144
288
3ti
e125 e125
146 e12
IAA,AAA .100,ufla
51A 274
e125
1492
411
7-12
el e 1st
53tl 447
e100 uaf alao (IAA
50S
78 1073
L'xample 8
inhibition of Binding Betw(mn hPCSK9 and hLDLR
Domains
The ability of selected anti-hPCSK9 mAbs to bkmk
hPC'SK9 binding to human I DI.R fiill length cxtnccllular
domain (hLDLR-ecto SL'Q ID NO:758), hLDLR I'GILA
domain (anuno acids 313-355 of SL'Q ID NO:758). or
hi DI R IACr'F-AB domains (amino acids of 314 393 ol'SEQ
ID NO:758) (LDLR Cienbank number NM 000527) was
evaluated using BIACORl '" 3000. Brietlyr hLDLR-ecto.
EGF-A-hpc, or EC)lmAB-hFc pmtein was amuie-coupled on
a I M5 chip to create a rcccmptor or receptor fragment surface
Selected anti-hPC:SK9 mAbs, at 62.5 nM (2.5 fold excess
over antigen). v ere premixed with 25 nlvi of hpCSK9 mndi,
I'ollowed by 40 mtn incubutiou at 25' to alloiv mitibody-
antigen binding to reach equilibrium to form equilibrated
solutiions The equilibrated solutions were injected over thc
receptor or receptor fragtuent surfaces at 2 tti(min for 40 nun
at 25" C. I'lianges in RU due to the binding of the anti-
hPC'SK9 mAbs 10 hI,DI.R-Ceto FGF-A-hFc. or FC1F-AB-
hkc v;ere determined. Results sluiii that HIH316V and
HI M300N blocked the binding ofhl'I'SK9-nunh to hLDLR-
ecto. hLDLR Efil'-A domaui. and hLDLR EGF-AB
domains; H111320V blocked the bindinoo of hl'C'S K9-mnih to
hI,DI,R-ceto and hl DI,R FCiF-A domain, and HHD21P
blocked the bindutg of hPCSK9-mmh to hLDLR EGImA
dtinl'IJB.
The ability of the mAbs to block hPCSK9 bulding to
hLDI,R-ecto. hLDLR kXiF-A domain, or hI.DI R I.ikik-AB
domains was also eialuatcd with an FI,ISA-based iluitlu-
noassay. Briefly. hLDLR-ecto, hLDLR L'Lilt-A-hpc or
hf,l)I.R Ftil'LAB-hFc. each at 2 pglml. was cuated on 0
96-v;ell plate in PBS buffer overnight at 4'., and nonspe-
citic binding sires blocked with BSA. Tlus plate was used to
measure free hPC'SK()-mmh in a Pf SK9-mmh solution pre-
equilibrated with varying concentrations of anti-hPCSK9
mAbs. A constmit amount of hVCSK9-nunh (500 plkl) was
The ability of the nuhbs to block hl'I'SK9 CiOF nuitant
IIVC'SK9(D374Y)-mmh binding to hLDLR Hik-A domain
or hLDLR EGF-AB domain (ICs„values in pM) was also
30 evaluated with the I')LISA-based inununoassay described
above using a constant amoiuit of0 05 nM IIPCSK 9(D374Y)-
liliull
TABLE 15
pH 72 pH
I'laic Coatui Sm tace
Ink ri krrriu I-Cka PCPau
316P
4t) Alm
Contml I
Coatml 0
Contmi ut
703
135
: I At),l)0(i
72
537
I 9
142
100„0 nl
57
427
11
3463
- ion.onn
I 9
803
1132
3(7
: lof)2)AA
118
692
The ability of the mAbs to block either mmPCSK9 or
mVCSK9 binding to hI,DLR-cecto domain, hI,DI R kCiF-A
domaui. or hLDI.R EGF-AB domain (ICsn values in pM) was
evaluated at neutral pH (7.2) ivith the ELISA-based immu-
noassay descnbe above using a constant iunount of' nM ol'
mndi-tagged mmPCSK9 or I BM ofmPCSK9.
TABI.E 16
I nhl )tnt(PCSK9-mph I )tht lt)P(. 5K9.)tt)tth
hLDLK-wlo huk-.s kol -XB huk-X h(ik-.su
31 6P :" 0 250
AAH 25 2 6 20 r ii))fu) ci3ta)0
Bi Thc ability ol'lm mAbs to block hPCSK9, mmP(.SK9,
rl'('SK9, maVCSK9, mIPCSK9, or mVCSK9 binding to
I'l DI R Hrl' doma'0'I (I( o values in PM) was evaluated nt
neutral pl I (7.2) (Table 17) acidic pH (5.5, Table 18) u 1th the
k L IS A-based inumuioa as ay described above using a constant
amoum of 0.5 nM of hP( SK9-mmh, I nM of mrnPCSK9-
nunh. I BM of rPC SK9-mmh. I nM ofmaPCSK9-h, 0. 3 BM
ofmil'I'SK9-mndi, or I nM of ml'k:SK9-nmdi.
31
TABLL'7
US 8,062,640 B2
32
hPCSK9 mrnPCSK9 (PCSK9 mnPCSK9 n(IPt:SK9 n(PCSK9
316P cl " 0 2662 349 3(J
UUN
Coiitr 11
Contml 0
C ntml uk
It!2
146
29 . 1!JUUUU 24) 672 -1(JOUUU
46(. clUO(!00 r IU(000 473 clUOUUU
: lonr in(i c lrliooii r lriiiiioo nit nr in(i c lrliioori
81 2)". 2038 361 86
TABLL'b
SP&:)K9 rnniPC)K9 rPC.SKO mePCSK! mP( SK9
16P
3((UN
Contml I
Coniiot 0
Contml HI
c12)
7 3
. 1()iloLI
90
'((4
: IUU(l'9
.2!0
376
4288(l
' 0( 000
: If(oooo
11 640
: I(l(sino
1299
: I ( i( ill Lli l
: I 0Ll 8(i
83 I 9
4 I4
991
':1(lax(0
: IUU(l'lil
2826
100000 20
Tlm nb i I ity of 31 6P mid ('ontro I I to block hPC SK9 binding
to RLDLR was also detenuined. Bnetly. mther recombinant
hLDLR or hLDLR-EGFA-mFc was inunobihzed onto BIA- „,-
CORFOM ( M5 chips vm amine coupling An nntigen-mltl-
body mixnire ol'100 nM hPCSK9-mmh and 316P. Comrol I
ntAb. or a non-hl'I SK9 specific mAb (each at 250 nM) was
ulcubated at RT for I Iu, and then injected over the hLDLR or
hLDLR-EGI'A surlace at the tlov, rare of 10 pltml for 15 nun tn
at 25" C ( hmlges in RU duc to thc binding bet)veen th'ree
hPCSK9-nunh In the mixture to either hLDLR or hLDLR-
E(iFA were recorrled Tlm binding of hPCSK9 to either
hLDLR or hLDLR-LGFA was completely blocked by 316P
tmd 300N but not by ( ontrol I mAb
Fxolrlplc 9
Lrpitope Mappln
4(i
In order to detennule epitope-bmding specificity, three
chimeric P('SK9-mmh proteins u cre genemted in which spe-
citic human PCSK9 domains wmc substitutcdl with mou)u
PCSK9 domains. ('himeric protein tr I consists of a mouse
PCSK9 pro-domain (amino acid residues 1-155 of SE(') ID 4.
NO 757) fill lou cd by a human P(SK9 catalvtic donmin frcsl-
dues 153-425 of SEQ ID NO:7SS) and a mouse PCSK9
(-mnninal donlain (residues 429-694 SFQ ID NO:757)
fmpro-hCat-mC-temt-mmh). Clumenc pmteln Ir2 cons& sts of
a human I'O.'SK9 pro-domain (residues 1-152 of SEQ ID 0
NO 755) filllouud by a mouse P6'SK9 catalytic domain (resi-
dues 156-42g of SEQ ID NO:757) and a mouse PCSK9
C-temlinal fhpro-mCat-mC-term-math). ('himeric protein
II3 consists of mouse P('SK9 pro-domnn and a mouse
PCSK9 catalytic domainfollowedbyahumanPCSK9C-ter- 6
miiml domaiit (residues 426-692 ofSFQ ID NO 755) finpro-
IHCat-hC-term-mnIII). In addition, hPCSK9 with a point
nnltation of D374Y BIPCSK9 fD374Y)-mnth) )tas gener-
ated
Binding specificity of nuAbs to test pmtelns hPCSK9- nl
mmh, mOuSC P6 SK(i-mnlhr ChimeriC prOteinS « I, «2, and 43,
and hP('SK9 (D374Y)-uuruh were tested us follows the
ntAbs were coated on 0 96-well plate overnight at 4'.'., then
each test protein (I 2 nM) was added to tlm plate. After I hr
butding at RT, Ihe plate was wttshed and b(ulud test pmteln 6
detcmted using HRI'-conjugated anti-myc polyclonal anti-
body ftt ODNI 0, + OD 0 4-1.0, — OD&04).
TABLL'9
Chrnicri Protcni
Xnnhnd hPCSK9 mPCSK9 nl 42 sl hPCSP!(D374Y!
HIMson
HIM3(!9
HIM311
H I M492
HIM493
H I M494
HIM49.
HIM!96
I I I M497
HIM498
H I M499
HIMio(i
HI MS(u
HIM((is
HIM)Ll4
HIM)0
HLM)((8
HIH ISP
HIH'1!4P
HIH316P
HIH'1 UP
Cmitml I
+t
+t
+t
t+
t+
tt +t ++
+t
++
++
++
++
++
++
++
++
++
++
++
++
++
Binding specificity of 316P. 300N and control anti-
hPCSK9 ntAbs to hPCSK9-nmth. mPCSK9-nunh,
mmPCSK9-mmh, mfPCSK9-mmh. rPCSK9-nunh, chimenc
protchls;it, 42, and «3, and hl'I'SK9 fD374Y)-nutlh werc
tested as dcscrib(xt above except that thc protein concentra-
uon is 1.7 aM(- OD&0.7:+ ODD.7-1.5; 4+ OD&1.5).
TABI,F, 20
316P ((UV C ntrot I L'ontml ll I'nntrot ul
hPCSK9 nnnh
mPL'SK9 rnmh
inmPCSK9-mmh
mtPL'SK9-nims
rP('SK9-mnih
C'tonier Pin(en((rl
( I(i(i(clio Pin(nil( 62
CIIIII(circ Pin(or(i "3
t(PCSKU(DS«4YJ
++
++ ++
++
++
++
++
++
++
++
++
++
++
++
t+
Similar results for selected nAbs were obtauted by BIA-
CORE v'inding m)say Bricfiy, 316P, 300N. or Control I
nuhb was captured on an amine-coupled anti-hfc CM5 chip
and 100 OM of each protein inj(x ted over the mAb-captured
surface. Changes ul RU due to the binding ofeach pmteln to
thc mAb surface was dctcnmncd.
US 8,062,640 B2
Anf (but)
33
TABLL 21
hP(')K'! mPCSK9 nl
f.h nlerl 'role(6
34
uptake by 50'!o) In addition, the experiment also showed thnt
both 316P and 300N i)ere able to completely reverse the
inlubitory efi'ect ofhPCSK9 on LDL uptake, vvlfile Control I
niAb or H1 M508 anti-hP( SK9 mAb revcrscd the inhibitory
5 efi'ect by about 5(P!o.
316P
30UN
Contin l I
3 0
65
507
13
7
529 461 46,
743 76 10
4 3 69
Antibn47
TABI,F, 23
IC et»btt
Tii further assess the bindino spcviticity of 316P, which
cross-reacts with ml'C'SK9-nunh, a cross-competition
FLISA assay was developed to deternune bindinno domain
spcciiicity Briefiy, mAbs specific for chimeric protein 01, ¹2,
or ¹3, were hrst coated on a 9(i-well plate overnight at I
pg/ml. Human V('SK9-mmh (2 pg/I) was then added to each
v'ell foll ou ed by I hr ulcubatiotl at RT. 316P (I pg/ml) was
added and uicubated for mlother hour at RT. Plate-bound
316P wns detected using HRP-conjugated anti-hFc poly-
clonal antibody. Although 316P binding to hp«SK9-nuuh
was not affected by the presence of mAbs specific for either
chimeric pmtein ¹2 or chimettc protein 43, 316P bulding hl
hP( SK9-mmh was greatly reduced by the presence of anti-
body specifi for chimeric pmtcin ¹I
Exmnple 10
BLXCORL")KBased Anti en Buxhn Profile
Assessment
10 316P
inn%
Control I
ulvl Us
21,30
12
270
7
Thc abihty ofanti-hP('SK9 mAbs to reverse the inhibitory
effect on LDL uptake by PCS K9 protein from different mam-
nialian spcvies was also tested in a HcpO2 cell line as
described above Briefiy I fop«r2 cells were incubated over-
night with serial dilutions ofantibody in LVDS medium (be-
0 ginning with 500 nM) nnd 50 iiM of hPCSK9-mndi,
mtPCSKp-nunh, mPCSK9-mnth. rp«SKp-mmh, or
map('SK9-h. Hep(12 cells werc also incubated oveniight
with senal ddut ious ofantibody in LPDS (beguuull8 u 1th 50
nM) and I nM llPC SK 9(D374Y). As shown in Table 24, wlule
316P was able to completely reverse the inhibitory effect on
LDL by all PCSK9 proteins tested. 300N v,as only able to
reverse the inhibitory effect on LDL uptal e by hl'CSK9,
hPC'SK9 (D374Y), and mlP('SK9. Values are expressed as
nM ICso.
"0
Antibody binding protiles were also established for 316P,
300N, Contml I, H, and Hl ntAbs using BIACORLF™1000.
Bl'letl)2 11V( SK9-nunh was capnlred on an anti-myc surface.
A lirst anti-hPCSK9 nuAb (50 ttg'ml) ives in)ected over the
PCSK9-bound surface for 10 nun. at a fiou rate of 10 pl/min
at 2&''A second miti-hPCSK9 mAb (50 pg/ml) uas then
uljected over the hrstmAb-bound surface tilr 10 min. at a Qou
rate of 10 ul/min at 25'. Ability of the first mAb to block
binding ol'he s)cvond mAb was mmisured and is cxprm))vd as
percent inlubiuon
hPCSK9 mmh
hP( SK9(IN74Y!-mmh
mtP('SK9-nims
mP('SK9-nnnh
IPCSK9-nnnh
rrlsPCSK9-0
14 I 12 6
2 I 1 I
147 1 4
I 7:70(l
7
144 -". Uli
: Si!U
:50(l
Ul I
13 4
0 ~ 06
14 136
19
219
295 127
TABI.F, 24
Control
16P 300N Con(mt I Ca(fret u ui
Tn Hl.l'1 22
Seeonu nish
First rnAb 16P 30fl) Control I Contmi 0 Contml ul
Exmnple 12
Neutralixation of Biological Fffi.ct of hp('SK9 In
4. Ylvo
."169
SUUN
C. ntrol I
Conirol u
C ntrolui
1 (Xi I fit 27 99
77 100 I 67
6 I 1 nil 6 9
91 102 -6 if((i
3 1I! -12 I 1 nfl
L'xample 11
Increase of I.DI. Upeake by Anti-hP('SK9
Antibodies
The ability ofanu-hPCSK9 mAbs to increase I DI, uptake
in vitro was detcisnined using a lumian hepatocellular liver
carcinoma cdl linc (Hcp«i2). HUT7«72 cells werc seeded onto
9)6-well plates at 9x10'ells/well in DML'M complete media
mid incubated at 37'.. 5'io «0„ filr 6 hr to foun Hep(12
monolayers. I lumen PCSK9-nuuh, at 50 nM in lipopmtein
deficient medium (Ll'DS), and a test nKAb was added in
various concentrations front 500 nM to 0 98 nM in I.VDS
medium. Data are expressed as IC„, values for each expets-
ment (IC„,—antibody concentration at which increases LDI.
To assess the biological etlbct of neutrahzulg PCSK9,
hPCSK9 v;as over-expressed in «57BL/6 mice by hydrody-
namic delivery (HDD) of DNA constnicls encodmg lidl-
0 length hPCSK9 nuuh. 4 mice (C57BL/6) were in)ected uith
empty vector/saline
(control 
). and 16 alice were ulj ected with
a 50 pg hPCSK9-nunh-DNA/saline mixture in the tail i cut
equal to 10% of their body weight At day 7 ufter HDD,
delivery of hP('SK9 resulted in a 1 6-fold elevation of total
5 cholesterol. 3.4-fold elevation in LDI.-U)mlesterol (I DL-C)
and a I 9-fold eleevation in non-HDL cholesterol (relative to
control) Serum hPCSK9 levels on day 7 is crc all grcnier than
I pg/ml. as assessed by quantitative LI.ISA.
Administration of HIM300N on day 6 after HDD to 3
ui cxpcrimcntal gmups (I, 5 or 10 mg/kg) (0 4 per group) via
intraperi tones 1 (i.p.) injection resulted in a sigiu an attenu-
ation of serum cholestenil levels. At 18 lxiurs after adminis-
tration, total cholesterol was reduced by 9.8%, 263% and
26.8!o, LDL-C was reduced by 5.1 'o. 52.34!o and 56.7%, and
non-HDI cholesterol uas reduced by 74%, 33.8% and
28.6% ul the I, 5 or 10 mg/kg I) IM300N treated youps.
respectively.
(jS 8,062,640 B2
35
Fxat'up le 13
Pharmacokinetic ond Serum Chemistry Study in
Monkeys
A phormacolunetic (I'K) study was conducted in naive
in:Ile cynonlolglls n'lolikeys (Maraca fasr/mdar/3) rvitll B
body weight range betuemi S-7 kg and aged betv,een 3-5
yean&
Crroup ossigiuuents. The monkeys &vere assignesI inui 5
Ireatmeut gmups Treaunent Cimup I (n 3) received control
buffer (10 mM sodium phosphate, pH 6, I ml/kg): Treatment
Group2(n 3)received I ml/k of316P(5mg/ml); Treatment
Group 3 (n 3) received I ml/ke 300N (S mg/ml); Treatment
Group 4 (n—3) received I mgkg 316P (15 mg/ml); and Treat-
ment Cimup 5 (n=3) rrxeivcd I ml/kg 300N (15 mg/ml) All
treatments were a&hninistercd by IV bolus followed by a I ml
~aline flush Total dose volunm (ml) ives calculated on thc
most recmnt body weight (mich animal uas rvciglmd twice
during acclimation and once weekly Ihroughout the study). A
single dose of test niAb or buffer control &v as a&hniru stered on
Day l.
Atumol care. Anunols 1& ere housed In a tempensture- and
humidity-monitored enviromnent. The targeted range of tem-
perature and rehstive luunidity svos between 18-29" C. Bnd
30-708!6. respectively An automatic lighting systmn provided
a 12-lxiur diurnal cycle The dark cycle could bc interrupted
for study- or facility-related activities. The onuuals were indi-
vidually housed ui cages that comply with the Animal Wel Iiue
Act and recommendations set forth in The Guide for the Care
mid IJse of I.aboratory Animoks (National Research I ouncil
19911)
Diet and Feeding. Animals were fed tv;ice per day accord-
uig to SNBI. I JSA SOPs Animals uvre fast&BI when required
by specilic procedures (e.g, prior to bi&rod draws for sciu&II
chemistry, urine collection. or when procedures involving
sedation are performed). The diet uas rouunely analyzed for
contmnuianLs and found to be within manul'acturer's speciTi-
cations No contominants werc expected to bc prcscnt at
levels that svould interfere u ith the outcome of the study.
Lixpenmentol Design. An appropnate number of animals
werc selected I'rom SNBI USA stock Animals ucre cx un-
ined for health by vetennory staff, ond had undergone serum
chemistry, iiematology, and coagulation screening. Sixteen
males. confirmed healthy, were assi ned to the study. I'ifieen
ma!ca werc assi ned to specific study roups mid the remain-
ing aninial v as available os a spore. A stnstificd nmdomiza-
tion scheme Incorporating serum cholesterol level (based on
the average of tv o dra&vs in eccl uuation) &5 as used to assign
iliunlals 10 61udy groups
Acclimation Period. Previously quarantined animals svere
acchmated to the study room for u muunnun of 14 days prior
to Initiation ofdosuig. Acchnmuon phase data was collected
I'rom all animals, iimloding thc spore All animals werc
assessed for belmvioral obnormahties that could affect per-
fonuance on study. 111e spare animal v.as returned to stock
after duy I
Blood collection. Bi&md uas collected by venipuncture
from o peripheral vein from restrained, conscious animals
Whenever possible. blood 15 as collected vio a single draw ond
then dn ided appropnately,
PK Study Blood mmiples (I 5 ml) were collecicd at prc-
dose, 2 min, 15, min, 30 nun, I hr, 2 lu. 4 lm 8 hr. 12 lm 24 lu;
TABLE 2S
316P 1&i&ix
PK Pmvoe! e& 5 mg kg 15 mg.kg . rrrg'k 15 Big,kg
'I, Ii&1
'I
r e /kr
O4 6 flias 4(&2 (&426
164 ", 26 I
63 164 15 166
Sr:nmi C'lministry Blood samples ur.rc collcctr.d ot pre-
'" dose. 12 hr, 48 lu; and subsequently once every 48 hr, for
chnical chemistry uialysis. in parucular hpid profiles (I.e.
cholesterol. LDL-C HDI,-C:. tnglycerides), With the excep-
tion of tlm 12 br post-dosvsanipfe. all animals uvre sub) cmt to
an ovcmight fast prior to sample collection 'I he sample vol-
ume v;as approximately I ml. Chemistry pammeters were
determined using Bn Olympus automated analyzer Param-
eters measurcdi (Xybion cwlc) Albumin (AI,B), Alknlinc
I'hosphatase (ALP): Alonine Anunotransferase (AL'I);
«m Aspariate Tmnsaminase (AST), Total Bilinibui (TBIL); Cal-
cium (C'a), Total Cholesteml (TCho): C reatine Knuise (CK);
Crcatinine (CRN); Cianuna Cilutamyltrmisaminase (CifiT);
Cilucose (GLU); Inorganic Phosphorus (IP): Total Protein
(TP); Tnglyceride (TRICI); Blood Urea Nitrogen (BUN);
C ilobu l in (GLOB): A lb unn n/Ci 1 oh ul ui Ratio (A/Ci). C'florida
(I I): I'otossiiun (K); Sodium (Na); LDL and HDI, choles-
terol. Residual serum was stored at -20" Ck or below ond
disposed of no sooner thur one week after analysis
RcsulLs I'rmu saniples throu h Day 105 post-dose time
-"I point are sho&vn in FICiS. 3-7. There was a reduction in total
cholesterol and LDL-I: in animals receiving 316P mid 300N,
regardless of dose, within 24 hours of the lirst dose. Senim
total cholesterol reduced rapidly and robustly (-35%, FIG. 3).
A robust decrease of-80% was seen in LDL-I: (FICi S. 4-5) by
day 6. In ommals that received a 15 me/kg dose of 300N, the
reduction in both total cholesterol (-10-15% reduction) and
I.DI.-C' —40% reduction) continued to ot leas1 daie 80 ol'Ihc
study. In addition, HDL-I'sas elevated in aninmls that
&, received 316V at 15 mg'kg (FICr. 6). Aninials that received a
6&1
higher dose (15 mgikg) o I'either 316P or 300N also slxiwed a
reduction in triglycendes dunng the course of study (FICJ. 7).
316P exhibited maximal suppression of I DI,-C: levels of up
Io 80% relative to baseline. The length ofthis suppression was
&5 dose-dependent with at leust 60'I'e silppression (relative to
baseline I.DI,-C'evels) lasting approximately 18 days (5
mg/kvg dose) ond approximately 45 &Lsys (15 mg/kg dose).
36
and subsequently once every 24 hr in senim separator tubes
(SST) Sprwiinen stomgc senun is transferred to 2 vials and
stored at -60''. or below.
Senun samples were analyzed using an optimized FI,ISA
5 (enzyme-linked Inununosorbant assay) procedure Bnetly, a
microtiter plate was first coated with hPCSK9-mmh. Test
nzkb 3 1 6V or 300N was then captured on the itpt 'SK9-nunh
plate. 'I he captured 316V or 300N was detectscd using a bioti-
1,1 nylated mouse miti-hlgC14 followed by binding to NeutrAvi-
din-HRP Varymg concenirations ol'316P or 300N. rmiging
I'rom 100 to I 56 ng/ml, u ere used as staiu1ards. Onc pcrccnt
m&mkay senon (assay matrix) ui the absence o I'3 16P or 300N
was used as thc zero (0 ng/ml) standard The results. shown in
" FICI. 2, indicate a dose-dependent increase in senuu 316V ond
300N levels. PK por uneters v, ere analyzed using WinNonhn
soltware (Noncompartmental analysis. Model 201-IV bolus
administration)
37
tjS 8,062,640 B2
38
300N exhibits a distinct pharmacodynamic profile from 316P.
I,DI.-C'uppression by 300N was sustained for a much longer
pened of time at comparable doses f50/i( I.DI.-C suppression
for 28 days folio~ uig a 5 mgqcg dose and 50% LDI.-C'up-
pression tiir approximately 90 days folloiving a 15 mg/kg
dose). There was little or no measurable change in liver fiuic-
tion as determined by AL f und AST measurements. All am-
ma is receiving an anti-I'('SK9 antibody in the study exhibited
a rapid suppression If LDL-C'nd total cholesterol.
A similar I.DI,-C'owering efl'ect of 316P mxl 300N was
also observed in cynomolgou s monkeys that received a single
subcutaneous CSC) adnunistration of either 5 mg(k 316P or
5 ni /kg 300N (I'IG, 8). Both 316P and 300N dmmatically
suppressed I DI -(. Imels and maintaiiwd an I DI,-('owering
effect for approximately 15 and 30 ILsys, respectively (FIO.
8). lite pharmacodynmnic effect Cupproximately 40%
I.DI,-C suppression) approxunately correlates with lium-
tional antibody levels in monkey serum (FICi. 9) As mitibody
levels decrease below 10 gg/ml, I.DI.-(i suppression
appear(x) to ihnunish as well. In addition, 300N demonstrated
a substantially kmgcr circulating hall(lifi. thmi 31CIP and
hence n longor observed I.DI -('uppression
approxiniately 27% from PBS alone 0 DI,-C/41 mg/dl
coniparedto PBS 5.6 mg/dl) Analysis el'I DI, receptor levels
in u separate cohon ol'ice (n 3 per treaunent group)
revealed a singiilicant reduction in LDL receptor levels with
6 PCSK9 admimstration, wluch was blocked by 316P but not
by the non-hPCSK9 specific mAb CFIO. 10).
Effect of different doses of 3161'as also evaluated in
PC:SK9'"'" mice with both clcvated I.DI.-C'nd elevated
I I hPC SK9 levels. PC'SK96" ill(cow(3IC fil'st placed one high
carbohydrate diet I'or 8 weeks, resulting in a -2-1'old elevation
in both I,DI -C and hPCSK9 levels Fither 316P or 6 non-
hPCSK9 specific nukb, each at I mg/kg. 5 mvgkg, or 10
mg/kg. were administered to the nuce. Sera were collected 24
hours later and LDL-('evels were analyzed. 3161'as effec-
uve in decreasing LDL-('evels in a dose-dependent manner
(FI(i 11) In addition, 316P administercxt nt a dose of 10
nig/ku, rapidly reduced I,DI.-('. levels hack to original Cprc-
6 dict) values witlun 24 hours
Exmuple 15
TABLE 26 Mouse PK Studies
PY P((tn1c(e('16P 36ou
T„„„!63
T(,fill
6(i
46
64
I-:xample 14
Attenuation of LDL Receptor Degmdation by
Anti-hP( SK9 Antibodies
Tb assess the biological effect of PCSK9 on hepatic LDL
receptor levels and subsequent etfects on senun LDL-C lev-
els, hPCSK9 was admuustered to uuce expressing hPC'SK9
but not mP(.SK9 CPCSK9""" mice) by intravenous injec-
tion. Specifically, PCSK9""6" mice were uijected v,ith PBS
Ccontml), or 1.2 mgikg hPCSK9-nunh viu the tail veui. Six
hours after delivery of IhpCSK9, 6 I 4-fold elevation (relative
to baseline level) in total cholesterol and a 2 ebfold elevation
in L13L-(.') in serum were observed. Analysis ofhepatic LDL
receptot'evels lil 6 septiiute cohort fn 3) of illllitials 4 ltoills
aficr hPC'SK9 administratiim rcvmiledl a signilicant rcx)action
in detectablc I,DI, receptor in liver homogcnatcs
To assess the biological effect of anti-hPCSK9 on hepatic
I DI reeceptor fuels and subsequent efli cts on senun I DI,-C.'vels.
316P and 6 non-hPCSK9 spew lie mAb were
administ-
eredd to P('SK96""" mice at equivalent dose (5 mg/kg i.p ) 20
hours poor to the hPCSK9-mmh proteui uijection descnbed
above. Four hours after the hPCSK9 admmistration, mice
were sacriliccxt und a total ol'cigfit tissues (liver, brain. lung.
kidney, heun, ileum, adrenal. und pancreas) were collected
and levels of LDL receptor ivere determined by Vgestern blot.
Ch uiges in LDI. receptor levels were only observed ui iver.
In companson to PBS control dosing. admuustration ol 316P
significantly blocked thc P('SK9-ntcdiatcd incrcascs in total
cholesterol and LDL cholesterol CLDL-C 2.49 mg/dl at base-
line and 3.1 mg/dl 6 hours alter PCSK9: a 25'!Av increase
compared to 135% with vehicle) Prior administration of the
non-hPCSK9 specific mAb blocked LDL-('ncreases by
A PK study was conducted in (i-wack-old ('57BI (6 mice
and 11-15 wack old hl'('SK9 hetcrozygous mice. A single
36 inlecumi ofControl I, 316P. or 300N, each at 10 mg/kg. was
admi metered S( .. Serum bleeds u ere met(surcxt for big Ci lev-
els at 0 hr (pre-bleed), 6 lu; day I. 3, 6. 10, 14. 21, 2K 35, 42
and 56, fora total of I 2 ume poutts, using an anti-hFc capture
and anti-hFc detecuon sandwich FLISA 0'l(iS. 12 and 13).
All mAbs aclueved their T,„„, at approximately 3 ILsys with
corresponding C,„„„ levels ofapproximately 47-115 gg/ml for
C'57BI,/6 mice and 55-196 pg/ml for hPC'SK9 lmterory ous
mice At Day 56, C'I1IItrol I inAb levels were about 12 pg/ml
46 and 300N levels were about 11 ug/inl whermis 316P levels
were about less thiui 0 02 pg'ml in C:57BI!6 mice Ai Dav 56
ui hPCSK') heterozygous mice, Control I mAb levels were
about 29 gghnl, win le both 300N and 31 6P levels were below
the quantifiable linut CB()L) of 0.02 9 /ml.
Example 16
Anti-hP('SK9 Antibody Binding to Mutantcyariant
hPCSK9
To I'urthcl assess lillxllilg bc(racon hprSK9 and alitl-
hPCSK9 niAbs, 21 vanant IIPCSK9 proteins in vvhich each
" vunant contained a single point nnitation and tv'o vanant
hPCSK9 proteins each contauted a double nuitation were
generated. L'ach selected antibody was captured on u F(ab')s
anti-hlg(i surface created through direct chemical coupling to
66
a BIA('(IRE(u chip to form a captured antibody surface.
I'iach mmh-tagged variant hP( SK9 at vnry ing concentrations
from 100 nM to 25 nM ives then in)ectcx) over the captured
antibody surface ate flowrate of C(0 pl(min for 240 sec, and the
dissociation ofvariant hPCSK9 and antibody wns monitored
rs uireal tune for 20 min at 25" C, nb: nobindin was observed
tmder these experimental conditimis CKo
—Mxlfi ',
'I
us—min; IV f—wildtypej.
39
TABLL'7
US 8,062,640 B2
40
116 P lor)K conn &I I I oooo) u Co piro I HI
Ko T» KU Ti, Ko Ko T,&
'ls I
P701
S)2" R
Di 9(
81479
Sl 3R
131(9R
T)6 R
Dl (j 9
R! 94E
E)97R
R21. II
R&l(F
FT W I.
R
2371'mll
8
434)R
1334&R
RW7H
E366K
D374Y
V38UM
P7A&1. S)4" F
E 36 6 K. VS 8( Vl
69 I 0 3oi)
68 8(& 19 0
8) I I(& 2(,0
40 88 22.9
07 4 211
56 141 36 6
82 94 "I i
&8 140 29 0
7 119 30
6 19 314
67 115 3(i
03 98 378
77 44,0
W )21 21,2
Ul lo(J 9 6
78 l.'5 9
')4 19A 2S i
18 89 27 A
G6 264
0 2 Ss
66 83 25.(&
tlc 28 2( 9
tli 24 235
I 5.5
I UA 37 0
1,42 32 I
2.40 36 I
),27 36 I
64 4
696 5 0
0 ')8 4( (J
13. 28
Uss 7) (
14 27
08G 41 I
090 4)
181 32
48 15
41(( I 0
I 4 21 0
78S G I
6 26 30 6
" 9 13 36
& 04 IS (
048 63
118 34 7'"
12 78
16 0 H .333
16 0,4 168
18 0,26 288
18 0 19 57
I 0 " 178
17 0 0'I 'I
16 0 08 3vl
17 0 09 322
I 0 09 .'26
16 0 07 389
I& 0 09 339
17 0 6. 49
16 448 12
I 3( 39
0 07 4tl)
19 A 24 )44
18 D 08
16 0 08 40
13 0 63 165
18 0 46 69
17 0 At) 28
17 0 15 lii
18 0 3 164
18 0.9 60
(&,90 3
0,5 50
0,75 415
0 2'468
33" 60
97 68
(J 48 362
oh oh
ol ot'ih
rit
(J 4 72
0 78 276
0 "3 880
& 89 4)
0 14 1273
0 88 200
4 13 66
I 91 896
0 38 8(ls
10 161
0 Ml "11
D.7'& 348
0 2 551
The resulhs show that whr:n residue D238 was mutated, thr.
bimlingatfinity of 316P liir hP( SK9 v;n rcduccd &400-liild,
from 0 K»of lx10 ' to 410x10 ': an61'll
2 Shortened
about 30-fold. from 37 to I min, 1nd1eaung that 3 16P binds an
epltope on hPCSK9 comp»sing D238 ofhPCSK9 (SIIQ ID
NO:755) Additionally, BIA( ORFrv ossays show that 31(iP
buiding affinlty mill Ti,& vere reduced about 5- to 10-fold
when a residue at 153, 159 or 343 v as mutated. Specificolly.
Kr& v'Rs I'cduclxi I'nnn about I x 10 M 10 bctw Uvu abAU(
5-Sxlfi ' when any one of S153. E159 or D343 were
mutated; while T, 2 was dccreascd from about 37 nlin to
belween about 4-6 min
300N binding to hp('SK9 iv as reduced about 50-fold when
the residim at position 366 wms nnuoted. resulting in 8
decreasedKJ,offromabout0.7x10 UMtoabout36x10 'M
and a shorter 'I, . from about 120 to 2 min. 1hese results
indicate that 300N binds an cpitopc on hP('SK9 comprising
E36(i of hPCSK9 (SEQ ID NO:755). Additionally, the BIA-
CORIP assays show that 300N binding affinity and T,,
were reduced bet)veen 2- to &10-fold when a residue at 147 or
380 was mutated. Specificall, K» was reduced fmm about
0 69xl0 9MR)betweenabom2-9x10 9Mv lmnanyoi'S147
or V380 were mutated; while T,, v, as shortened from about
120 min to between about 24-66 nun. Compared to 316P,
300N bind&ng to hPCSK9 was not reduccxf by 0 nnltatlon ot
residue 238.
In contrast, Control I antibody did not exhibit an altered
blndmg afiinlty or Tl 7 ul I'espouse 10 lul)'f the positional
mutations tested; ('ontrol II antibody exhibitoxt a 40-fold
decreased aftinity when residue 215 wms nultatcd (R215F)
(lmm -01x10 'o -4.5x10 '), mid T, &
wms about 27-fold
shorter (from -333 to 12 min); while Control III antibody
exhibited 0 decrcascd atlinity when residue 237 was mutated
(K» decreased from -0.6xl0 'o -5.9x10, and T, &
decreased from —481 to -43 min)
Binding speclticlty of 316P. 300N, and control ann-
hPCSK9 mAbs to ltp('SK9 varmnts ssas tested using an
FI.ISA-based innninl(&assay Anti-P(.'SK9 mAbs were coated
on a 96-well plate ovennght at 4" C. Liach mn)h-togged von-
ant hPCSK9 in (7HO-kl tronsient tmnsfection lysate super-
"0
4((
(J
:&
60
TABLE 28
SPI.SK9 o& I'&»rot
Cor&t& ol Cor&uol
316P SUUF I (orsrol H HI
EPCSK9(W I)
hPCSK9(S)27R)
EPCSK9(D)29OI
hPCSK9(S)5)R)
hPCSK9(R")50)
hPCSK9i F2161 )
hPCSK9(R23" Ei
hP( sr9(D238R&
EPCSK9(4)4IR&
SPCSK9!1334)R1
hPCSK9(R357H)
hPt'SK9(EISJR)
hPCSK9(1162R)
kIPCSF9(D)92R)
hPI.SK9(R)94E)
hPCSK9(F197RI
hPt:sKU(RD)GF(
hPt SK9(P70 3)
hPt sxs!8)471'1
EPCSK9ik366rl
hPCSK9(V)8AM I
hPI. SK9iP70A. S)471'I
EPCSK9(83G6K 3 'Sl(M)
t+ +t
t+
t+ t+
+t t+ ++
++ ++ ++
t+ +t ++
++ t+ ++
t+
tt tt +t
++ +t ++
++ ++ ++
t+
+4
+4 tt +4
4+ +4 +t
++ +t ++
++ t+ ++
++ tt ++
++ ++ ++
++ t
t( ++
tt tt
+ +4
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
I.xomple 17
L'fleet of 316P on Nonnohpenuc ond llyperhpemlc
I louis(el'he
ability of anti-PCSK9 numb 3161'o reduce ac»un
LDI.-( was tested in normolipemic or hyperlipemic ()old
Syriatl hamstem (Mrsar rice(as aaraius). Male Syrian Ilam-
sters. age (i-8 iveeks, weighing benvceen 80-100 grams. v ere
natants was addid to the antibody-c(ra(cd plate at various
concmltrations ranging I'rom 0 to 5 nM After I hr binding ol
RT, the plate was washed ond bound variant liPCSK9 was
detected usuig IIRP-Uoniugated anti-myc polyclonal anti-
body (- OD&0 7:+ OD 0 7-1.5, t+ OD&15).
41
US 8,062,640 B2
42
allowed to acclimate for a period of 7 days before entry into
the study. Alf anunals ivere placed on esther a standard chov;
dtet or a hyperlipmntc dtet ofchow supplemented w ith 0.1%
cholesterol and 10% coconut oil. Tlm 316P nLAb was deliv-
ered to lmmsters by 0 sutgle subcutaneous inlectton at doses
of 1, 3, or 10 mg/kg for nomlolipemic hamsters and at doses
of 3, 10. or 30 mgikg for hyperltpetmc lumtsters. Senuu
samples were taken fmm all groups at 24 lu and 7, 14. and 22
days post injection. St which time scnIm lipid levels werc
assessed and compared to baseline levuls taken 7 days prior ro
the adtnintstratton of the mAbs. Circulating total cholesterol
and L13L-('n normoltpemic hamsters was significantly
reduced in a dose-dcpcndcnt manner compartd to vehicle
I ullection.As shown in 1616i. 14, admimstrauon of316p effec-
tively reduced L13L-(: levels by up to 60'40 sevell days post
ullectton at the Inghest dose (10 mgykg) tested Similar cho-
lesterol reducing efi'ect of 316P was not observed In hyper-
bpcmic hmnstcrs
SEQUENCE LISTING
160 NUMBER OF SEQ ID NOS 763
210 SEQ ID NO I
211 IENGTH 351
212 TYPE DNA
213 ORGANISM Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORMATION Synthetic
400 SEQUENCE I
caggtccagc tggtgcagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt tactct.aagt. agttacgaca tgcactgggt ccgccaatct 120
acaggaaaag gt.ctggagtg ggtctcagct attggttcta ccggt.gacac atactat.cca 100
ggctccgtga agggccgat.t caccatcacc agagaaaaag ccaagaactc cgtgtatctt 240
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgtgtaag agaggggtgg 300
gaggtaccct ttgactactg gggccaggga accctggtca ctgtctcctc a 351
210 SEQ ID NO 2
211 LEIIGTH 117
212 TYPE PRT
213 ORG33IISM Artifrcial Sequence
220 FE TURB
223 OTHER INFORMATION Synthetrc
400 SEQUENCE 2
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Pl:e Thr Leu Ser Ser Tyr
20 25 30
Asp ttet. Hrs Trp Val Arg Gln Ser Thr Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Pro Gly Ser Val Ly
50 55 60
Gly Arg Phe Thr Ile Thr Arg Glu Ly Ala Lys Asn Ser Val Tyr Leu
65 70 5 50
Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Pla Val Tyr Tyr Cys Val
05 90 95
Arg Glu Gly Trp Glu Val Pro Phe Asp Tyr Trp Cly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser
115
210 SEQ ID NO 3
211 LENGTH 24
212 TYPE DNA
213 ORGAIIISI4 Art.i
220 PEATURE.
223 OTHER INPORMAT
ficral Sequence
ION Synthetic
43
US 8,062,640 B2
-continued
44
400 SEQUENCE 3
ggatttactc taagtagtta cgac
c210 SEQ ID NO
c211 LENGTH 8
212 TYPE PRT
213 ORGANISE Artrfrctal Sequence
220 FEATURE
223 OTHER INFORHATIOE Synthetrc
400 SEQUENCE 4
Gly Phe Thr Leu Ser Sez Tyz A p
I 5
210 SEQ ID NO 5
211. LENGTH 21
212 TYPE DNA
213 ORGANISE Artrftcral Sequence
220 FEATUPE
223 OTHER INFORNPTION Synthetrc
400 5'EQUENCE 5
attggttct.a ccggtgacac a 21
210 SEQ ID NO
211 LEI'GTH 7
212 TYPE PRT
213 ORGANISN Aztrfrczal Sequence
220 FEATURE
c223 OTHER INPORNATION Synthetrc
400 SEQUENCE 6
Ile Gly Ser Thr Gly Aap Thr
1 5
210 SEQ ID NO 7
211 LEIIGTH 33
212 TYPE DNA
213 ORGANIS'N Aztrfrczal Sequence
220. PEATURE.
223. OTHER INFORNATION Synthetzc
400 SEQURECE 7
gtaagagagg ggtgggaggt accctttgac tac 33
210 SEQ ID NO 8
211 LENGTH ll
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORHATIOE Synthetrc
400 SEQUENCE 8
Val lrg Glu Gly Trp Glu Val Pzc Phe Aap Tyr
5 10
210 SEO ID NO 9
211 LENGTH 327
212 TYPE DNA
213 ORGANISE .Artrfrctal Sequence
220 FEATURE
223 OTHER INPORKATION Synthetrc
400 SEQUENCE 9
gacatccaga tgacccagtc tccagccacc ctgtctgtgt ctccagggga aagagccgcc 60
ct.ctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca ccagaaacct 120
45
US 8,062,640 B2
-continued
46
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc 180
aggttcagtg gcattgggtc tgggacagag ttcactctca ttatcagcag cctgcagtct 240
gaagatt.ttg cattttattt ctgtcagcag tataat.aact ggcctccatt. cactttcggc
cctgggacca aggtggagat caaacga
300
327
210 SEQ ID NO 10
211 LENGTH 109
212 TYPE PRT
213 ORGAEISN Artrfrc
220 FEATURE.
223 OTHER INFORMATION
ral Sequence
Synthetrc
400 SEQUENCE 10
4 p Ile Gln Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
I 5 10 15
Glu Arg Ala Ala Leu Ser Cye Arg Ala Ser Gln Ser Val Ser Ser Aen
20 25 30
Leu Ala Trp Tyr Hr- Gln Lya Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 0
Ile Gly Ser Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Ser
70 75 80
Glu Aep Phe Ala Phe Tyr Phe Cya Gln Gln Tyr Aen Aen Trp Pro Pro
85 90 95
Phe Thr Phe Gly Pro Gly Thr Lye Val Glu Ile Ly Arg
100 105
210 SEQ ID NO 11
211 LENGTH 18
212 TYPE DNA
213 ORGAEISM Artrfrc
220 FEATURE.
223 OTHER INFORMATION
ral Sequence
Synthetrc
400. SEQUENCE 11
cagagtgtta gcagcaac 15
210 SEQ ID NO 12
211 LEI'GTH 6
212 TYPE PRT
213 ORGAIIISM Artrfrc
220 FEATURE;
223 OTHER INPORMATION
ral Sequence
Synthetrc
400 SEQUENCE 12
Gln Ser Val Ser Ser Aan
I 5
tal sequence
Synthetrc
210 SEQ ID NO 13
211 LENGTH 9
212 TYPE DNA
213 ORGANISM Arttftc
220 FEATURE
223 OTHER INFORMATION
400 SEQUENCE 13
ggtgcatcc
210 SEQ ID NO 14
211 LENGTH 3
47
US 8,062,640 B2
-continued
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORHPTION Synthetrc
r400 SEQUENCE 14
Gly Ala er
I
210 SEQ ID NO 15
211 LENGTH 30
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 15
cagcagtata ataactggcc tccattcact 30
210 SEQ ID NO I
211 LENGTH 10
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE:
223 OTHER IKFOPMATIOK Synthetrc
400 SEQUENCE 16
Gln Gln Tyr Asn Asn Trp Pro Pro Phe Thr
5 10
210 SEQ ID I'10 17
211 LENGTH 351
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORHATIOK Synthetrc
400 SEQUENCE 17
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc
tcctgtgcag ccr.ctggatt tactctaagt agttacgaca t.gcactgggt ccgccaatct 12 0
acaggaaaag gtctggagtg ggtctcagct attggttcta ccggtgacac atactatcca 180
ggctccgtoa agggccgatt cac«atcacc agagaaaaag ccaagaactc cgtgtatctt 240
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgtgtaag agaggggtgg 300
gaggtaccct ttqactactg gggccaggga accctggtca ccgtctcctc a 351
210 SEQ ID NO 18
211 LENGTH 117
212 TYPE PRT
213 ORGANISN Artrfrc
220 FEATURE
223 OTHER INPORNATION
ral Sequence
Synthetrc
400 SEQUENCE 18
Glu val Gln Leu val Glu ser Gly Gly Gly Leu val Gln Pro Gly Gly
I 5 10 3.5
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
Asp Het Hrs Trp Val Arg Gln Ser Thr Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyt Pro Gly Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Thr Arg Glu Lys Ala Lys Asn Ser Val Tyr Leu
49
US 8,062,640 B2
-continued
65 70 80
Gln Het Asn Ser Leu Azg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Val
85 90 95
Arg Glu Gly Tzp Glu Val Pro Phe .'. p Tyz Trp Gly Gln Gly Thz Leu
100 105 110
Val Thr Val Ser Ser
115
210 SEQ ID NO 19
211 LENGTH 324
212 TYPE DNA
213 ORGAEISH Artzfzczal Sequence
220 FEATURE:
223 oTHER INPORHATION Synthetzc
400. SEQUENCE 19
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccgcc 60
ctctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca ccagaaacct 120
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc 180
aggttcagtg gcattgggtc tgggacagag ttcactctca ttatcagcag cctgcagtct 240
gaagattttg cattttattt ctgtcagcag tataataact ggcctccatt t.actttcggc 300
cctgggacca aagtggatat casa 324
210 SEQ ID NO 20
s211 LENGTH 108
212 TYPE PRT
213 ORGANIISN Artzfzczal Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 20
Glu Ile Val Net Thr Gln Sez Pzo Ala Thr Leu Ser Val Sez Pro Gly
I 5 10 15
Glu Arg Ala Ala Leu Sez Cys Azg Ala Ser Gln Ser Val Sez Sez Asn
20 25 30
Leu Ala Trp Tyr Hzs Gln Lys Pro Gly Gln Ala Pro Arg Leu * eu Ile
35 40 45
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ile Gly er Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Phe Tyr Phe Cys Gln Gln Tyr Asn Asn Trp Pro Pro
85 90 95
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
210 SEQ ID NO 21
211 LEI'GTH 351
212 TYPE DNA
213 ORGANISE Artzfzczal Sequence
220 PEATURE:
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 21
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt tactctaagt agttacoaca tgcactgggt ccgccaagct 120
acaggaaaag gtctggagtg ggtctcagct attggttcta ccggtgacac atactatcca 180
51
US 8,062,640 B2
-continued
ggctccgtga agggccgatt caccatctcc agagaaaatg ccaagaactc c.tt.gtatctt 240
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgtgtaag agaggggtgg 300
gaggtaccct ttgactactg gggccaggga accctggtca ccgtctcctc a 351
210 SEQ ID I'10 22
211 LENGTH 117
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 22
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
Asp Net Hrs Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Ser Thr Gly .. p Thr Tyr Tyr Pzo Gly Ser Val Ly-
50 55 60
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu
65 70 75 50
Gln Het Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Val
85 90 95
Arg Glu Gly Trp Glu Val Pro Phe Asp Tyr Tzp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser
115
210 SEQ ID NO 23
211 LENGTH 324
212 TYPE DNA
213 ORGAEISH Artzfrcral Sequence
220 FEATURE.
223 OTHER INFOPHATION Synthetrc
400. SEQUENCE 23
gaaatagtaa tgacgcagtc tccagccacc ctgtctgtgt. ctccagggga aagagccacc
ctctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca gcagaaacct 12 0
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc 180
aggtt.cagtg gcagtgggtc tgggacagag ttcactct.ca ccatcagcag cctgcagtct 240
gaagattttg cagtttatta ctgtcagcag tataataact ggcctccatt c.act.ttcggc 300
cctgggacca aagtggatat casa 324
210 SEQ ID NO 24
211 LENGTH 108
212 TYPE PRT
213 ORGANZISH Artrfrc
220 FEATURE.
223 OTHER INFORMATION
ral Sequence
Synthetrc
400 SEQUENCE 24
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
10
Glu Arg Ala Thr Leu Ser Cys Azg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
53
US 8,062,640 B2
-continued
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr A:n Aan Trp Pro Pzo
85 90 95
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
210 SEQ ID NO 25
211 LEIIGTH 342
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
220 PEATURE:
223. OTHER INFORNATION Synthetrc
400 SEQUENCE 25
caggtgcagc tggtgcagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 120
ccaggcaagg ggctggagtg ggtggcgttt ataggatttg atggaagtaa tatacattat 180
ggagactccg tgaggggccg aatcatcata tcc.agagaca attccgagaa c.acgttgtat 240
ctggaaatga acagcctgag agccgaggac acggcaatgt actattgtgc gagagagaag 300
ggtttagact ggggccaggg aaccacggtc accgtctcct ca 342
210 SEQ ID I'10 26
211 LENGTH 114
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTIIER INFORNZTION Synthetrc
400 SEQUENCE 26
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Azg
I 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Het Hrs Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Phe Ile Gly Phe Asp Gly Ser Asn Ile Hrs Tyr Gly Asp Ser Val
50 55 60
Arg Gly Arg Ile Ile Ile Ser Azg .'-. p A n Set Glu Asn Thr Leu Tyr
65 70 75 50
Leu Glu Het Asn Ser Leu I\rg I\la Glu Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Arg Glu Lys Gly Leu Asp Trp Gly Gln Gly Thr Thr Val Thr Val
100 105 110
Ser Ser
210 SEQ ID I'10 27
211 LENGTH 24
212 TYPE DNZ
213 ORGANISE Artrfrc
220 FETTURE
223 OTI'ER INFORIBATION
ral Sequence
Synthetzc
400 SEQUENCE 27
ggattcacct tcagtagcta tggc
55
US 8,062,640 B2
-continued
210 SEQ ID No 28
211 LEI'GTH 8
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
c220 FEATURE;
c223 OTI'ER INPORI44TION. Synthetrc
400 SEQUENCE 28
Gly Phe Thr Phe Ser Ser Tyr Gly
I 5
210 SEQ ID No 29
211 LEIIGTH 24
212 TYPE DNA
213 ORGANISE Arttftctal Sequence
220 PEATURE:
223. OTHER INFORNATION Synthettc
400 SEQUENCE 29
ataggatttg atggaagtaa tata
210 SEQ ID No 30
211 LENGTH 8
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORH'TION Synthetrc
400 SEQUENCE 30
Ile Gly Phe Aep Gly Ser I; n Ile
I 5
210 SEQ ID No 31
211 LENGTH 21
212 TYPE DNA
213 ORGANISE .Artrfrctal Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 31
gcgagagaca agggtttaga c 21
210 SEQ ID No 32
211 LENGTH 7
212 TYPE PPT
213 ORGIUIISN Artrftctal Sequence
220 FEATURE:
223 OTHER IEFORHATION Synthetrc
400 SEQUENCE 32
Ala Arg Glu Lya Gly Leu Aap
I 5
210 SEQ ID No 33
211 LENGTH 321
212 TYPE DNA
213 ORGPIIISH Artrftctal Sequence
220 FEATURE:
223 oTHER INPORHATION Synthettc
400 SEQUENCE 33
gccatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 50
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagaaacca 120
gggaaagccc ctaagctcct gatctataag gcgtctagtt tagaaagtgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct 240
57
US 8,062,640 B2
-continued
gatgattttg caacttatta ctgccaacag tataatagtt attacacttt tggccagggg 300
accaaggtgg aaatcaaacg a 321
a210 SEQ ID NO 34
211 LEI'GTH 107
212 TYPE PRT
213 ORGANISM Artrftctal Sequence
220 FEATURE.
223 OTHER INFORFIATION Synthetzc
400 SEQUENCE 34
Ala Ile Gln lect Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
I 5 10 15
4 p Arg Val Thr Ile Thr Cya Arg Ala Sez Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lya Pro Gly Lya fla Pro Lya Leu Leu Ile
35 40 45
Tyr Lya Ala Ser Ser Leu Glu Ser Gly Val Pzo Ser Arg Phe Sez Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Lau Gln Pro
65 70 75 80
Aep Aap Phe Ala Thr Tyr Tyr Cy Gln Gln Tyr Aan Ser Tyr Tyr Tlar
85 90 95
Phe Gly Gln Gly Thr Lya Val Glu Ile L. 8 Arg
100 105
210 SEQ ID NO 35
211 LENGTH 18
212 TYPE DNA
213 ORGANISN Artrftc
220 FEATURE
223 OTHER INFORMATION
ral Sequence
Synthetzc
400 SEQUENCE 35
cagagtatta gtagctgg 18
210 SEQ ID NO 36
211 LENGTH 6
212 TYPE PRT
213 ORGANISN Artzftc
220 FEATURE
223 OTHER INFORM'TION
tal Sequence
Synthetzc
400 SEQUENCE 36
Gln Ser Ile Ser Ser Trp
I 5
210 SEQ ID NO 37
211 LENGTH 9
212 TYPE DNA
213 ORGANISN Artzfzc
220 PEATURE:
223 OTHER INFORNATZON
tal Sequence
aynt hat rc
400 SEQIIENCE 37
aaggcgtct
210 SEQ ID NO 38
211 LENGTH 3
212 TYPE PRT
213 ORGANISM AZtzfZC
220 FEATURE.
223 OTHER INFORMATION
zal Sequence
Synthetzc
59
US 8,062,640 B2
-continued
60
400 SEQUENCE 38
Lys Ala Ser
210 SEQ ID I'10 39
211 LENGTH 24
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 39
caacagtata atagr.tatta cact 2 'I
210s SEQ ID NO 40
211 LEHGTH 8
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 40
Gln Gln Tyr Asn Ser Tyr Tyr Thr
I 5
210 SEQ ID NO 41
211 LENGTH 342
212 TYPE DNA
c213 ORGANIS14 Artrfrcral Sequence
220 FEATURE:
223 OTHER INFORHATION. Synthetrc
400 SEQUENCE 41
caggtgcacc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc
tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 12 0
ccaggcaagg ggctggagtg ggtggcgttt ataggatttg atggaagtaa tatacattat 180
ggagactccg tgaggggccg aatcatcata tccagagaca attccgagaa cacgt.tgtat
ctggaaatga acagcctgag agccgaggac acggcaatgt. act.attgtgc gagagagaag
240
300
ggtttagact ggggccaggg aac«ctggtc accgtctcct ca 342
210 SEQ ID NO 42
211 LENGTH 114
212 TYPE PRT
213 ORG.SIISN AZtrfrC
220 PEATURR.
223 OTHER INPORSIATION
ral Sequence
Synthetrc
400 SEQUENCE 42
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
I 5 10 15
Ser Leu Arg Leu Ser Cy. Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Het Hr- Trp Val Arg Gln Ala Pro Gly Ly- Gly Leu Glu Trp Val
35 40 45
Ala Phe Ile Gly Phe Asp Gly Ser Asn Ile Hrs Tyr Gly Asp Ser Val
50 55 50
Arg Gly Arg Ile Ile Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr
55 70 75 80
Leu Glu lect Asn Ser Leu Arg Ala Glu F.cp Thr Ala Het Tyr Tyr Cys
85 90 95
61
US 8,062,640 B2
-continued
62
Ala Arg Glu Lys Gly Leu Asp Trp Gly Gln Gly Thr Leu Val Thr Val
100 105 110
Ser Ser
210 SEQ ID I'10 43
211 LENGTH 318
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 43
gacatccaga r.gacccagtc tcctt.ccacc ctgtctgcat. ctgr.aggaga cagagt.cacc 40
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagaaacca 120
gggaaagccc ctaagctcct gatctataag gcgtctagtt tagaaagtgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct 240
gatqattttg caacttatta ctgccaacag tataatagtt attacacttt tggccagggg 300
accaaqctgq agatcaaa 318
210 SEQ ID NO 44
211 LENGTH 105
212 TYPE PRT
213 ORGAEISN Artrfrcral Sequence
220 FEATURE
223 OTHER INPORKATION Synthetrc
400 SEQUENCE 44
Asp Ile Gln Net Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
I 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lya Ala Ser ser Leu Glu ser Gly Val Pro ser Arg Phe ser Gly
50 55 0
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Tyr Thr
85 90 95
Phe Gly Gln Gly Thr Ly. Leu Glu Ile Ly
100 105
210 SEQ ID NO 45
211 LENGTH 342
212 TYPE DNA
213 ORGAEISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFOPNP.TION Synthetrc
400 SEQUENCE 45
caggtgcaac tggtggagtc tgggggaggc gtggtccagc ctgggaggt.c cctgagactc
tcctgtgcag cctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 12 0
ccaggcaagg ggctggagtg ggtggcagtt ataggatttg atggaagtaa tatatactat 180
gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatga acagcctgag agctgaggac acggctgtgt attactgtgc gagagagaag 300
ggtttagact ggggccaggg aaccctggtc accgtctcct ca 342
63
US 8,062,640 B2
-continued
64
210 SEQ ID NO 46
211 LENGTH 114
212 TYPE PRT
a213 ORGANIISN AZtzfzCzal SequenCe
a220 FEATURE:
223 OTHER INFORNATION Synthetzc
400 SEQUENCE 46
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Het Hze Trp Val Arg Gln Ala Pro Gly Ly- Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Gly Phe Asp Gly Ser Asn Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Net A n Ser Leu Azg Ala Glu A p Thz Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Ly" Gly Leu Asp Trp Gly Gln Gly Thr Leu Val Thr Val
100 105 110
Ser Ser
a210 SEQ ID NO 47
211 LEI'GTH 319
212 TYPE DNA
213 ORGPZIISH Artzfzc
220 FEATURE.
223 OTHER INFORKATION
zal Sequence
Synthetzc
400 SEQUENCE 47
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagaaacca 120
gggaaagccc ctaagctcct gatctataag gcgtctagtt t.agaaagtgg ggt.cccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cct.gcagcct 240
gatgattttg caacttatta ctgccaacag tataatagtt attacacttt tggccagggg 300
accaagctgg agatcaaac 319
210 SEQ ID NO 48
211 LENGTH 10
212 TYPE PRT
213 ORGANISE Artzfzc
220 FEATURE
223 OTHER INPORKATION
zal Sequence
Synthetzc
400 SEQUENCE 48
Asp Ile Gln Net Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
I 5 10 15
A p Arg Val Thr Ile Thr Cy. I.rg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ly Ala 6'er Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
65
US 8,062,640 B2
-continued
66
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Tyr Thr
85 90 95
Phe Gly Gln Gly Thr Lys Leu Glu Ile L. 8
100 105
210 SEQ ID NO 49
211 LENGTH 342
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFOPHP.TION Synthetrc
400 SEQUENCE 49
caggtgcacc tgcaggagtc tgggggaggc gtggtccagc ctgggaggt.c cctgagactc
tcctgtgcag cgtctggatt caccttcagt agctatggca t.gcactgggt ccgccaggct
ccaggcaagg ggctggagtg ggtggcgttt ataggatttg atggaagtaa tatatattat
12 0
180
ggagactccg tgaggggccg aatcatcata tccagagaca attccgagaa cacgttgtat 240
ctggaaatga acagcctgag agccgaggac acggcagtgt attattgtgc gagagagaag
ggttt.agact ggggccaggg aaccctggtc actgtctcct ca
300
342
210 SEQ ID NO 50
211 LEIcGTH 114
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE
c223 OTHER INPORNATION Synthetrc
400 SEQUENCE 50
Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys !\Za !\Za Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly iset Hrs Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Phe Ile Gly Phe Asp Gly Ser Asn Ile Tyr Tyr Gly Asp Ser Val
50 55 0
Arg Gly Arg Ile Ile Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr
70 75 80
Leu Glu lect Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Ly Gly Leu .'. p Tzp Gly Gln Gly Thr Leu Val Thr Val
100 105 110
Ser Ser
210 SEQ ID NO 51
211 LENGTH 24
212 TYPE DNA
213 ORGANIISN Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 51
ggattcacct tcagtagcta tggc
210 SEQ ID NO 52
211 LENGTH 8
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE
67
US 8,062,640 B2
-continued
223 OTHER INPORHATION Synthetrc
400 SEQUENCE 52
Gly Phe Thr Phe Ser Ser Tyr Gly
1 5
210 SEQ ID NO 53
211 LENGTH 24
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFOPHP.TION Synthetrc
400 SEQUENCE 53
ataggatttg atggaagtaa tata 24
210 SEQ ID NO 54
211 LENGTH 8
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE:
223 OTHER INPORNATION Synthetrc
400 SEQUENCE 54
Ile Gly Phe Aap Gly Ser A"n Ile
I 5
210 SEQ ID NO 55
211 LENGTH 21
e212 TYPE DNA
213 ORGANHSN Artrf feral Sequence
220 FEATURE:
223 OTHER INPORNATION: Synthet rc
400 SEQUENCE 55
gcgagagaga agggtttaga c 21
210 SEQ ID NO 56
211 LENGTH 7
212a TYPE PRT
213a ORGPIIISN ArtrfrCral SequenCe
220 FEATURE:
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 5
Ala Arg Glu Lye Gly Leu Aep
1 5
210 SEQ ID NO 57
211 LENGTH 342
212 TYPE DNA
213 ORGANISN Artrf
220 FEATURE
223 OTHER INPORKATI
rcral Sequence
ON Synthetrc
400 SEQUENCE 57
gccatccaaa tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc
atcaactgca agtccagcca gagtgttttt cacacctcca acaataagaa ct.act.tagtt 12 0
tggtatcagc agaaaccagg acagcctcct aagttgctcc tttactgggc ctctacccgg 180
gaatccgggg tccctgaccg attcagtggc agcgggtctg ggacagattt cactctcacc 240
atcagcagcc tgcaggctga agatgtggca aattattact gtcaccaata ttacagtatt 300
ccgtggacgt tcggccaagg gaccaaggtg gagatcaaac ga 342
69
US 8,062,640 B2
-continued
70
210 SEQ ID NO 58
211 LENGTH 114
212 TYPE PRT
213 ORGAEISN Artificial Sequence
220 FEATURE
r223 OTHER INFORHATION Synthetic
400 SEQUENCE 58
Ala Ile Gln 14et Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Phe His Thr
20 25 30
Ser Asn Asn Ly Asn Tyr Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Ly Leu Leu Leu Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 0
Pro Asp frg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Asn Tyr Tyr Cye His Gln
85 90 95
Tyr Tyr Ser Ile Pro Trp Thr Phe Gly Gln Gly Thr Ly. Val Glu Ile
100 105 110
Ll 8 Arg
210 SEQ ID NO 59
211 LENGTH 36
r212 TYPE DNA
213 ORGANIISN Artificial Sequence
220 FEATURE:
223 OTHER INPORNATION: Synthetic
400 SEQUENCE 59
cagagtgttt ttcacacctc caacaataag aactac 36
210 SEQ ID NO 60
211 LENGTH 12
212s TYPE PRT
213s ORGANISE Artificial Sequence
220 FEATURE:
223 OTHER INFORNATION Synthetic
400 SEQUENCE 60
Gln Ser Val Phe His Thr Ser Asn Asn Lys Isn Tyr
1 5 10
210
211
212
213
220
223
SEQ ID NO I
LENGTH 9
TYPE DNA
ORGANISN Artificial Sequence
FEATURE
OTHER INPORKATION Synthetic
400 SEQUENCE 61
tgggcctct
210
211
212
213
220
223
SEQ ID NO 62
LENGTH 3
TYPE PRT
ORGANISE Artificial Sequence
FEATURE.
OTHER INFOPHATION Synthetic
400 5'EQUENCE 62
Trp Ala Ser
71
US 8,062,640 B2
-continued
72
210 SEQ ID NO 63
211 LENGTH 27
.212 TYPE DNA
.213 ORGANIS14 Aztificial Sequence
220 FEATURE:
223 OTHER INFORHATION Synthetic
400 SEQUENCE 63
caccaatatt acagtattcc gtggacg
210 SEQ ID NO 64
211 LENGTH 9
212 TYPE PRT
213 ORGWIISN Artificial Sequence
220. FEATURE.
223 OTHER INFORN'TION Synthetic
400 SEQUENCE 64
Hls Gln Tyr Tyr Ser Ile Pro Tzp Thr
I 5
210 SEQ ID NO 65
211 LENGTH 342
212 TYPE DNA
213 ORG32IISH Artificial Sequence
220 FEATURE
223 OTHER INFORFLATION Synthetic
.400 SEQUENCE 65
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 12 0
ccaggcaaag ggctggagtg ggtggcgttt ataggatttg atggaagtaa tatatattat 180
ggagactccg tgaggggccg aatcatcata tccagagaca attccgagaa cacgttgtat 240
ctggaaatga acagcctgag agccgaggac acggcagtgt attattgtgc gagagagaag 300
ggtttagact ggggccaggg aaccctggtc accgtctcct. ca 342
210 SEQ ID NO 66
211 LENGTH 114
212 TYPE PRT
213 ORGANISE Artific
220 FEATURE
223 OTHER INFORNATION
ial Sequence
Synthetic
400 SEQUENCE 66
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
I 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Het His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Phe Ile Gly Phe Asp Gly Ser A n Ile Tyr Tyr Gly A p Ser Val
50 55 60
Arg Gly Arg Ile Ile Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr
65 70 7 80
Leu Glu tset Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala 'rg Glu Ly. Gly Leu A p Tzp Gly Gln Gly Thr Leu Val Thz Val
100 105 110
73
US 8,062,640 B2
-continued
74
Ser Ser
210 SEQ ID NO 67
211 LENGTH 339
e212 TYPE DNA
e213 ORGANIS14 Aztzfzczal Sequence
220 FEATURE:
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 67
gacatcgtga tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc 60
atcaactgca agtccagcca gagtgttttt cacacctcca acaataagaa ctacttagtt 12 0
tggtatcagc agaaaccagg acagcct.cct aagttgctcc tttactgggc ct.ctacccgg
gaatccgggg tccctgaccg attcagtggc agcgggtctg ggacagattt cact.ctcacc
180
240
atcagcagcc tgcaggctga agatgtggca aattattact gtcaccaata tt.acagtatt 300
ccgtggacat tcggccaagg gaccaaggtg gaaatcaaa 339
210 6'EQ ID NO 68
211 LENGTH 113
212 TYPE PRT
213 ORGANISE Artzfzczal Sequence
220 PEATURR.
223 OTHER INFORFIATION Synthetzc
400 SEQUENCE 68
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
I 5 10 15
Glu Arg Ala Thr Ile Aen Cye Lys Ser Ser Gln Ser Val Phe Hie Thr
20 25 30
Ser Asn Asn Lys Asn Tyr Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Ly Leu Leu Leu Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Sez Sez Leu Gln Ala Glu Asp Val Ala Asn Tyr Tyr Cys Hzs Gln
85 90 95
Tyr Tyr Ser Ile Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
100 105 110
Ly
210 SEQ ID NO 9
211 LENGTH 342
212 TYPE DNA
213 ORGANISN Artzfzczal Sequence
220 FEATURE
223 OTHER INPORKATION Synthetzc
400 SEQUENCE 69
caggtgcaoc tggrggagtc tgggggaggc gtggtccagc ctgggaggtc cct.gagactc
tcctgtgcag cctctggatt. caccttcagt agctatggca tgcactgggt ccgccaggct 12 0
ccaggcaagg ggctggagtg ggtggcagtt ataggatttg atggaagtaa tatatactat 180
gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatga acagcctgag agctgaggac acggctgtgt attactgtgc gagagagaag 300
ggtttagact ggggccaggg aaccctggtc accgtctcct ca 342
75
US 8,062,640 B2
-continued
76
210 SEQ ID NO 70
211 LENGTH 114
212 TYPE PRT
213 ORGANISN Artzfzczal Sequence
220 FEATURE
c223 OTHER INFORHATION Synthetzc
400 SEQUENCE 70
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
I 5 10 15
Ser Leu Azg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Sez Tyz
20 25 30
Gly Het Hzs Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Gly Phe Asp Gly Sez Asn Ile Tyr Tyr Ala Asp Sez Val
50 55 0
Lys Gly frg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
70 75 80
Leu Gln iset Asn Ser Leu Arg Ala Glu Asp Tht Ala Val Tyr Tyz Cys
85 90 95
Ala Arg Glu Ly Gly Leu Asp Trp Gly Gln Gly Thr Leu Val Thr Val
100 105 110
Ser Ser
210 SEQ ID NO I
211 LENGTH 339
c212 TYPE DNA
213 ORGANIISH Artzfzc
220 FEATURE:
223 OTHER INFORNATION
zal Sequence
Synt hat zc
400 SEQUENCE 71
gacatcgtga tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc 60
atcaactgca agtccagcca gagtgttttt cacacctcca acaataagaa ctacttagct 120
tggtaccagc agaaaccagg a«agcctcct aagctgctca tttactgggc ctctacccgg 180
gaatccggog tccctgaccg attcagtggc agcgggtctg ggacagattt cactctcacc 240
atcagcagcc tgcaggctga agatgtggca gtttattact. gtcaccaata t.tacagtatt 300
ccgtggacgt tcggccaagg gaccaaggtg gaaatcaaa 339
210 SEQ ID NO 72
211 LENGTH 113
212 TYPE PRT
213 ORGANISE Artzfzc
220 FEATURE.
223 OTHER INFORHATION
zal Sequence
Synthetzc
400 SEQUENCE 2
A p Ile Val Met Thr Gln Sez Pzo Asp Ser Leu Ala Val Ser Leu Gly
5 10
Glu Arg Ala Thz lie Asn Cys '. Ser Ser Gln Ser Val Phe Hi Thr
20 25 30
Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pzo Gly Gln
35 40 45
Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Azg Phe Ser Gly Sez Gly Sez Gly Tht Asp Phe Thr Leu Thz
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Hzs Gln
77
US 8,062,640 B2
-continued
85 90 95
Tyr Tyr Ser Ile Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
100 105 110
210 SEQ ID NO 73
211 LENGTH 354
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFOPHP.TION Synthetrc
400 SEQUENCE 73
gaagtgcacc tggtgcagtc tgggggaggc ttggtacagc ctggggggt.c cctgagactc
tcctgtgcag cctctggatt cacctttaac aactatgcca t.gaactgggt ccgccaggct 12 0
ccaggaaagg gactggactg ggtctcaact attagtgota gcggtggtac tacaaactac 180
gcagactccg tgaagggccg tttcattatt tcccgagaca gttccaaaca cacgctgtat 240
ctgcaaatga acagcctgag agccgaggac acggccgtat attactgtgc gaaagattct 300
aactggggaa at.ttcgatct ctggggccgt ggcaccacgg tcactgtctc ctca 354
210 SEQ ID NO 74
211 LEI'GTH 118
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE
c223 OT!'ER INPOR!NATION Synthetrc
400 SEQUENCE 74
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cys !\Ia !\Ia Ser Gly Phe Thr Phe Asn !\sn Tyr
20 25 30
Ala !set Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu .4 p Trp Val
35 40 45
Ser Thr Ile Ser Gly Ser Gly Gly Thr Thz Asn Tyr Ala Asp Ser Val
50 55 0
Lys Gly Arg Phe Ile Ile Ser Arg Asp Ser Ser Lys Hrs Thr Leu Tyr
70 75 80
Leu Gln !4et Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Ly. Asp Ser Asn Trp Gly .'. n Phe A p Leu Trp Gly Arg Gly Thr
100 105 110
Thr Val Thr Val Ser Ser
115
210 SEQ ID NO 75
211 LENGTH 24
212 TYPE DNA
213 ORGAIIISH Artrfrcral Sequence
220 FEATURE:
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 75
ggattcacct ttaacaacta tgcc
210 SEQ ID NO 75
211 LENGTH 8
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
79
US 8,062,640 B2
-continued
80
220 PEATURR.
223 OTHER INFORN"TION Synthetic
400 SEQUENCE 75
Gly Phe Thr Phe Aen Aen Tyr Ala
I 5
210 SEQ ID NO 77
211 LENGTH 24
212 TYPE DNA
213 ORGANISN Artificial Sequence
220 FEATURE
223 OTHER INPORFZATZON Synthetic
400 SEQUENCE 77
attagtggta gcggtggtac tace
210 SEQ ID NO 78
211 LENGTH 8
212 TYPE PRT
213 ORGANISN Artificial Sequence
220 FEATURE:
223 OTHER INPORNATION Synthetic
400 SEQUENCE 78
Ile Ser Gly Ser Gly Gly Thr Thr
5
210 SEQ ID NO 79
c211 LENGTH 33
212 TYPE DZ'IA
213 ORGANIISN Artificial Sequence
220 FEATURE.
223 OTHER INFORNATION Synthetic
400 SEQUENCE 79
gcgaaagatt ctaactgggg aaatttcgat ctc 33
210 SEQ ID NO 80
211e LENGTH 11
212a T'ZPE PRT
213 ORGANISE Artificial Sequence
220 FEATURE:
223 OTHER INFORNATION Synthetic
400 SEQUENCE 80
Ala Ly. Aep Ser Aen Trp Gly .4 n Phe Aep Leu
1 5 10
210 SEQ ID NO 81
211 LENGTH 342
212 TYPE DNA
213 ORGANISN Artif
220 FEATURE
223 OTHER INFORNATI
icial Sequence
ON Synthetic
400 SEQUENCE 81
gacatccaga r.gacccagtc tccagactcc ctggctgtgt. ctcrgggcga gagggccacc
at.caactgca agtccagcca gagtgtttta tacaggtcca acaataggaa cttcttaggt 12 0
tggtaccagc agaaaccagg gcagcctcct aatctactca tttactgggc at.ctacccgg 180
gaatccgggg tccctgaccg attcagtggc agcgggtctg ggacagattt cactctcacc 240
atcagcaqcc tgcaqgctqa agatgtggca gtttattact gtcaacaata ttatactact 300
ccgtacactt ttggccaggg gaccaaggtg gaaatcaaac ga 342
81
US 8,062,640 B2
-continued
82
210 SEQ ID NO 82
211 LEIsGTH 114
212 TYPE PRT
213 ORGANISN Artzfzctal Sequence
s220 FEATURE;
s223 OTI'ER INPORI44TION. Synthetzc
400 SEQUENCE 82
Asp Ile Gln Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
I 5 10 15
Glu Arg Ala Thr Zle Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Arg
20 25 30
Ser Asn Asn Arg Asn Phe Leu Gly Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Asn Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu .'. p Val Ala Val Tyr Tyr Cy- Glr Glr
85 90 95
Tyr Tyr Thr Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
100 105 110
Lys Arg
210 SEQ ID NO 83
s211 LENGTH 36
212 TYPE DZ'IA
213 ORGANIISN Artrf tcral Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 83
cagagtgttt tatacaggtc caacaatagg aacttc 36
210 SEQ ID NO 84
211s LENGTH 12
212s T'ZPE PRT
213 ORGANISE Arttftctal Sequence
220 FEATURE:
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 84
Gln Ser Val Leu Tyr Arg Ser .4 n A n Arg A n Phe
I 5 10
210 SEQ ID NO 85
211 LENGTH 9
212 TYPE DNA
213 ORGANISN Artzfzctal Sequence
220 FEATURE
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 85
tgggcatct
210 SEQ ID NO 8
211 LENGTH 3
212 TYPE PRT
213 ORGAEISN Artzftctal Sequence
220 FEATURE:
223 OTHER INFORNATION Synthetzc
400 SEQUENCE 86
83
US 8,062,640 B2
-continued
84
Trp ala Ser
I
210 SEQ ID NO 87
a211 LENGTH 27
a212 TYPE DNA
213 ORGANIISN Artzfzczal Sequence
220 FEATURE.
223 OTHER INFORMATION Synthetzc
400 SEQUENCE 87
caacaatatt atactactcc gtacact 27
210 SEQ ID NO 88
211 LENGTH 9
212 TYPE PRT
213a ORGMIISN Art.zfzczal Sequence
220 FEATURE
223 OTHER INPORKATION Synthetzc
400 SEQUENCE 88
Gln Gln Tyr Tyr Thr Thr Pro Tyr Thr
I 5
210 SEQ ID NO 89
211 LENGTH 354
212 TYPE DNA
213 ORGAEISN Artzfzczal Sequence
220 FEATURE
223 OTHER INPORKATION Synthetzc
400 SEQUENCE 89
gaggtgcaoc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cct.gagactc 60
tcctgtgcag cctctggatt cacctttaac aactatgcca tgaactgggt ccgccaggct 120
ccaggaaagg gactggactg ggtctcaact attagtggta gcggtggtac tacaaactac 180
gcagactccg tgaagggccg tttcattatt tcccgagaca gttccaaaca cacgctgtat 240
ctgcaaatga acagcctgag agccgaggac acggccgtat attactgtgc gaaagattct 300
aactggggaa atttcgatct ctggggccgt ggcaccctgg t.cactgtctc ctca 354
210 SEQ ID NO 90
211 LENGTH 118
212 TYPE PPT
213 ORGIUIISN Artzfzc
220 FEATURE:
223 OTHER IEFORHATION
zal Sequence
Synthetzc
400 SEQUENCE 90
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Asn Tyr
20 25 30
Ala Het Aan Trp Val Arg Gln Ala Pro Gly Ly Gly Leu Aap Trp Val
35 40 45
Ser Thr Ile Ser Gly Ser Gly Gly Thr Thr Asn Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Ile Ile Ser Arg Asp Ser Ser Lys Hzs Thr Leu Tyr
65 70 75 80
Leu Gln Het Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala L. Asp Ser Asn Trp Gly A n Phe F.cp Leu Trp Gly Arg Gly Trr
100 105 110
85
US 8,062,640 B2
-continued
86
Leu Val Thr Val Ser Ser
115
s210 SEQ ID NO 91
s211 LENGTH 339
212 TYPE Dl'IA
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 91
gacatcgtga tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc 60
atcaactgca agtccagcca gagtgtttta tacaggtcca acaataggaa ctt.cttaggt 120
tggtaccagc agaaaccagg gcagcctcct aatctactca t.ttactgggc atctacccgg 180
gaatccgggg tccctgaccg attcagtggc agcgggtctg ggacagattt cactctcacc 240
atcagcagcc tgcaggctga agatgtggca gtttattact gtcaacaata ttatactact 300
ccgtacactt ttggccagqg gaccaagctg gaqatcaaa 339
210 SEQ ID EO 92
211 LENGTH 113
212 TYPE PRT
213 ORGANISbl Artrfrcral Sequence
220 FEATURE
223 OTHER INFORHFTION Synthetrc
400 SEQUENCE 92
Asp Ile Val Het Thr Gln Ser Pzo 5 p Ser Leu Ala Val Ser Leu Gly
I 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Arg
20 25 30
Ser Asn Asn Arg .Asn Phe Leu Gly Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Asn Leu Leu Ile Tyr Tzp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Thr Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
100 105 110
210 SEQ ID NO 93
211 LENGTH 354
212 TYPE DNA
213 ORGAEISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFOPHP.TION Synthetrc
400 SEQUENCE 93
gaggtgcaac tggtggagtc tgggggaggc ttggtacagc crggggggt.c cctgagactc
tcctgtgcag cctctggatt cacctttaac aactatgcca tgagctgggt ccgccaggct 12 0
ccagggaagg ggctggagtg ggtctcagct attagtgota gcggtggtac tacatactac 180
gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatga acagcctgag agccgaggac acggccgtat attactgtgc gaaagattct 300
aactggggaa atttcgatct ctggggccgt ggcaccctgg tcactgtctc ctca 354
87
US 8,062,640 B2
-continued
88
210 SEQ ID NO 94
211 LENGTH 118
212 TYPE PRT
a213 ORGPSIISN AZtzfzCzal SequenCe
a220 FEATURE:
223 OTHER INFORNATION Synthetzc
400 SEQUENCE 94
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
I 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe A n A n Tyr
20 25 30
Ala Het Ser Trp Val Arg Gln Ala Pro Gly Ly- Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Net A n Ser Leu Azg Ala Glu A p Thz Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Asp Ser Asn Trp Gly Asn Phe asp Leu Trp Gly Arg Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115
210 SEQ ID I'10 95
211 LENGTH 339
212 TYPE DNA
213 ORGANISE Artrfzc
220 FEATURE
223 OTIIER INFORNITION
ral Sequence
Synthetzc
400 SEQUENCE 95
gacatcgtga tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc
atcaactgca agtccagcca gagtgtttta tacaggtcca acaataggaa cttct.tagct 12 0
tggtaccagc agaaaccagg acagcctcct aagctgctca t.tt.actgggc atctacccgg 180
gaatccggqg tccctgaccg att«agtggc agcgggtctg ggacagattt cactctcacc 240
atcagcagcc tgcaggctga agatgtggca gtttattact gtcaacaata ttatactact 300
ccgtacactt ttqgccaggg gaccaagctg qagatcaaa 339
210 SEQ ID NO 96
211 LENGTH 113
212 TYPE PRT
213 ORGANISN Artzfrc
220 FEATURE
223 OTHER INPORKATION
zal Sequence
Synthetzc
400 SEQUENCE 96
Asp Ile Val Net Thr Gln Ser Pro 4 p Ser Leu Ala Val Ser Leu Gly
I 5 10 3.5
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Arg
20 25 30
Ser Asn fsn Arg Asn Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Ile Tyz Tzp Ala Ser Tht Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
89
US 8,062,640 B2
-continued
90
65 70 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Thr Tlr Pro Tyr Thr Phe Gly Gln Gly Thr Ly- Leu Glu Ile
100 105 110
Lys
210 SEQ ID NO 97
211 LENGTH 351
212 TYPE DNA
213 ORGANISN Artzfzczal Sequence
220 FEATURE.
223 OTHER INFORNATION Synthetzc
400 SEQUENCE 97
caggtgcagc tggtgcagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60
tcctgtgcag tctctggatt caccctcagt agctacgata tgcactgggt ccgccaacct 120
acaqgaaaag qtctqgagtg ggtctcagct attggttcta ctgqtgaca- atactatcca 180
ggctccgtga agqgccqatt caccatctcc agagaaaatg ccaagaactc cttgtatctt 240
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgt.gcaag agagggatgg 300
gacgtaccct ttgacttctg gggccaggga accctggtca ccgtctcctc a 351
210 SEQ ID NO 98
211 LENGTH 117
r212 TYPE PRT
213 ORGANHSN Artzfzczal Sequence
220 FEATURE:
223 OTHER INPORNATION: Synthetzc
400 SEQUENCE 98
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
4 p Het Hzs Trp Val Arg Gln Pro Thr Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu
65 70 75 80
Gln Het Asn Ser Leu Arg Ala Gly .'-. p Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Glu Gly Trp Asp Val Pro Phe Asp Phe Trp Gly Gln Gly Thr Lsu
100 105 110
Val Thr Val Ser Ser
115
210 SEQ ID NO 99
211 LENGTH 24
212 TYPE DNA
213 ORGANISN Artzfzctal Sequence
220 FEATURE
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 99
ggattcaccc tcagtagcta cgat
210 SEQ ID NO 100
91
US 8,062,640 B2
-continued
92
211 LENGTH 8
212 TYPE PPT
213 ORMEISM Artrftctal Sequence
220 FEATURE
223 OTHER INFORFZATION Synthetrc
c400 SEQUENCE 100
Gly Phe Thr Leu Ser Ser Tyr Aep
I 5
210 SEQ ID No 101
211 LENGTH 21
212 TYPE DNA
213 ORGAEISM Artrfrcral Sequence
220 FEATURE:
223 OTHER INFORMATION Synthettc
400. SEQUENCE 101
attggttcta ctggtgacac a
210 SEQ ID No 102
211 LENGTH I
212 TYPE PRT
213 ORGPSNSN Artrfrcral Sequence
220 FEATURE.
223 OTHER INPORMATION Synthettc
400 SEQUENCE 102
Ile Gly Ser Thr Gly Aap Thr
I 5
210 SEQ ID No 103
211 LENGTH 33
212 TYPE DNA
213 ORGANISN Arttftctal Sequence
220 FEATURE
223 OTHER INFORMATION Synthetrc
400 SEQUENCE 103
gcaagagagg gatgggacgt a«cctttgac ttc 33
210 SEQ ID No 104
211 LENGTH 11
212 TYPE PRT
213 ORGANISN Artrftctal Sequence
220 FEATURE
223 OTHER INFORM'TION Synthetrc
400 SEQUENCE 104
Ala Arg Glu Gly Trp Aap Pal Pro Phe Aap Phe
I 5 10
210 SEQ ID No 105
211 LENGTH 324
212 TYPE DNA
213 ORGAEISN Artrfrcral Sequence
220 PEATURE:
223 OTHER INPORNATZON: Synthet rc
400 SEQUENCE 105
gccatccagt tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 40
atcacttgcc gggcaagtca ggacattaga aatgatttag gctggtatca gcagaaacca 120
gggaaagccc ctaagctcct gatctatgct gcatccagtt tacaaagtgg ggtcccatca 180
cggttcagcg gcagtggatc tggcacagat ttcactctca ccatcagcag cctgcagcct 240
gaagattttg caacttatta ctgtctacaa gattacaatt acccgtggac gttcggccaa 300
93
US 8,062,640 B2
-continued
94
gggaccaagg tggagatcaa acga 324
210 SEQ ID NO 106
a211 LENGTH 108
a212 TYPE PRT
213 ORGANIISN Artrfzc
220 FEATURE.
223 OTHER INFORMATION
zal Sequence
Synthetzc
400 SEQUENCE 106
Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
I 5 10 15
A p Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg A n A p
20 25 30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
3 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glr pzo
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105
a210 SEQ ID NO 107
211 LEI'GTH 18
212 TYPE DNA
213 ORGPIIISH Artzftc
220 FEATURE.
223 OTHER INFORKATION
zal Sequence
Synthetzc
400 SEQUENCE 107
caggacatta gaaatgat
210s SEQ ID NO 108
211s LENGTH 6
212 TYPE PRT
213 ORGANISbl Artzfzc
220 FEPTUPE
223 OTHER INPORNPTION
tal Sequence
Synthetzc
400 SEQUENCE 108
Gln Asp Ile Arg Asn Asp
I 5
210 SEQ ID NO 109
211 LENGTH 9
212 TYPE DNA
213 ORGAEISN Artzfzc
220 FEATURE
223 OTHER INFORHPTION
zal Sequence
Synthetzc
400 SEQUENCE 109
gctgcatcc
210 SEQ ID NO 110
211 LENGTH 3
212 TYPE PRT
213 ORGANIS'N Artzfzc
220 FEATURE:
223 OTHER INPORHATION
zal Sequence
Synthetzc
400 SEQUENCE 110
95
US 8,062,640 B2
-continued
96
Ala Ala Ser
a210 SEQ ID NO 111
a211 LENGTH 27
212 TYPE Dl'IA
213 ORGANISE Artzfzczal Sequence
220 FEATURE
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 111
ctacaagatt acaattaccc gtggacg 27
210 SEQ ID I'10 112
211 LENGTH 9
212s T'IPE PRT
213 ORGANISE Artzfzczal Sequence
220 FETTURE
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 112
Leu Gln Asp Tyr Asn Tyr Pzo Trp Thr
I 5
210 SEQ ID NO 113
211 LEI'GTH 351
212 TYPE DNA
213 ORGANISN Artzfzczal Sequence
220 FEATURE
a223 OTHER INPORNATION Synthetzc
400 SEQUENCE 113
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60
tcctgtgcag tctctggatt caccctcagt agctacgata tgcactgggt ccgccaacct 120
acaggaaaag gtctggagtg ggtctcagct attggttcta ctggtgacac atactatcca 180
ggctccgtga agggccgatt caccatctcc agagaaaatg ccaagaactc cttgtatctt 240
caaatgaaca gcctgagagc cggggacacg gctgtgtatt. actgtgcaag agagggatgg 300
gacgtaccct ttgacttctg gggccaggga accctggtca ccgtctcctc a 351
210 SEQ ID NO 114
211 LENGTH 117
212 TYPE PRT
213 ORGANISN Artzfzc
220 FEATURE:
223 OTHER INFORNATION
zal Sequence
Synthetzc
400 SEQUENCE 114
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
5 10 15
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
Asp Net Hz Trp Val Arg Gln Pro Thr Gly Ly Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu
65 70 75 80
Gln Het Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
!\rg Glu Gly Trp Asp Val Pro Phe !\sp Phe Trp Gly Gln Gly Thr Leu
97
US 8,062,640 B2
-continued
100 105 110
Val Thr Val Ser Ser
115
c210 SEQ ID NO 115
211 LEI'GTH 321
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORSIATION Synthetrc
400 SEQUENCE 115
gccatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc
atcacttgcc gggcaagtca ggacattaga aatgatttag gct.ggtatca gcagaaacca
gggaaagccc ctaagctcct gatctatgct gcatccagtt t.acaaagtgg ggt.cccatca
12 0
180
cggttcagcg gcagtggatc tggcacagat ttcactctca ccatcagcag cctgcagcct 240
gaagattttg caacttatta ctgtctacaa gattacaatt acccgtggac gttcggccaa 300
gggaccaagg tggaaatcaa a 321
210 SEQ ID NO 11
211 LENGTH 107
212 TYPE PRT
213 ORG62IISH Artrfrcral Sequence
220 FEATURE
223 OTHER INFORFIATION Synthetzc
c400 SEQUENCE 116
Ala Ile Gln Net Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
I 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Asn Asp
20 25 30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly L. Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala 6'er Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 ". 5 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Ly. Val Glu Ile Lys
100 105
210 SEQ ID NO 117
211 LENGTH 351
212 TYPE DNA
213 ORGANISN Artzfzczal Sequence
220 FEATURE
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 117
gaggtgcagc r.ggtggagtc tgggggaggc ttggtacagc crggggggr.c cctgagactc
tcctgtgcag cctctggatt caccctcagt agctacgata tgcactgggt ccgccaagct 12 0
acaggaaaag gtctggagtg ggt.ctcagct attggttcta ctggtgacac at.actatcca 180
ggctccgtga agggccgatt caccatctcc agagaaaatg ccaagaactc cttgtatctt 240
caaatgaaca qcctqagaqc cggggacacg gctgtgtatt actgtgcaag agagggatgg 300
gacgtaccct ttgacttctg gggccaggga accctggtca ccgtctcctc a 351
99
US 8,062,640 B2
-continued
100
210 SEQ ID NO 118
211 LElsGTH 117
212 TYPE PRT
213 ORGANISN Artzfzczal Sequence
s220 FEATURE;
s223 OTHER INPORftATION. Synthetzc
400 SEQUENCE 118
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
A p Net Hrs Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu
65 70 75 80
Gln Net Asn Ser Leu Arg Ala Gly A p Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Glu Gly Trp Asp Val Pro Phe Asp Phe Trp Gly Gln Gly Tlsr Leu
100 105 110
Val Thr Val Ser Ser
115
s210 SEQ ID NO 119
211 LEI'GTH 321
212 TYPE DNA
213 ORGAIIISN Artzfrc
220 FEATURE.
223 OTHER INFORKATION
zal Sequence
Synthetrc
400 SEQUENCE 119
gccatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggcaagtca ggacattaga aatgatttag gctggtatca gcagaaacca 120
gggaaagccc ctaagctcct gatctatgct gcatccagtt t.acaaagtgg ggt.cccatca 180
aggttcagcg gcagtggatc tggcacagat ttcactctca ccatcagcag cct.gcagcct 240
gaagattttg caacttatta ctgtctacaa gattacaatt acccgtggac gttcggccaa 300
gggaccaagg tggaaatcaa a 321
210 SEQ ID NO 120
211 LENGTH 107
212 TYPE PRT
213 ORGANISE Artrfrc
220 FEATURE
223 OTHER INPORKATION
ral Sequence
Synthetzc
400 SEQUENCE 120
Ala Ile Gln Net Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
I 5 10 15
A p Arg Val Thr Ile Thr Cy. I.rg Ala Ser Gln Asp Ile Arg Asn Asp
20 25 30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala 6'er Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
101
US 8,062,640 B2
-continued
102
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
210 SEQ ID NO 121
211 LENGTH 384
212 TYPE DNA
213 ORGANISN Artzfzczal Sequence
220 FEATURE
223 OTHER INFOPMP.TION Synthetzc
400 SEQUENCE 121
caggtgcacc tgcaggagtc ggggccagga ctggtgaagc ctt.cggagac cctgt.ccctc
acctgcactg tctctgggga ctccatcaat acttactact ggagctggtt ccggcagccc 12 0
ccagggaagg gactggagtg gattgggtat atctattata gtggaaccac caactacaac 180
ccctccctca agagtcgagt caccatatca atagacacgc ccaggaacca gttctccctg 240
aagctgatct ctgtgaccgc agcggacacg gccgtgtatt actgtgcgag agagaggatt
actatgatt.c ggggagttac cctctactat tactcctacg gtatggacgt ctggggccaa
300
360
gggaccacgg tcaccgtctc ctca 384
210 SEQ ID NO 122
211 LENGTH 128
212 TYPE PRT
c213 ORGANISI4 Artzfzczal Sequence
220 FEATURE:
223 OTHER INFORMATION. Synthetzc
400 SEQUENCE 122
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
I 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile A n Thr Tyr
20 25 30
Tyr Trp Ser Trp Phe Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Ile Asp Thr Pro Arg Asn Gln Phe Ser Leu
65 70 75 80
Ly. Leu Ile Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Glu Arg Ile Thr Met Ile Arg Gly Val Thr Leu Tyr Tyr Tyr Ser
100 105 110
Tyr Gly Iset Asp 'Zal Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 123
211 LENGTH 24
212 TYPE ONA
213 ORGANISM Artzfzczal Sequence
220 FEATURE
223 OTHER INFORMATION Synthetzc
400 SEQUENCE 123
ggggactcca tcaatactta ctac 24
210 SEQ ID NO 124
211 LENGTH 8
103
US 8,062,640 B2
-continued
104
212 TYPE PRT
213 ORGANISM Artificial Sequence
220 FEATURE
223 OTHER INFORMPTION Synthetic
r400 SEQUENCE 124
Gly Asp er Ile Aan Thr Tyr Tyr
I 5
210 SEQ ID NO 125
211 LENGTH 21
212 TYPE DNA
213 ORGANISN Artificial Sequence
220 FEATURE.
223 OTHER INFORMATION Synthetic
400 SEQUENCE 125
atctattata gtggaaccac c 21
210 SEQ ID NO 12
211 LENGTH 7
212 TYPE PRT
213 ORGANISN Artificial Sequence
220 FEATURE:
223 OTHER INFOPMATION Synthetic
400 SEQUENCE 126
Ile Tyr Tyr Ser Gly Thr Thr
5
210 SEQ ID I'10 127
211 LENGTH 66
212 TYPE DNA
213 ORGANISM Artificial Sequence
220 FEATURE
223 OTHER INFORNPTION Synthetic
400 SEQUENCE 127
gcgagagaga ggattactat gattcgggga gttaccctct actattactc ctacggtatg
gacgtc
210 SEQ ID NO 128
211 LENGTH 22
212 TYPE PRT
213 ORGANISM Artificial Sequence
220 FEATURE
223 OTHER INFORMATION Synthetic
400 SEQUENCE 128
Ala Arg Glu Arg Ile Thr Met Ile Arg Gly Val Thr Leu Tyr Tyr Tyr
I 5 10 15
Ser T.r Gly Met Aap Yal
20
210 SEQ ID NO 129
211 LENGTH 324
212 TYPE DNA
213 ORGANISM Artificial Sequence
220 FEATURE
223 OTHER INFORMATION Synthetic
400 SEQUENCE 129
gacatccaga tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc
atcacttgct gggccagtca ggacattagc agttatttag cctggtatca gcaaaaacca 12 0
gggatagccc ctaagctcct gatctatgct gcatccactt tgcaaagtgg ggtcccatca 180
105
US 8,062,640 B2
-continued
106
aggttcggcg gcagtggatc tgggacagaa ttcactctca caatcagcag cctgcagcct 240
gaagattttg caacttatta ctgtcaacag cttaatagtt accctcggac gttcggccaa 300
gggaccaagg tggaaatcaa acga 324
210 SEQ ID NO 130
211 LENGTH 108
212 TYPE PRT
213 ORGANISN Artrftc
220 FEATURE
223 OTHER INFORHPTION
ral Sequence
Synthetrc
400 SEQUENCE 130
2 p Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
I 5 10 15
Asp Arg Val Thr Ile Thr Cys Trp Ala Ser Gln Asp Ile Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Ile Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Gly Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 SO
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Ly Arg
100 105
210 SEQ ID NO 131
211 LENGTH 18
212 TYPE DNA
213 ORGANISE .Artrfrc
220 FEATURE.
223 OTHER INFORHATION
tal Sequence
Synthetrc
400 SEQUENCE 131
caggacatta gcagttat 18
210 SEQ ID NO 132
211 LENGTH 6
212 TYPE PPT
213 ORGINIISN Artrftc
220 FEATURE:
223 OTHER IEFORHATION
ral Sequence
Synthetrc
400 SEQUENCE 132
Gln Asp Ile Ser Ser Tyr
I 5
210 SEQ ID NO 133
211 LENGTH 9
212 TYPE DNA
213 ORGPNISH Artrf tc
220 FEATURE:
223 OTHER INPORHATION
tal Sequence
Synthettc
400 SEQUENCE 133
gctgcatcc
210 SEQ ID NO 134
211 LENGTH 3
212 TYPE PRT
213 ORGANISE Artrfrctal Sequence
107
US 8,062,640 B2
-continued
220 PEATURR.
223 OTHER INFORN"ZION Synthetic
400 SEQUENCE 134
..Za Ala Ser
I
210 SEQ ID NO 135
211 LENGTH 27
212 TYPE DNA
213 ORGAEISN Artificial Sequence
220 FEATURE
223 OTHER INPORFZATION Synthetic
400 SEQUENCE 135
caacagctta atagttaccc tcggacg 27
210 SEQ ID NO 136
211 LENGTH 9
212 TYPE PRT
213 ORGANISN Artificial Sequence
220 FEATURE:
223 OTHER INPORNATION Synthetic
400 SEQUENCE 13
Gln Gln Leu Asn Ser Tyr Pro Arg Thr
5
210 SEQ ID NO 137
e211 LENGTH 384
212 TYPE Dl'IA
213 ORGANIISN Artificial Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetic
400 SEQUENCE 137
caggtgcagc tgcaggagtc ggggccagga ctggtgaagc cttcggagac cctgtccctc 60
acctgcactg tctctgggga ctccatcaat acttactact ggagctggtt ccggcagccc 120
ccagggaagg gactggagtg gattgggtat atctattata gtggaaccac caact.acaac 180
ccctccctca agagtcgagt caccatatca atagacacgc ccaggaacca gtt.ctccctg 240
aagctgatct ctgtgaccgc agcggacacg gccgtgtatt actgtgcgag agagaggatt 300
actatgattc ggggagttac cctctactat tactcctacg gtatggacgt ctggggccaa 360
gggaccacgq tcaccgtctc ctca 384
210 SEQ ID NO 138
211 LENGTH 128
212 TYPE PRT
213 ORGANISN Artific
220 FEATURE
223 OTHER INPORKATION
ial Sequence
Synthetic
400 SEQUENCE 138
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Ly Pro Ser Glu
I 5 10 1.5
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Asn Thr Tyr
20 25 30
Tyr Trp Ser Trp Phe Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyt Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Ile Asp Thr Pro Arg Asn Gln Phe Ser Leu
109
US 8,062,640 B2
-continued
65 70 80
Lys Leu Ile Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Glu Azg Ile Thr Het Ile Azg Gly Val Thr Leu Tyr Tyr Tyz Sez
100 105 110
Tyr Gly Het Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 139
211 LENGTH 321
212 TYPE DNA
213 ORGAEISH Artzfzczal Sequence
220 FEATURE:
223 oTHER INPORNATION Synthetzc
400. SEQUENCE 139
gacatccaga tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgct gggccagtca ggacattagc agttatttag cctggtatca gcaaaaacca 120
gggatagccc ctaagctcct gatctatgct gcatccactt tgcaaagtgg ggtcccatca 180
aggttcggcg gcagtggatc tgggacagaa ttcactctca caatcagcag cctgcagcct 240
gaagattttg caacttatta ctgtcaacag cttaatagtt accctcggac gttcggccaa 300
gggaccaagg tggaaatcaa a 321
210 SEQ ID NO 140
s211 LENGTH 107
212 TYPE PRT
213 ORGANNSN Artzfzczal Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 140
Asp Ile Gln Net Thr Gln Sez Pzo Sez Phe Leu Ser Ala Sez Val Gly
I 5 10 15
Asp Arg Val Thr Ile Thz Cys Tzp Ala Ser Gln Asp Ile Sez Sez Tyz
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Ile Ala Pro Lys Leu 'u Ile
35 40 45
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Gly Gly
50 55 60
Ser Gly er Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
210 SEQ ID NO 141
211 LEI'GTH 384
212 TYPE DNA
213 ORGANISE Artzfzczal Sequence
220 PEATURE:
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 141
caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc 60
acctgcactg tctctgggga ctccatcaat acttactact ggagctggat ccggcagccc 120
ccagggaagg gactggagtg gattgggtat atctattata gtggaaccac caactacaac 180
111
US 8,062,640 B2
-continued
ccctccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gtt.ctccctg 240
aagctgagct ctgtgaccgc tgcggacacg gccgtgtatt actgtgcgag agagaggatt 300
actatgattc ggggagttac cctctactat tactcctacg gtatggacgt ctggggccaa 360
gggaccacgg tcaccgtctc ct.ca 384
210 SEQ ID NO 142
211 LENGTH 128
212 TYPE PRT
213 ORGANISN Artzfzczal Sequence
220 FEATURE
223 OTHER INPORIAATION Synthetzc
400 SEQUENCE 142
Gln Val Gln Leu Gln Glu ser Gly Pro Gly Leu Val Lys Pro ser Glu
I 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly fsp Ser Zle Asn Thr Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pzo Pro Gly Ly- Gly Leu Glu Trp Ile
35 40 45
Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyt Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Glu Azg Ile Thr Sist Ile Azg Gly Val Thr Leu Tyr Tyr Tyr Sez
100 105 110
Tyr Gly Het Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 143
211 LEIIGTH 321
212 TYPE DNA
213 ORGANIS'N Artzfzczal Sequence
220. PEATURE.
223. OTHER INFORNATION Synthetzc
400 SEQURNCE 143
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggcaagtca ggacattagc agttatttag gctggtatca gcagaaacca 120
gggaaagccc ctaagcgcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca caatcagcag c.ctgc.agcct 240
gaagattttg caacttatta ctgtcaac.ag cttaatagtt accctcggac gttcggc.caa 300
gggaccaagg tggaaatcaa a 321
210 SEQ ID NO 144
211 LEI'GTH 107
212 TYPE PRT
213 ORGANISE Artzfzczal Sequence
220 PEATURE:
223 OTHER INFORNATION Synthetzc
400 SEQUENCE 144
Asp Ile Gln Met Thr Gln Ser Pzo Ser Ser Leu Ser Ala Ser Val Gly
I 5 10 15
A p 'rg Val Thr Ile Thr Cy- ..zg Ala Ser Gln A p Ile Ser Sez Tyr
20 25 30
113
US 8,062,640 B2
-continued
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
210 SEQ ID NO 145
211 LENGTH 378
212 TYPE DNA
213s ORGANISM Art.rfrcral Sequence
220 FEATURE
223 OTHER INPORKATION Synthetrc
400 SEQUENCE 145
caggtgcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc
tcctgcaagg ct.tctggtta cacctrtacc aactatggta tcagctgggt gcgacaggcc 12 0
cctggacaag gacttgagtt aatgggatgg attagtggtt acaatggtaa c.acaaactat 180
gcacaagaac tccaggccag agtcaccatg accacagaca catccacgag cacagcctac 240
atggagctga ggaacctgag atctgacgac acggccgtat attactgtgc gagagataga 300
gt.cgttgtag cagctgctaa ttact.acttt tattct.atgg acgtctgggg ccaagggacc 360
acggt.caccg tctcctca 378
210 SEQ ID NO 146
211 LENGTH 126
212 TYPE PRT
213 ORGANISM Artrfrc
220 FEATURE.
223 OTHER INFORFZATION
ral Sequence
Synthetrc
400. SEQUENCE 146
Gln Val Gln Leu Val Gln Sez Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Gly Ile er Trp Val Azg Gln Ala Pro Gly Gln Gly Leu Glu Leu Net
35 40 45
Gly Trp Ile Ser Gly Tyr A"n Gly Asn Thr Asn Tyr Ala Gln Glu Leu
50 55 0
Gln Ala Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Tlsr Ala Tyr
65 70 75 80
Met Glu Leu Arg Asn Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Azg Val Val Val Ala Ala Ala Asn Tyr Tyr Phe Tyr Ser
100 105 110
Net Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 147
211 LENGTH 24
212 TYPE DNA
213 ORGANISM Aztrfrc
220 FEATURE.
223 OTHER INFORMATION
ral Sequence
Synthetrc
115
US 8,062,640 B2
-continued
400 SEQUENCE 147
ggttacacct ttaccaacta tggt
c210 SEQ ID NO 148
211 LEI'GTH 8
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORSIATION Synthetrc
400 SEQUENCE 148
Gly Tyr Thr Phe Thr A n Tyr Gly
I 5
210s SEQ ID NO 149
211 LEHGTH 24
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 149
attagtggtt acaatggtaa ceca
210 SEQ ID NO 150
211 LENGTH 8
212 TYPE PRT
213 ORGAEISN Artrfrcral Sequence
c220 FEATURE:
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 150
Ile Ser Gly Tyr Asn Gly Asn Thr
I 5
210 SEQ ID NO 151
211 LENGTH 57
212 TYPE DNA
213s ORGWIISN Artrfrcral Sequence
220. FEATURE.
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 151
gcgagagata gagtcgttgt agcagctgct aattactact tttattctat ggacgtc 57
210 SEQ ID EO 152
211 LENGTH 19
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORHATI013 Synthetrc
400 SEQUENCE 152
Ala Arg Asp Arg Val Val Val Ala Ala Ala Asn Tyr Tyr Phe Tyr Ser
I 5 10 15
Het A p Val
210 SEQ ID NO 153
211 LENGTH 339
212 TYPE DNA
213 ORGAEISN Artrfrcral Sequence
220 FEATURE:
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 153
117
US 8,062,640 B2
-continued
gccatccaga tgacccagtc tccactctcc ctgtccgtca cccttggaca gccggcctcc 60
atctcctgca ggtctagtca aagcctcgta tacagtgatg gagacaccta cttgaattgg 120
tttcagcaga ggccaggcca atctccaagg cgcctaattt ataaggtttc taaccgggac 180
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgctttcac actgaaaatc 240
agcggggtgg aggccgagga tgttggggtt tactactgca tgcaagctac acactggcct 300
cggacgttcg gccaagggac caaggtggaa atcaaacga 339
210 SEQ ID NO 154
211 LENGTH 113
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 PEATURE:
223 UTHER INpoRNATIUN synthetrc
400 SEQUENCE 154
Ala Ile Gln Met Thr Gln Ser Pro Leu Ser Leu Ser Val Thr Leu Gly
I 5 10 15
Gln Pro Ala Ser Ile Ser Cye Azg Ser Ser Gln Ser Leu Val Tyz Ser
20 25 30
Asp Gly Asp Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
35 40 45
Pro Arg Prg Leu Ile Tyr Lys Val Ser Asn Prg Asp Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Lys Ile
65 70 75 80
Ser Gly Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cy. Net Gln Ala
85 90 95
Thr Hzs Trp Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110
Arg
210 SEQ ID NO 155
211a LENGTH 33
212a T'ZPE DNA
213 ORGANISE Artrfrcral Sequence
220 FEATURE:
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 155
caaagcctcu tatacantga tggagacacc tac 33
210 SEQ ID NO 156
211 LENGTH 11
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INPORKATION Synthetzc
400 SEQUENCE 156
Gln Ser Leu Val Tyr Ser Asp Gly 4 p Thr Tyr
I 5 10
210 SEQ ID NO 157
211 LENGTH 9
212 TYPE DNA
213 ORGANISN Artzfrcral Sequence
220 FEATURE:
223 OTHER INFORNATION Synthetzc
400 SEQUENCE 157
119
US 8,062,640 B2
-continued
120
aaggtttct
210 SEQ ID NO 1.58
211 LENGTH 3
a212 TYPE PRT
a213 ORGANIS14 Aztrfrcral Sequence
220 FEATURE:
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 158
Lya Val Ser
210 SEQ ID NO 159
211 LENGTH 27
212 TYPE DNA
213a ORGPIIISN Art.rfrcral Sequence
220 FEATURE
223 OTHER INPORKATION Synthetrc
400 SEQUENCE 159
atgcaagcta cacactggcc tcggacg 27
210 SEQ ID NO 160
211 LENGTH 9
212 TYPE PRT
213 ORG63IISH Artrfrcral Sequence
220 FEATURE
223 OTHER INFORFLATION Synthetrc
a400 SEQUENCE 160
feet Gln Ala Thr Hre Tzp Pzo Arg Thr
1 5
210 SEQ ID NO 161
211 LENGTH 378
212 TYPE DNA
213 ORGAEISH Artrfrcral Sequence
220 FEATURE.
223 OTHER INFOPHATION Synthetrc
400. SEQUENCE 161
caggttcaac tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agt.gaaggtc
tcctgcaagg cttctggtta cacctttacc aactatggta tcagctgggt gcgacaggcc 12 0
cctggacaag gacttgagtt aatgggatgg attagtgott acaatggtaa cacaaactat 180
gcacaagaac tccaggccag agtcaccatg accacagaca catccacgag cacagcctac 240
atggagctga ggaacctgag atctgacgac acggccgtat attactgtgc gagagataga 300
gtcgttgtag cagctgctaa ttactacttt tattctatgg acgtctgggg ccaagggacc 360
acggtcaccg tctcctca 378
210 SEQ ID NO 162
211 LEI'GTH 126
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 PEATURE:
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 162
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lye Lya Pro Gly Ala
I 5 10 15
Ser Val Ly. Val Ser Cy- Lya Ala Ser Gly Tyr Thr Phe Thr A r Tyr
20 25 30
121
US 8,062,640 B2
-continued
122
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Leu Net
35 40 45
Gly Trp Ile Ser Gly Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Glu Leu
50 55 60
Gln Ala Arg val Thr Het Thr Thr 4 p Thr ser Thr ser Thr I;la Tyr
65 70 75 80
Net Glu Leu Arg Asn Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Arg Val Val Val Ala Ala Ala Asn Tyr Tyr Phe Tyr Ser
100 105 110
Het Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210a SEQ ID NO 163
211 LEHGTH 33
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 163
gatgttgtga tgactcagtc tccactctcc ctgtccgtca ccctt.ggaca gccggcctcc 0
atctcctgca ggtctagtca aagcctcgta tacagtgatg gagacaccta cttgaattgg 120
tttcagcaga ggccaggcca atctccaagg cgcctaattt ataaggtttc taaccgggac 180
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgctttcac actgaaaatc 240
agcggggtag aggccgagga tgttggggtt tactactgca tgcaagctac acact.ggcct 300
cggacgttcg gccaagggac caaggtggaa atcaaa 336
210 SEQ ID NO 164
211 LENGTH 112
212 TYPE PRT
213 ORGAEISH Artrfrc
220 FEATURE.
223 OTHER INFORHATION
ral Sequence
Synthetrc
400. SEQUENCE 164
Asp Val Val tfet Thr Gln Ser Pro Leu Ser Leu Ser Val Thr Leu Gly
5 10
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
.Aep Gly Asp Thr Tyr Leu .Aen Trp Phe Gln Gln Arg Pro Gly Gln Ser
35 40 45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Lys Ile
65 70 75 80
Ser Gly Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
Thr Hzs Trp Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110
210 SEQ ID NO 165
211 LENGTH 378
212 TYPE DNA
213 ORGANIS'N Artrfrc
220 FEATURE:
223 OTHER INPORHATION
ral Sequence
Synthetrc
400 SEQUENCE I 5
123
US 8,062,640 B2
-continued
124
caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc
tcctgcaagg cttctggtta cacctttacc aactatggta tcagctgggt gcgacaggcc 12 0
cctggacaag ggcttgagtg gatgggatgg attagtggtt acaatggtaa cacaaactat 180
gcacagaacc tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccgtgt attactgtgc gagagataga 300
gtcgttgtag cagctgctaa ttactacttt tattctatgg acgtctgggg ccaagggacc 360
acggtcaccg tctcctca 378
210 SEQ ID NO 166
211 LENGTH 126
212 TYPE PRT
213s ORGPIIISN Art.ificial Sequence
220 FEATURE
223 OTHER INPORKATION Synthetic
400 SEQUENCE I
Gln Val Gln Leu Val Gln Sez Gly Ala Glu Val Ly- Ly- Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Ser Gly Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu
50 55 60
Gln Gly Arg Val Thr Net Thr Thr 5 p Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Net Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Arg Val Val Val Ala Ala F.la Asn Tyr Tyr Phe Tyr Ser
100 105 110
Net Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 167
211 LENGTH 336
212 TYPE DNA
213 ORGANISE Artificial Sequence
220 FEATURE
223 OTHER INFORPATION Synthetic
400 SEQUENCE 167
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc
atctcctgca ggtctagtca aagcctcgta tacagtgatg gagacaccta cttgaattgg 12 0
tttcagcaga ggccaggcca atctccaagg cgcctaattt ataaggtttc taaccgggac 180
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc 240
agcagggtcg aggctgagga tgttggggtt tattactgca t.gcaagctac acactggcct
cggacgttcg gccaagggac caaggtggaa atcaaa
300
336
nce
10
210 SEQ ID NO 168
211 LENGTH 112
212 TYPE PRT
213 ORGANIS'N Artificial Seque
220 FEATURE:
223 OTHER INPORHATION Synt!1st
400 SEQUENCE I 8
125
US 8,062,640 B2
-continued
126
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
5 10
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
Asp Gly Asp Thr Tyr Leu A n Tzp Phe Gln Gln Azg Pro Gly Gln Sez
35 40 45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 0
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
Thr Hrs Trp Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110
210 SEQ ID NO I 9
211 LENGTH 375
212 TYPE DNA
213 ORGANISN Artrfrc
220 FEATURE:
223 OTHER INFOPMATION
ral Sequence
Synthetrc
400 SEQUENCE 169
caggtccact tgaaggagtc tggtcctacg ctggtgaaac ccacacagac cctcacgctg 60
acctgcacct tctctggatt ctcactcatc actagtggag tgggtgtggg ctggattcgt 12 0
cagccccccg gaaaggccct ggagtggctt gcactcattt. attggaatgg t.gataagcgc 180
tacagcccat ctctgaagag caggctcacc atcaccaagg acacctccaa aaaccaggtg 240
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacagg 300
at.aactgaaa ctagttacta cttctactac ggtatggacg tctggggcca agggaccacg 360
gtcaccgtct cctca 375
210s SEQ ID NO 170
211s LENGTH 125
212 TYPE PRT
213 ORGANISbl Artrfrc
220 FEATUPE
223 OTHER INPORNTTION
ral Sequence
Synthetrc
400 SEQUENCE 170
Gln Val Hz Leu Ly. Glu Ser Gly Pro Thr Leu Val Ly. Pro Thr Gln
I 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ile Thr Ser
20 25 30
Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
35 40 45
Trp Leu Ala Leu Ile Tyr Trp Asn Gly Asp Lys Arg Tyr Ser Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Thr Lys A p Thr Ser Lys A n Gln Val
65 70 75 80
Val Leu Tlzr Met Thr Asn Met !\sp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Hzs Arg Ile Thr Glu Thr Ser Tyr Tyr Phe Tyr Tyr Gly Net
100 105 110
A p Val Tzp Gly Gln Gly Thz Thr Val Thr Val Ser Ser
115 12 0 125
127
US 8,062,640 B2
-continued
210 SEQ ID NO 171
211 LEI'GTH 30
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
c220 FEATURE;
c223 OTI'ER INPORI44TION. Synthetrc
400 SEQUENCE 171
ggattctcac tcatcactag tggagtgggt 30
210 SEQ ID NO 172
211 LENGTH 10
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 PEATURE:
223 OTHER 111PORNATION Synthetrc
400 SEQUENCE 172
Gly Phe Ser Leu Ile Thr Ser Gly Val Gly
I 5 10
210 SEQ ID NO 173
211 LENGTH 21
212 TYPE DILA
213 ORGANISE Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORH'TION Synthetrc
400 SEQUENCE 173
at.ttattgga atggtgataa g 21
210 SEQ ID NO 174
211 LENGTH 7
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INPORI4ATION Syntretrc
400 SEQUENCE 174
Ile Tyr Trp Acn Gly Aap Lya
I 5
210 SEQ ID NO 175
211 LENGTH 51
212 TYPE DNA
213 ORGIUIISN Artrfrcral Sequence
220 FEATURE:
223 OTHER IEFORHATION Synthetrc
400 SEQUENCE 175
gcacacagca taactgaaac tagttactac ttctactacg gtatggacgt c 51
210 SEQ ID NO 176
211 LENGTH 17
212 TYPE PRT
213 ORGANIISH Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORINATION Synthetrc
400 SEQUENCE 176
Ala Hra Arg Ile Thr Glu Thr Ser Tyr Tyr Phe Tyr Tyr Gly Het Aep
10
Val
210 SEQ ID NO 177
211 LENGTH 339
129
US 8,062,640 B2
-continued
130
212 TYPE DNA
213 ORGANISE Artrftcral Sequence
220 FEATURE
223 OTHER INFORHPTION Synthetrc
c400 SEQUENCE 177
geest.cease tgacccagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgca ggtctagtca gagcctcctg catagtcatg gatacgacta tttggattgg 12 0
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactccg 300
ctcactttcg gcggagggac caaggtggaa atcaaacga 339
210 SEQ ID NO 178
211 LENGTH 113
212 TYPE PRT
213 ORGANISN Artrfrctal Sequence
220 FEATURE:
223 OTHER INFORI44TION Synthetrc
400 SEQUENCE 178
A p Ile Gln Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
I 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Hrs Ser
20 25 30
Mic Gly Tyr Asp Tyr Leu I; p Trp Tyr Leu Gln Ly Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu lie Tyr Leu Gly Ser asn Arg Ala Ser Gly Val Pro
50 55 0
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu .5 p Val Gly Val Tyr Tyr Cys Het Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Ly-
100 105 110
Arg
210 SEQ ID NO 179
211 LEIsGTH 33
212 TYPE DNA
213 ORGPIIISH Artrfrcral Sequence
220 FEATURE;
223 OTHER INFORIIATION Synthetrc
400 SEQUENCE 179
cagagcctcc tgcatagtca tggatacgac tat 33
210 SEQ ID NO 180
211 LEI'GTH 11
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 PEATURE:
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 180
Gln Ser Leu Leu Hrs Ser Hrs Gly Tyr Asp Tyr
I 5 10
210 SEQ ID NO 181
211 LENGTH 9
131
US 8,062,640 B2
-continued
132
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORNPTION Synthetrc
c400 SEQUENCE 181
ttgggttct
210 SEQ ID NO 182
211 LENGTH 3
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 182
Leu Gly Ser
I
210 SEQ ID NO 183
211 LENGTH 27
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE:
223 OTHER INFOPMATION Synthetrc
400 SEQUENCE 183
atgcaagctc tacaaactcc gctcact 27
c210 SEQ ID NO 184
211 LEI'GTH 9
212 TYPE PRT
213 ORGPIIISH Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORKATION Synthetrc
400 SEQUENCE 184
Net Gln Ala Leu Gln Thr Pro Leu Thr
I 5
210a SEQ ID NO 185
211 LENGTH 375
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFORH'TION Synthetrc
400 SEQUENCE 185
cagat.cacct tgaaggagtc tggt.cctacg ctqgtgaaac ccacacagac cctcacgctg 60
acctgcacct tctctggatt ctcactcatc actagtggag tgggtgtggg ctggattcgt 120
cagccccccg gaaaggccct ggagtggctt gcactcattt attggaatgg tgataagcgc 180
tacagcccat ctctgaagag caggctcacc atcaccaagg acacctccaa aaaccaggtg 240
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacagg 300
ataactgaaa ctagttacta cttctactac ggtatggacg t.ctggggcca agggaccacg 360
gtcaccgtct cctca 375
210 SEQ ID NO 186
211 LENGTH 125
212 TYPE PRT
213 ORGANIS'N Artrfrcral Sequence
220 FEATURE:
223 OTHER INPORNATION Synthetrc
400 SEQUENCE 18
133
US 8,062,640 B2
-continued
134
Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln
5 10
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ile Thr Ser
20 25 30
Gly Val Gly Val Gly Trp Ile Azg Gln Pro Pzo Gly Lys Ala Leu Glu
35 40 45
Trp Leu Ala Leu Ile Tyr Trp Asn Gly Asp Lys Arg Tyr Ser Pro Ser
50 55 0
Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys .Asn Gln Val
65 70 75 80
Val Leu Thr Net Thr Asn Net. A p Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
cys Ala Hrs Arg lie Thr Glu Thr ser Tyr Tyr phe Tyr Tyr Gly Net
100 105 110
Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 187
211 LENGTH 336
212 TYPE D1CA
213 ORGANISE Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORN'TION Synthetzc
400 SEQUENCE 187
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc SO
atctcctgca ggtctagtca gagcctcctg catagtcatg gatacgacta tttggattgg 120
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactccg 300
ctcactttcg gcggagggac caaggtggag atcaaa 336
210s SEQ ID NO 188
211 LENGTH 112
212 TYPE PRT
213 ORGANISN Artzfrc
220 FEATURE
223 OTHER INFORN'TION
tal Sequence
Synthetzc
400 SEQUENCE 188
.'. p Ile Val Net Thr Gln Ser Pzo Leu Ser Leu Pro Val Thr Pro Gly
I 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Hzs Ser
20 25 30
Hzs Gly Tyr Asp Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu 'Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
50 55 60
A p Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ly. Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Net Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
210 SEQ ID NO 189
135
US 8,062,640 B2
-continued
136
211 LENGTH 375
212 TYPE DNA
213 ORMEISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFORFLATION Synthetrc
a400 SEQUENCE 189
cagatcacct tgaaggagtc tggtcctacg ctggtgaaac ccacacagac cctcacgctg
acctgcacct tctctggatt ctcactcatc actagtggag tgggtgtggg ctggatccgt 12 0
cagcccccag gaaaggccct ggagtggctt gcactcattt attggaatgg tgataagcgc 180
tacagcccat ctctgaagag caggctcacc atcaccaagg acacctccaa aaaccaggtg 240
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacagg 300
ataactgaaa ctagttacta cttctactac ggtatggacg t.ctggggcca agggaccacg 360
gtcaccgtct cctca 375
210 SEQ ID NO 190
211 LENGTH 125
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE:
223 OTHER INFOPMATION Synthetrc
400 SEQUENCE 190
Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln
5 10 15
Thr Leu Thr Leu Thr Cy Thr Phe Ser Gly Phe Ser Leu Ile Thr Ser
20 25 30
Gly val Gly val Gly Trp Ile .'. g Gln Pro Pro Gly Ly Ala Leu Glu
35 40 45
Trp Leu Ala Leu Ile Tyr Trp Asn Gly Asp Lys Arg Tyr Ser Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys A n Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met A p Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Hr" Arg Ile Thr Glu Thr Ser Tyr Tyr Phe Tyr Tyr Gly Net
100 105 110
Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 191
211 LENGTH 33
212 TYPE DNA
213 ORGANISE Artrfrcral Seque
220 FEATURE
223 OTHER INPORKATION Synthet
nce
10
400 SEQUENCE 191
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc
at.ctcctgca ggtctagtca gagcctcctg catagtcatg gatacgacta tt.tggattgg
60
120
tacctgcaua agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactccg 300
ctcactttcg qcggagggac caaggtggag atcaaa 336
210 SEQ ID NO 192
137
US 8,062,640 B2
-continued
211 LENGTH 112
212 TYPE PPT
213 ORG32IISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFORFIATION Synthetzc
c400 SEQUENCE 192
Asp Ile Val Net Thr Gln Ser Pro L u Ser Leu Pro Val Thr Pro Gly
I 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln
20 25
Ser Leu Leu His Ser
30
Hz Gly Tyr Asp Tyr Leu Asp Trp Tyr Leu Gln Ly Pro Gly Gln Ser
35 40 45
Pro Gin Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Net Gln Ala
85 90 95
Leu Gln Thz Pro Leu Thr Phe Gly Gly Gly Thz Lys Val Glu Ile Lys
100 105 110
210 SEQ ID NO 193
211 LEI'GTH 375
212 TYPE DNA
213 ORGANISN Artzfzc
220 FEATURE
c223 OTHER INPORNATION
zal Sequence
Synthetzc
400 SEQUENCE 193
cagatcacct tgaaggagtc tggtcctact ctggtgaaac cctcacagac cctcacgctg
acctgcacct tctctgggtt ctcactcagc actagtggag tgggtgtggg ctggatccgt 12 0
cagcccccag gaaaggccct ggagtggctt gcactcattt attggaattc tgataagcgc 180
tacagcccat ctctgaagag caggctcacc atcaccaagg acacctccaa aaaccaggta 240
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg t.gcacacaga 300
catgacagct cgtcctacta cttctactac ggtatggacg t.ct.ggggcca agggatcacg 360
gtcaccgtct cctca 375
210 SEQ ID NO 194
211 LENGTH 125
212 TYPE PRT
213 ORG.SIISN AZtrfzC
220 PEATURR.
223 OTHER INFORFIATION
ral Sequence
Synthetrc
400 SEQUENCE 194
Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln
I 5 10 15
Thr Leu Thr Leu Thr Cy Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Val Gly Val Gly Trp Ile I.rg Gln Pro Pro Gly Ly. Ala Leu Glu
35 40 45
Trp Leu Ala Leu Ile Tyr Trp Asn Ser Asp Lys Arg Tyr Ser Pro Ser
50 55 60
Leu Ly 6'er Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80
Val Leu Thr Net Thr Asn Net A p Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
139
US 8,062,640 B2
-continued
140
Cys Ala His Arg His Asp Ser Ser Ser Tyr Tyr Phe Tyr Tyr Gly Het
100 105 110
Asp Val Trp Gly Gln Gly Ile Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 195
211 LENGTH 30
212 TYPE DNA
213 ORGANISN Artificial Sequence
220 FEATURE
223 OTHER INFOPHP.TION Synthetic
400 SEQUENCE 195
gggttctcac tcagcactag tggagtgggt 30
210 SEQ ID NO 196
211 LENGTH 10
212 TYPE PRT
213 ORGAHISN Artificial Sequence
220 FEATURE:
223 OTHER INPORNATION Synt!istic
400 SEQUENCE 196
Gly Phe Ser Leu Ser Thr Ser Gly Val Gly
1 5 10
210 SEQ ID NO 197
211 LENGTH 21
s212 TYPE DNA
213 ORGAHIISH Artificial Sequence
220 FEATURE:
223 OTHER INPORNATZON: Synthetic
400 SEQUENCE 197
at.ttattgga attctgataa g 21
210 SEQ ID NO 198
211 LENGTH 7
212s TYPE PRT
213s ORGM4ISN ArtifiCial SequenCe
220 FEATURE:
223 OTHER INFORNATIOE Synthetic
400 SEQUENCE 198
Ile Tyr Trp Asn Ser Asp Lys
1 5
210 SEQ ID NO 199
211 LENGTH 51
212 TYPE DNA
213 ORGANISN Artificial Sequence
220 FEATURE
223 OTHER INPORKATION Synthetic
400 SEQUENCE 199
gcacacagac atgacagctc gtcctactac ttctactacg gtatggacgt c 51
210 SEQ ID NO 200
211 LENGTH 17
212 TYPE PRT
213 ORGANISE Artificial Sequence
220 FEATURE.
223 OTHER INFOPNATION Synthetic
400 5'EQUENCE 200
!\Za His Arg His Asp Ser Ser Ser Tyr Tyr Phe Tyr Tyr Gly Met !\sp
141
US 8,062,640 B2
-continued
142
10 15
Val
s210 SEQ ID NO 201
s211 LENGTH 339
212 TYPE DZ'IA
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 201
gacatccaga tgacccagtc tccgctctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgca ggtctagtca gagcctcctc catagtcatg gatacaacta tttggattgg 120
tacctgcaga agccagggca gtctccacaa ctcctgatct. atttgggttc t.aatcgggcc 180
tccggggtcc ctgacaggtt cagtggcggt ggatcaggca cagattttac actgaaaatc 240
agcagagtug aggctgagga tgttgggatt tattactgca tgcaagctct acagactcct 300
ctcactttcg qcggagggac caaggtggag atcaaacga 339
210 SEQ ID EO 202
211 LENGTH 113
212 TYPE PRT
213 ORGANISbl Artrfrcral Sequence
220 FEATURE
223 OTHER INFORHPTION Synthetrc
400 SEQUENCE 202
Asp Ile Gln Het Thr Gln Ser Pzo Leu Ser Leu Pzo Val Thr Pro Gly
I 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
20 25 30
His Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pzo
50 55 60
4 p Arg Phe Ser Gly Gly Gly Ser Gly Thz Asp Phe Thr Leu 's Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
..rg
210 SEQ ID NO 203
211 LENGTH 33
212 TYPE DNA
213 ORGAEISN Artzfrcral Sequence
220 FEATURE
223 OTHER INFOPHP.TION Synthetzc
400 SEQUENCE 203
cagagcctcc tccatagtca tggatacaac tat 33
210 SEQ ID NO 204
211 LENGTH 11
212 TYPE PRT
213 ORGANIS'N Artzfzcral Sequence
220 FEATURE:
223 OTHER INPORHATION Synthetrc
400 SEQUENCE 204
143
US 8,062,640 B2
-continued
144
Gln Ser Leu Leu Hrs Ser Hrs Gly Tyr Asn Tyr
5 10
e210 SEQ ID NO 205
e211 LENGTH 9
212 TYPE DZ'IA
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 205
ttgggttct
210 SEQ ID NO 206
211 LENGTH 3
212s T'ZPE PRT
213 ORGANISE Artrfrcral Sequence
220 FEZTURE
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 206
Leu Gly er
1
210 SEQ ID NO 207
211 LEI'GTH 27
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE
e223 OTHER INPORNATION Synthetrc
400 SEQUENCE 207
at.gcaagctc tacagactcc tct.cact 27
210 SEQ ID NO 208
211 LENGTH 9
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE:
223. OTHER INPOPNATION Synthetrc
400 SEQUENCE 208
Net Gln Ala Leu Gln Thr Pro Leu Thr
I 5
210 SEQ ID NO 209
211 LENGTH 375
212 TYPE DNA
213 ORGANISE Artrf
220 FEATURE.
223 OTHER INFORHATI
rcral Sequence
ON Synthetrc
400 SEQUENCE 209
cagatcacct tgaaggagtc tggtcctact ctggtgaaac cctcacagac cctcacgctg
acctgcaccr. r.ctcrgggr.t ctcactcagc actagtggag tgggtgtggg ctggar.ccgt
cagcccccag gaaaggccct ggagr.ggctt gcactcattt. attggaattc tgar.aagcgc
12 0
180
tacagcccat ctctgaagag caggctcacc atcaccaagg acacctccaa aaaccaggta 240
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacaga 300
catgacagct cgtcctacta cttctactac ggtatggacg tctggggcca agggaccacg 360
gtcaccgtct cctca 375
210 SEQ ID NO 210
145
US 8,062,640 B2
-continued
146
211 LENGTH 125
212 TYPE PPT
213 ORMEISN Aztzfzczal Sequence
220 FEATURE
223 OTHER INFORFLATION Synthetzc
c400 SEQUENCE 210
Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln
I 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Val Gly Val Gly Trp Ile Azg Gln Pro Pzo Gly Lys Ala Leu Glu
35 40 45
Trp Leu Ala Leu Ile Tyr Trp Asn Ser Asp Ly- Arg Tyr Ser Pro Ser
50 55 60
Leu Lys Ser Azg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80
Val Leu Thr Net Thr Asn Net Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cy Ala Hz Azg Hzs Asp Ser Ser Ser Tyr Tyr Phe Tyr Tyr Gly Net
100 105 110
A p Val Trp Gly Gln Gly Thr Thz Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 211
211 LENGTH 336
c212 TYPE DNA
213 ORGAEIISN Artzfzczal Sequence
220 FEATURE:
223 OTHER INPORNATZON: Synthet zc
400 SEQUENCE 211
gatattgtga tgactcagtc tccgctctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgca ggtctagtca gagcctcctc catagtcatg gatacaacta tttggattgg 120
tacctgcaga agccagggca gtctccacaa ctcctgatct atttgggttc taatcgggcc 180
tccggggtcc ctgacaggtt cagtggcggt ggatcaggca cagattt.tac act.gaaaatc 240
agcagagtog aggctgagga tgttgggatt tattactgca tgcaagctct acagactcct 300
ct.cactttcg gcggagggac caaggtggag atcaaa 336
210 SEQ ID NO 212
211 LENGTH 112
212 TYPE PRT
213 ORGANISE Artzfzc
220 FEATURE.
223 OTHER INFORNATIOE
zal Sequence
Synthetzc
400 SEQUENCE 212
A p Ile Val Met Thr Gln Sez Pzo Leu
5
Ser Leu Pzo Val
10
Thr Pro Gly
Glu Pro Ala Ser lie Ser Cys A g Ser Ser Gln Ser Leu Leu Hi Ser
20 25 30
His Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Zle Tyr Leu Gly Ser Asn frg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Sez Gly Gly Gly Sez Gly Thz Asp Phe Thz Leu Ly- Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr Tyr Cys Net Gln Ala
147
US 8,062,640 B2
-continued
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
c210 SEQ ID NO 213
211 LEI'GTH 375
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORPIATION Synthetrc
400 SEQUENCE 213
cagatcacct tgaaggagtc tggtcctacg ctggtgaaac ccacacagac cctcacgctg
acctgcacct tctcrgggtt. ctcactcagc actagtggag tgggt.gtggg ctggatccgt
cagcccccag gaaaggccct ggagtggctt gcactcattt ar.tggaattc tgataagcgc
12 0
180
tacagcccat ctctgaagag caggctcacc atcaccaagg acacctccaa aaaccaggtg 240
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacaga 300
catgacagct cgtcctacta cttctactac ggtatggacg tctggggcca agggaccacg 360
gtcaccgtct cctca 375
210 SEQ ID NO 214
211 LEI'GTH 125
212 TYPE PRT
213 ORGANISN Artzfzcral Sequence
220 FEATURE
c223 OTI'ER INPORINATION Synthetzc
400 SEQUENCE 214
Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln
I 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Val Gly Val Gly Trp Ile Azg Gln Pro Pro Gly Lys Ala Leu Glu
35 40 45
Trp Leu Ala Leu lie Tyr Trp Asn Ser Asp Lys Arg Tyr Ser Pro Ser
50 55 0
Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val
70 75 80
Val Leu Thr Met Thr Asn Het Asp Pro Val lsp Thr Ala Thr Tyr Tyr
85 90 95
Cy Ala Hr Arg Hrs A p Ser Ser Ser Tyr Tyt Phe Tyr Tyr Gly Net
100 105 110
Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 215
211 LENGTH 336
212 TYPE DNA
213 ORGFNISH Artrfrcral Sequence
220 FEATURE:
223 OTHER INPORNATION Synthetrc
400 SEQUENCE 215
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc
atctcctgca ggtctagtca gagcctcctc catagtcatg gatacaacta tttggattgg 12 0
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240
149
US 8,062,640 B2
-continued
150
agcagagtqg aggctgagga tgttggqgtt tattactgca tgcaagctct acagactcct 300
ctcactttcg gcggagggac caagqtggag atcaaa 336
a210 SEQ ID NO 216
211 LEI'GTH 112
212 TYPE PRT
213 ORGANISM Artrfrctal Sequence
220 FEATURE.
223 OTHER INFORBIATION Synthetrc
400 SEQUENCE 216
A p Ile Val lset Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
I 5 10 15
Glu Pro Ala Ser Ile Ser Cy- Arg Ser Ser Gln Ser Leu Leu Hia Ser
20 25 30
Hts Gly Tyr fsn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser iten Azg Ala Ser Gly Val Pzo
50 55 60
Aep Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 BO
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
210 SEQ ID NO 217
211 LENGTH 381
212 TYPE DNA
213 ORGANISN Artrftcral Sequence
220 FEATURE
223 OTHER INFORMATION Synthetrc
400 SEQUENCE 217
gagatgcaac tggtggagtc tgggggaggc ttggtccagc ctggggggtc cctgagactc
tcctgtgcag cctctggatt cacctttagt agtcactgga t.gaagtgggt ccgccaggct 12 0
ccagggaaag ggctggagtg ggtggccaac ataaaccaag atggaagtga gaaat.actat 180
gtggactctg tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgttt 240
ctgcaaatga acagcctgag agccgaqgac acggctgtgt attactgtgc gagagatatt 300
gtact.aatgg tctatgatat ggactactac tactacggta tggacgtctg gggccaaggg 360
accacggtca ccgtctcctc a 381
210 SEQ ID NO 218
211 LENGTH 12
212 TYPE PRT
213 ORGANISN Artzfrc
220 FEATURE
223 OTHER INPORMATION
ral Sequence
Synt.hetrc
400 SEOUENCE 218
Glu Met Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pto Gly Gly
I 5 10 15
Ser Leu frg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Hzs
20 25 30
Trp Met Lys Trp Val Arg Gln Ala Pzo Gly Ly- Gly Leu Glu Trp Val
35 40 45
Ala Asn Ile Asn Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val
151
US 8,062,640 B2
-continued
152
50 55
Lys Gly Prg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe
70 75 80
Leu Gln Het Asn Ser Leu Arg Ala Glu A p Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Ile Val Leu tset Val Tyr Asp Net Asp Tyr Tyr Tyr Tyr
100 105 110
Gly Het Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 219
211 LENGTH 24
212 TYPE DNA
213 ORGWIISN Arttftctal Sequence
220. FEATURE.
223 OTHER INFORN'ZION Synthettc
400 SEQUENCE 219
ggattcacct ttagtagtca ctgg
210 SEQ ID EO 220
211 LENGTH 8
212 TYPE PRT
213 ORGANISbl Artrftcral Sequence
220 FEATURE
223 OTHER INFORNZTION Synthettc
400 SEQUENCE 220
Gly Phe Thr Phe Ser Ser Hrs Trp
I 5
210 SEQ ID NO 221
211 LENGTH 24
212 TYPE DNZ
213 ORGANISN Arttftcral Sequence
220 FEATURE.
223 OTI'ER INFORFIATION Synthettc
400. SEQUENCE 221
ataaaccaag atggaagtga gaea 24
210 SEQ ID NO 222
211 LENGTH 8
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE:
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 222
Ile Asn Gln Asp Gly Ser Glu Lys
5
210 SEQ ID NO 223
211 LEZ'GTH 60
212 TYPE DNA
213 ORGANISE Artrftcral Sequence
220 PEATURE:
223 OTHER INFORNATION Synthettc
400 SEQUENCE 223
gcgagagata ttgtactaat ggtctatgat atggactact actactacgg tatggacgtc
210 5'EQ ID NO 224
211 LENGTH 20
212 TYPE PRT
153
US 8,062,640 B2
-continued
154
213 ORGANISM Artzfzczal Sequence
220 FEATURE
223 OTHER INFORM'TION Synthetzc
400 SEQUENCE 224
Ala 'rg Aep Ile Val Leu Net. Val Tyr A p Net Aep Tyr Tyr Tyr Tyr
I 5 10 15
Gly Met Aep Val
20
210 SEQ ID NO 225
211 LENGTH 336
212 TYPE DNA
213 ORGANISM Artzfzczal Sequence
220 PEATURE:
223 UTHER INpoRMATIUN synthetzc
400 SEQUENCE 225
gatattgtua tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctoca ogtctagtca gagcctcctg catagtaatg gaaacaacta tttggattgg 120
tacctocaga agccagogca gtctccacag ctcctgatct atttgogttc taatcgggcc 180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagat.tttac actgaaaatc 240
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaaactct acaaactccg 300
ctcactttcg gcggagggac caaggtggag atcaaa 336
r210 SEQ ID NO 226
211 LEI'GTH 112
212 TYPE PRT
213 ORGAIIISM Artzfzczal Sequence
220 FEATURE.
223 OTHER INFORKATION Synthetzc
400 SEQUENCE 22
A p Ile Val Ifet Thr Gln Ser Pro Leu
I 5
Ser Leu Pro Val Thr
10
Pro Gly
15
Glu Pro Ala Ser Ile Ser Cya Arg Ser Ser Gln Ser Leu Leu Hia Ser
20 25 30
Aen Gly Aan Aan Tyr Leu Aap Trp Tyr Leu Gln Lye Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Aen Arg Ala Ser Gly Val Pro
50 55 60
.Aep Arg Phe Ser Gly Ser Gly Ser Gly Thr Aep Phe Thr Leu Lye Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Aap Val Gly Val Tyr Tyr Cya Met Gln Tlar
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lye 'Ial Glu Ile Lye
100 105 110
210 SEQ ID NO 227
211 LENGTH 33
212 TYPE DNA
213 ORGANISM Artzfzczal Sequence
220 FEATURE
223 OTHER INFORMATION Synthetzc
400 SEQUENCE 227
cagagcctcc tgcatagtaa tggaaacaac tat 33
210 SEQ ID NO 228
211 LENGTH 11
155
US 8,062,640 B2
-continued
156
212 TYPE PRT
213 ORGANISE Artrftcral Sequence
220 FEATURE
223 OTHER INFORHPTION Synthetrc
c400 SEQUENCE 228
Gln Ser Leu Leu Hre Ser A n Gly 5 n Aen Tyt
I 5 10
210 SEQ ID NO 229
211 LENGTH 9
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 229
ttgggttct
210 SEQ ID NO 230
211 LENGTH 3
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE:
223 OTHER INFOPMATION Synthetrc
400 SEQUENCE 230
Leu Gly Ser
210 SEQ ID I'10 231
211 LENGTH 27
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 231
atgcaaactc tacaaactcc gctcact 27
210. SEQ ID NO 232
211 LENGTH 9
212 TYPE PRT
213 ORGANISN Artrfrctal Sequence
220 FEATURE
223 OTHER INFORH'TION Synthetrc
400 SEQUENCE 232
Net Gln Thr Leu Gln Thr Pro Leu Thr
1 5
210 SEQ ID NO 233
211 LENGTH 381
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 UTFER INpoRHATIUN, synthetrc
400 SEOUENCE 233
gaggtgcanc tggtggagtc tgggggaggc ttggtccagc ctggggggtc cctgagactc 80
tcctgtgcag cctctggatt cacctttagt agtcactgga tgaagtgggt ccgccaggct 120
ccagggaagg ggctggagtg ggtggccaac ataaaccaag atggaagtga gaaatactat 180
gtgqactctg tgaaqggccg attcaccatc tccagaqaca acgccaagaa ctcactgttt 240
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatatt 300
157
US 8,062,640 B2
-continued
gtat.taatgg tctatgatat ggactactac tat.tacggta tggacgtctg gggct.aaggg 360
accacggtca ccgtctcctc a 381
s210 SEQ ID NO 234
s211 LENGTH 127
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 234
Glu Val Gln Leu 'Zal Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cy. Ala Ala Ser Gly Phe Thr Phe Ser Ser Hia
20 25 30
Trp Het Lys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Asn Ile Asn Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val
50 55 60
Ly. Gly Arg Phe Thr Ile Ser Arg A p Asn Ala Lys Asn Ser Leu Phe
65 70 75 80
Leu Gln Net Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Ile Val Leu Met Val Tyr Asp tfet Asp Tyr Tyr Tyr Tyr
100 105 110
Gly Het Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 235
211 LENGTH 33
212 TYPE DNA
213 ORGANISE .Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 235
gatattgtoa tgactcagtc tccactct.cc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgca ggtctagtta gagcctcctg catagtaatg gaaacaatta t.tt.ggattgg 120
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 180
tccggggtcc ctgacaggtt cagtggcagt ggatcagoca cagattttac actgaaaatc 240
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaaactct acaaactccg 300
ctcactttcg gcggagggac caaggtggag atcaaa 336
210 SEQ ID NO 23
211 LENGTH 112
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INPORHATION, Synthetrc
400 SEOUENCE 236
Asp Ile Val Net Thr Gln Ser Pro Leu
1 5
Ser Leu Pro Val Thr
10
Pto Gll'5
Glu Pro fla Ser Zle Ser Cys Arg Ser Ser Gln Ser Leu Leu Hts Ser
20 25 30
Asn Gly Asn Asn Tyr Leu Asp Trp Tyr Leu Gln Ly- Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
159
US 8,062,640 B2
-continued
160
50 55
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
70 75 80
Sez Arg Val Glu Ala Glu .'. p Val Gly Val Tyr Tyr Cy- Net Gln Thz
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
210 SEQ ID NO 237
211 LENGTH 381
212 TYPE DNA
213 ORGAEISH Artificial Sequence
220 FEATURE:
223 oTHER IEPORNATION Synthetic
400. SEQUENCE 237
gaggtgcagc tggtggagtc tgggggaggc ttggtccagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt cacctttagt agtcactgga tgagctgggt ccgccaggct 120
ccagggaagg ggctggagtg ggtggccaac ataaaccaag atggaagtga gaaatactat 180
gtggactctg tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat 240
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatatt 300
gtactaatgg tctatgatat ggactactac tactacggta tggacgtctg ggggcaaggg 360
accacggtca ccgtctcctc a 381
210 SEQ ID I'10 238
211 LENGTH 127
212 TYPE PRT
213 ORGANISE Artificial Sequence
220 FEATURE
223 OTIIER INFORNTTIOE Synthetic
400 SEQUENCE 238
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser His
20 25 30
Trp Het Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Asn Ile Asn Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val
50 55 60
Ly. Gly Arg Phe Thr Ile Ser Azg .'-. p A n Ala Ly- Asn Ser Leu Tyr
65 70 75 80
Leu Gln Net Asn Ser Leu I\rg I\la Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Ile Val Leu Met Val Tyr Asp Net Asp Tyr Tyr Tyr Tyr
100 105 110
Gly Net Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 239
211 LENGTH 336
212 TYPE DNA
213 ORGANISE Artificial Sequence
220 FEATURE.
223 OTHER INFOPHATION Synthetic
400 6'EQUENCE 239
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc
161
US 8,062,640 B2
-continued
162
atctcctgca ggtctagtca gagcctcctg catagtaatg gaaacaacta tttggattgg 120
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240
agcagagtog aggctgagga tgttggggtt tattactgca tgcaaactct acaaactccg 300
ctcactttcg gcggagggac caaggtggag atcaaa 336
210 SEQ ID NO 240
211 LENGTH 112
212 TYPE PRT
213 ORGAEISH Artzfzczal Sequence
220 FEATURE:
223 OTHER INPORHATION Synthetzc
400. SEQUENCE 240
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
I 5 10 15
Glu Pro Ala Ser Ile Ser Cys Azg Ser Ser Gln Ser Leu Leu Hzs Ser
20 25 30
Asn Gly Asn Asn Tyr Leu Asp Trp Tyr Leu Gln Ly Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Sez Arg Val Glu Ala Glu A p Val Gly Val Ty» Tyr Cys Het Gln Thz
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
210 SEQ ID NO 241
211 LEIIGTH 381
212 TYPE DNA
213 ORGANIS'N Artzfzczal Sequence
220. PEATURE.
223. OTHER INFORNATION Synthetzc
400 SEQURNCE 241
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag tctctggatt caccttcagt agctatgcca tgcactgggt ccgccaggct 120
ccaggcaagg ggctggagtg ggtggcagct atatcatatg atggaagtaa taaatactat 180
gtagactccg tgaagggccg attcaccatc tccagagaca attccaagaa aacgc.tgtat 240
ctgcaaatoa acagcctgag agctgaggac acggctgtgt ataattgtgc gaaaaatatt 300
gtactagtga tgtatgatat agactatcac tactatggga tggacgtctg gggccaaggg 360
accacggtca ccgtctcctc a 381
210 SEQ ID NO 242
211 LENGTH 127
212 TYPE PRT
213 ORGANISN Artzfzczal Sequence
220 FEATURE
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 242
Gln Val Gln Leu Val Glu Sez Gly Gly Gly Val Val Gln Pro Gly Azg
I 5 10 15
Ser Leu Arg Leu Ser Cys !\Za Val Ser Gly Phe Thr Phe Ser Ser Tyr
163
US 8,062,640 B2
-continued
164
20 25 30
Gly Het His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Ala Ile Ser Tyr Asp Gly Ser .'. n Ly. Tyr Tyr Val A p Ser Val
50 55 so
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Thr Leu Tyr
65 70 75 80
Leu Gln Het fsn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Asn Cys
85 90 95
Ala L. Asn Ile 'Zal Leu Val Net Tyr F.op Ile Asp Tyr Hi.r. Tyr Tyr
100 105 110
Gly Het Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 243
211 LENGTH 24
212 TYPE DNA
213 ORGANISN Artificial Sequence
220 FEATURE:
223 OTHER INPORNATION Synthetic
400 SEQUENCE 243
ggattcacct tcagtagcta tggc
210 SEQ ID NO 244
211 LENGTH 8
s212 TYPE PRT
213 ORGANZISN Artificial Sequence
220 FEATURE:
223 OTHER INPORNATZON: Synthetic
400 SEQUENCE 244
Gly Phe Thr Phe Ser Ser Tyr Gly
I 5
210 SEQ ID NO 245
211s LENGTH 24
212s T'ZPE DNA
213 ORGANISE Artificial Sequence
220 FEATURE:
223 OTHER INFORHATION Synthetic
400 SEQUENCE 245
atatcatatu atugaautaa taaa 24
210 SEQ ID NO 246
211 LENGTH 8
212 TYPE PRT
213 ORGANISN Artificial Sequence
220 FEATURE
223 OTHER INPORKATION Synthetic
400 SEQUENCE 246
Ile Ser Tyr A p Gly Ser Asn
I 5
210 SEQ ID NO 247
211 LENGTH 60
212 TYPE DNA
213 ORGAEISN Artificial Sequence
220 FEATURE:
223 OTHER INFORNATION Synthetic
400 SEQUENCE 247
165
US 8,062,640 B2
-continued
166
gcgaaaaata ttgtactagt gatgtatgat atagactatc actactatgg gat.ggacgtc 60
210 SEQ ID NO 248
211 LENGTH 20
a212 TYPE PRT
a213 ORGANIS14 Aztrfrcral Sequence
220 FEATURE:
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 248
Ala Lys Asn Ile Val Leu Val Net Tyr Asp Ile Asp Tyr Hzs Tyr Tyr
5 10
Gly Het Asp Val
20
210a SEQ ID NO 249
211 LEHGTH 33
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFORNATION Synthetzc
400 SEQUENCE 249
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccct.ggaga gccggcctcc 0
atctcctgca ggtctagtca gagcctcctg catagtaatg gatacaacta tttggattgg 120
tacctgcaga agccagggca gtctccacaa ctcctgatct atttgggttt taatcgggcc 180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240
agcagagtog aggctgagga tgttggggtt tattactgca tgcaagctct acaaactcct 300
ctcactttcg gcggagggac caaggtggag atcaga 336
210 SEQ ID NO 250
211 LENGTH 112
212 TYPE PRT
213 ORGAEISH Artzfrc
220 FEATURE.
223 OTHER INFORHATION
ral Sequence
Synthetrc
400. SEQUENCE 250
Asp Ile Val 14et Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
I 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Hzs Ser
20 25 30
.Aen Gly Tyr Asn Tyr Leu .Aep Trp Tyr Leu Gln Ly Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Arg
100 105 110
210 SEQ ID NO 251
211 LENGTH 33
212 TYPE DNA
213 ORGANIS'N Artzfzc
220 FEATURE:
223 OTHER INPORHATION
ral Sequence
Synthetzc
400 SEQUENCE 251
167
US 8,062,640 B2
-continued
cagagcctcc tgcatagtaa tggatacaac tat 33
210 SEQ ID NO 252
c211 LENGTH 11
c212 TYPE PRT
213 ORGANHSN Artzfzczal Sequence
220 FEATURE.
223 OTHER INFORMATION Synthetzc
400 SEQUENCE 252
Gln Ser Leu Leu Hza Ser Aan Gly Tyr Aen Tyr
I 5 10
210 SEQ ID I'10 253
211 LENGTH 9
212a T'ZPE DNA
213 ORGANISE Artzftctal Sequence
220 FEZTURE
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 253
ttgggtttt
210 SEQ ID NO 254
211 LENGTH 3
212 TYPE PRT
213 ORGANISN Artzfzctal Sequence
220 FEATURE
223 OTHER INPORKATION Synthetzc
400 SEQUENCE 254
Leu Gly Phe
I
210 SEQ ID NO 255
211 LENGTH 27
212 TYPE DNA
213 ORGANISN Artzfzczal Sequence
220 FEATURE:
223. OTHER INPOPNATION Synthetzc
400 SEQUENCE 255
atgcaagctc tacaaactcc tct«act 27
210 SEQ ID NO 255
211 LENGTH 9
212 TYPE PRT
213 ORGANZISN Aztzfzczal Sequence
220 PEATURR.
223 OTHER INFORPIATION Synthettc
400 SEQUENCE 25
Het Gln Ala Leu Gln Thr Prc Leu Thr
I 5
210 SEQ ID NO 257
211 LENGTH 321
212 TYPE DIZA
213 ORGANISN Arttftctal Sequence
220 FEATURE
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 257
cagctgcagc tggtcgagtc tgggggaggc gtcgtccagc ctgggaggtc cctgagactc 50
tcctgtgcag tctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 120
169
US 8,062,640 B2
-continued
ccaggcaagg ggctggagtg ggtggcagct atatcatatg atggaagtaa t.aaatactat 180
gtagactccg tgaagggccg attcaccatc tccagagaca attccaagaa aacgctgtat 240
ctgcaaatga acagcctgag agctgaggac acggctgtgt ataattgtgc gaaaaatatt 300
gtactagtga tgtatgatat agact.atcac tactatggga tggacgtctg gggccaaggg 360
accacggtca ccgtctcctc a 381
210 SEQ ID NO 258
211 LENGTH 127
212 TYPE PRT
213 ORGANISN Artzfzczal Sequence
220 FEATURE.
223 OTHER INFORNATION Synthetzc
400 SEQUENCE 258
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
5 10
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Net Hz Trp Val Azg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Thr Leu Tyr
65 70 75 80
Leu Gln Net Asn Ser Leu Azg Ala Glu A p Thr Ala Val Tyr I; n Cya
85 90 95
Ala Ly Asn Ile val Leu val Net Tyr asp Ile Asp Tyr Hi Tyr Tyr
100 105 110
Gly Het Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 259
211 LENGTH 336
212s TYPE DNA
213a ORGM4ISN ArtzfzCzal SequenCe
220 FEATURE:
223 OTHER INFORNATION Synthetzc
400 SEQUENCE 259
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgca ggtctagtca gagcctcctg catagtaatg gatacaacta tttggattgg 120
tacctgcaga agccagggca gtctccacaa ctcctgatct atttgggttt t.aat.c.gggcc 180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactcct 300
ctcactttcg gcggagggac caaggtggag atcaaa 336
210 SEQ ID NO 260
211 LENGTH 112
212 TYPE PRT
213 ORGANISN Artzfzczal Sequence
220 FEATURE
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 260
Asp Ile Val Net Thr Gln Sez Pzo Leu Ser Leu Pro Val Thr Pro Gly
I 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Hzs Ser
171
US 8,062,640 B2
-continued
172
20 25 30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Phe A n Azg Ala Ser Gly Val Pzo
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Het Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Ly Val Glu Ile Lys
100 105 110
210 SEQ ID NO 2 I
211s LENGTH 381
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
220 FEATUPE
223 OTHER INFORNTTION Synthetrc
400 5'EQUENCE 261
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag cctctggatt cacct.tcagt agt.tatggca tgcactgggt c.cgcc.aggct 12 0
ccaggcaagg ggctggagtg ggtggcagtt atatcatatg atggaagtaa taaatactat 180
gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240
ct.gcaaatga acagcctgag agctgaggac acggctgtgt attactgtgc gaaaaatatt
gtactagr.ga tgtatgatat agactat.cac tactatggga tggacgtctg ggggcaaggg
300
360
accacggtca ccgtctcctc a 381
210 SEQ ID NO 2 2
211 LENGTH 127
212 TYPE PRT
213 ORGANISN Artzfrc
220 FEATURE:
223. OTHER INPOPNATION
ral Sequence
Synthetrc
400 SEQUENCE 262
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
I 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Het Hr Tzp Val Azg Gln Ala Pro Gly Ly- Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Het Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cy
85 90 95
Ala Ly- Asn Ile Val Leu Val Net Tyr Asp Ile Asp Tyr His Tyr Tyr
100 105 110
Gly Het Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
12 0 125
210 SEQ ID NO 263
211 LENGTH 336
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
173
US 8,062,640 B2
-continued
174
220 PEATURR.
223 OTHER INFORN"ZION Synthetrc
400 SEQUENCE 263
gatat.tgtga tgactcagtc tccactctcc ctgcccgt.ca cccctggaga gccggcctcc 60
atctcctgca ggtctagtca gagcctcctg catagt.aatg gatacaacta t.t.tggattgg 12 0
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttt taatcgggcc 180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactcct 300
ct.cactttcg gcggagggac caaggtggag atcaaa 33
210 SEQ ID NO 2
211s LENGTH 112
212 TYPE PRT
213 ORGANISE Artrftcral Sequence
220 FEATUPE
223 OTHER INFORNTTION Synthetrc
400 5'EQUENCE 264
Asp Ile Val Net Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
I 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
20 25 30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 .5 80
Ser Arg Val Glu .Ala Glu Asp Val Gly Val Tyr Tyr Cys Het Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
210 SEQ ID NO 265
211 LENGTH 381
212 TYPE DNA
213 ORGANISN Artrfrctal Sequence
220 FEATURE
223 OTHER INFORH'TION Synthetrc
400 SEQUENCE 265
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc t.ctgagactc
tcctgtgcag tctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 12 0
ccaggcaagg ggctggagtg ggtggcagct atatcatatg atggaagtaa taaatactat 180
gtagactccg tgaagggccg attcaccatc tccagagaca attccaagaa aacgctgtat 240
ctqcaaatga acagccrgag agctgaggac acggctgtgt ataatrgtgc gaaaaatatt
gtactagtga tgtatgatat agact.atcac tactatggga tggacgtctg gggccaaggg
300
360
accacggtca ccgtctcctc a 381
210 SEQ ID NO 266
211 LENGTH 127
212 TYPE PRT
213 ORGANISN Arttf
220 FEATURE:
223 OTHER INFORNATI
1cral Sequence
ON Synthetrc
175
US 8,062,640 B2
-continued
176
400 SEQUENCE 266
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
I 5 10 15
Ser Leu Arg Leu Ser Cy- Ala Val Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Het Hzs Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Val Asp Ser Val
50 55 60
Ly Gly Arg Phe Thr Ile Ser Arg A p F.cn Ser Ly Lys Thr Leu Tyr
65 70 75 80
Leu Gln Net Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Asn Cy-
85 90 95
Ala Lys Asn Ile Val Leu Val Net Tyr Asp Ile Asp Tyr Hzs Tyr Tyr
100 105 110
Gly Het Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID EO 267
211 LENGTH 24
212 TYPE DNA
213 ORGANISbl Artrfrcral Sequence
220 FEATURE
223 OTHER INFORNPTION Synthetzc
400 SEQUENCE 267
ggatt.cacct tcagtagcta tggc
210 SEQ ID NO 268
211 LENGTH 8
212 TYPE PRT
213 ORGANISE .Artzfrcral Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 268
Gly Phe Thr Phe Ser Ser Tyr Gly
I 5
210 SEQ ID NO 2 9
211 LENGTH 24
212 TYPE DNA
213 ORGANISN Artzfzcral Sequence
220 FEATURE:
223 OTHER INFORNATION Synthetzc
400 SEQUENCE 269
atatcatatg atggaagtaa taaa
210 SEQ ID NO 270
211 LENGTH 8
212 TYPE PRT
213 ORGAIIISN Artrfrcral Sequence
220 FEATURE:
223 OTHER INPORHATION Synthetrc
400 SEQUENCE 270
Ile Ser Tyr Isp Gly Ser Asn Lys
I 5
210 6'EQ ID NO 271
211 LENGTH 0
212 TYPE DNI
177
US 8,062,640 B2
-continued
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORN'TION Synthetrc
400 SEQUENCE 271
gcgaaaaata ttgtactagt gatgt.atgat atagactatc actactatgg gatggacgtc 60
210 SEQ ID NO 272
211 LENGTH 20
212 TYPE PRT
213 ORGAEISN Artrfrcral Sequence
220 FEATURE
223 OTHER INPORFZATION Synthetrc
400 SEQUENCE 272
Ala Lye Aen Ile Val Leu Val Net Tyr aep Ile Asp Tyr His Tyr Tyr
I 5 10 15
Gly Het fsp Val
20
210 6'EQ ID NO 273
211 LENGTH 336
212 TYPE DEA
213 ORGANISE Artrfrcral Sequence
220 PEATURR.
223 OTHER INPOR6ZATION Synthetrc
400 SEQUENCE 273
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgca ggtctagtca gagcctcctg catagtaatg gatacaacta tttggattgg 120
tacctgcaoa agccagggca gtctccacaa ctcctgatct atttgggttt taatcgggcc 180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactcct 300
ctcactttcg gcggagggac caaggtggag atcaga 33
210s SEQ ID NO 274
211e LENGTH 112
212 TYPE PRT
213 ORGANISbl Artrfrc
220 FEATUPE
223 OTHER INPORNPTION
ral Sequence
Synthetrc
400 SEQUENCE 274
.Aep Ile Val Net Thr Gln Ser Pro Leu
I 5
Ser Leu Pro Val
10
Thr Pr'o Gly
15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
20 25 30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Zle Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro
50 55 60
A p Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu .Ala Glu Asp Val Gly Val Tyr Tyr Cys Net Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Arg
100 105 110
210 SEQ ID NO 275
211 LENGTH 33
179
US 8,062,640 B2
-continued
212 TYPE DNA
213 ORGANISE Arttftctal Sequence
220 FEATURE
223 OTHER INFORHPTION Synthettc
c400 SEQUENCE 275
cagagcctcc tgcatagtaa tggatacaac tat 33
210 SEQ ID NO 275
211 LENGTH 11
212 TYPE PRT
213 ORGANISN Arttftctal Sequence
220 FEATURE.
223 OTHER INFORHATION Synthettc
400 SEQUENCE 275
Gln Ser Leu Leu Hte Ser Aan Gly Tyr Aan Tyr
I 5 10
210 SEQ ID NO 277
211 LENGTH 9
212 TYPE DNA
213 ORGANISN Artrftctal Sequence
220 FEATURE:
223 OTHER INFOPMATION Synthettc
400 SEQUENCE 277
ttgggtttt
c210 SEQ ID NO 278
211 LEI'GTH 3
212 TYPE PRT
213 ORGPIIISH Arttftctal Sequence
220 FEATURE.
223 OTHER INFORKATION Synthettc
400 SEQUENCE 278
Leu Gly Phe
I
210. SEQ ID NO 279
211 LENGTH 27
212 TYPE DNA
213 ORGANISN Arttftctal Sequence
220 FEATURE
223 OTHER INFORH'TION Synthettc
400 SEQUENCE 279
atgcaagct.c tacaaactcc tctcact 27
210 SEQ ID NO 280
211 LENGTH 9
212 TYPE PRT
213 ORGAEISN Arttftctal Sequence
220 FEATURE
223 OTHER INFOPHP.TION Synthettc
400 SEQUENCE 280
Net Gln Ala Leu Gln Thr Pro Leu Thr
I 5
210 SEQ ID NO 281
211 LENGTH 381
212 TYPE DNA
213 ORGANISN Arttftctal Sequence
220 FEATURE:
223 OTHER INFORNATION Synthettc
181
US 8,062,640 B2
-continued
182
400 SEQUENCE 281
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc
tcctgtgcag tctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 12 0
ccaggcaagg ggctggagtg ggtggcagct atatcatatg atggaagtaa taaatactat 180
gtagactccg tgaagggccg attcaccatc tccagagaca attccaagaa aac.gctgtat 240
ctgcaaatga acagcctgag agctgaggac acggctgtgt ataattgtgc gaaaaatatt 300
gtactagtga tgtatgatat agactatcac tactatggga tggacgtctg gggccaaggg 360
accacggtca ccgtctcctc a 381
210 SEQ ID NO 282
211 LENGTH 127
212s T'ZPE PRT
213 ORGANISE Artrfrcral Sequence
220 FETTURE
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 282
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Net Hrs Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Ala Ile Ser Tyr Asp Gly Ser 5 n Lya Tyr Tyr Val A p Ser Val
50 55 60
Ly Gly Arg Phe Thr lie Ser .'. g Asp Asn Ser Ly Ly Thr Leu Tyr
65 70 75 80
Leu Gln Net Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Asn Cys
85 90 95
Ala Lys Asn Ile Val Leu Val Net Tyr Asp Ile Asp Tyr Hrs Tyr Tyr
100 105 110
Gly Net Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 283
211 LENGTH 336
212 TYPE DNA
213 ORGZGZISN Artrfrcral Sequence
220 FEATURE:
223 OTHER IEFORNATION Synthetrc
400 SEQUENCE 283
gatattgtna tgactcagtc tccactctcc ctgcccgtca cccctggaga gcc.ggcc.tcc
atctcctgca ggtctagtca gagcctcctg catagtaatg gatacaacta tttggattgg 12 0
tacctgcaga agccagggca gtctccacaa ctcctgatct atttgggttt taatcgggcc 180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactcct
240
300
ct.cactttcg gcggagggac caaggtggag atcaaa 336
nce
10
210 SEQ ID NO 284
211 LENGTH 112
212 TYPE PRT
213 ORGANISN Artrfrcral Seque
220 FEATURE:
223 OTHER INFORNATION Synthet
183
US 8,062,640 B2
-continued
184
400 SEQUENCE 284
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pto Gly
I 5 10 15
Glu Pro Ala Ser Ile Ser Cys Azg Ser Ser Gin Ser Leu Leu His Ser
20 25 30
Asn Gly Tyr Asn Tyr Leu I\sp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cy. Met Gln Ala
85 90 95
Leu Gin Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
210 SEQ ID NO 285
211 LENGTH 381
212 TYPE DNA
213 ORGPSHSN Artrfzc
220 FEATURE.
223 OTHER INPORHATION
ral Sequence
Synthetrc
400 SEQUENCE 285
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc
tcctgtgcag cctctggatt cacct.tcagt agctatggca tgcactgggt. ccgccaggct 12 0
ccaggcaagg ggctggagtg ggr.ggcagtt atatcatatg atggaagtaa taaatactat 180
gcagactccg tgaagggccg att.caccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatna acagcctgag agctgaggac acggctgtgt attactgtgc gaaaaatatt 300
gtactagtga tgtatgatat agactatcac tactatggga tggacgtctg ggggcaaggg 360
accacggtca ccgtctcctc a 381
210s SEQ ID NO 286
211 LEKGTH 127
212 TYPE PRT
213 ORGANISN Artrfrc
220 FEATURE
223 OTHER INFORH'TION
ral Sequence
Synthetrc
400 SEQUENCE 286
Gln Val Gin Leu Val Glu Sez Gly Gly Gly Val Val Gin Pro Gly Azg
I 5 10 15
Ser Leu Arg Leu Ser Cys I\la I\la Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Het Hzs Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asn Ly- Tyr Tyr Ala Asp Ser Val
50 55 60
Ly- Gly Arg Phe Thr Ile Ser I.rg Asp Asn Ser Ly- Asn Thr Leu Tyr
65 70 75 80
Leu Gin Net Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Ly Asn Ile Val Leu Val Net Tyr Asp Ile Asp Tyr H1s Tyr Tyr
100 105 110
Gly Het Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
185
US 8,062,640 B2
-continued
186
210 SEQ ID NO 287
211 LENGTH 336
212 TYPE DNA
c213 ORGANIISN AZtzfZCzal SequenCe
c220 FEATURE:
223 OTHER INFORNATION Synthetzc
400 SEQUENCE 287
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc
atctcctgca ggtctagtca gagcctcctg catagtaatg gatacaacta tttggattgg 12 0
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttt taatcgggcc 180
tccggggtcc ctgacaggtt. cagtggcagt ggatcaggca cagat.tttac actgaaaatc
agcagagtog aggctgagga tgttggggtt tattactgca t.gcaagctct acaaact.cct
240
300
ctcactttcg gcggagggac caaggtggag atcaaa 336
210 SEQ ID NO 288
211 LENGTH 112
212 TYPE PRT
213 ORGPSHSN Artzfzczal Sequence
220 FEATURE.
223 OTHER INPORHATION Synthetzc
400 SEQUENCE 288
Asp Ile Val Het Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
I 5 10 15
Glu Pro Ala Sez Ile Ser Cye Azg Sez Sez Gln Ser Leu Leu Hie Ser
20 25 30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Net Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
210 SEQ ID NO 289
211 LENGTH 372
212 TYPE DNA
213 ORGANISE Artzf
220 FEATURE.
223 OTHER INFORHATI
zczal Sequence
ON Synthetzc
400 SEQUENCE 289
cagatcacct tgaaggagtc tggtcctacg ctggtaaaac ccacacagac cctcacgctg
acctgcacct. t.ctctgggt.t ctcactcagc gctagtggag tgggtgtggg ctggtt.ccgt
cagcccccag gaaaggccct ggagt.ggctt gcactcattt. attggaatga tgat.aagcgt
12 0
180
tacagcccat ctctaaagaa cagcctcacc atcaccaagg acacctccaa aaaccaggtg 240
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacaga 300
atacatctat ggtcctactt ctactacggt atggacgtct ggggccaagg gaccacggtc 360
accutctcct ca 372
210 SEQ ID NO 290
187
US 8,062,640 B2
-continued
188
211 LENGTH 124
212 TYPE PPT
213 ORMEISN Artificial Sequence
220 FEATURE
223 OTHER INFORFIATION Synthetic
c400 SEQUENCE 290
Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln
I 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Ala Ser
20 25 30
Gly Val Gly Val Gly Trp Phe Arg Gln Pro Pro Gly Lys Ala Leu Glu
35 40 45
Trp Leu Ala Leu Ile Tyr Trp Asn Asp Asp Ly- Arg Tyr Ser Pro Ser
50 55 60
Leu Lys Asn Ser Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80
Val Leu Thr Net Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cy. Ala Hi Arg Ile His Leu Trp Ser Tyr Phe Tyr Tyr Gly Net 5 p
100 105 110
Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0
210 SEQ ID NO 291
211 LENGTH 30
c212 TYPE DNA
213 ORGAEIISN Artificial Sequence
220 FEATURE:
223 OTHER INPORNATION: Synthetic
400 SEQUENCE 291
gggttctcac tcagcgctag tggagtgggt 30
210 SEQ ID NO 292
211 LENGTH 10
212s TYPE PRT
213a ORGM4ISN ArtifiCial SequenCe
220 FEATURE:
223 OTHER INFORNATION Synthetic
400 SEQUENCE 292
Gly Phe Ser Leu Ser Ala Ser Gly Val Gly
I 5 10
210 SEQ ID NO 293
211 LENGTH 21
212 TYPE DNA
213 ORGANISN Artificial Sequence
220 FEATURE
223 OTHER INPORKATION Synthetic
400 SEQUENCE 293
atttattgca atgargataa g 21
210 SEQ ID NO 294
211 LENGTH 7
212 TYPE PRT
213 ORGANISE Artificial Sequence
220 FEATURE.
223 OTHER INFOPHATION Synthetic
400 6'EQUENCE 294
Ile Tyr Trp Asn Asp Asp Lys
189
US 8,062,640 B2
-continued
190
210 SEQ ID NO 295
211 LENGTH 48
r212 TYPE DNA
r213 ORGANIS14 Aztificial Sequence
220 FEATURE:
223 OTHER INFORHATION Synthetic
400 SEQUENCE 295
gcacacagaa tacatctatg gtcctacttc tactacggta tggacgtc
210 SEQ ID NO 296
211 LENGTH 16
212 TYPE PRT
213 ORGWIISN Artificial Sequence
220. FEATURE.
223 OTHER INFORN'TIDE Synthetic
400 SEQUENCE 29
Ala His Azg Ile His Leu Trp Ser Tyr Phe Tyr Tyr Gly Net Asp Val
I 5 10 15
210 SEQ ID NO 297
211 LENGTH 33
212 TYPE DNA
213 ORG62IISH Artificial Sequence
220 FEATURE
223 OTHER INFORFLATION Synthetic
r400 SEQUENCE 297
gatat.tgtga tgactcagtc t.ccactctcc ctgcccgtca cccctggaga gccggcctcc 60
at.ctcctgca ggtctagtca gactctcctg catagtaatg gatacaacta tt.tcgattgg 12 0
tacctgcaoa agccagggca gtctccacag ctcctgatct atttgggttc teat.cgggcc 180
tccggggtcc ctgacagatt cagtggcagt ggatcaggca cagattttac actgaaaatc 240
agcagagtgg aggctgagga tgttggaatt tattactgca tgcaagctct acaaactcct 300
ctcactttcg gcggagggac caaggtggag atcaga 336
210 SEQ ID NO 298
211 LENGTH 112
212 TYPE PRT
213 ORGANISE Artific
220 FEATURE
223 OTHER INFORHATION
ial Sequence
Synthetic
400 SEQUENCE 298
Asp Ile Val 14et Thr Gln Ser Pro Leu
I 5
Ser Leu Pro Val Thr
10
P1'0 Gly
15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Thr Leu Leu His Ser
20 25 30
Asn Gly Tyr Asn Tyr Phe Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser A n Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Plie Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 7 80
Ser Arg Val Glu Ala Glu .Asp Val Gly Ile Tyr Tyr Cys Net Gln Ala
85 90 95
Leu Gln Thr Pzo Leu Thr Phe Gly Gly Gly Thr Ly- Val Glu Ile Azg
100 105 110
191
US 8,062,640 B2
-continued
192
210 SEQ ID NO 299
211 LEI'GTH 33
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
c220 FEATURE;
c223 OTI'ER INPORI44TION. Synthetrc
400 SEQUENCE 299
cagactctcc tgcatagtaa tggatacaac tat 33
210 SEQ ID NO 300
211 LENGTH 11
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 PEATURE:
223 OTHER 111PORNATION Synthetrc
400 SEQUENCE 300
Gln Thr Leu Leu Hra Ser Aen Gly Tyr Aan Tyr
I 5 10
210 SEQ ID NO 301
211 LENGTH 9
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORH'TION Synthetrc
400 SEQUENCE 301
ttgggttct
210 SEQ ID NO 302
211 LENGTH 3
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INPORI4ATION Syntretrc
400 SEQUENCE 302
Leu Gly Ser
I
210 SEQ ID NO 303
211 LENGTH 27
212 TYPE DNA
213 ORGIUIISN Artrfrcral Sequence
220 FEATURE:
223 OTHER IEFORHATION Synthetrc
400 SEQUENCE 303
atgcaagctc tacaaactcc tctcact 27
210 SEQ ID NO 304
211 LENGTH 9
212 TYPE PRT
213 ORGANIISH Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORINATION Synthetrc
400 SEQUENCE 304
Net Gln Ala Leu Gln Thr Pro Leu Thr
210 SEQ ID NO 305
211 LENGTH 372
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
193
US 8,062,640 B2
-continued
194
220 PEATURR.
223 OTHER INFORN"TION Synthetrc
400 SEQUENCE 305
cagat.cacct tgaaggagtc tggtcctacg ctggtaaaac ccacacagac cctcacgctg 60
acctgcacct tctctgggtt ctcactcagc gctagtggag tgggtgtggg ct.ggttccgt 12 0
cagcccccag gaaaggccct ggagtggctt gcactcattt attggaatga tgataagcgt 180
tacagcccat ctctaaagaa cagcctcacc atcaccaagg acacctccaa aaaccaggtg 240
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacaga 300
atacatctat ggtcctactt ctactacggt atggacgtct ggggccaagg gaccacggtc 360
accgtctcct ca 372
210 SEQ ID NO 306
211 LENGTH 124
212 TYPE PRT
213 ORGANISN Artrftctal Sequence
220 FEATURE:
223 OTHER INPORNATION Synthetrc
400 SEQUENCE 306
Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln
I 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phs Ser Gly Phe Ser Leu Ser Ala Ser
20 25 30
Gly Val Gly Val Gly Tzp Phe Arg Gln Pro Pro Gly Ly Ala Leu Glu
35 40 45
Trp Leu Ala Leu lie Tyr Trp A n 4 p Anp Ly Arg Tyr Ser Pro Ser
50 55 0
Leu Lys Asn Ser Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80
Val Leu Thr Iset Thr A n Net Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Ht- Arg Ile Hts Leu Trp Ser Tyr Phe Tyr Tyr Gly Met A p
100 105 110
Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0
210 SEQ ID NO 307
211 LENGTH 336
212 TYPE DEA
213 ORGANIISN Aztrfrcral Sequence
220 PEATURR.
223 OTHER INFORFIATION Synthetrc
400 SEQUENCE 307
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc
atctcctgca ggtctagtca gactctcctg catagtaatg gatacaacta tttcgattgg 12 0
tacctgcaca agccagggca gtctccacag ctcctgatct attrgggttc taatcgggcc
tccggggtcc ctgacagatt. cagtggcagt ggatcaggca cagattttac actgaaaatc
180
240
agcagagtgg aggctgagga tgttggaatt tattactgca tgcaagctct acaaactcct 300
ct.cactttcg gcggagggac caaggtggag atcaaa 336
210 SEQ ID NO 308
211 LENGTH 112
212 TYPE PRT
213 ORGANISE Arttfrctal Sequence
195
US 8,062,640 B2
-continued
196
220 PEATURR.
223 OTHER INFORN"TION Synthetzc
400 SEQUENCE 308
.'. p Ile Val Met Thr Gln Sez Pzo Leu Sez Leu Pzo Val Thr Pro Gly
I 5 10 15
Glu Pro Ala Ser Ile Ser Cys I\rg S r Ser Gln Thr Leu Leu Hzs Ser
20 25 30
Asn Gly Tyr Isn Tyr Phe Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser F.cn Arg Ala Ser Gly Val Pro
50 55 60
2 p Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ly. Ile
65 70 75 BO
Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr Tyr Cys Net Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
210 SEQ ID EO 309
211 LENGTH 372
212 TYPE DNA
213 ORGANISBI Artzfzc
220 FEATURE
223 OTHER INFORHATION
zal Sequence
Synthetzc
400 SEQUENCE 309
cagat.cacct tgaaggagtc tggtcctacg ctggtgaaac ccacacagac cctcacgctg
acctgcacct. Ictctgggz.t ctcactcagc gctagtggag t.gggtgtggg ctggatccgt
60
12 0
cagcccccag gaaaggccct ggagtggctt gcactcattt attggaatga tgataagcgc 180
tacagcccat ctctgaagag caggctcacc atcaccaagg acacctccaa aaaccaggtg 240
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacaga 300
atacatctat ggtcctactt ctactacggt atggacgtct gggggcaagg gaccacggtc 360
accgtctcct ca 372
210 SEQ ID NO 310
211 LENGTH 124
212 TYPE PPT
213 ORGIUIISN Artzftc
220 FEATURE:
223 OTHER IEFORHATION
zal Sequence
Synthetzc
400 SEQUENCE 310
Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln
I 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Ala Ser
20 25 30
Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly lys Ala Leu Glu
35 40 45
Trp Leu Ala Leu Ile Tyr Trp Asn Asp Asp Ly- Arg Tyr Ser Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80
Val Leu Thr Net Thr Asn Het Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cy Ala Hz Arg Ile Hzs Leu Trp Ser Tyr Phe Tyr Tyr Gly Het A p
100 105 110
197
US 8,062,640 B2
-continued
Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0
a210 SEQ ID NO 311
a211 LENGTH 336
212 TYPE Dl'IA
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 311
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgca ggtctagtca gactctcctg catagtaatg gatacaacta tttggattgg 120
tacctgcaga agccagggca gtctccacag ctcctgatct. atttgggttc t.aatcgggcc 180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240
agcagagtug aggctgagga tgttggggtt tattactgca tgcaagctct acaaactcct 300
ctcactttcg qcggagggac caaggtggag atcaaa 336
210 SEQ ID EO 312
211 LENGTH 112
212 TYPE PRT
213 ORGANISBI Artrfrcral Sequence
220 FEATURE
223 OTHER INFORHTTION Synthetrc
400 SEQUENCE 312
Asp Ile Val Het Thr Gin Ser Pzo Leu Ser Leu Pzo Val Thr Pro Gly
I 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Thr Leu Leu His Ser
20 25 30
!\sn Gly Tyr Asn Tyr Leu !\sp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pzo
50 55 60
4 p Arg Phe Ser Gly Ser Gly Ser Gly Thz Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
210 SEQ ID NO 313
211 LENGTH 381
212 TYPE DNA
213 ORGANISN Artrfrcral Seque
220 FEATURE
223 OTHER INPORKATION Synthet
nce
10
400 SEQUENCE 313
caggttcaac tggtgcagtc tggacctgag gtgaagaacc ctggggcctc agt.gaaggtc
tcctgcaaag ct.tctggtta cacctttacc acctatggta tcagttgggt acgacaggcc 12 0
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaacgat 180
gcacagaagt tccaggacag agtcgccatg accacagaca catccacgag cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccattt attactgttc gagagatcgt 300
ttagtagtac cacctgccct taattattcc tactacgtta tggacgtctg gggccaaggg 360
accacggtca ccgtctcctc a 381
199
US 8,062,640 B2
-continued
200
210 SEQ ID NO 314
211 LENGTH 127
212 TYPE PRT
s213 ORGANIISN AZtzfzCzal SequenCe
s220 FEATURE:
223 OTHER INFORNATION Synthetzc
400 SEQUENCE 314
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Asn Pro Gly Ala
5 10 15
Ser Val Ly Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Net
35 40 45
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Asp Ala Gln Lys Phe
50 55 60
Gln Asp Arg Val Ala Het Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Net Glu Leu Arg Ser Leu Azg Ser A p Asp Thz Ala Ile Tyr Tyr Cys
85 90 95
Ser Arg Asp Arg Leu Val Val Pro Pro
100 105
ala Leu Asn Tyr Ser Tyr Tyr
110
Val Het Asp Val Trp Gly Gln Gly Thr
115 12 0
Thr Val Thr Val Ser Ser
125
210 SEQ ID I'10 315
211 LENGTH 24
212 TYPE DNA
213 ORGANISE Arttftctal Sequence
220 FEATURE
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 315
ggttacacct ttaccaccta tggt 24
210s SEQ ID NO 316
211 LENGTH 8
212 TYPE PRT
213 ORGANISN Artzftctal Sequence
220 FEATURE
223 OTHER INFORH'TION Synthetzc
400 SEQUENCE 316
Gly Tyr Thr Phe Thr Thr Tyr Gly
I 5
210
211
212
213
220
223
SEQ ID NO 317
LENGTH 24
TYPE DNA
ORGANISN Artzfzczal Sequence
FEATURE
UTFER INpoRHATION, synthetzc
400 SEOUENCE 317
at.cagcggtt acaatggtaa aaca
210
211
212
213
220
223
SEQ ID NO 318
LENGTH 8
TYPE PRT
ORGANISN Artzfzczal Sequence
FEATURE:
OTHER INFORNATION Synthetzc
201
US 8,062,640 B2
-continued
202
400 SEQUENCE 318
Ile Ser Gly Tyr Asn Gly Lys Thr
I 5
c210 SEQ ID NO 319
211 LEI'GTH 60
212 TYPE DNA
213 ORGANISE Artzfzctal Sequence
220 FEATURE.
223 OTHER INFORFIATION Synthetzc
400 SEQUENCE 319
tcgagagatc gtttagtagt accacctgcc cttaattatt cctactacgt tatggacgtc 60
210 SEQ ID NO 320
211s LENGTH 20
212 TYPE PRT
213 ORGANISE Artzfzczal Sequence
220 FEATUPE
223 OTHER INFORNTTION Synthetzc
400 6'EQUENCE 320
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Asn Tyr Ser Tyr Tyr
I 5 10 15
Val Het Asp Val
20
210 SEQ ID NO 321
c211 LENGTH 336
212 TYPE Dl'IA
213 ORGANIISN Artzfzczal Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 321
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 60
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg 120
tctcagcaga ggccaggtca atctccaagg cgcctaattt. ataaggtttc t.aaccgggac 180
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac act.gaaaatc 240
agcagggtcg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg 300
tacacttttg gccaggggac caagctggag atcaaa 33
210 SEQ ID EO 322
211 LENGTH 112
212 TYPE PRT
213 ORGANISE Artzfzczal Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 322
Asp Val Val Met Thr Gln Ser Pro Leu
I 5
Ser Leu Pro Val
10
Thr Leu Gly
15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
!\sp Gly Asn Thr Tyr Leu !\sn Trp Ser Gln Gln Arg Pro Gly Gln Ser
3 40 45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pzo
50 55 60
A p 'rg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
203
US 8,062,640 B2
-continued
204
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Het Gln Gly
85 90 95
Thr Hrs Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
210 SEQ ID I'10 323
211 LENGTH 3'3
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORI45TION Synthetrc
400 SEQUENCE 323
caaagcctcg tatacagtga tggaaacacc tac 33
210a SEQ ID NO 324
211 LEHGTH 11
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFORNATION Synthetzc
400 SEQUENCE 324
Gln Ser Leu Val Tyr Ser Asp Gly Asn Thr Tyr
I 5 10
210 SEQ ID NO 325
211 LENGTH 9
212 TYPE DNA
e213 ORGANIS14 Artrfrcral Sequence
220 FEATURE:
223 OTHER INFORHATION. Synthetrc
400 SEQUENCE 325
aaggtttct
210 SEQ ID NO 324
211 LENGTH 3
212 TYPE PRT
213a ORGWIISN Artrfrcral Sequence
220. FEATURE.
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 32
Lys Val Ser
210 SEQ ID NO 327
211 LENGTH 27
212 TYPE DNA
213 ORGANISE Artrfrctal Sequence
220 FEATURE
223 OTHER INPORKATION Synthetzc
400 SEQUENCE 327
atqcaaggta cacactggcc gtacacr. 27
210 SEQ ID NO 328
211 LENGTH 9
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 FEITURE
223 OTI'ER INFORI4ATION Synthetzc
400 SEQUENCE 328
Net Gln Gly Thr Hzs Trp Pro Tyr Thr
I 5
205
US 8,062,640 B2
-continued
206
210 SEQ ID NO 329
211 LENGTH 381
212 TYPE DNA
c213 ORGASIISN AZtzfzCzal SequenCe
c220 FEATURE:
223 OTHER INFORNATION Synthetzc
400 SEQUENCE 329
caggttcagc tggtgcagtc tggacctgag gtgaagaacc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc acctatggta tcagttgggt acgacaggcc 120
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaacgat 180
gcacagaaat tccaggacag agtcgccatg accacagaca cat.ccacgag cacagcctac 240
atggagctaa ggagcctgag atctgacgac acggccattt att.actgttc gagagat.cgt 300
ttagtagtac cacctgccct taattattcc tactacgtta tggacgtctg gggccaaggg 360
accacggtca ccgtctcctc a 381
210 SEQ ID NO 330
211 LENGTH 127
212 TYPE PRT
213 ORGANISE Arttftctal Sequence
220 FEATURE.
223 OTHER INFORH'TION Synthetzc
400 SEQUENCE 330
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Ly Asn Pro Gly Ala
I 5 10 15
Ser Val Ly Val Ser Cy Ly Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Net
35 40 45
Gly Trp Ils Ser Gly Tyr .4 n Gly Lys Thr Asn Asp Ala Gln Lys Phe
50 55 60
Gln Asp Arg Val Ala Net Thr Thr asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
flat Glu Leu Azg Ser Leu Arg Ser Asp Asp Thr Ala Ile Tyr Tyr Cys
85 90 95
Ser Arg Asp Azg Leu Val Val Pro Pro Ala Leu Asn Tyr Ser Tyr Tyr
100 105 110
Val tset Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 331
211 LENGTH 336
212 TYPE DNA
213 ORGAEISN Artzf
220 FEATURE
223 OTHER INFORHPTI
tctal Sequence
ON Synthetzc
400 SEQUENCE 331
gatgttgtaa tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg 12 0
tctcagcaga ggccaggtca atctccaagg cgcctaattt ataaggtttc taaccgggac 180
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc 240
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg 300
tacacttttg gccaggggac caagctggag atcaaa 336
207
US 8,062,640 B2
-continued
208
210 SEQ ID NO 332
211 LENGTH 112
212 TYPE PRT
c213 ORGANIISN AZtzfzCzal SequenCe
c220 FEATURE:
223 OTHER INFORNATION Synthetzc
400 SEQUENCE 332
Asp Val Val ilet Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
5 10 15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
3 p Gly Asn Thr Tyr Leu Asn Trp Ser Gln Gln Arg Pra Gly Gln Ser
35 40 45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu .Asp Val Gly Val Tyz Tyr Cys Net Gln Gly
85 90 95
Thr Hzs Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
210 SEQ ID NO 333
211 LENGTH 381
c212 TYPE DNA
213 ORGANIISN Artzfzc
220 FEATURE:
223 OTHER INFORNATION
ral Sequence
Synt hat zc
400 SEQUENCE 333
caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc acctatggta tcagctgggt gcgacaggcc 120
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaactat 180
gcacagaaac tccagggcag agtcaccatg accacagaca cat.ccacgag cacagcctac 240
atggagctaa ggagcctgag atctgacgac acggccgtgt. attactgttc gagagatcgt 300
ttagtagtac cacctgccct taattattcc tactacgtta tggacgtctg ggggcaaggg 360
accacggtca ccgtctcctc a 381
210 SEQ ID NO 334
211 LENGTH 127
212 TYPE PRT
213 ORGANISE Artrfrc
220 FEATURE
223 OTHER INPORKATION
tal Sequence
Synthetzc
400 SEQUENCE 334
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Ly lys Pro Gly Ala
I 5 10 15
Ser Val Ly Val Ser Cy- Ly. Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Net
35 40 45
Gly Trp Ile 5'er Gly Tyr Asn Gly Lya Thr Asn Tyr Ala Gln Lya Leu
50 55 60
Gln Gly Arg Val Thr Net Thr Thr A p Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
209
US 8,062,640 B2
-continued
210
Het Glu Leu Azg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Asn Tyr Ser Tyr Tyr
100 105 110
Val tset Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID No 335
211 LENGTH 336
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE.
223 OTHER INFOR1NATION Synthetrc
400 SEQUENCE 335
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 60
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg 120
tttcagcaga qgccaggcca atctccaagg cgcctaattt ataaggttt- taaccgggac 180
tctggqgtcc caqacaqatt cagcggcagt qggtcaggca ctgatttcac actgaaaatc 240
agcagggtgg aggctgagga tgttggggtt tattactgca t.gcaaggtac acactggccg 300
tacacttttg gccaggggac caagctggag atcaaa 336
210 SEQ ID No 336
211 LENGTH 112
s212 TYPE PRT
213 ORGANIISN Arttfrctal Sequence
220 FEATURE:
223 OTHER INPORNATION: Synthet rc
400 SEQUENCE 336
Asp Val Val Net Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
I 5 10 15
Gln Pro Ala Ser Ile Ser Cys Azg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
4 p Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
35 40 45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr lsp Phe Thr Leu Lys Ile
65 70 75 Bo
Sez Arg Val Glu Ala Glu .'. p Val Gly Val Tyt Tyr Cy- Net Gln Gly
85 90 95
Thr Hrs Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
210 SEQ ID No 337
211 LENGTH 354
212 TYPE DNA
213 ORGAIIISH Artrftcral Sequence
220 FEATURE:
223 OTHER INPORHATION Synthettc
400 SEQUENCE 337
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt agctatagca tggactgggt ccgccaggct 120
ccagggaagg ggctggagtg ggtctcatcc attagtagta gtagtagtta catatactac 180
gcagactctg tgaagggccg attcaccatc tccagagaca ccgccaagaa ctcactgtat 240
211
US 8,062,640 B2
-continued
212
ctgcaaatga acagcctgag agacgaggac acggctgttt attactgtgc gagagagggc 300
agtagcagac tttttgacta ctggggccag ggaaccctgg tcaccgtctc ctca 354
c210 SEQ ID NO 338
211 LEI'GTH 118
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORBIATION Synthetrc
400 SEQUENCE 338
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ser Het fsp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Ser Ser Ser Sez Ser Tyr Ile Tyt Tyr Ala Asp Sez Val
50 55 60
Ly. Gly Arg Phe Thr Ile Ser Arg Asp Thr Ala Ly Asn Ser Leu Tyr
65 70 75 90
Leu Gln Het Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cy
85 90 95
Ala Arg Glu Gly Ser Ser Arg Leu Phe Psp Tyr Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115
210 SEQ ID NO 339
211 LENGTH 24
212 TYPE DNT
213 ORGANISN Artrfrcral Sequence
220 FEATURE.
223 OTI'ER INFORIBATION Synthetrc
400. SEQUENCE 339
ggattcacct tcagtagcta tagc 24
210 SEQ ID NO 340
211 LENGTH 8
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE:
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 340
Gly Phe Thr Phe Ser Ser Tyr Ser
5
210 SEQ ID NO 341
211 LEI'GTH 24
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
220 PEATURE:
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 341
attagtagta gtagtagtta cata 24
210 5'EQ ID NO 342
211 LENGTH 8
212 TYPE PRT
213
US 8,062,640 B2
-continued
214
213 ORGANISE Artzfzczal Sequence
220 FEATURE
223 OTHER INFORH'TION Synthetzc
400 SEQUENCE 342
Ile Ser Ser Ser Ser Ser Tyr Ile
I 5
210 SEQ ID NO 343
211 LENGTH 33
212 TYPE DNA
213 ORGAEISN Artzfzczal Sequence
220 FEATURE.
223 OTHER INFORNATION Synthetzc
400 SEQUENCE 343
gcgagagaog gcagtagcag actttttgac tac 33
210 SEQ ID NO 344
211 LENGTH 11
212 TYPE PRT
213 ORnaNISH Aztzfzczal Sequence
220 FEATURE:
223 OTHER IEFORHATION Synthetzc
400 SEQUENCE 344
Ala Arg Glu Gly Ser Ser Arg Leu Phe Aap Tyr
I 5 10
a210 SEQ ID NO 345
211 LEI'GTH 321
212 TYPE DNA
213 ORGANISE Artzfzczal Sequence
220 FEATURE.
223 OTHER INFORKATION Synthetzc
400 SEQUENCE 345
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagagacca 120
gggaaagccc ctaagctcct gatctataag gcgtctagtt t.agaaggtgg agt.cccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cct.gcagcct 240
gaggattttg caacttatta ctgccaacag tataatagtt attggtacac ttttggccag 300
gggaccaagc tggagatcaa a 321
210 SEQ ID NO 346
211 LENGTH 107
212 TYPE PRT
213 ORGANISE Artzfzc
220 FEATURE
223 OTHER INPORKATION
zal Sequence
Synthetzc
400 SEQUENCE 346
Aep Ile Gln Net Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
I 5 10 15
A p Arg Val Thr Ile Thr Cy. I.rg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Arg Pro Gly Lya Ala Pro Lye Leu Leu Ile
35 40 45
Tyr Ly Ala 6'er Ser Leu Glu Gly Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
215
US 8,062,640 B2
-continued
216
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Trp Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
210 SEQ ID NO 347
211 LENGTH 18
212 TYPE DNA
213 ORGANISN Artificial Sequence
220 FEATURE
223 OTHER INFOPHP.TION Synthetic
400 SEQUENCE 347
cagagtatta gtagctgg 18
210 SEQ ID NO 348
211 LENGTH 6
212 TYPE PRT
213 ORGANISN Artificial Sequence
220 FEATURE:
223 OTHER INPORNATION Syntlietic
400 SEQUENCE 348
Gln Ser Ile Ser Ser Trp
1 5
210 SEQ ID NO 349
211 LENGTH 9
c212 TYPE DNA
213 ORGANHSN Artificial Sequence
220 FEATURE:
223 OTHER INPORNATZON: Synthetic
400 SEQUENCE 349
aaggcgtct
210 SEQ ID NO 350
211 LENGTH 3
212s TYPE PRT
213s ORGANISE Artificial Sequence
220 FEATURE:
223 OTHER INFORNATIOE Synthetic
400 SEQUENCE 350
Lys Ala Ser
1
210 SEQ ID NO 351
211 LENGTH 27
212 TYPE DNA
213 ORGANISN Artificial Sequence
220 FEATURE
223 OTHER INPORKATION Synthetic
400 SEQUENCE 351
caacagtata atagr.tattg gtacact 27
210 SEQ ID NO 352
211 LENGTH 9
212 TYPE PRT
213 ORGANISE Artificial Sequence
220 FEATURE.
223 OTHER INFOPHATION Synthetic
400 6'EQUENCE 352
Gln Gln Tyr Asn Ser Tyr Trp Tyr Thr
217
US 8,062,640 B2
-continued
210 SEQ ID NO 353
211 LENGTH 354
a212 TYPE DNA
a213 ORGANIS14 Aztzfrczal Sequence
220 FEATURE:
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 353
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt agctatagca tggactgggt ccgccaggct 12 0
ccagggaagg ggctggagtg ggtct.catcc attagtagta gr.agtagtt.a cat.atactac 180
gcagactctg tgaagggccg attcaccatc tccagagaca ccgccaagaa ctcactgtat 240
ctgcaaatga acagcctgag agacgaggac acggctgttt attactgtgc gagagagggc 300
agtagcagac tttttgacta ctggggccag ggaaccctgg tcaccgtctc ctca 354
210 6'EQ ID NO 354
211 LENGTH 118
212 TYPE PRT
213 ORGANISE Aztrfzczal Sequence
220 PEATURR.
223 OTHER INFORFIATION Synthetrc
400 SEQUENCE 354
Glu Val Gln Leu Val Glu Sez Gly Gly Gly Leu Val Lys Pro Gly Gly
I 5 10 15
Ser Leu Azg Leu Ser Cy. Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ser Het Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Sez Ser Ile Ser Ser Sez Sez Sez Tyr Ile Tyr Tyr Ala A p Sez Val
50 55 60
Lys Gly Azg Phe Thr Ile Sez Azg Asp Thr Ala Lys Asn Sez Leu Tyz
65 70 75 90
Leu Gln Het Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyz Cys
85 90 95
Ala Arg Glu Gly Ser Ser Arg Leu Phe Asp Tyr Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115
210 SEQ ID NO 355
211 LENGTH 321
212 TYPE DNA
213 ORGANISN Aztzf
220 FEATURE
223 OTHER INFORNATI
zczal Sequence
ON Synthetzc
400 SEQUENCE 355
gacatccaga r.gacccagtc tcctt.ccacc ctgtctgcat. ctgr.aggaga cagagt.cacc
at.cacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagagacca 12 0
gggaaagccc ctaagctcct gat.ctataag gcgtctagtt tagaaggtgg agtcccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct 240
gagqattttg caacttatta ctgccaacag tataatagtt attggtacac ttttggccag 300
gggaccaagc tggagatcaa a 321
219
US 8,062,640 B2
-continued
220
210 SEQ ID NO 356
211 LEI'GTH 107
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
c220 FEATURE;
c223 OTHER INPORftATION. Synthetrc
400 SEQUENCE 35
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
I 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Arg Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Gly Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyz Cyc Gln Gln Tyr A:n Ser Tyr Trp Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
210 SEQ ID NO 357
211 LENGTH 354
212 TYPE DNA
c213 ORGANIS14 Artrfrc
220 FEATURE:
223 OTHER INFORHATION
ral Sequence
Synt.hettc
400 SEQUENCE 357
gaggtgcauc tggtggagtc tgggggaggc ctggtcaagc ctggggggtc cctgagactc
tcctgtgcag cctctggatt caccttcagt agctatagca tgaactgggt ccgccaggct 12 0
ccagggaagg ggctggagtg ggtctcatcc attagtagta gtagtagtta catatactac 180
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat 240
ctgcaaatga acagcctgag agccgaggac acggctgtgt. att.actgtgc gagagagggc 300
agtagcagac tttttgacta ctggggccaa ggaaccctgg tcaccgtctc ctca 354
210 SEQ ID NO 358
211 LENGTH 118
212 TYPE PRT
213 ORGANIISN AZtrfrC
220 PEATURR.
223 OTHER INFORFIATION
ral Sequence
Synthetrc
400 SEQUENCE 358
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cy. Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ser Het Asn Trp Val Arg Gln Ala Pro Gly Ly- Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Ser Ser 9er Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln lust Asn Ser Leu Arg Ala Glu F.cp Thr Ala Val Tyr Tyr Cys
85 90 95
221
US 8,062,640 B2
-continued
222
Ala Arg Glu Gly Ser Ser Arg Leu Phe Asp Tyr Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115
210 SEQ ID NO 359
211 LENGTH 321
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFOPHF.TION Synthetrc
600 SEQUENCE 359
gacatccaqa tgacccagtc tccttccacc ctgtctgcat. ctgr.aggaga cagagtcacc
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagaaacca 12 0
gggaaagccc ctaagctcct gatctataag gcgtctaott tagaaagtgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct 260
gatgatt.ttg caacttatta ctgccaacag tataat.agtt attggtacac ttttggccag 300
gggaccaagc tggagatcaa a 321
210 SEQ ID NO 360
211 LEI'GTH 107
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE
s223 OT!'ER INPOR!NATION Synthetrc
800 SEQUENCE 360
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
!\sp Arg Val Thr Ile Thr Cys !\rg !\Ia Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pzo Gly Lys Ala Pro Lys Leu Leu Ile
35 60 65
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 0
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Trp Tyr
85 90 95
Thz Phe Gly Gln Gly Thz Lys Leu Glu Ile Ly-
100 105
210 SEQ ID NO 361
211 LENGTH 386
212 TYPE DNA
213 ORGAEISN Artrfrcral Sequence
220 FEATURE
223 UTFER INpoRHATION, synthetrc
500 SEOUENCE 361
caggtgcacc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc
tcctgtgcag cctctggatt caccttcagt gaccactaca tgagctggat ccgccaggct 12 0
ccagggaagg ggctggagtg gatttcatac attagtaatg atggtggtac caaatactat 180
gtgqactctg tggaqggccg attcatcatt tccaggqaca acgccaaqaa ctcattgtat 260
ctacatatga acagcctcag agccgacgac acggccgtgt attactgtgc gagagatcag 300
223
US 8,062,640 B2
-continued
224
ggatatattg gctacgactc gtattattac tattcctacg gtatggacgt t.tggggccaa 360
gggaccacgg tcaccgtcgc ctca 384
a210 SEQ ID NO 362
a211 LENGTH 128
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 362
Gln Val Hr Leu Val Glu Ser Gly Gly Gly Leu Val Lyr. Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cy. Ala Ala Ser Gly Phe Thr Phe Ser Asp Hia
20 25 30
Tyr Het Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Ser Tyr Ile Ser Asn Asp Gly Gly Thr Lys Tyr Tyr Val Asp Ser Val
50 55 60
Glu Gly Arg Phe Ile Ile Ser Arg A p Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Hrs Net Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gln Gly Tyr Ile Gly Tyr Asp Ser Tyr Tyr Tyr Tyr Ser
100 105 110
Tyr Gly Net Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val 3;la Ser
115 12 0 125
210 SEQ ID NO 363
211 LENGTH 24
212 TYPE DNA
213 ORGIINISH .Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 363
ggattcacct tcagtgacca ctac 24
210 SEQ ID NO 364
211 LENGTH 8
212 TYPE PPT
213 ORGIQIISN Artrfrcral Sequence
220 FEATURE:
223 OTHER IEFORHATION Synthetrc
400 SEQUENCE 364
Gly Phe Thr Phe Ser Asp Hrs Tyr
1 5
210 SEQ ID NO 365
211 LENGTH 24
212 TYPE DNA
213 ORGFNISH Artrfrcral Sequence
220 FEATURE:
223 OTHER INPORNATION Synthetrc
400 SEQUENCE 3 5
attagtaatg atggtggtac caaa
210 SEQ ID NO 366
211 LENGTH 8
212 TYPE PRT
213 ORGIINISH Artrfrcral Sequence
225
US 8,062,640 B2
-continued
226
220 PEATURR.
223 OTHER INFORN"ZION Synthetrc
400 SEQUENCE 366
Ile Ser Asn Asp Gly Gly Thr Lys
I 5
210 SEQ ID NO 367
211 LENGTH 63
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INPORFZATZON Synthetrc
400 SEQUENCE 367
gcgagagatc agggatatat tggctacgac tcgtattatt. actattccta cggtatggac
gt c 63
210 SEQ ID NO 3 8
211 LENGTH 21
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE:
223 OTHER INFOPMATION Synthetrc
400 SEQUENCE 368
Ala Arg Asp Gln Gly Tyr Ile Gly Tyr Asp Ser Tyr Tyr Tyr Tyr Ser
5 10 15
Tyr Gly Net Asp Val
20
210 SEQ ID NO 369
211 LENGTH 321
212 TYPE DNA
213 ORGZZNISN .Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 369
aaaattgtct tgacgcagtc tccaggcacc ctgcctttgt t.tccagggga aagagccacc
ctctcctgta gggccagtca gagtgttaac aacaaattct. tagcctggta ccagcagaaa 12 0
tctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca 180
gacaggttca gtggcagtgg gtctgggacc gacttcactc tcaccatcag cggactggag 240
cctgaagat.t ttgaagtgta ttattgtcaa gtatatggta actcactcac tctcggcgga
gggaccaagg tggagatcaa g
300
321
210 SEQ ID NO 370
211 LENGTH 10
212 TYPE PRT
213 ORGANISN Artrfrc
220 FEATURE
223 OTHER INPORNATION
ral Sequence
synt.hetrc
400 SEOUENCE 370
Lys Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Pro Leu Phe Pro Gly
1 5 10 15
Glu Arg fla Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Asn Lys
20 25 30
Phe Leu Ala Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser Ser !\rg !\Za Thr Gly Ile Pro .Asp Arg Phe Ser
227
US 8,062,640 B2
-continued
228
50 55
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr lie Ser Gly Leu Glu
70 75 80
Pro Glu Asp Phe Glu Val Tyr Tyr Cy. Gln Val Tyr Gly A n Ser Leu
85 90 95
Thr Leu Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
210 SEQ ID No 371
211 LENGTH 21
212 TYPE DNA
213 ORGAEISM Artrfrcral Sequence
220 FEATURE:
223 oTHER INFORMATION Synthettc
400. SEQUENCE 371
cagagtgtta acaacaaatt c
210 SEQ ID No 372
211 LENGTH 7
212 TYPE PRT
213 ORGPSHSN Artrfrcral Sequence
220 FEATURE.
223 OTHER INPORMATION Synthettc
400 SEQUENCE 372
Gln Ser Val Asn Asn Lys Phe
I 5
210 SEQ ID 110 373
211 LENGTH 9
212 TYPE DNA
213 ORGANISN Arttftctal Sequence
220 FEATURE
223 OTHER INFORMATION Synthetrc
400 SEQUENCE 373
ggtgcatcc
210 SEQ ID No 374
211 LENGTH 3
212 TYPE PRT
213 ORGANISN Artrftctal Sequence
220 FEATURE
223 OTHER INFORM'TION Synthetrc
400 SEQUENCE 374
Gly Ala Ser
I
210 SEQ ID No 375
211 LENGTH 24
212 TYPE DNA
213 ORGANISN Artrfrctal Sequence
220 PEATURE:
223 OTHER INPORNATZON: Synthet rc
4OO SEQIIENCE 375
caagtatatg gtaactcact cact
210 SEQ ID No 374
211 LENGTH 8
212 TYPE PRT
213 URGANISM Artrftcral sequence
220 FEATURE.
223 OTHER INFORMATION Synthetrc
229
US 8,062,640 B2
-continued
230
400 SEQUENCE 376
Gln Val Tyr Gly Asn Ser Leu Thr
5
210 SEQ ID I'10 377
211 LENGTH 384
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORI4ATION Synthetrc
400 SEQUENCE 377
caggtgcagc r.ggtggagtc tgggggaggc ttggtcaagc crggagggr.c cct.gagactc 60
tcctgtgcag cctctggatt caccttcagt gaccactaca t.gagctggat ccgccaggct 120
ccagggaagg ggctggagtg gatttcatac attagtaatg atggtggtac caaatactat 180
gtggactctg tggagggccg attcatcatt tccagggaca acgccaagaa ctcattgtat 240
ctacatatga acagcctcag agccgacgac acqgccqtgt attactgtg- gagagatcag 300
ggatatatrq gctacgactc gtattattac tattcctacg gtatgqacgt ctggggccaa 360
gggaccacgg tcaccgtctc ctca 384
210 SEQ ID NO 378
211 LENGTH 128
212 TYPE PRT
213 ORGAEISN Artrfrcral Sequence
c220 FEATURE:
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 378
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser A p Hrs
20 25 30
Tyr Iset Ser Trp Ile Arg Gln Ala Pro Gly Ly Gly Leu Glu Trp Ile
35 40 45
Ser Tyr Ile Ser Asn Asp Gly Gly Thr Ly- Tyr Tyr Val Asp Sez Val
50 55 60
Glu Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Hr Net A n Ser Leu Arg Ala A p A p TI z Ala Val Tyr Tyr Cy
85 90 95
Ala Arg Asp Gln Gly Tyr Ile Gly Tyr Asp Ser Tyr Tyr Tyr Tyr Ser
100 105 110
Tyr Gly lset Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 379
211 LEI'GTH 321
212 TYPE DNA
213 ORGANISE Artrfrc
220 PEATURE:
223 OTHER INFORHATION
ral sequence
Synthetrc
400 SEQUENCE 379
gaaattgtgt tgacgcagtc tccaggcacc ctgcctttgt ttccagggga aagagccacc
ctctcctqta qggccagtca gagtgttaac aacaaattct tagcctgqta ccagcagaaa 12 0
tctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca 180
231
US 8,062,640 B2
-continued
232
gacaggttca gtggcagtgg gtctgggacc gac.ttcactc tcaccatcag c.ggac.tggag 240
cctgaagatt ttgaagtgta ttattgtcaa gtatatggta actcactcac tctcggcgga 300
gggaccaagg tggagatcaa a 321
210 SEQ ID I'10 380
211 LENGTH 107
212 TYPE PRT
213 ORGANISE Artzfzczal Sequence
220 FEATURE
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 380
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Pro Leu Phe Pro Gly
I 5 10 15
Glu Arg Ala Thz Leu Ser Cfs Arg Ala Sez Gln Ser Val Asn Asn 's
20 25 30
Phe Leu Ala Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser Ser Arg ..Ia Thr Gly Ile Pzo A p Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Gly Leu Glu
65 70 75 80
Pro Glu Asp Phe Glu Val Tyr Tyr Cys Gln Val Tyr Gly Asn Ser Leu
85 90 95
Thr Leu Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
210 SEQ ID NO 381
211 LENGTH 384
212 TYPE DNA
213 ORGANISN Artzfzczal Sequence
220 FEATURE
223 OTHER INPORFIATION Syntretzc
400 SEQUENCE 381
caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc
tcctgtgcag cctctggatt caccttcagt gaccactaca t.gagctggat ccgccaggct 12 0
ccagggaaqg ggctggagtg ggtttcatac attagtaatg atggtggtac caaatactac 180
gcagactctg tgaagggccg attcaccatc tccagggaca acgccaagaa ctcactgtat 240
ctgcaaatga acagcctgag agccgaggac acggccgtqt attactgtgc gagagatcag
ggatatattg qctacgactc gtat.tattac tatt.cctacg gtatggacgt. ctgggggcaa
300
360
gggaccacgg tcaccgtctc ctca
210 SEQ ID NO 382
211 LENGTH 128
212 TYPE PRT
213 ORGANISN Artzfzc
220 PEATURE:
223 OTHER INFORNATION
zal Sequence
aynth et zc
400 SEQUENCE 382
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser .5 p Hzs
20 25 30
Tyr Net Ser Tzp Ile Azg Gln Ala Pro Gly Ly- Gly Leu Glu Trp Val
35 40 45
233
US 8,062,640 B2
-continued
234
Ser Tyr Ile Ser Asn Asp Gly Gly Thr Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Net Asn Ser Leu Azg Ala Glu A p Thr Ala Val Tyr Tyr Cye
85 90 95
Ala Arg Asp Gln Gly Tyr Ile Gly Tyr Asp Ser Tyr Tyr Tyr Tyr Ser
100 105 110
Tyr Gly tset Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 383
211 LENGTH 321
212 TYPE DNA
213s ORGANISN Art.rfrcral Sequence
220 FEATURE
223 OTHER INPORKATION Synthetrc
400 SEQUENCE 383
gaaattgtgt tgacgcagtc tccaggcacc ctgtct.ttgt ctccagggga aagagccacc BO
ctctcctgca gggccagtca gagtgttaac aacaaattct tagcctggta ccagcagaaa 120
cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac t.ggcatccca 180
gacaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagactggag 240
cctgaagatt ttgcagtgta ttactgtcaa gtatatggta actcactcac tttcggcgga 300
gggaccaagg tggagatcaa a 321
210 SEQ ID NO 384
211 LENGTH 107
212 TYPE PRT
213 ORGANISN Artrfrctal Sequence
220 FEATURE
223 OTHER INPORFZATION Syntretrc
400 SEQUENCE 384
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
I 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Asn Lys
20 25 30
Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Tyr Gly Asn Ser Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
210 SEQ ID NO 385
211 LENGTH 360
212 TYPE DNT
213 ORGANISE Artrfrcral Sequence
220 FETTURE
223 OTHER INFORSZATION Synthetrc
400 SEQUENCE 385
gaggtgcaga aggtggagtc tgggggaggc ctggtcaagc cgggggggtc cctgagactc
235
US 8,062,640 B2
-continued
236
tcctgtacag cctctggatt caccttcagt acttataaca tgaattgggt c.cgcc.aggct 120
ccagggaagg gactggagtg ggtctcatcc attaggagta gtagtaatta catatactac 180
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ttcactgtat 240
ctgcaaatga acagcctgag agccgatgac acggctgtgt attactgtgc gagagatggc 300
agcagttgct acgactactc tgactactgg ggccagggaa ccctggtcac cgtctcc.tca 360
210 SEQ ID NO 386
211 LENGTH 120
212 TYPE PRT
213 ORGANISN Artificial Sequence
220 FEATURE.
223 OTHER INFORNATION Synthetic
400 SEQUENCE 386
Glu Val Gln Lys Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
5 10
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Thr Tyr
20 25 30
Asn Net A n Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Net Asn Ser Leu Arg Ala 4 p A p Thr Ala Val Tyr Tyr Cya
85 90 95
Ala Arg Asp Gly Ser Ser Trp Tyr 4 p Tyr Ser Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 12 0
210 SEQ ID NO 387
211 LENGTH 24
212a TYPE DNA
213a ORGM4ISN ArtifiCial SequenCe
220 FEATURE:
223 OTHER INFORNATION Synthetic
400 SEQUENCE 387
ggattcacct tcagtactta taac
210 SEQ ID NO 388
211 LENGTH 8
212 TYPE PRT
213 ORGANISE Artificial Sequence
220 FEATURE
223 OTHER INPORKATION Synthetic
400 SEQUENCE 388
Gly Phe Thr Phe Ser Thr Tyr Asn
1 5
210 SEQ ID NO 389
211 LENGTH 24
212 TYPE DNA
213 ORGANISE Artificial Sequence
220 FEATURE.
223 OTHER INFOPHATION Synthetic
400 6'EQUENCE 389
at.taggagta gtagtaatta cata
237
US 8,062,640 B2
-continued
238
210 SEQ ID NO 390
211 LENGTH 8
212 TYPE PRT
r213 ORGANIISN AZtzfzCzal SequenCe
r220 FEATURE:
223 OTHER INFORNATION Synthetzc
400 SEQUENCE 390
Ile Arg Ser Ser Ser Aen Tyr Ile
5
210 SEQ ID NO 391
211 LENGTH 39
212 TYPE DNA
213 ORGWIISN Artzfzczal Sequence
220. FEATURE.
223 OTHER INFORN'ZION Synthetzc
400 SEQUENCE 391
gcgagagatg qcagcagttg gtacgactac tctgactac 39
210 SEQ ID EO 392
211 LENGTH 13
212 TYPE PRT
213 ORGANISFI Artzfzczal Sequence
220 FEATURE
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 392
Ala Arg Aep Gly Ser Ser Trp Tyz 5 p Tyz Ser Aep Tyr
I 5 10
210 SEQ ID NO 393
211 LENGTH 321
212 TYPE DNI
213 ORGANISN Artzfzczal Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetzc
400. SEQUENCE 393
gacatccaga tgacccagtc tccttccacc ctgtctgcat. ctgtaggaga cagagtcacc
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca acagatacca 12 0
gggaaagccc ctaaactcct gatctataag gcgtctagtt tagaaaatgg ggtcccatca 180
aggttcagcq gcagtgqatc tgggacagaa ttcactctca tcatcagcag cctgcagcct 240
gatqatt.ttg caacttatta ctgccaacag tatatt.agtt attctcggac gttcggccaa 300
gggaccaagg tggaaatcaa a 321
210 SEQ ID NO 394
211 LENGTH 107
212 TYPE PRT
213 ORGANISN Artzfzc
220 PEATURE:
223 OTHER INFORNATZON
zal Sequence
synt hat zc
400 SEQUENCE 394
Aep Ile Gln Net Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
I 5 10 15
Aep Arg Ual Thr Ile Thr Cya Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Tzp Tyr Gln Gln Ile Pzo Gly Ly Ala Pzo Ly- Leu Leu Ile
35 40 45
239
US 8,062,640 B2
-continued
240
Tyr Lya Ala Ser Ser Leu Glu Aen Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Pro
65 70 75 80
5 p A p Phe Ala Thr Tyr Tyr Cya Gln Gln Tyr Ile Ser Tyr Ser Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lya Val Glu Ile Lya
100 105
210 SEQ ID NO 395
211 LENGTH 18
212 TYPE DNA
213 ORGANISE Artificial Sequence
220 PEATURE:
223 UTFER INpoRNATIDN synthetic
400 SEQUENCE 395
cagagtatta gtagctgg 18
210 6'EQ ID NO 396
211 LEhGTH 6
212 TYPE PRT
213 ORGANISE Artificial Sequence
220 PEATURR.
223 OTHER INFOR61ATION Synthetic
400 SEQUENCE 396
Gln Ser Ile Ser Ser Trp
I 5
210 SEQ ID NO 397
211 LENGTH 9
212 TYPE DNA
213 ORGANISN Artificial Sequence
220 FEATURE
223 OTHER INPORFZATION Syntretic
400 SEQUENCE 397
aaggcgtct
210 SEQ ID NO 398
211 LENGTH 3
212 TYPE PRT
213 ORGANISE Artificial Sequence
220 FEATURE
223 OTHER INFORNATION Synthetic
400 SEQUENCE 398
Lya Ala Ser
I
210 SEQ ID NO 399
211 LENGTH 27
212 TYPE DNA
213 ORGANIISH Artificial Sequence
220 FEATURE.
223 OTHER INFORNATION Synthetic
400 SEQUENCE 399
caacagtata ttagttattc tcggacg 27
210 SEQ ID NO 400
211 LENGTH 9
212 TYPE PRT
213 ORGANISN Artificial Sequence
220 FEATURE
241
US 8,062,640 B2
-continued
242
223 OTHER INPORHATION Synthetrc
400 SEQUENCE 400
Gln Gln Tyr Ile Ser Tyr Ser Arg Thr
1 5
210 SEQ ID NO 401
211 LENGTH 360
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFOPHP.TION Synthetrc
400 SEQUENCE 401
gaggtgcanc tggtggagtc tgggggaggc ctggtcaagc cgggggggt.c cctgagactc 0
tcctgtacag cctctggatt caccttcagt acttataaca t.gaattgggt ccgccaggct 120
ccagggaagg gactggagtg ggtctcatcc attaggaota gtagtaatta catatactac 180
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ttcactgtat 240
ctgcaaatga acagcctgag agccgatgac acggctgtgt attactgtgc gagagatggc 300
agcagttggt acgactactc tgactactgg ggccagggaa ccctggtcac cgtctcctca 360
210 SEQ ID NO 402
211 LEI'GTH 120
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE
e223 OTHER INPORCATION Synthetrc
400 SEQUENCE 402
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Thr !\la Ser Gly Phe Thr Phe Ser Thr Tyr
20 25 30
Asn iset Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val
50 55 0
Lys Gly Arg Phe Thr Ile Ser Arq Asp Asn Ala Lys Asn Ser Leu Tyr
70 75 80
Leu Gln tset Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Prg Asp Gly Ser Ser Trp Tyr .'-. p Tyr Set Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 12 0
210 SEQ ID NO 403
211 LENGTH 321
212 TYPE DNA
213 ORGPIIISH Artrfrcral Sequence
220 FEATURE:
223 OTHER INPORHATION Synthetrc
400 SEQUENCE 403
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca acagatacca 12 0
gggaaagccc ctaaactcct gatctataag gcgtctagtt tagaaaatgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca tcatcagcag cctgcagcct 240
243
US 8,062,640 B2
-continued
244
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa 300
gggaccaagg tggaaatcaa a 321
s210 SEQ ID NO 404
211 LEI'GTH 107
212 TYPE PRT
213 ORGANISM Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORBIATION Synthetzc
400 SEQUENCE 404
A p Ils Gln fset Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
I 5 10 15
4 p Arg Val Thr Ile Thr Cya Arg Ala Sez Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Ile Pro Gly Lys fla Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Asn Gly Val Pzo Ser Arg Phe Sez Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cy Gln Gln Tyr Ile Ser Tyr Ser Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
210 SEQ ID NO 405
211 LENGTH 360
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFORMATION Synthetzc
400 SEQUENCE 405
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc ctggggggtc cctgagactc
tcctgtgcag cctctggatt caccttcagt acttataaca t.gaactgggt ccgccaggct 12 0
ccagggaaag ggctggagtg ggtctcatcc attaggagta gtagtaatta cat.at.actac 180
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat 240
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatggc 300
agcagttggt acgactactc tgactactgg ggccaaggaa ccctggtcac cgtctcctca 360
210 SEQ ID NO 406
211 LENGTH 120
212 TYPE PRT
213 ORGANISN Artzfzc
220 FEATURE
223 OTHER INFORMATION
zal Sequence
Synthetzc
400 SEQUENCE 406
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cys !\Za !\Za Ser Gly Pire Thr Phe Ser Thr Tyr
20 25 30
Asn iset Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Azg Ser Ser Sez .'. r Tyr Ile Tyr Tyr Ala A p Sez Val
50 55 60
245
US 8,062,640 B2
-continued
246
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Iset Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala 'rg Asp Gly Ser Ser Tzp Tyr 4 p Tyr Ser Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 12 0
210 SEQ ID NO 407
211 LENGTH 321
212 TYPE DNA
213 ORGANISM Artrfrcral Sequence
220 PEATURE:
223 UTFER INpoRMATIUN synthetrc
400 SEQUENCE 407
gacatccaqa tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc
atcacttqcc qggccagtca gagtattagt agctggttgg cctqgtatca gcagaaacca 12 0
gggaaagccc ctaagctcct gatctataag qcgtctagtt tagaaagtgq ggtcccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct 240
gatgattttg caacttatta ctgccaacag tatattagtt. attctcggac gttcggccaa 300
gggaccaagg tggaaatcaa a 321
s210 SEQ ID NO 408
211 LEI'GTH 107
212 TYPE PRT
213 ORGPIIISM Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORKATION Synthetzc
400 SEQUENCE 408
A p Ils Gln lect Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
I 5 10 15
4 p Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Ly" Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cy Gln Gln Tyr Ile Ser Tyr Ser Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
210 SEQ ID NO 409
211 LENGTH 360
212 TYPE DNA
213 ORGANISM Artrfrcral Sequence
220 FEATURE
223 OTHER INFORMATION Synthetzc
400 SEQUENCE 409
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc cgggggggtc cctgagactc
tcctgtacag cctctggatt caccttcagt acttataaca tgaattgggt ccgccaggct 12 0
ccagggaagg gactggagtg ggtctcatcc attaggagta gtagtaatta catatactac 180
247
US 8,062,640 B2
-continued
248
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ttcactgtat 240
ctgcaaatga acagcctgag agccgatgac acggctgtgt attactgtgc gagagatggc 300
agcagttggt acgactactc tgactactgg ggccagggaa ccctggtcac cgtctcctca 360
210 SEQ ID NO 410
211 LENGTH 120
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFOPHP.TION Synthetrc
400 SEQUENCE 410
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Ly. Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Thr Tyr
20 25 30
Asn Het Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Arg Ser Ser Ser 5 n Tyr Ile Tyr Tyr Ala A p Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 SO
Leu Gln lect Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys
85 80 95
Ala 'rg Asp Gly Ser Ser Trp Tyr 5 p Tyr Ser Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu val Thr val ser ser
115 12 0
210 SEQ ID NO 411
211 LENGTH 24
212 TYPE DNA
213 ORGAEISN Artrfrcral Sequence
220 FEATURE:
223. OTHER INPOPNATION Synthetrc
400 SEQUENCE 411
ggattcacct tcagtactta taa«
210 SEQ ID NO 412
211 LENGTH 8
212 TYPE PRT
213 ORGANIISN Artrfrcral Sequence
220 PEATURR.
223 OTHER INFORFZATION Synthetrc
400 SEQUENCE 412
Gly Phe Thr Phe Ser Thr Tyr Asn
I 5
210 SEQ ID NO 413
211 LENGTH 24
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 413
attaggaqta qtagtaatta cata
210 SEQ ID NO 414
249
US 8,062,640 B2
-continued
250
211 LENGTH 8
212 TYPE PPT
213 ORMEISM Artrfrcral Sequence
220 FEATURE
223 OTHER INFOR!48TZON Synthetzc
c400 SEQUENCE
Ile Arg Ser Ser Ser Asn Tyr Ile
1 5
210 SEQ ID NO 415
211 LENGTH 39
212 TYPE DNA
213 ORGAEISM Artzfzczal Sequence
220 FEATURE:
223 OTHER INFORMATION Synthetrc
400. SEQUENCE 415
gcgagagatg gcagcagttg gtacgactac tctgactac
210 SEQ ID NO 416
211 LENGTH 13
212 TYPE PRT
213 ORGPSNSN Artzfzczal Sequence
220 FEATURE.
223 OTHER INPORMATION Synthetrc
400 SEQUENCE 416
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr
I 5 10
210 SEQ ID NO 417
211 LENGTH 321
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFORMATION Synthetrc
400 SEQUENCE 417
gacatccaga tgacccagtc t«cttccacc ctgtctgcat ctgtaggaga cagagtcacc
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca acagatacca 12 0
gggaaagccc ctaaactcct gatctataag gcgtctagtt. tagaaaatgg ggt.cccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca tcatcagcag cctgcagcct 240
gatgattttg caacttatta ctgccaacag tatattactt attctcggac gttcggccaa 300
gggaccaagg tggaaatcaa a 321
210 SEQ ID NO 418
211 LENGTH 107
212 TYPE PRT
213 ORGAEISN Artzfzc
220 FEATURE
223 OTHER INFORMATION
zal Sequence
Synthetrc
400 SEQUENCE 418
A p Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
!\sp Arg Val Thr Ile Thr Cys !\rg !\Za Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Ile Pzo Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu .'. r Gly Val Pzo Ser Azg Phe Sez Gly
50 55 60
251
US 8,062,640 B2
-continued
252
Ser Gly Ser Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Pro
65 70 75 80
Aap Aep Phe Ala Thr Tyr Tyr Cya Gln Gln Tyr Ile Ser Tyr Ser Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lye Val Glu Ile Ly
100 105
210 SEQ ID NO 419
211 LENGTH 18
212 TYPE DNA
213 ORGAEISN Artrfrctal Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 419
cagagtatta gtagctgg 18
210 SEQ ID NO 420
211 LENGTH 6
212 TYPE PRT
213 DRONISH Artrftcral Sequence
220 FEATURE:
223 OTHER IEFORHATION Synthetrc
400 SEQUENCE 420
Gln Ser Ile Ser Ser Trp
I 5
c210 SEQ ID NO 421
211 LEI'GTH 9
212 TYPE DNA
213 ORGPIIISN Artrfrctal Sequence
220 FEATURE.
223 OTHER INFORKATION Synthetrc
400 SEQUENCE 421
aaggcgtct
210a SEQ ID NO 422
211e LENGTH 3
212 TYPE PRT
213 ORGANISbl Artrfrctal Sequence
220 FEATUPE
223 OTHER INPORNATION Synthetrc
400 SEQUENCE 422
Ly Ala Ser
1
210 SEQ ID NO 423
211 LENGTH 27
212 TYPE DNA
213 ORGAEISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFOPNP.TION Synthetrc
400 SEQUENCE 423
caacagtata tt.agttattc tcggacg 27
210 SEQ ID NO 424
211 LENGTH 9
212 TYPE PRT
213 ORGANIS'N Artrfrctal Sequence
220 FEATURE:
223 OTHER INPORNATION Synthetrc
400 SEQUENCE 424
253
US 8,062,640 B2
-continued
254
Gln Gln Tyr Ile Ser Tyr Ser Arg Thr
5
r210 SEQ ID NO 425
r211 LENGTH 360
212 TYPE DZ'IA
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 425
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc cgggggggtc cctgagactc 60
tcctgtacag cctctggatt cacct.tcagt acttataaca tgaattgggt ccgccaggct 120
ccagggaagg gactggagtg ggtctcatcc attaggagta gtagtaatta catat.actac 180
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa tt.cactgtat 240
ctgcaaatua acagcctgag agccgatgac acggctgtgt attactgtgc gagagatqgc 300
agcagttqgt acgactactc tgactactgg ggccagqgaa ccctggtca- cgtctcctca 360
210 SEQ ID EO 426
211 LENGTH 120
212 TYPE PRT
213 ORGANISbl Artrfrcral Sequence
220 FEATURE
223 OTHER INFORHFTION Synthetrc
400 SEQUENCE 426
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Thr Tyr
20 25 30
!\sn Het Asn Trp Val Arg Gln !\Za Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala .8 p Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Het Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln
100 105 110
Gly Thz Leu Val Thr Val Sez Sez
115 12 0
210 SEQ ID NO 427
211 LENGTH 321
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INPORHATION, Synthetrc
400 SEOUENCE 427
gacatccaua tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca acagatacca 120
gggaaagccc ctaaactcct gatctataag gcgtctagtt tagaaaatgg ggtcccatca 180
aggttcaqcg qcagtggatc tgggacagaa ttcactctca tcatcagcag cctgcagcct 240
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa 300
255
US 8,062,640 B2
-continued
256
gggaccaagg tggaaatcaa a 321
210 SEQ ID NO 428
211 LENGTH 10
s212 TYPE PRT
s213 ORGANIS14 Aztzfzczal Sequence
220 FEATURE:
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 428
A p Ile Gln Met Thr Gln Sez Pzo Ser Thr Leu Ser Ala Ser Val Gly
5 10
A p Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Sez Sez Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Ile Pro Gly Ly" Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys fla Ser Ser Leu Glu Asn Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Sez Gly Sez Gly Thr Glu Phe Thz Leu Ile Ile Ser Ser Leu Gln Pzo
65 70 75 80
Aep Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyt Ile Ser Tyr Ser Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
210 SEQ ID NO 429
s211 LENGTH 360
212 TYPE Dl'IA
213 ORGANIISN Artzf feral Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 429
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt acttataaca tgaactgggt ccgccaggct 120
ccagggaagg ggctggagtg ggtctcatcc attaggagta gtagtaatta catat.actac 180
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat 240
ctgcaaataa acagcctgag agc«gaggac acggctgtgt attactgtgc gagagatggc 300
agcagttggt acgactactc tgactactgg ggccaaggaa ccctggtcac cgtctcctca 360
210 SEQ ID EO 430
211 LENGTH 120
212 TYPE PRT
213 ORGANISE Aztzfzc
220 FEATURE.
223 OTHER INPORHATION
zal Sequence
Synthetzc
400 SEQUENCE 430
Glu Val Gln Leu Val Glu Sez Gly Gly Gly Leu Val Lys Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Sez Thr Tyr
20 25 30
!\sn 14et Asn Trp Val Arg Gln !\Za Pro Gly Lys Gly Leu Glu Trp Val
3 40 45
Ser Ser Ile Azg Sez Ser Sez Asn Tyr Ile Tyr Tyr Ala .5 p Sez Val
50 55 60
Ly- Gly Azg Phe Thr Ile Ser ..zg A p A n Ala Ly- A n Sez Leu Tyz
65 70 75 80
257
US 8,062,640 B2
-continued
258
Leu Gln Het Asn Ser Leu Arg Ala Glu asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 12 0
210 SEQ ID NO 431
211 LENGTH 321
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 431
gacatccaoa tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagaaacca 120
gggaaagccc ctaagctcct gatctataag gcgtctagtt tagaaagtgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct 240
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa 300
gggaccaagg tggaaatcaa a 321
210 SEQ ID NO 432
211 LENGTH 10
212 TYPE PRT
e213 ORGANIS14 Artrfrcral Sequence
220 FEATURE:
223 OTHER INFORHATION. Synthetrc
400 SEQUENCE 432
Asp Ile Gln Net Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
I 5 10 15
A p Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Ly" Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ly" Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
.Aep Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
210 SEQ ID NO 433
211 LENGTH 360
212 TYPE DNA
213 ORGANIISH Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 433
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc cgggggggtc cctgagactc 60
tcctgtacag cctctggatt caccttcagt acttataaca tgaattgggt ccgccaggct 120
ccaoggaagg uactugagtg ggtctcatcc attaggagta gtagtaatta catatactac 180
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagag ttcactgtat 240
259
US 8,062,640 B2
-continued
260
ctgc.aaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatggc 300
agcagttggt acgactactc tgactactgg ggccagggaa ccctggtcac cgtctcctca 360
c210 SEQ ID NO 434
c211 LENGTH 120
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 434
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lyr. Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cy- Thr Ala Ser Gly Phe Thr Phe Ser Thr Tyr
20 25 30
Asn Het Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Arg Ser Ser Ser I\sn Tyr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Ly. Gly Arg Phe Thr Ile Ser Arg A p Asn Ala Lys Ser Ser Leu Tyr
65 70 75 80
Leu Gln Net Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 12 0
210 SEQ ID NO 435
211 LENGTH 24
212 TYPE DNA
213 ORGIINISH .Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 435
ggattcacct tcagtactta taac 24
210 SEQ ID NO 43
211 LENGTH 8
212 TYPE PPT
213 ORGIQIISN Artrfrcral Sequence
220 FEATURE:
223 OTHER IEFORHATION Synthetrc
400 SEQUENCE 436
Gly Phe Thr Phe Ser Thr Tyr I\sn
1 5
210 SEQ ID NO 437
211 LENGTH 24
212 TYPE DNA
213 ORGFNISH Artrfrcral Sequence
220 FEATURE:
223 OTHER INPORNATION Synthetrc
400 SEQUENCE 437
attaggagta gtagtaatta cata
210 SEQ ID NO 438
211 LENGTH 8
212 TYPE PRT
213 ORGIINISH Artrfrcral Sequence
261
US 8,062,640 B2
-continued
262
220 PEATURR.
223 OTHER INFORN"ZION Synthetic
400 SEQUENCE 438
Ile Arg Ser Ser Ser Aen Tyr Ile
I 5
210 SEQ ID NO 439
211 LENGTH 39
212 TYPE DNA
213 ORGANISN Artificial Sequence
220 FEATURE
223 OTHER INPORFZATION Synthetic
400 SEQUENCE 439
gcgagagatg gcagcagttg gtacgactac tctgactac
210 SEQ ID NO 440
211 LENGTH 13
212 TYPE PRT
213 ORGANISN Artificial Sequence
220 FEATURE:
223 OTHER INPORNATION Synthetic
400 SEQUENCE 440
Ala Arg Aap Gly Ser Ser Trp Tyr Aep Tyr Ser Aap Tyr
5 10
210 SEQ ID NO 441
o211 LENGTH 321
212 TYPE Dl'IA
213 ORGANIISN Artificial Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetic
400 SEQUENCE 441
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca acaggtacca 120
gggaaagccc ctaaactcct gatctataag gcgtctagtt. t.agaaaatgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca t.catcagcag cct.gcagcct 240
gatgattttg caacttatta ctg«caacag tatattagtt attctcggac gttcggccaa 300
gggaccaagg tggaaatcaa a 321
210 SEQ ID EO 442
211 LENGTH 107
212 TYPE PRT
213 ORGANISE Artific
220 FEATURE.
223 OTHER INPORHATION
ial Sequence
Synthetic
400 SEQUENCE 442
Aep Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
I 5 10 15
A p Arg Val Thr Ile Thr Cye Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Val Pro Gly Lye Ala Pro Lye Leu Leu Ile
3 40 45
Tyr Lye Ala Ser Ser Leu Glu Aen Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Sez Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Glr Pzo
65 70 75 80
263
US 8,062,640 B2
-continued
264
8 p Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
210 SEQ ID I'10 443
211 LENGTH 18
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORIAATION Synthetrc
400 SEQUENCE 443
cagagtatta gtagctgg
210a SEQ ID NO 444
211 LENGTH 6
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFORNATION Synthetzc
400 SEQUENCE 444
Gln Ser Ile Ser Ser Trp
I 5
210 SEQ ID NO 445
211 LENGTH 9
212 TYPE DNA
a213 ORGANIS14 Artrfrcral Sequence
220 FEATURE:
223 OTHER INFORHATION. Synthetrc
400 SEQUENCE 445
aaggcgtct
210 SEQ ID NO 446
211 LENGTH 3
212 TYPE PRT
213a ORGWIISN Artrfrcral Sequence
220. FEATURE.
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 44
Lys Ala Ser
210 SEQ ID NO 447
211 LENGTH 27
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INPORKATION Synthetzc
400 SEQUENCE 447
caacagtata ttagttatt.c t.cggacg 27
210 SEQ ID I'10 448
211 LENGTH 9
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 FEITURE
223 OTI'ER INFORIAATION Synthetzc
400 SEQUENCE 448
Gln Gln Tyr Ile Ser Tyr Ser Arg Thr
I 5
265
US 8,062,640 B2
-continued
266
210 SEQ ID NO 449
211 LENGTH 360
212 TYPE DNA
a213 ORGANZISN AZtzfzCzal SequenCe
a220 FEATURE:
223 OTHER INFORNATION Synthetzc
400 SEQUENCE 449
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc cgggggggtc cctgagactc 60
tcctgtacag cctctggatt caccttcagt acttataaca tgaattgggt ccgccaggct 120
ccagggaagg gactggagtg ggtctcatcc attaggagta gtagtaatta catatactac 180
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagag t.tcactgtat 240
ctgcaaatoa acagcctgag agccgaggac acggctgtgt att.actgtgc gagagat.ggc 300
agcagttggt acgactactc tgactactgg ggccaggoaa ccctggtcac cgtctcctca 360
210 SEQ ID NO 450
211 LENGTH 120
212 TYPE PRT
213 ORGPSHSN Artzfzczal Sequence
220 FEATURE.
223 OTHER INPORHATION Synthetzc
400 SEQUENCE 450
Glu Val Gln Leu 'Zal Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
I 5 10 15
Sez Leu Zzg Leu Ser Cye Thr Ala Sez Gly Phe Thr Phe Ser Thr Tyz
20 25 30
Asn Het Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thz Ile Ser Azg Asp Asn Ala Lys Sez Ser Leu Tyr
65 70 75 80
Leu Gln Het Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 12 0
210 SEQ ID NO 451
211 LENGTH 321
212 TYPE DNA
213 ORGANISN Artzf
220 FEATURE
223 OTHER INPORKATI
zczal Sequence
ON Synthetzc
400 SEQUENCE 451
gacatccaoa tgacccagtc tccttccacc ctgtctgcat ctgt.aggaga cagagtcacc
atcacttgcc gggccagtca gagtattagt agctggttgg cct.ggtatca acaggtacca 12 0
gggaaagccc ctaaactcct gatctataag gcgtctagtt tagaaaatgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca tcatcagcag cctgcagcct 240
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa 300
gggaccaagg tggaaatcaa a 321
267
US 8,062,640 B2
-continued
268
210 SEQ ID NO 452
211 LENGTH 107
212 TYPE PRT
213 ORGANISN Artzfzczal Sequence
220 FEATURE
r223 OTHER INFORRATION Synthetzc
400 SEQUENCE 452
Asp Ile Gln tfet Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
A p Arg Val Thr Ile Thr Cys Azg Ala Ser Gln Ser Ile Ser Sez Tzp
20 25 30
Leu Ala Trp Tyr Gln Gln Val Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyz Lya Ala Ser Ser Leu Glu Asn Gly Val Pro Ser Arg Phe Sez Gly
50 55 0
Ser Gly Ser Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Pro
70 75 80
Asp Asp Phe Ala Thr Tyr Tyz Cys Gln Gln Tyt Ile Ser Tyr Sez Azg
85 90 95
Thz Phe Gly Gln Gly Thr Lys Val Glu Ile Ly
100 105
210 SEQ ID NO 453
211 LENGTH 360
212 TYPE DNA
213 ORGAEISN Aztzfzczal Sequence
r220 FEATURE:
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 453
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt acttataaca tgaactgggt ccgccaggct 120
ccagggaagg ggctggagtg ggtctcatcc attaggagta gtagtaatta catatactac 180
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat 240
ctgcaaatca acagcctgag agccgaggac acggctgtgt att.actgtgc gagagat.ggc 300
agcagttgot acgactactc tgactactgg ggccagggaa ccctggtcac cgt.ct.cctca 3 0
210 SEQ ID NO 454
211 LEI'GTH 120
212 TYPE PRT
213 ORGAAHSN Artzfzc
220 FEATURE;
223 OTHER INPORRATION
zal Sequence
Synthetzc
400 SEQUENCE 454
Glu Val Gln Leu 'Zal Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
I 5 10 15
Sez Leu Azg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thz Tyz
20 25 30
A n Het Asn Trp Val Azg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile frg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Azg Phe Thz Ile Sez Azg Asp Asn Ala Lys Asn Ser Leu Tyz
65 70 75 80
Leu Gln Het Asn Ser Leu Azg Ala Glu Asp Thr Ala Val Tyz Tyz Cyc
85 90 95
269
US 8,062,640 B2
-continued
270
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 12 0
210 SEQ ID I'10 455
211 LENGTH 321
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 455
gacatccaga r.gacccagtc tcctt.ccacc ctgtctgcat. ctgr.aggaga cagagt.cacc 60
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagaaacca 120
gggaaagccc ctaagctcct gatctataag gcgtctagtt tagaaagtgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct 240
gatqattttg caacttatta ctgccaacag tatattagtt attctcgga- gttcggccaa 300
gggaccaagq tgqaaatcaa a 321
210 SEQ ID NO 456
211 LENGTH 107
212 TYPE PRT
213 ORGAEISN Artrfrcral Sequence
220 FEATURE
223 OTHER INPORKATION Synthetrc
400 SEQUENCE 456
Asp Ile Gln Net Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
I 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lya Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 0
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Ly
100 105
210 SEQ ID NO 457
211 LENGTH 360
212 TYPE DNA
213 ORGAEISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFOPNP.TION Synthetrc
400 SEQUENCE 457
gaggtgcaac tggtggagtc tgggggaggc ctggtcaagc cgggggggt.c cctgagactc
tcctgtacag cctctggatt caccttcagt acttataaca tgaattgggt ccgccaggct 12 0
ccagggaagg gactggagtg ggtctcatcc attaggaata gtagtaatta catatactac 180
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ttcactgtat 240
ctgcaaatga acagcctgag agccgatgac acggctgtgt attactgtgc gagagatggc 300
agcagttggt acgactactc tgactactgg ggccagggaa ccctggtcac cgtctcctca 360
271
US 8,062,640 B2
-continued
272
210 SEQ ID NO 458
211 LENGTH 120
212 TYPE PRT
c213 ORGANIISN AZtzfzCzal SequenCe
c220 FEATURE:
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 458
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
5 10 15
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Thr Tyr
20 25 30
2 n Het Asn Trp Val Arg Gln Ala Pro Gly Ly- Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Psn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Net A n Ser Leu Azg Ala A p A p Thz Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 12 0
210 SEQ ID I'10 459
211 LENGTH 24
212 TYPE DNA
213 ORGANISE Arttftctal Sequence
220 FEATURE
223 OTHER INFORHATION Synthettc
400 SEQUENCE 459
ggattcacct tcagtactta taac 24
210a SEQ ID NO 460
211 LENGTH 8
212 TYPE PRT
213 ORGANISN Arttftctal Sequence
220 FEATURE
223 OTHER INFORH'TION Synthettc
400 SEQUENCE 460
Gly Phe Thz Phe Ser Thz Tyz .'. n
I 5
210 SEQ ID NO 461
211 LENGTH 24
212 TYPE DNA
213 ORGANISN Artzfzczal Sequence
220 FEATURE
223 OTHER INPORHATION, Synthetzc
400 SEOUENCE 461
at.taggagta gtagtaatta cata
210 SEQ ID NO 462
211 LENGTH 8
212 TYPE PRT
213 ORGANISN Artzfzczal Sequence
220 FEATURE:
223 OTHER INFORNATION Synthetzc
273
US 8,062,640 B2
-continued
274
400 SEQUENCE 462
Ile Arg Ser Ser Ser Aan Tyr Ile
I 5
c210 SEQ ID NO 463
211 LEI'GTH 39
212 TYPE DNA
213 ORGANISE Artzfzczal Sequence
220 FEATURE.
223 OTHER INFORPIATION Synthetzc
400 SEQUENCE 463
gcgagagatg gcagcagttg gtacgactac tctgactac 39
210 SEQ ID NO
211e LENGTH 13
212 TYPE PRT
213 ORGANISE Artzfzczal Sequence
220 FEATUPE
223 OTHER INFORNITION Synthetzc
400 6'EQUENCE 464
Ala Arg Acp Gly Ser Ser Trp Tyr Acp Tyr Set Acp Tyr
I 5 10
210 SEQ ID NO 465
211 LENGTH 321
212 TYPE DNA
213 ORGAEISN Artzfzczal Sequence
c220 FEATURE:
223 OTHER INFORNATION Synthetzc
400 SEQUENCE 465
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
at.cacttgcc gggccagtca gagtattagt agctggttgg cctggtatca acagatacca 120
gggaaagccc ctaaactcct gatctataag gcgtctagtt tagaaaatgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca tcatcagcag cctgcagcct 240
gatgattttg caacttatta ctgccaacag tatattagtt att.ctcggac gtt.cggccaa 300
gggaccaacg tggaaatcaa a 321
210 SEQ ID NO 466
211 LEIcGTH 107
212 TYPE PRT
213 ORGPIIISH Artzfzc
220 FEATURE;
223 OTHER INPORHATION
zal Sequence
Synthetzc
400 SEQUENCE 46
Aep Ile Gln Net Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
I 5 10 15
Aep Arg Val Thr Zle Thr Cya Arg Ala Ser Gln Ser Zle Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Ile Pro Gly Lya Ala Pto Lyc Leu Leu Ile
35 40 45
Tyr Lye Ala Ser Ser Leu Glu Aan Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thz Glu Phe Thr Leu Ile Ile Ser Sez Leu Gln Pzo
65 70 75 80
A p Aep Phe Ala Thr Tyr Tyz Cye Gln Gln Tyr Ile Ser Tyr Sez Azg
85 90 95
275
US 8,062,640 B2
-continued
276
Thr Phe Gly Gln Gly Thr Lye Val Glu Ile Lye
100 105
210 SEQ ID NO 467
c211 LENGTH 18
c212 TYPE DNA
213 ORGANHSN Artzf feral Sequence
220 FEATURE.
223 OTHER INFORMATION Synthetzc
400 SEQUENCE 467
cagagtatta gtagctgg 18
210 SEQ ID NO 468
211 LENGTH 6
212 TYPE PRT
213a ORGAZIISM Art.zfzczal Sequence
220 FEATURE
223 OTHER INPORKATION Synthetzc
400 SEQUENCE 4 8
Gln Ser Ile Ser Ser Trp
1 5
210 SEQ ID NO 469
211 LENGTH 9
212 TYPE DNA
213 ORGANISN Artzfzczal Sequence
220 FEATURE
223 OTHER INPORKATION Synthetzc
400 SEQUENCE 469
aaggcgtct
210 SEQ ID NO 470
211 LENGTH 3
212 TYPE PRT
213 ORGAEISM Artzfzczal Sequence
220 FEATURE.
223 OTHER INFOPMATION Synthetzc
400. SEQUENCE 470
Lye Ala Ser
I
210 SEQ ID NO 471
211 LEhGTH 27
212 TYPE DEA
213 ORGANHSN Aztzf feral Sequence
220 PEATURR.
223 OTHER INFORPZATION Synthetzc
400 SEQUENCE 471
caacagtata ttagttattc tcggacg 27
210 SEQ ID NO 472
211 LENGTH 9
212 TYPE PRT
213 ORGANISM Artzfzczal Sequence
220 FEATURE
223 OTHER INFORMATION Synthetzc
400 SEQUENCE 472
Gln Gln Tyr Ile Ser Tyr Ser Azg Thr
I 5
210 SEQ ID NO 473
277
US 8,062,640 B2
-continued
278
211 LENGTH 360
212 TYPE DNA
213 ORMEISN Artificial Sequence
220 FEATURE
223 OTHER INFORFIATION Synthetic
c400 SEQUENCE 473
gaggtgcaoc tggtggagtc tgggggaggc ctggtcaagc cgggggggtc cctgagactc
tcctgtacag cctctggatt caccttcagt acttataaca tgaattgggt ccgccaggct 12 0
ccagggaagg gactggagtg ggtctcatcc attaggagta gtagtaatta catatactac 180
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ttcactgtat 240
ct.gcaaatga acagcctgag agccgat.gac acggctgtgt. attactgtgc gagagatggc
agcagttggt acgactactc tgactactgg ggccagggaa ccctggtcac cgtct.cctca
300
360
210 SEQ ID NO 474
211 LENGTH 120
212 TYPE PRT
213 ORGANISN Artificial Sequence
220 FEATURE:
223 OTHER INPORNATION Synthetic
400 SEQUENCE 474
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
5 10
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Thr Tyr
20 25 30
Asn Net Asn Tzp Val Arg Gln Ala Pro Gly Ly Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val
50 55 0
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln tset Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyz Ser Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 12 0
210 SEQ ID NO 475
211 LENGTH 321
212 TYPE DNA
213 ORGANISE Artif
220 FEATURE.
223 OTHER INFORHATI
icial Sequence
ON Synthetic
400 SEQUENCE 475
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc
atcacttgcc gggccagtca gagtatt.agt agctggttgg cctggtatca acagat.scca
gggaaagccc ctaaactcct gatcr.at.aag gcgtctagtt. tagaaaatgg ggtcccatca
12 0
180
aggttcagcg gcagtggatc tgggacagaa ttcactctca tcatcagcag cctgcagcct 240
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gt.tcggccaa 300
gggaccaagg tggaaatcaa a 321
210 6'EQ ID NO 476
211 LENGTH 107
212 TYPE PRT
279
US 8,062,640 B2
-continued
280
213 ORGANISE Artificial Sequence
220 FEATURE
223 OTHER INFORN'TION Synthetic
400 SEQUENCE 476
8 p Ile Gln Net Thr Gln Sez Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Tzp Tyr Gln Gln Ile Pzo Gly Lys Ala Pzo Lys Leu Leu Ile
35 40 45
Tyz Lys Ala Ser Ser Leu Glu Arn Gly Val Pro Ser Arg Phe Sez Gly
50 55 60
Sez Gly Ser Gly Thr Glu Phe Thz Leu Ile Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe fla Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg
85 90 95
Thz Phe Gly Gln Gly Tlir Ly- Val Glu Ile Ly-
100 105
210 SEQ ID NO 477
211 LENGTH 360
212 TYPE DNA
213 ORMEISN Aztific
220 FEATURE
223 OTHER INFORFLATION
ial Sequence
Synthetic
r400 SEQUENCE 477
gaggtgcagc r.ggtggagtc t.gggggaggc ctggtcaagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt acttataaca tgaactgggt ccgccaggct 12 0
ccagggaang ggctggagtg ggtctcatcc attaggagta gtagtaatta catatactac 180
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat 240
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatggc 300
agcagttggt acgactactc tgactactgg ggccaaggaa ccctggtcac cgtct.cctca 360
210 SEQ ID NO 478
211 LENGTH 120
212 TYPE PRT
213 ORGANISE Artific
220 FEATURE
223 OTHER INFORfBATION
ial Sequence
Synthetic
400 SEQUENCE 478
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr
20 25 30
Asn Net Asn Tzp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Arg Ser Sez Ser A n Tyr Ile Tyr Tyr Ala A p Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 7 80
Leu Gln teer Asn Sez Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyz Cys
85 90 95
Ala 'rg Asp Gly Ser Sez Tzp Tyz A p Tyz Ser Asp Tyr Trp Gly Glr
100 105 110
281
US 8,062,640 B2
-continued
282
Gly Thr Leu Val Thr Val Ser Ser
115 12 0
210 SEQ ID NO 479
e211 LENGTH 321
e212 TYPE DNA
213 ORGANNSN Artrf feral Sequence
220 FEATURE.
223 OTHER INFORMATION Synthetrc
400 SEQUENCE 479
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagaaacca 12 0
gggaaagccc ct.aagctcct. gatctataag gcgtctagtt. tagaaagtgg ggtcccatca
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cct.gcagcct
180
240
gatgattttg caacttatta ctgccaacag tatattaqtt attctcggac gttcggccaa 300
gggaccaagg tggaaatcaa a 321
210 SEQ ID NO 480
211 LENGTH 107
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORH'TION Synthetrc
400 SEQUENCE 480
4 p Ile Gln Piet Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
I 5 10 15
aep Arg Val Thr lie Thr Cye 5 g Ala Ser Gln Ser lie Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lye Pro Gly Lye Ala Pro Lye Leu Leu Ile
35 40 45
Tyr Lye Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 50
Aep Aep Phe Ala Thr Tyr Tyr Cye Gln Gln Tyr Ile Ser Tyr Ser Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lya Val Glu Ile Lye
100 105
210 SEQ ID NO 481
211 LENGTH 354
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INPORKATION Synthetrc
400 SEQUENCE 481
gaqgtgcaac tagtggagt.c t.gggggaggc ttggtacagc ctggggggtc cctgagactc
tcctgtgtag tctctggatt cacct.tcggt gactacgaca tgcactgggt ccgtcaagct
60
120
acaggaagag gtctggagtg ggtctcaggt attgctcctg ctggtgacac atcctataca 180
ggctccgtga agggccgatt caccatctcc agagagaatg ccaagaactc ct.tgcatctt 240
caaatgaaca gcctgacaac cggggacacg gctatatatt attgtgctag agaggatata 300
gcaqtgcctg qttttgatta ctggggccag ggaaccctgg tcaccgtctc ctca 354
210 SEQ ID NO 482
283
US 8,062,640 B2
-continued
284
211 LENGTH 118
212 TYPE PPT
213 ORMEISN Artificial Sequence
220 FEATURE
223 OTHER INFORFIATION Synthetic
c400 SEQUENCE 482
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cys Val Val Ser Gly Phe Thr Phe Gly Asp Tyr
20 25 30
Asp Het Hi Trp Val Arg Gln Ala Thr Gly Arg Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ala Pro Ala Gly Asp Thr Ser Tyr Thr Gly Ser Val Ly.
50 55 60
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu His Leu
65 70 75 80
Gln Het Asn Ser Leu Thr Thr Gly Asp Thr Ala Ile Tyr Tyr Cys Ala
85 90 95
Arg Glu Asp Ile Ala Val Pzo Gly Phe Asp Tyz Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115
210 SEQ ID NO 483
211 LENGTH 24
c212 TYPE DNA
213 ORGANIISN Artificial Sequence
220 FEATURE:
223 OTHER INPORNATION: Synthetic
400 SEQUENCE 483
ggattcacct tcggtgacta cgac
210 SEQ ID NO 484
211 LENGTH 8
212s TYPE PRT
213a ORGM4ISN ArtifiCial SequenCe
220 FEATURE:
223 OTHER INFORNATION Synthetic
400 SEQUENCE 484
Gly Phe Thr Phe Gly Asp Tyr Asp
I 5
210
211
212
213
220
223
SEQ ID NO 485
LENGTH 21
TYPE DNA
ORGANISN Artificial Sequence
FEATURE
OTHER INPORKATION Synthetic
400 SEQUENCE 485
attgctcctg ctggrgacac a 21
210
211
212
213
220
223
SEQ ID NO 486
LENGTH 7
TYPE PRT
ORGANISE Artificial Sequence
FEATURE.
OTHER INFOPHATION Synthetic
400 6'EQUENCE 486
Ile Ala Pro Ala Gly Asp Thr
285
US 8,062,640 B2
-continued
286
210 SEQ ID NO 487
211 LENGTH 36
.212 TYPE DNA
.213 ORGANIS14 Aztificial Sequence
220 FEATURE:
223 OTHER INFORHATION Synthetic
400 SEQUENCE 487
gctagagagg atatagcagt gcctggtttt gattac 36
210 SEQ ID NO 488
211 LENGTH 12
212 TYPE PRT
213 ORGWIISN Artificial Sequence
220. FEATURE.
223 OTHER INFORN'TIDE Synthetic
400 SEQUENCE 488
Ala Arg Glu Aap Ile Ala Val Pzo Gly Phe Aap Tyr
I 5 10
210 SEQ ID NO 489
211 LENGTH 324
212 TYPE DNA
213 ORnaIIISH Artificial Sequence
220 FEATURE
223 OTHER INFORFLATION Synthetic
.400 SEQUENCE 489
gaaat.agtga tgacgcagtc t.ccagccacc ctgtctgtgt ctccagggga acgaggcacc 60
ct.ctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca gcagaaacct 12 0
ggccaggctc ccagactcct catctatggt gcatccacga gggccactgg cttcccagcc 180
aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag cctgcagtct 240
gaagattttg cagtttatta ctgtcagcag tataataagt ggcctccgtt cactttcggc 300
cctgggacca aagtggattt caaa 324
210 SEQ ID NO 490
211 LENGTH 108
212 TYPE PRT
213 ORGANISE Artificial Sequence
220 FEATURE
223 OTHER INFORNATION Synthetic
400 SEQUENCE 490
Glu Ile Val 14et Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
I 5 10 15
Glu Arg Gly Thr Leu Ser Cya Arg Ala Ser Gln Ser 'Ial Ser Ser Aen
20 25 30
Leu Ala Tzp Tyr Gln Gln Lya Pro Gly Gln Ala Pzo Arg Leu Leu Ile
35 40 45
Tyr Gly Ala Ser Thr Azg Ala Thr Gly Phe Pro Ala Azg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 7 80
Glu Aap Phe Ala Val Tyr Tyz Cya Gln Gln Tyr Aan Lya Trp Pro Pzo
85 90 95
Phe Thz Phe Gly Pzo Gly Thz Ly- Val A p Phe Ly-
100 105
287
US 8,062,640 B2
-continued
288
210 SEQ ID NO 491
211 LEI'GTH 18
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
c220 FEATURE;
c223 OTI'ER INPORI44TION. Synthetrc
400 SEQUENCE 491
cagagtgtta gcagcaac 18
210 SEQ ID NO 492
211 LENGTH
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 PEATURE:
223 OTHER INPORNATION Synthetrc
400 SEQUENCE 492
Gln Ser Val Ser Ser Aen
I 5
210 SEQ ID NO 493
211 LENGTH 9
212 TYPE DIIA
213 ORGANISE Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORH'TION Synthetrc
400 SEQUENCE 493
ggtgcat.cc
210 SEQ ID NO 494
211 LENGTH 3
212 TYPE PRT
213 ORGANISN Artrfrctal Sequence
220 FEATURE
223 OTHER INPORI4ATION Syntretrc
400 SEQUENCE 494
Gly Ala Ser
I
210 SEQ ID NO 495
211 LENGTH 30
212 TYPE DNA
213 ORGIUIISN Artrfrcral Sequence
220 FEATURE:
223 OTHER IEFORHATION Synthetrc
400 SEQUENCE 495
cagcagtata ataagtggcc tccgttcact 30
210 SEQ ID NO 496
211 LENGTH 10
212 TYPE PRT
213 ORGANIISH Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORINATION Synthetrc
400 SEQUENCE 496
Gln Gln Tyr Aen Lye Trp Pro Pro Phe Thr
10
210 SEQ ID NO 497
211 LENGTH 354
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
289
US 8,062,640 B2
-continued
290
220 PEATURR.
223 OTHER INFORN"TION Synthetrc
400 SEQUENCE 497
gaggtgcaac tagtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc
tcctgtgtag tctctggatt caccttcggt gactacgaca tgcactgggt ccgtcaagct
60
12 0
acaggaagag gtctggagtg ggtctcaggt attgctcctg ctggtgacac atcctataca 180
ggctccgtga agggccgatt caccatctcc agagagaatg ccaagaactc cttgcatctt 240
caaatgaaca gcctgacaac cggggacacg gctatatatt attgtgctag agaggatata 300
gcagtgcctg gttttgatta ctggggccag ggaaccctgg tcaccgtctc ctca 354
210 SEQ ID NO 498
211s LENGTH 118
212 TYPE PRT
213 ORGANISM Arttftctal Sequence
220 FEATUPE
223 OTHER INFORNTTION Synthetrc
400 6'EQUENCE 498
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cys Val Val Ser Gly Phe Thr Phe Gly Asp Tyr
20 25 30
Asp Met Hts Trp Val Arg Gln Ala Thr Gly Arg Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ala Pro Ala Gly Asp Thr Ser Ty» Thr Gly Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu His Leu
65 70 .5 80
Gln Met Asn Ser Leu Thr Thr Gly !\sp Thr Ala Ile Tyr Tyr Cys !\Ia
85 90 95
Arg Glu Asp Ile Ala Val Pro Gly Phe Asp Tyr Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115
210 SEQ ID NO 499
211 LENGTH 324
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE:
223 OTHER INFORNATION Synthettc
400 SEQUENCE 499
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga acgaggcacc
ctctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca gcagaaacct 12 0
ggccaggctc ccagactcct catctatggt gcatccacga gggccactgg cttcccagcc 180
aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag cct.gcagtct
gaagattttg cagtttatta ctgtcagcag tataataagt. ggcctccgt.t cactt.tcggc
240
300
cctgggacca aagtggatat casa 324
210 SEQ ID NO 500
211 LENGTH 108
212 TYPE PRT
213 ORGANISM Arttfrctal Sequence
220 FEATURE.
223 OTHER INFORMATION Synthetrc
291
US 8,062,640 B2
-continued
292
400 SEQUENCE 500
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
5 10 15
Glu 'rg Gly Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser A n
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Phe Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cy- Gln Gln Tyr Asn Lys Trp Pro Pro
85 90 95
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
210 6'EQ ID NO 501
211 LENGTH 354
212 TYPE DEA
213 ORGANISE Arttfrc
220 PEATURR.
223 OTHER INPORPIATION
tal Sequence
Synthettc
400 SEQUENCE 501
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcggt gactacgaca tgcactgggt ccgccaagct 120
acaggaaaag gtctggagtg ggtctcagct attgctcctg ctggtgacac atactatcca 180
ggctccgtga agggccgatt caccatctcc agagaaaatg ccaagaactc cttgtatctt 240
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgtgctag agaggatata 300
gcagtgcctg gttttgatta ctggggccaa ggaaccctgg tcaccgtctc ctca 354
210s SEQ ID NO 502
211s LENGTH 118
212 TYPE PRT
213 ORGANISbl Arttftc
220 PEATUPE
223 OTHER INPORNITION
tal Sequence
Synthetzc
400 SEQUENCE 502
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asp Tyr
20 25 30
Asp Het Hzs Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Ala Pro Ala Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Glu A n Ala Lys Asn Ser Leu Tyr Leu
65 70 75 80
Gln ffet Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Glu Asp Ile Ala Val Pro Gly Phe Asp Tyr Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115
293
US 8,062,640 B2
-continued
294
210 SEQ ID NO 503
211 LEIsGTH 324
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
s220 FEATURE;
s223 OTHER INPORf44TION. Synthetrc
400 SEQUENCE 503
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca gcagaaacct 120
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc 180
aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag cct.gcagtct 240
gaagattttg cagtttatta ctgtcagcag tataataagt. ggcctccgtt cactt.tcggc 300
cctgggacca aagtggatat casa 324
210 SEQ ID NO 504
211 LENGTH 108
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE:
223 OTHER INFOPMATION Synthetrc
400 SEQUENCE 504
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
5 10 15
Glu 'rg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser A n
20 25 30
Leu Ala Trp Tyr Gln Gln ' Pro Gly Gln Ala Pro Arg Leu 'u Ile
35 40 45
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cy- Gln Gln Tyr Asn Lys Trp Pro Pro
85 90 95
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile
100 105
Lvs
210 SEQ ID NO 505
211 LENGTH 378
212 TYPE DEA
213 ORGANIISN Artrfrcral Seque
220 PEATURR.
223 OTHER INFORSZATION Synthet
nce
10
400 SEQUENCE 505
caaattctgc tggtgcaatc tggacctgag gtgaaggagc ctggggcctc agtgaaggtc
tcctgcaagg cttctggtta cacctttacc aactacgcta tcagctgggt gcgacaggtc 12 0
cctggacaag ggct.rgagtg gatgggatgg gtcagcgctt acaatggtca cacaaactat 180
gcacatgaag tccagggcag agtcaccatg accacagaca cat.ccacgac cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccatgt attactgtgc gagagggggt 300
gtagtcgtgc cagttgctcc ccacttctac aacggtatgg acgtctgggg ccaagggacc 360
acggtcaccg tctcctca 378
210 SEQ ID NO 506
211 LENGTH 126
295
US 8,062,640 B2
-continued
296
212 TYPE PRT
213 ORGANISE Artzfzczal Sequence
220 FEATURE
223 OTHER INFORHPTION Synthetzc
s400 SEQUENCE 506
Gln Ile Leu Leu Val Gln Ser Gly Pro Glu Val Ly Glu Pro Gly Ala
I 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Val Pro Gly Gln Gly Leu Glu Tzp Net
35 40 45
Gly Trp Val Ser Ala Tyr Asn Gly Hzs Thr Asn Tyr Ala His Glu Val
50 55 60
Gln Gly Arg Val Thr Net Thr Thr Asp Thr Ser Thr Thr Thr Ala Tyr
65 70 75 80
Net Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala 'rg Gly Gly Val Val Val Pzo Val Ala Pro Hz- Phe Tyr A 71 Gly
100 105 110
Het Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 507
211 LENGTH 24
212 TYPE DNA
s213 ORGANIS14 Artzfzczal Sequence
220 FEATURE:
223 OTHER INFORHATION. Synthetzc
400 SEQUENCE 507
ggttacacct ttaccaacta cgct
210 SEQ ID NO 508
211 LENGTH 8
212 TYPE PRT
213s ORGWIISN Artrfrcral Sequence
220. FEATURE.
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 508
Gly Tyr Thr Phe Thr Asn Tyr Ala
5
210 SEQ ID NO 509
211 LENGTH 24
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INPORKATION Synthetzc
400 SEQUENCE 509
gtcagcgctt acaatggtca ceca 24
210 SEQ ID I'10 510
211 LENGTH 8
212 TYPE PRT
213 ORGANISE Artzfzczal Sequence
220 FEPTURE
223 OTI'ER INFORI4ATION Synthetzc
400 SEQUENCE 510
Val Ser Ala Tyr Asn Gly Hzs Thr
I 5
297
US 8,062,640 B2
-continued
298
210 SEQ ID NO 511
211 LENGTH 57
212 TYPE DNA
c213 ORGANZISN ArtrfrCral SequenCe
c220 FEATURE:
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 511
gcgagagggg gtgtagtcgt gccagttgct ccccacttct acaacggtat ggacgtc 57
210 SEQ ID NO 512
211 LEIIGTH 19
212 TYPE PRT
213 ORGANISE Arttftctal Sequence
220 PEATURE:
223. OTHER INFORNATION Synthettc
400 SEQUENCE 512
Ala Arg Gly Gly Val Val Val Pro Val Ala Pro Hts Phe Tyr Asn Gly
I 5 10 15
Net A p Val
210 SEQ ID NO 513
211 LENGTH 33'12
TYPE DNA
213 ORGANISN Artrftctal Sequence
220 FEATURE
223 OTHER INPORKATION Synthettc
400 SEQUENCE 513
gatattgtoa tgacr.cagt.t tccactctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgca ggtctagtca gagcctcctg catattaatg aatacaacta tttggattgg 120
tacctaaaga agccagggca gtctccacag ctcctgatct atttgggttt taatcgggcc 180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240
agcagagtgg aggctgagga tgttggggtc tattactgca tgcaagctct tcaaactccg 300
tggacgttag gccaagggac caaggtggaa atcaaa 336
210 SEQ ID NO 514
211 LENGTH 112
212 TYPE PPT
213 ORGZUIISN Arttftc
220 FEATURE:
223 OTHER IEFORHATION
tal Sequence
Synthetrc
400 SEQUENCE 514
Asp Ile Val Net Thr Gln Phe Pro Leu
I 5
Ser Leu Pro Val Thr
10
Pro Gly
15
Glu Pro Ala Ser 'Zle Ser Cys Arg Ser Ser Gln Ser Leu Leu Hrs Ile
20 25 30
Asn Glu Tyr Aen Tyr Leu Asp Trp Tyr Leu Ly Ly Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly 9er Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Trp Thr Leu Gly Gln Gly Thr Ly Val Glu Ile Lys
100 105 110
299
US 8,062,640 B2
-continued
300
210 SEQ ID No 515
211 LENGTH 33
212 TYPE DNA
a213 ORGANIISN ArtrfrCral SequenCe
a220 FEATURE:
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 515
cagagcctcc tgcatattaa tgaatacaac tat 33
210 SEQ ID No 516
211 LEIIGTH 11
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 PEATURE:
223. OTHER INFORNATION Synthetrc
400 SEQUENCE 516
Gln Ser Leu Leu Hrs Ile Asn Glu Tyr Psn Tyr
I 5 10
210 SEQ ID Eo 517
211 LENGTH 9
212 TYPE DNA
213 ORGANISFI Artrfrcral Sequence
220 FEATURE
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 517
ttgggtttt
210 SEQ ID No 518
211 LENGTH 3
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 518
Leu Gly Phe
I
210 SEQ ID No 519
211 LENGTH 27
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE:
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 519
atgcaagctc ttcaaactcc gtggacg 27
210 SEQ ID No 520
211 LENGTH 9
212 TYPE PRT
213 ORGPIIISH Artrfrcral Sequence
220 FEATURE:
223 OTHER INPORHATION Synthetrc
400 SEQUENCE 520
Net Gln Ila Leu Gln Thr Pro Trp Thr
I 5
210 6'EQ ID No 521
211 LENGTH 378
212 TYPE DNI
301
US 8,062,640 B2
-continued
302
213 ORGANISE Artificial Sequence
220 FEATURE
223 OTHER INFORH'TION Synthetic
400 SEQUENCE 521
caggttcagc tggtgcagtc tggacctgag gtgaaggagc ctggggcctc agtgaaggtc 6O
tcctgcaaug cttctggtta cacctttacc aactacgcta tcagctgggt gcgacaggtc 120
cctggacaag ggcttgagtg gatgggatgg gtcagcgctt acaatggtca cacaaactat 180
gcacatgaag tccagggcag agtcaccatg accacagaca catccacgac cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccatgt attactgtgc gagagggggt 300
gtagtcgtgc cagttgctcc ccact.tctac aacggtatgg acgtctgggg ccaagggacc 360
acggtcaccg tcr.cctca 378
210 SEQ ID NO 522
211 LENGTH 126
212 TYPE PRT
213 ORGANISN Artificial Sequence
220 FEATURE:
223 OTHER INPORNATION Synthetic
400 SEQUENCE 522
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Glu Pro Gly Ala
5 10
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Ala Ile er Tzp Val Arg Gln Val Pro Gly Gln Gly Leu Glu Trp Het
35 40 45
Gly Trp Val Ser Ala Tyr Asn Gly His Thr Asn Tyr Ala His Glu Val
50 55 0
Gln Gly Arg Val Thr Net Thr Thr !\sp Thr Ser Thr Thr Thr !\Ia Tyr
65 70 75 80
Net Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Net Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Val Val Val Pro Val Ala Pro His Phe Tyr Asn Gly
100 105 110
Net Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 523
211 LENGTH 336
212 TYPE DNA
213 ORGANISE Artificial Seque
220 FEATURE.
223 OTHER INFORHATION Synthet
nce
10
400 SEQUENCE 523
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc
atctcctgca ggtctagtca gagcctcctg catattaarg aatacaacta tttggattgg
tacctaaaga agccagggca gtctccacag ctcctgatct. attrgggttt tsar.cgggcc
12 0
180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240
agcagagtgg aggctgagga tgt.tggggtc tattactgca tgcaagctct tcaaactccg 300
tggacgttag gccaagggac caaggtggaa atcaaa 336
210 6'EQ ID NO 524
211 LENGTH 112
212 TYPE PRT
303
US 8,062,640 B2
-continued
304
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORN'TION Synthetzc
400 SEQUENCE 524
5 p Ile Val Net Thr Gln Sez Pro Leu Ser Leu Pzo Val Thr Pro Gly
I 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Hzs Ile
20 25 30
A n Glu Tyr Asn Tyr Leu Asp Tzp Tyr Leu Lys Lys Pro Gly Gln Sez
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Phs Asn Arg Ala Ser Gly Val Pro
50 55 60
4 p Arg Phe Ser Gly Sez Gly Sez Gly Thz Asp Phe Thr Leu Ly- Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Net Gln Ala
85 90 95
Leu Gln Thz Pzo Tzp Thr Leu Gly Gln Gly Thr Ly- Val Glu Ile Lys
100 105 11.0
210 SEQ ID NO 525
211 LENGTH 378
212 TYPE DNA
213 ORMEISN Aztzfrc
220 FEATURE
223 OTHER INFORFLATION
ral Sequence
Synthetzc
r400 SEQUENCE 525
caggt.tcagc tggtgcagtc t.ggagcrgag gtgaagaagc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc aactacgcta tcagctgggt gcgacaggcc 12 0
cctggacaag ggcttgagtg gatgggatgg gtcagcgctt acaatggtca cacaaactat 180
gcacagaagc tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccgtgt attactgtgc gagagggggt 300
gtagtcgtgc cagttgctcc ccacttctac aacggtatgg acgtctgggg gcaagggacc 360
acggtcaccg tctcctca 3,8
210 SEQ ID NO 52
211 LENGTH 126
212 TYPE PRT
213 ORGANISN Aztzfzc
220 FEATURE:
223 OTHER INFORNATION
ral Sequence
Synthetzc
400 SEQUENCE 526
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyz
20 25 30
Ala Ile ser Tzp val Azg Gln Ala pro Gly Gln Gly Leu Glu Trp Net
35 40 45
Gly Trp Val Ser Ala Tyr Asn Gly Hzs Thr Asn Tyr Ala Gln Lys Leu
50 55 60
Gln Gly frg Val Thr Net Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Net Glu Leu Azg Ser Leu Arg Sez Asp Asp Thr Ala Val Tyr Tyz Cys
85 90 95
Ala Arg Gly Gly Val Val Val Pro Val Ala Pro Hzs Phe Tyr Asn Gly
305
US 8,062,640 B2
-continued
306
100 105 110
Het Asp Val Tzp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
c210 SEQ ID NO 527
211 LEI'GTH 336
212 TYPE DNA
213 ORGANISE Artzfrczal Sequence
220 FEATURE.
223 OTHER INFORBIATION Synthetzc
400 SEQUENCE 527
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc
atctcctgca ggtcr.agtca gagcctcctg catattaatg aat.acaact.a t.ttggattgg
tacctgcaca agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc
12 0
180
tccggggtcc ctgacaggtt cagtggcagt ggatcagqca cagattttac actgaaaatc 240
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct tcaaactccg 300
tggacgttcg gccaagggac caaggtggaa atcaaa 336
210 SEQ ID NO 528
211 LENGTH 112
212 TYPE PRT
213 ORG63IISH Aztzfzczal Sequence
220 FEATURE
223 OTHER INFORFIATION Synthetzc
c400 SEQUENCE 528
Asp Ile Val Net Thr Gln Ser Pro Leu Ser Leu Pzo Val Thr Pro Gly
I 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ile
20 25 30
Asn Glu Tyr Asn Tyr Leu Asp Tzp Tyr Leu Gln Ly Pro Gly Gln Sez
35 40 45
Pro Gln Leu Leu Ile Tyz Leu Gly Sez Asn Azg Ala Ser Gly Val Pzo
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu * ye Ile
65 70 ". 5 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Het Gln Ala
85 90 95
Leu Gln Thr Pzo Tzp Thr Phe Gly Gln Gly Thz Lys Val Glu Ile Ly
100 105 110
210 SEQ ID NO 529
211 LENGTH 351
212 TYPE DNA
213 ORGANISN Aztzf
220 FEATURE
223 OTHER INFORHATI
zczal Sequence
ON Synthetzc
400 SEQUENCE 529
gaggtgcagc r.ggtggagtc tgggggaggc ttggtacagc crggggggt.c cctgagactc
tcctgtgcag cctctggatt caccctaagt agctacgaca tgcactgggt ccgccaagca 12 0
acaggaaaag gtctggagtg ggt.ctcagct attggcagta ctggtgacac at.actataca 180
ggctccgtga tgggccgatt caccatctcc agagacgctg ccaaaaactc cttctatctt 240
gaaatgaaca qcctqagaqt cggggacacg gctgtatatt actgtgcaag agagggaata 300
agaacaccct atgattattg gggccaggga gcccgggtca ccgtctcctc a 351
307
US 8,062,640 B2
-continued
308
210 SEQ ID NO 530
211 LEI'GTH 117
212 TYPE PRT
213 ORGANISN Artrfrctal Sequence
c220 FEATURE;
c223 OTHER INPORftATION. Synthetrc
400 SEQUENCE 530
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
A p Het Hts Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val
35 40 45
ser Ala Ile Gly ser Thr Gly Asp Thr Tyr Tyr Thr Gly ser val Net
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Ala Ala Lys Asn Ser Phe Tyr Leu
65 70 75 80
Glu Net Asn Ser Leu Arg Val Gly A p Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Glu Gly Ile Arg Thr Pro Tyr Asp Tyr Trp Gly Gln Gly Ala Arg
100 105 110
Val Thr Val Ser Ser
115
c210 SEQ ID NO 531
211 LEI'GTH 24
212 TYPE DNA
213 ORGPZZISN Arttftctal Sequence
220 FEATURE.
223 OTHER INFORKATION Synthetrc
400 SEQUENCE 531
ggattcaccc taagtagcta cgac
210a SEQ ID NO 532
211a LENGTH 8
212 TYPE PRT
213 ORGANISbl Arttftctal Sequence
220 FEATUPE
223 OTHER INPORNATION Synthetrc
400 SEQUENCE 532
Gly Phe Thr Leu Ser Ser Tyr .4 p
I 5
210 SEQ ID NO 533
211 LENGTH 21
212 TYPE DNA
213 ORGAEISN Artrftctal Sequence
220 FEATURE
223 OTHER INFOPNP.TION Synthetrc
400 SEQUENCE 533
attggcagta ctggtgacac a 21
210 SEQ ID NO 534
211 LENGTH 7
212 TYPE PRT
213 ORGANIS'N Artrfrctal Sequence
220 FEATURE:
223 OTHER INPORNATION Synthetrc
400 SEQUENCE 534
309
US 8,062,640 B2
-continued
310
Ile Gly Ser Thr Gly Asp Thz
5
s210 SEQ ID NO 535
s211 LENGTH 33
212 TYPE Dl'IA
213 ORGANISE Artzfzczal Sequence
220 FEATURE
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 535
gcaagagagg gaataagaac accctatgat tat 33
210 SEQ ID NO 536
211 LENGTH 11
212s T'IPE PRT
213 ORGANISE Artzfzczal Sequence
220 FEITURE
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 536
Ala Arg Glu Gly Ile Arg Thr Pro Tyr Asp Tyz
I 5 10
210 SEQ ID NO 537
211 LEI'GTH 324
212 TYPE DNA
213 ORGANISN Aztzfzczal Sequence
220 FEATURE
s223 OTHER INPORNATION Synthetrc
400 SEQUENCE 537
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 60
ct.ctcctgca gggccagtca gagtgttagc agcaatgtag cctggtacca gcagaaacct 120
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc 180
aggttcagtg gcagtgggtc tgggacagaa ttcactctca ccatcagcag cctgcagtct 240
gaagattttg cagtttatta ctgtcagcag tataataatt. ggcctccatt cactt.tcggc 300
cctgggacca aagtggatat casa 324
210 SEQ ID NO 538
211 LENGTH 108
212 TYPE PRT
213 ORGANISN Aztzfzc
220 FEATURE:
223 OTHER INFORNATION
zal Sequence
Synthetrc
400 SEQUENCE 538
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
5 10 15
Glu lrg Ala Thr Leu Ser Cys Azg Ala Ser Gln Ser Val Ser Sez Asn
20 25 30
Val Ala Trp Tyz Gln Gln ' Pro Gly Gln Ala Pzo Azg Leu 'u Ile
35 40 45
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyz Tyz Cys Gln Gln Tyt Asn Asn Trp Pro Pzo
85 90 95
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
311
US 8,062,640 B2
-continued
312
100 105
210 SEQ ID NO 539
211 LENGTH 18
.212 TYPE DNA
.213 ORGANIS14 Artrfrcral Sequence
220 FEATURE:
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 539
cagagtgtta gcagcaat 18
210 SEQ ID NO 540
211 LENGTH 6
212 TYPE PRT
213 ORGWIISN Artrfrcral Sequence
220. FEATURE.
223 OTHER INFORN'TIDE Synthetrc
400 SEQUENCE 540
Gln Ser Val Ser Ser Aan
I 5
210 SEQ ID NO 541
211 LENGTH 9
212 TYPE DNA
213 ORG42IISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFORI45TION Synthetrc
.400 SEQUENCE 541
ggtgcatcc
210 SEQ ID NO 542
211 LENGTH 3
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE.
223 OTI'ER INFORI44TION Synthetrc
400. SEQUENCE 542
Gly Ala Ser
I
210 SEQ ID NO 543
211 LEI'GTH 30
212 TYPE DNA
213 ORGPIIISH Artrfrcral Sequence
220 FEATURE;
223 OTHER INPORHATION Synthetrc
400 SEQUENCE 543
cagcagtata ataattggcc tccattcact 30
210 SEQ ID NO 544
211 LEI'GTH 10
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 PEATURE:
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 544
Gln Gln Tyr Aan Aan Trp Pro Pro Phe Thr
I 5 10
210 SEQ ID NO 545
211 LENGTH 351
313
US 8,062,640 B2
-continued
314
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORHPTION Synthetrc
c400 SEQUENCE 545
gaggtgcacc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt caccctaagt agctacgaca tgcactgggt ccgccaagca 12 0
acaggaaaag gtctggagtg ggtctcagct attggcagta ctggtgacac atactataca 180
ggctccgtga tgggccgatt caccatctcc agagacgctg ccaaaaactc cttctatctt 240
gaaatgaaca gcctgagagt cggggacacg gctgtatatt actgtgcaag agagggaata 300
agaacaccct argar.tattg gggccaggga accctggtca ccgtctcct.c a 351
210 SEQ ID NO 546
211 LENGTH 117
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE:
223 OTHER INPORNATION Synthetrc
400 SEQUENCE 546
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
4 p Het 518 Trp Val Arg Gln Ala Thr Gly Ly Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Ser Thr Gly .'. p Tlr Tyr Tyr Thr Gly Ser Val Ner.
50 55 0
Gly Arg Phe Thr Ile Ser Arg Asp Ala Ala Lys Asn Ser Phe Tyr Leu
65 70 75 80
Glu Het Asn Ser Leu Arg Val Gly Arp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Glu Gly Ile Arg Thr Pro Tyr Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser
115
210 SEQ ID NO 547
211 LENGTH 324
212 TYPE DEA
213 ORGASIISN Artrfrcral Sequence
220 PEATURR.
223 OTHER INFORFIATION Synthetrc
400 SEQUENCE 547
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc
ctctcctgca gggccagtca gagtgttagc agcaatgtag cctggtacca gcagaaacct 12 0
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tat.cccagcc
aggttcagtg gcagtgggtc tgggacagaa ttcactctca ccatcagcag cctgcagtct
180
240
gaagattttg cagtttatta ctgtcagcag tataataatt ggcctccatt cactttcggc 300
cctgggacca aagtggatat caaa 324
210 SEQ ID NO 548
211 LENGTH 108
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
315
US 8,062,640 B2
-continued
316
220 PEATURR.
223 OTHER INFORN"TION Synthetzc
400 SEQUENCE 548
Glu Ile Val Met Thr Gln Sez Pzo Ala Thz Leu Ser Val Ser Pro Gly
I 5 10 15
Glu Arg Ala Thr Leu Ser Cys I\rg Ala Ser Gln Ser Val Ser Ser I\sn
20 25 30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Gly Ala Sez Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro
85 90 95
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
210 SEQ ID EO 549
211 LENGTH 351
212 TYPE DNA
213 ORGANISBI Artzfzc
220 FEATURE
223 OTHER INFORNITION
zal Sequence
Synthetzc
400 SEQUENCE 549
gaggtgcacc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc
tcctgtgcag cctctggatt caccctaagt agctacgaca t.gcactgggt ccgccaagct
60
12 0
acaggaaaag gtctggagtg ggtctcagct attggcagta ctggtgacac atactatcca 180
ggctccgtga agggccgatt caccatctcc agagaaaatg ccaagaactc cttgtatctt 240
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgtgcaag agagggaata 300
agaacaccct atgattattg gggccaagga accctggtca ccgtctcctc a 351
210 SEQ ID NO 550
211 LENGTH 117
212 TYPE PRT
213 ORGANISN Artzfzc
220 FEATURE
223 OTHER INFORN'TION
tal Sequence
Synthetzc
400 SEQUENCE 550
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
A p iset Hzs Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Ser Thr Gly A p Tlr Tyr Tyr Pzo Gly Ser Val
50 55 60
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu
65 70 75 80
Gln Net fsn Ser Leu Arg Ala Gly Asp Thr fla Val Tyr Tyr Cys Ala
85 90 95
Arg Glu Gly Ile Arg Thr Pro Tyr Asp Tyr Tzp Gly Gln Gly Thz Leu
100 105 110
Val Thr Val Ser Ser
317
US 8,062,640 B2
-continued
115
210 SEQ ID NO 551
211 LENGTH 324
s212 TYPE DNA
s213 ORGANIS14 Aztzfzczal Sequence
220 FEATURE:
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 551
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttagc agcaatttag cctggtacca gcagaaacct 12 0
ggccaggctc ccaggctcct catct.at.ggt gcatccacca gggccactgg tat.cccagcc 180
aggttcagtg gcagtgggtc tgggacagag ttcactctca ccar.cagcag cctgcagtct 240
gaagattttg cagtttatta ctgtcagcag tataataatt ggcctccatt cactttcggc 300
cctgggacca aagtggatat casa 324
210 6'EQ ID NO 552
211 LENGTH 108
212 TYPE PRT
213 ORGANISE Artzfzczal Sequence
220 PEATURR.
223 OTHER INFORFIATION Synthetzc
400 SEQUENCE 552
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
I 5 10 15
Glu Arg Ala Thr Leu Ser Cye Arg Ala Ser Gln Ser Val Ser Ser 5 n
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Gly Ala Sez Thr Arg Ala Trr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 90
Glu Asp Phe Ala Val Tyr Tyz Cys Gln Gln Tyr Asn Asn Trp Pro Pro
85 90 95
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
210 SEQ ID EO 553
211 LENGTH 351
212 TYPE DNA
213 ORGANISE Artzfzczal Seque
220 FEATURE.
223 OTHER INFORHATION Synthet
nce
10
400 SEQUENCE 553
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc
tcctgtgcag cctctggatt caccctaagt agctacgaca t.gcactgggt ccgccaagca
acaggaaaag gt.ctggagtg ggtctcagct attggcagta ctggtgacac at.act.ataca
60
12 0
180
ggctccgtga tgggccgatt caccatctcc agagacgctg ccaaaaactc cttctatctt 240
gaaatgaaca gcctgagagt cggggacacg gctgtatatt actgtgcaag agagggaata 300
agaacaccct atgattattg gggccaggga gcccgggtca ccgtctcctc a 351
210 SEQ ID NO 554
211 LENGTH 117
319
US 8,062,640 B2
-continued
320
212 TYPE PRT
213 ORGANISE Artrfzczal Sequence
220 FEATURE
223 OTHER INFORHPTION Synthetrc
s400 SEQUENCE 554
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
Asp Iset Hzs Trp Val Arg Gln Ala Thr Gly Ly Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Ser Thr Gly A p Thr Tyr Tyr Thr Gly Ser Val Net
50 55 60
Gly Arg Phe Thr lie Ser Arg Asp Ala Ala Lys Asn Ser Phe Tyr 'u
65 70 75 80
Glu Het Asn Ser Leu Arg Val Gly Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Glu Gly Ile Arg Thr Pro Tyr A p T.r Trp Gly Gln Gly Ala ..zg
100 105 110
Val Thr Val Ser Ser
115
210 SEQ ID NO 555
211 LENGTH 24
212 TYPE DNA
s213 ORGANIS14 Artrfrcral Sequence
220 FEATURE:
223 OTHER INFORHATION. Synthetrc
400 SEQUENCE 555
ggattcaccc taagtagcta cgac
210 SEQ ID NO 556
211 LENGTH 8
212 TYPE PRT
213s ORGWIISN Artrfrcral Sequence
220. FEATURE.
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 55
Gly Phe Thr Leu Ser Ser Tyr Asp
5
210 SEQ ID NO 557
211 LENGTH 21
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INPORKATION Synthetzc
400 SEQUENCE 557
attggcagta ctggtgacac a 21
210 SEQ ID I'10 558
211 LENGTH 7
212 TYPE PRT
213 ORGANISE Artrfzczal Sequence
220 FEPTURE
223 OTI'ER INFORI4ATION Synthetzc
400 SEQUENCE 558
Ile Gly Ser Thr Gly Asp Thr
I 5
321
US 8,062,640 B2
-continued
322
210 SEQ ID NO 559
211 LENGTH 33
212 TYPE DNA
c213 ORGPSIISN AZtzfzCzal SequenCe
c220 FEATURE:
223 OTHER INFORNATION Synthetzc
400 SEQUENCE 559
gcaagagagg gaataagaac accctatgat tat 33
210 SEQ ID NO 560
211 LEIIGTH 11
212 TYPE PRT
213 ORGANISE Artzfzczal Sequence
220 PEATURE:
223. OTHER INFORNATION Synthetzc
400 SEQUENCE 560
Ala Arg Glu Gly Ile Arg Thr Pro Tyr Asp Tyr
I 5 10
210 SEQ ID EO 561
211 LENGTH 324
212 TYPE DNA
213 ORGANISFI Aztzfzczal Sequence
220 FEATURE
223 OTHER INFORHPTION Synthetzc
400 SEQUENCE 561
gaaat.agtca tgacgcagtc tccagccacc ctgtctgtgt. ctccagggga aagagccacc
ctctcctgca gggccagtca gagtgttagc agcaatgtag cctggtacca gcagaaacct
60
12 0
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc 180
aggttcagtg gcagtgggtc tgggacagaa ttcactctca ccatcagcag cctgcagtct 240
gaagattttg cagtttatta ctgtcagcag tataataatt ggcctccatt cactttcggc 300
cctgggacca aagtggatat casa 324
210 SEQ ID NO 562
211 LENGTH 108
212 TYPE PRT
213 ORGANISN Artzfzc
220 FEATURE
223 OTHER INFORH'TION
zal Sequence
Synthetzc
400 SEQUENCE 562
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
I 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30
Val lla Tzp Tyr Gln Gln Lys Pzo Gly Gln Ala Pzo Arg Leu Leu Ile
35 40 45
Tyr Gly Ala Ser Thr Azg Ala Thr Gly Ile Pro Ala Azg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe fla Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro
85 90 95
Phe Thz Phe Gly Pzo Gly Thz Ly- Val Asp Ile Ly-
100 105
323
US 8,062,640 B2
-continued
324
210 SEQ ID No 563
211 LENGTH 18
212 TYPE DNA
213 ORGANISN Artificial Sequence
220 FEATURE
c223 OTHER INFORMATION Synthetic
600 SEQUENCE 563
cagagtgtta gcagcaat 18
210 SEQ ID No 566
211 LENGTH 6
212 TYPE PRT
213 ORGAEISM Artificial Sequence
220 FEATURE:
223 oTHER INFORMATION Synthetic
600. SEQUENCE 566
Gln
I
Ser Pal Ser Ser Asn
5
210 6'EQ ID No 565
211 LENGTH 9
212 TYPE DEA
213 ORGANISM Artificial Sequence
220 PEATURR.
223 OTHER INFORFZATION Synthetic
600 SEQUENCE 565
gg'tgcatcc
210 SEQ ID No 566
211 LENGTH 3
212 TYPE PRT
213 ORGANISN Artificial Sequence
220 FEATURE
223 OTHER INFORMATION Synthetic
600 SEQUENCE 566
Gly
I
Ala Ser
210 SEQ ID No 567
211 LENGTH 30
212 TYPE DNA
213 ORGANISM Artificial Sequence
220 FEATURE
223 OTHER INFORMATION Synthetic
600 SEQUENCE 567
cagcagtata ataattggcc tccattcact 30
210 SEQ ID No 568
211 LENGTH 10
212 TYPE PRT
213 ORGANISN Artificial Sequence
220 PEATURE:
223 OTHER INPORMATZON: Synthetic
6OO SEQUENCE 568
Gln
1
Gln Tyr Isn .Asn Trp Pro Pro Phe Thr
5 10
210 SEQ ID No 569
211 LENGTH 351
212 TYPE DNA
213 ORGANISN Artificial Sequence
220 FEATURE
325
US 8,062,640 B2
-continued
326
223 OTHER INPORNATION Synthetrc
400 SEQUENCE 569
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc
tcctgtgcag cctctggatt caccctaagt agctacgaca tgcactgggt. ccgccaagca 12 0
acaggaaaag gtctggagtg ggtctcagct attggcagta ctggtgacac atactataca 180
ggctccgtga tgggccgatt caccatctcc agagacgctg ccaaaaactc cttctatctt 240
gaaatgaaca gcctgagagt cggggacacg gctgtatatt actgtgcaag agagggaata 300
agaacaccct atgattattg gggccaggga accctggtca ccgtctcctc a 351
210 SEQ ID NO 570
211 LENGTH 117
212s T'IPE PRT
213 ORGANISE Artrfrcral Sequence
220 FEITURE
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 570
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
Asp Net Hrs Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Ser Thr Gly A p Thr Tyr Tyr Thr Gly Ser Val Net
50 55 60
Gly Arg Phe Thr lie Ser Srg A p Ala Ala Ly Asn Ser Phe Tyr 'u
65 70 75 80
Glu Het Asn Ser Leu Arg Val Gly Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Glu Gly Ile Arg Thr Pro Tyr Arp Tyr Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser
115
210 SEQ ID NO 571
211 LENGTH 324
212 TYPE DNA
213 ORGINIISN Artrfrcral Sequence
220 FEATURE:
223 OTHER IEFORNATION Synthetrc
400 SEQUENCE 571
gaaatagtna tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagcc.acc
ctctcctgca gggccagtca gagtgttagc agcaatgtag cctggtacca gcagaaacct 12 0
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc 180
agqttcagtg gcagtgggtc tgggacagaa ttcactctca ccatcagcag cctgcagtct
gaagattttg cagtttatta ctgtcagcag tataataatt. ggcctccatt cacr.tt.cggc
240
300
cctgggacca aagtggatat casa 324
210 SEQ ID NO 572
211 LENGTH 108
212 TYPE PRT
213 ORGANISN Artrf
220 FEATURE:
223 OTHER INFORNATI
1cral Sequence
ON Synthetrc
327
US 8,062,640 B2
-continued
328
400 SEQUENCE 572
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pto Gly
I 5 10 15
Glu Arg Ala Tlr Leu Ser Cys Azg Ala Ser Gln Ser Val Ser Ser .'. n
20 25 30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cy- Gln Gln Tyr Asn Asn Trp Pro Pro
85 90 95
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
210 SEQ ID NO 573
211 LENGTH 351
212 TYPE DNA
213 ORGASHSN Artzfzc
220 FEATURE.
223 OTHER INPORHATION
zal Sequence
Synthetzc
400 SEQUENCE 573
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc
tcctgtgcag cctctggatt caccctaagt agctacgaca tgcactgggt. ccgccaagct
acaggaaaag gtctggagtg ggr.ctcagct attggcagta ctggtgacac at.actatcca
12 0
1st
ggctccgtga agggccgatt caccatctcc agagaaaatg ccaagaactc ct.tgtatctt 240
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgtgcaag agagggaata 300
agaacaccct atgattattg gggccaagga accctggtca ccgtctcctc a 351
210 SEQ ID NO 574
211o LENGTH 117
212a T'ZPE PRT
213 ORGANISE Artzfzc
220 FEATURE:
223 OTHER INFORHATION
zal sequence
Synthetzc
400 SEQUENCE 574
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
Asp Het Hzs Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser lla Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys
50 55 60
Gly Arg Phe Thz lie Ser Szg Glu Asn Ala Ly Asn Ser Leu Tyr 'u
65 70 75 80
Gln Het Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Glu Gly Ile Arg Thr Pro Tyr Asp Tyr Tzp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser
115
329
US 8,062,640 B2
-continued
330
210 SEQ ID NO 575
211 LENGTH 324
212 TYPE DNA
213 ORGANISN Artzfzczal Sequence
220 FEATURE
s223 OTHER INFORHATION Synthetzc
400 SEQUENCE 575
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttagc agcaatttag cctggtacca gcagaaacct 120
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc 180
aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag cctgcagtct 240
gaagattttg cagttt.etta ctgtcagcag tataataatt. ggcct.ccatt cactt.tcggc 300
cctgggacca aagtggatat casa 324
210 SEQ ID NO 57
211 LENGTH 108
212 TYPE PRT
213 DRONISH Aztzfzczal Sequence
220 FEATURE:
223 OTHER IEFORHATION Synthetrc
400 SEQUENCE 576
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pto Gly
I 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Sez Asn
20 25 30
Leu Ala Tzp Tyr Gln Gln Lys Pro Gly Gln Ala Pzo Azg Leu Leu Ile
35 40 45
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Sez Gly Ser Gly Thr Glu Phe Trz Leu Thr Ile Ser Ser Leu Gln Sez
65 70 75 80
Glu Asp Phe Ala Val Tyz Tyz Cys Gln Gln Tyr Asn Asn Trp Pro Pzo
85 90 95
Phe Thz Phe Gly Pro Gly Thz Lys Val Asp Ile Lys
100 105
210 SEQ ID NO 577
211 LElsGTH 363
212 TYPE DNA
213 ORGAZIISH Artzfzczal Sequence
220 FEATURE;
223 OTHER INPORIZATION Synthetzc
400 SEQUENCE 577
gaagtgcagc tggtggagtc tgggggaggc ttggtacagc ctggcaggtc cctgagactc 60
tcctgtgcag cctctggatt cacctttgat gattatgcca tgcactgggt ccggcaagct 120
ccagggaagg gcctggagtg ggt.ctcaggt attaattgga acagtggtag cataggctat 180
gcggactctg tgaagggccg attcaccatc tccagagaca acgccaagca ctccctgtat 240
ctgcaaataa acagtctgag acctgaggac acggccttgt attactgtgt aaaagaggtg 300
actacgggat actactacgg tat.ggacgtc tggggccaag ggaccacggt caccgtctcc 360
tca 363
210 8'EQ ID NO 578
211 LENGTH 121
212 TYPE PRT
331
US 8,062,640 B2
-continued
332
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORH'TION Synthetzc
400 SEQUENCE 578
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
I 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
20 25 30
Ala iset Hzs Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Asn Trp A n Ser Gly Ser Ile Gly Tyr Ala A p Ser Val
50 55 60
Lya Gly Arg Phe Thr Ile Ser Arg anp asn Ala Lys Hrs Ser Leu Tyr
65 70 75 80
Leu Gln Net fsn Ser Leu Arg Pro Glu Asp Thr Ala Leu Tyr Tyr Cys
85 90 95
Val Lys Glu Val Thr Thr Gly Tyr Tyr Tyr Gly Net Asp Val Trp Gly
100 105 11.0
Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0
210 SEQ ID NO 579
211 LENGTH 24
212 TYPE DNA
213 ORGAEISN Artzfzczal Sequence
c220 FEATURE:
223 OTHER INFORNATION Synthetzc
400 SEQUENCE 579
ggattcacct ttgatgatta tgcc
210 SEQ ID NO 580
211 LEIIGTH 8
212 TYPE PRT
213 ORGANIS'N Artzfzczal Sequence
220. PEATURE.
223. OTHER INFORNATION Synthetrc
400 SEQURNCE 580
Gly Phe Thr Phe Asp Asp Tyr Ala
I 5
210
211
212
213
220
223
SEQ ID EO 581
LENGTH 24
TYPE DNA
ORGANISE Artzfrczal Sequence
FEATURE.
OTHER INFORHATI014 Synthetzc
400 SEQUENCE 581
attaattgga acagtggtag cata
210
211
212
213
220
223
SEO ID NO 582
LENGTH 8
TYPE PRT
ORGANISE .Artzfrctal Sequence
FEATURE
OTHER INPORKATION Synthetzc
400 SEQUENCE 582
Ile A n Trp A n Ser Gl . Ser Ile
I 5
333
US 8,062,640 B2
-continued
334
210 SEQ ID NO 583
211 LEI'GTH 42
212 TYPE DNA
213 ORGANISN Artzfzczal Sequence
s220 FEATURE;
s223 OTI'ER INPORIBATION. Synthetzc
400 SEQUENCE 583
gtaaaagagg tgactacggg atactactac ggtatggacg tc
210 SEQ ID NO 584
211 LENGTH 14
212 TYPE PRT
213 ORGANISE Artrftcral Sequence
220 PEATURE:
223 OTHER INPORNATION Synthetrc
400 SEQUENCE 584
Val Lys Glu Val Thr Thr Gly Tyr Tyr Tyr Gly Met Asp Val
I 5 10
210 SEQ ID NO 585
211 LENGTH 321
212 TYPE D145
213 ORGANISE Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORN'TION Synthetzc
400 SEQUENCE 585
gacatccagt tgacccagtc tccat.ccttc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgct gggccagtca gggcatt.agc agttatttag cctggtatca gaaaaaacca 120
gggaaagccc ctaacctcct gat.ctatgat gcatccactt tgcaaagtgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca cactcagcag cctgcagcct 240
gaagattttg caacttatta ctgtcaacag cttaatattt acccattcac tttcggccct 300
gggaccaaag tggatatcaa a 321
210s SEQ ID NO 586
211 LENGTH 107
212 TYPE PRT
213 ORGANISN Artrfrc
220 FEATURE
223 OTHER INFORH'TION
tal Sequence
Synthetrc
400 SEQUENCE 586
.'. p Ile Gln Leu Thr Gln Sez Pzo Sez Phe Leu Ser Ala Sez Val Gly
I 5 10 15
Asp Arg Val Thr Ile Thr Cys Trp Ala Ser Gln Gly Ile Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Lys Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Leu Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ile Tyr Pro Phe
85 90 95
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Ly
100 105
210 SEQ ID NO 587
335
US 8,062,640 B2
-continued
336
211 LENGTH 18
212 TYPE DNA
213 ORGaIIISH Artrfrcral Sequence
220 FEATURE
223 OTHER INFORFZATION Synthetrc
c600 SEQUENCE 587
cagggcatta gcagttat 18
210 SEQ ID NO 588
211 LENGTH 6
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORNATION Synthetrc
600 SEQUENCE 588
Gln Gly Ile Ser Ser Tyr
5
210 SEQ ID NO 589
211 LENGTH 9
212 TYPE DNA
213 ORGPANSN Artrfrcral Sequence
220 FEATURE.
223 OTHER INPORHATION Synthetrc
600 SEQUENCE 589
gatgcatcc
210 SEQ ID I'10 590
211 LENGTH 3
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORHATION Synthetrc
600 SEQUENCE 590
Aep Ala Ser
I
210 SEQ ID NO 591
211 LENGTH 27
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFORH'TION Synthetrc
600 SEQUENCE 591
caacagctta atatttaccc attcact 27
210
211
212
213
220
223
SEQ ID NO 592
LENGTH 9
TYPE PRT
ORGAEISN Artrfrcral Sequence
FEATURE
OTHER INPORHATION, Synthetrc
800 SEOUENCE 592
Gln Gln Leu Aen Ile Tyr Pro Phe Thr
I 5
210
211
212
213
220
223
SEQ ID NO 593
LENGTH 363
TYPE DNA
DRGANIBH Artrfrcral sequence
FEATURE.
OTHER INFORMATION Synthetrc
337
US 8,062,640 B2
-continued
338
400 SEQUENCE 593
gaagtgcagc tggtggagtc tgggggaggc ttggtacagc ctggcaggtc cctgagactc
tcctgtgcag cctctggatt cacctttgat gattatgcca tgcactgggt. ccggcaagct
ccagggaacg gcctggagtg ggtctcaggt attest.tgga acagtggtag cataggctat
12 0
180
gcggactctg tgaagggccg attcaccatc tccagagaca acgccaagca ctccctgtat 240
ctgcaaatga acagtctgag acctgaggac acggccttgt attactgtgt aaaagaggtg 300
actacgggat actactacgg tatggacgtc tggggccaag ggaccacggt caccgtctcc 360
tca 363
210 SEQ ID NO 594
211a LENGTH 121
212 TYPE PRT
213 ORGANISM Artrfrcral Sequence
220 FEPTUPE
223 OTHER INFORNPTION Synthetrc
400 6'EQUENCE 594
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
I 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
20 25 30
Ala Met Hzs Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Asn Trp A n Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Hrs Ser Leu Tyr
65 70 .5 80
Leu Gln iset Asn Ser Leu Arg Pro Glu Asp Thr Ala Leu Tyr Tyr Cys
85 90 95
Val Lys Glu Val Thr Thr Gly Tyr Tyr Tyr Gly Met Asp Val Trp Gly
100 105 110
Gln Gly Thr Thr Val Thr Val ser ser
115 12 0
210 SEQ ID NO 595
211 LENGTH 321
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE:
223 OTHER INFORNATION Synthetzc
400 SEQUENCE 595
gacatccagt tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc
atcacttgct gggccagtca gggcattagc agttatttag cctggtatca gaaaaaacca 12 0
gggaaagccc ctaacctcct gatctatgat gcatccactt tgcaaagtgg ggtcccatca 180
aggttcagcg gcagrggatc tgggacagaa ttcactctca cacr.cagcag cct.gcagcct 240
gaagattttg caacttatta ctgtcaacag cttaatattt. acccattcac t.ttcggccct 300
gggaccaaag tggatatcaa a 321
210 SEQ ID NO 596
211 LENGTH 107
212 TYPE PRT
213 ORGANISM Aztzfrczal Sequence
220 FEATURE.
223 OTHER INFORMATION Synthetrc
339
US 8,062,640 B2
-continued
340
400 SEQUENCE 596
Aap Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
5 10 15
4 p 'rg Val Thr Ile Thr Cys Trp Ala Ser Gln Gly Ile Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Lys Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Leu Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cy- Gln Gln Leu Asn Ile Tyr Pro Phe
85 90 95
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
210 6'EQ ID NO 597
211 LENGTH 363
212 TYPE DEA
213 ORGANISE Artrfrc
220 PEATURR.
223 OTHER INPORPIATION
ral Sequence
Synthetrc
400 SEQUENCE 597
gaagtgcagc tggtggagtc tgggggaggc ttggtacagc ctggcaggtc cctgagactc 60
tcctgtgcag cctctggatt cacctttgat gattatgcca tgcactgggt ccggcaagct 120
ccagggaacg gcctggagtg ggtctcaggt attaattgga acagtggtag cat.aggctat 180
gcggactctg tgaagggccg attcaccatc tccagagaca acgccaagaa ctccctgtat 240
ct.gcaaatga acagtctgag agctgaggac acggccttgt attactgtgt aaaagaggtg 300
actacgggat actactacgg tatggacgtc tgggggcaag ggaccacggt caccgtctcc 360
tca 363
210 SEQ ID NO 598
211 LENGTH 121
212 TYPE PRT
213 ORGANISN Artrfrc
220 FEATURE
223 OTHER INPORN'TION
ral Sequence
Synthetrc
400 SEQUENCE 598
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
I 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
20 25 30
Ala iset Hrs Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Asn Tzp Asn Ser Gly Ser Ile Gly Tyr Ala A p Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Net fsn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys
85 90 95
Val Lys Glu Val Thr Thr Gly Tyr Tyr Tyr Gly Net Asp Val Trp Gly
100 105 110
Gln Gly Thr Thr Val Thr Val Ser Ser
341
US 8,062,640 B2
-continued
342
115 12 0
210 SEQ ID NO 599
211 LENGTH 321
.212 TYPE DNA
.213 ORGANIS14 Aztzfzczal Sequence
220 FEATURE:
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 599
gacatccagt tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gggcattagc agttatttag cctggtatca gcaaaaacca 12 0
gggaaagccc ctaagctcct gatct.at.gat gcatccactt. tgcaaagtgg ggt.cccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca caar.cagcag cctgcagcct 240
gaagattttg caacttatta ctgtcaacag cttaatattt acccattcac tt.tcggccct 300
gggaccaaag tggatatcaa a 321
210 6'EQ ID NO 600
211 LENGTH 107
212 TYPE PRT
213 ORGANISE Aztrfrcral Sequence
220 PEATURR.
223 OTHER INFOR61ATION Synthetrc
400 SEQUENCE 600
Asp Ile Gln Leu Thr Gln Sez Pro Ser Phe Leu Ser Ala Ser Val Gly
I 5 10 15
Asp Arg Val Thr Ile Thr Cye Arg Ala Ser Gln Gly Ile Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Arp Ala Ser Thr Leu Gln Sez Gly Val Pzo Ser Arg Phe Sez Gly
50 55 60
Sez Gly Ser Gly Thr Glu Phe Thz Leu Thr Ile Ser Ser Leu Gln Pzo
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyz Cys Gln Gln Leu Asn Ile Tyr Pro Phe
85 90 95
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
210 SEQ ID EO 601
211 LENGTH 366
212 TYPE DNA
213 ORGANISE Aztrfrcral Seque
220 FEATURE.
223 OTHER INFORHATI014 Synthet
nce
10
400 SEQUENCE 601
gaggtgcagt tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc
tcctgtgcag cctctggatt cacgtttagt agctatgcca t.gaactgggt ccgccaggct
ccagggaaog ggctggattg ggtctcaggt atcagtggta atggtggtag cacct.actac
60
12 0
180
gcagactccg tgaagggccg gttcaccatc tccagagaca tttccaagaa cacgctgtat 240
gtgcaaatgc acagcctgag agtcgaggac acggccgttt actactgtgc gaaagcccgt 300
tattacgatt tttggggggg gaatttcgat ctctggggcc gtggcaccca ggtcactgtc 360
tcctca 366
343
US 8,062,640 B2
-continued
344
210 SEQ ID NO 02
211 LENGTH 122
212 TYPE PRT
213 ORGANISN Artzfzctal Sequence
220 FEATURE
r223 OTHER INFORHATION Synthetzc
400 SEQUENCE 602
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cya Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Het Aan Trp Val Arg Gln Ala Pro Gly Lya Gly Leu A p Trp Val
35 40 45
Ser Gly Ile Ser Gly Aan Gly Gly Ser Thr Tyr Tyr Ala Anp Ser Val
50 55 0
Lya Gly Irg Phe Thr Ile Ser Arg Aep Ile Ser Lye Aen Thr Leu Tyr
70 75 80
Val Gln ifet Hza Ser Leu Arg Val Glu Aap Tht Ala Val Tyr Tyz Cya
85 90 95
Ala Ly Ala Arg Tyr Tyr Aap Phe Trp Gly Gly Aan Phe A p Leu Trp
100 105 110
Gly Arg Gly Thr Gln Val Thr Val Ser Ser
115 12 0
210 SEQ ID NO 603
r211 LENGTH 24
212 TYPE Dl'IA
213 ORGANIISN Artzfrczal Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 603
ggattcacgt ttagtagcta tgcc
210 SEQ ID NO 604
211e LENGTH 8
212. T'ZPE PRT
213 ORGANISE Artrftcral Sequence
220 FEATURE:
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 604
Gly Phe Thr Phe Ser Ser Tyr Ala
1 5
210 SEQ ID NO 05
211 LENGTH 24
212 TYPE DNA
213 ORGANISN Artzfzcral Sequence
220 FEATURE
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 605
at.cagtggta atggtggtag cacc
210 SEQ ID NO 60
211 LENGTH 8
212 TYPE PRT
213 ORGANISN Artzfrcral Sequence
220 FEATURE:
223 OTHER INFORNATION Synthetzc
400 SEQUENCE 606
345
US 8,062,640 B2
-continued
346
Ile Ser Gly Asn Gly Gly Ser Thz
I 5
210 SEQ ID NO 607
e211 LENGTH 45
e212 TYPE DNA
213 ORGANIISN Artzfrcral Sequence
220 FEATURE.
223 OTHER INFORMATION Synthetzc
400 SEQUENCE 07
gcgaaagccc gttattacga tttttggggg gggaatttcg atctc
210 SEQ ID NO 608
211 LENGTH 15
212 TYPE PRT
213s ORGAIIISN Azt.rfrcral Sequence
220 FEATURE
223 OTHER INPORKATION Synthetzc
400 SEQUENCE 08
Ala L. Ala Arg Tyr Tyz A p Phe Trp Gly Gly A n Phe A p Leu
1 5 10 15
210 SEQ ID NO 09
211 LENGTH 324
212 TYPE DNA
213 ORGAEISN Artzfzczal Sequence
220 FEATURE
223 OTHER INPORKATION Synthetzc
400 SEQUENCE 609
gaaattgtot tgacgcagt.c tccaggcacc ctgtctttgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttagc atcaggtact tagcctggta tcagcagaaa 120
cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca 180
gacaggttca gtgtcagtgt gtctgggaca gacttcactc tcaccatcac tagactggag 240
cctgaagatt ttgcagtcta ttactgtcag caatatggta gttcaccgct cactttcggc 300
ggagggacca aggtggagat casa 324
Sequence
nthetzc
210 SEQ ID NO 610
211 LENGTH 108
212 TYPE PPT
213 ORGZUZISN Aztzfzczal
220 FEATURE:
223 OTHER IEFORHATION Sy
400 SEQUENCE 10
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ile Arg
20 25 30
Tyr Leu Ala Trp Tyr Gln Gln Lye Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyz Gly Ala Ser Ser Arg Ala Thz Gly Ile Pro Asp Azg Phe Ser
50 55 60
Val Ser Val Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyz Tyz Cys Gln Gln Tyr Gly Sez Sez Pzo
85 90 95
Leu Thz Phe Gly Gly Gly Thz Lys Val Glu lie Ly
100 105
347
US 8,062,640 B2
-continued
348
210 SEQ ID No 611
211 LENGTH 21
212 TYPE DNA
a213 ORGANIISN ArtrfrCral SequenCe
a220 FEATURE:
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 611
cagagtgtta gcatcaggta c 21
210 SEQ ID No 612
211 LEIIGTH 7
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 PEATURE:
223. OTHER INFORNATION Synthetrc
400 SEQUENCE 12
Gln Ser Yal Ser Ile Arg Tyr
I 5
210 SEQ ID Eo 613
211 LENGTH 9
212 TYPE DNA
213 ORGANISFI Artrfrcral Sequence
220 FEATURE
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 613
ggtgcatcc
210 SEQ ID No 614
211 LENGTH 3
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 614
Gly Ala Ser
I
210 SEQ ID No 615
211 LENGTH 27
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE:
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 15
cagcaatatg gtagttcacc gctcact 27
210 SEQ ID No 616
211 LENGTH 9
212 TYPE PRT
213 ORGPIIISH Artrfrcral Sequence
220 FEATURE:
223 oTHER INPORHATION Synthetrc
400 SEQUENCE 61
Gln Gln Tyr Gly Ser Ser Pro Leu Thr
I 5
210 6'EQ ID No 617
211 LENGTH 366
212 TYPE DNI
349
US 8,062,640 B2
-continued
350
213 ORGANISE Artificial Sequence
220 FEATURE
223 OTHER INFORH'TION Synthetic
400 SEQUENCE 617
gaggtgcagt tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc
tcctgtgcag cctctggatt cacgtttagt agctatgcca tgaactgggt ccgccaggct 12 0
ccagggaagg ggctggattg ggtctcaggt atcagtggta atggtggtag cacctactac 180
gcagactccg tgaagggccg gttcaccatc tccagagaca tttccaagaa cacgctgtat 240
gtgcaaatgc acagcctgag agtcgaggac acggccgttt actactgtgc gaaagcccgt 300
tattacgatt r.ttggggggg gaatt.tcgat ctctggggcc gtggcaccct ggt.cactgtc 360
tcctca 366
210 SEQ ID NO 18
211 LENGTH 122
212 TYPE PRT
213 ORGANISN Artificial Sequence
220 FEATURE:
223 OTHER INPORNATION Synthetic
400 SEQUENCE 618
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
5 10
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Het Aon Trp Val Arg Gln Ala Pro Gly Ly Gly Leu Aop Trp Val
35 40 45
Ser Gly Ile Ser Gly Asn Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 0
Lys Gly Arg Phe Thr Ile Ser !\rg !\sp Ile Ser Lys Asn Thr Leu Tyr
65 70 75 80
Val Gln tset Hi Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Ala Arg Tyr Tyr Asp Phe Trp Gly Gly Asn Phe Asp Leu Trp
100 105 110
Gly Arg Gly Thr Leu Val Thr Val Ser Ser
115 12 0
210 SEQ ID NO 619
211 LENGTH 324
212 TYPE DNA
213 ORGANISE Artificial Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetic
400 SEQUENCE 619
gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc
ctctcctgca gggccagtca gagtgtt.agc atcaggtact tagcctggta tcagcagaaa
cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca
12 0
180
gacaggttca gtgtcagtgt gtctgggaca gacttcactc tcaccatcac tagactggag 240
cctgaagatt ttgcagtcta ttactgtcag caatatggta gttcaccgct cactttcggc 300
ggagggacca aggtggagat casa 324
210 6'EQ ID NO 620
211 LENGTH 108
212 TYPE PRT
351
US 8,062,640 B2
-continued
352
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORN'TION Synthetzc
400 SEQUENCE 620
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ile Arg
20 25 30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Val Sez Val Ser Gly Thr Aap Phe Thr Leu Tht Ile Thr rrg Leu Glu
65 70 75 80
Pro Glu fsp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95
Leu Thr Phe Gly Gly Gly Thz Lya Val Glu Ile Ly-
100 105
210 SEQ ID NO 621
211 LENGTH 36
212 TYPE DNA
213 ORMEISN Artzfrc
220 FEATURE
223 OTHER INFORFZATZON
ral Sequence
Synthetzc
r400 SEQUENCE 621
gaggtgcagc tgttggagtc t.gggggaggc ttggtacagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt cacgtttagt agctatgcca tgagctgggt ccgccaggct 12 0
ccagggaaug ggctggagtg ggtctcagct atcagtggta atggtggtag cacctactac 180
gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatga acagcctgag agccgaggac acggccgtat attactgtgc gaaagcccgt 300
tattacgatt tttggggggg gaatttcgat ctctggggcc gtggcaccct ggtcactgtc
tcctca
360
366
210 SEQ ID NO 622
211 LENGTH 122
212 TYPE PRT
213 ORGANISN Artzfzc
220 FEATURE:
223 OTHER INFORNATION
ral Sequence
Synthetzc
400 SEQUENCE 22
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Net Ser Tzp Val Azg Gln Ala Pro Gly Ly Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Ser Gly Asn Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly frg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln iset Asn Ser Leu Arg Ala Glu Asp Tht Ala Val Tyr Tyz Cya
85 90 95
!\Za Lys Ala Arg Tyr Tyr !\sp Phe Trp Gly Gly Asn Phe Asp Leu Trp
353
US 8,062,640 B2
-continued
354
100 105 110
Gly Arg Gly Thr Leu Val Thr Val Ser Ser
115 12 0
c210 SEQ ID NO 623
211 LEI'GTH 324
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORPIATION Synthetrc
400 SEQUENCE 623
gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc
ctctcctgca gggccagtca gagtgttagc atcaggtact. tagcctggt.a ccagcagaaa 12 0
cctggccaog ctcccaggct cctcatct.at ggtgcatcca gcagggccac tggcatccca 180
gacaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagactggag 240
cctgaagatt ttgcagtgta ttactgtcag caatatggta gttcaccgct cactttcggc 300
ggagggacca aggtggagat casa 324
210 SEQ ID NO 624
211 LENGTH 108
212 TYPE PRT
213 ORG631ISH Artrfrcral Sequence
220 FEATURE
223 OTHER INFORFIATION Synthetzc
c400 SEQUENCE 624
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
I 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ile Arg
20 25 30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg * eu Glu
65 70 ". 5 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95
Leu Thr Phe Gly Gly Gly Thr Ly. Val Glu Ile Lys
100 105
210 SEQ ID NO 25
211 LENGTH 381
212 TYPE DNA
213 ORGANISN Artzfzcral Seque
220 FEATURE
223 OTHER INFORHATION Synthet
nce
10
400 SEQUENCE 625
caggttcagc r.ggtgcagtc tggacct.gag gtgaagaacc ctggggcctc agtgaaggtc
tcctgcaacg cttctggtta cacctttacc acctatggta tcagttgggt acgacaggcc 12 0
cctggacaag ggcttgagtg gat.gggatgg atcagcggtt acaatggtaa aacaaacgat 180
gcacagaagt tccaggacag agtcgccatg accacagaca catccacgag cacagcctac 240
atgqagctga qgagcctgag atctgacgac acqgccattt attactgttc gagagatcgt 300
ttagtagtac cacctgccct ttattattcc tactacgtta tggacgtctg gggccaaggg 360
355
US 8,062,640 B2
-continued
356
accacggtca ccgtctcctc a 381
210 SEQ ID NO 626
211 LENGTH 12
a212 TYPE PRT
a213 ORGANIS14 Aztrfrcral Sequence
220 FEATURE:
223 OTHER INFORMATION Synthetrc
400 SEQUENCE 626
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Asn Pro Gly Ala
5 10
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Net
35 40 45
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr fsn Asp Ala Gln Lys Phe
50 55 60
Gln Asp Azg Val Ala Met Thz Thr Asp Thr Set Thr Ser Thr Ala Tyr
65 70 75 80
Net Glu Leu Arg Ser Leu Arg Ser Asp Asp Tht Ala Ile Tyr Tyr Cys
85 90 95
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Tyr Tyr Ser Tyr Tyr
100 105 110
Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 627
211 LENGTH 24
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFORMATION Synthetzc
400 SEQUENCE 627
ggttacacct ttaccaccta tggt
210 SEQ ID NO 28
211 LENGTH 8
212 TYPE PRT
213 ORGANISN Artzfrcral Sequence
220 FEATURE
223 OTHER INFORM'TION Synthetzc
400 SEQUENCE 628
Gly Tyr Thr Phe Thr Thr Tyr Gly
I 5
210
211
212
213
220
223
SEQ ID NO 629
LENGTH 24
TYPE DNA
ORGANISN Artzfzcral Sequence
PEATURE:
OTHER INPORNATION: Synthet ac
400 SEQUENCE 629
atcagcggtt acaatggtaa aaca
210
211
212
213
220
223
SEQ ID NO 630
LENGTH 8
TYPE PRT
URGANIEM Aztzfrczal sequence
FEATURE.
OTHER INFORMATION Synthetzc
357
US 8,062,640 B2
-continued
358
400 SEQUENCE 630
Ile Ser Gly Tyr Asn Gly Lys Thz
5
210 SEQ ID I'10 631
211 LENGTH 60
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 631
tcgagagatc gtttagtagt accacct.gcc ctttattatt. cctactacgt tatggacgtc
210s SEQ ID NO 632
211 LEHGTH 20
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 632
Sez Arg Asp Azg Leu Val Val Pro Pro Ala Leu Tyr Tyr Ser Tyr Tyz
I 5 10 15
Val Net Psp Val
20
c210 SEQ ID NO 633
211 LEI'GTH 336
212 TYPE DNA
213 ORGAIIISH Aztrfrcral Sequence
220 FEATURE.
223 OTHER INFORKATION Synthetrc
400 SEQUENCE 633
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg 12 0
tttcagcaca ggccaggtca atctccaagg cgcctaattt ataaggtttc taaccgggac 180
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac act.gaaaatc 240
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg 300
tacacttttg gccaggggac caagctggag atcaaa 336
210 SEQ ID NO 634
211 LENGTH 112
212 TYPE PRT
213 ORGANISE Artrfrc
220 FEATURE
223 OTHER INPORKATION
ral Sequence
Synthetzc
400 SEQUENCE 634
Asp Val Val Het Thr Gln Sez Pro Leu
I 5
Ser Leu Pro val
10
Thz Leu Gly
15
Gln Pro Ala Ser Ile Ser Cy. I.rg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
35 40 45
Pro Arg Azg Leu Ile Tyz Lys Val Sez Asn Azg Asp Ser Gly Val Pzo
50 55 60
Asp Arg Phe Ser Gly Sez Gly Sez Gly Thz Asp Phe Thr Leu Lys Ile
65 70 75 80
359
US 8,062,640 B2
-continued
360
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Het Gln Gly
85 90 95
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
210 SEQ ID NO 635
211 LENGTH 33
212 TYPE DNA
213 ORGANISN Artificial Sequence
220 FEATURE
223 OTHER INFOPHP.TION Synthetic
400 SEQUENCE 635
caaagcctcg tatacagtga tggaaacacc tac 33
210 SEQ ID NO 36
211 LENGTH 11
212 TYPE PRT
213 ORGANISN Artificial Sequence
220 FEATURE:
223 OTHER INPORNATION Syntlietic
400 SEQUENCE 636
Gln Ser Leu Val Tyr Ser Asp Gly Asn Thr Tyr
1 5 10
210 SEQ ID NO 637
211 LENGTH 9
e212 TYPE DNA
213 ORGANNSll Artificial Sequence
220 FEATURE:
223 OTHER INPORNATZON: Synthetic
400 SEQUENCE 37
aaggtttct
210 SEQ ID NO 638
211 LENGTH 3
212s TYPE PRT
213a ORGM4ISN ArtifiCial SequenCe
220 FEATURE:
223 OTHER INFORNATIOE Synthetic
400 SEQUENCE 638
Lys Val Ser
1
210 SEQ ID NO 39
211 LENGTH 27
212 TYPE DNA
213 ORGANISN Artificial Sequence
220 FEATURE
223 OTHER INPORKATION Synthetic
400 SEQUENCE 639
atgcaaggta cacactggcc gtacact 27
210 SEQ ID NO 640
211 LENGTH 9
212 TYPE PRT
213 ORGANISE Artificial Sequence
220 FEATURE.
223 OTHER INFOPNATION Synthetic
400 5'EQUENCE 640
Net Gln Gly Thr His Trp Pro Tyr Thr
361
US 8,062,640 B2
-continued
362
210 SEQ ID NO 641
211 LENGTH 381
s212 TYPE DNA
s213 ORGAEIS14 Artrfrcral Sequence
220 FEATURE:
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 641
caggttcagc tggtgcagtc tggacctgag gtgaagaacc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc acctatggta tcagttgggt acgacaggcc 12 0
cctggacaag ggctrgagtg gatgggatgg atcagcggtt. acaatggtaa aacaaacgat 180
gcacagaagt tccaggacag agtcgccatg accacagaca catccacgag cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccattt attactgttc gagagatcgt 300
ttagtagtac cacctgccct ttattattcc tactacgtta tggacgtctg gggccaaggg 360
accacggtca ccgtctcctc a 381
210 SEQ ID EO 642
211 LENGTH 127
212 TYPE PRT
213 ORGANISbl Artrfrcral Sequence
220 FEATURE
223 OTHER INFORNITION Synthetrc
400 SEQUENCE 642
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Ly Aan Pro Gly Ala
I 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Net
35 40 45
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Asp Ala Gln Lys Phe
50 55 60
Gln Asp Arg Val Ala Net Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Net Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Ile Tyr Tyr Cys
85 90 95
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Tyr Tyr Ser Tyr Tyr
100 105 110
Val Het Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 643
211 LENGTH 336
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INPORNATION, Synthetrc
400 SEOUENCE 643
gatgttgtua tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta ct.tgaattgg 12 0
tttcagcaga ggccaggtca atctccaagg cgcctaattt ataaggtttc taaccgggac 180
tctugggtcc cagacagatt cagcggcagt ggotcaugca ctgatttcac actgaaaatc 240
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg 300
363
US 8,062,640 B2
-continued
364
tacacttttg gccaggggac caagctggag atc.aaa 336
210 SEQ ID NO 644
211 LENGTH 112
c212 TYPE PRT
c213 ORGANIS14 Aztzfzczal Sequence
220 FEATURE:
223 OTHER INFORNATIOK Synthetrc
400 SEQUENCE 644
A p Val Val Met Thr Gln Sez Pzo Leu Ser Leu Pzo Val Thr Leu Gly
5 10
Gln Pro Ala Ser Ile Ser Cys Arg Sez Ser Gln Ser Leu Val Tyz Sez
20 25 30
4 p Gly Aan Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Sez
35 40 45
Pro Arg frg Leu Zle Tyr Lys Val Ser Asn frg Asp Ser Gly Val Pro
50 55 60
Asp Arg Phe Sez Gly Ser Gly Sez Gly Thz Asp Phe Thr Leu Lys Ile
65 70 75 80
Sez Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cy. Met Gln Gly
85 90 95
Thr Hzs Trp Pzo Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Ly
100 105 110
210 SEQ ID NO 645
c211 LENGTH 381
212 TYPE Dl'IA
213 ORGANNSN Artzfzc
220 FEATURE.
223 OTHER INFORNATIOK
zal sequence
Synthetzc
400 SEQUENCE 645
caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc acctatggta tcagctgggt gcgacaggcc 120
cctggacaag ggcttgagtg gatgggatgg atcagcggtt. acaatggtaa aacaaactat 180
gcacagaagc tccagggcag agtcaccatg accacagaca cat.ccacgag cacagcctac 240
atggagctca ggagcctgag atctgacgac acggccgtgt attactgttc gagagatcgt 300
ttagtagtac cacctgccct ttattattcc tactacgtta tggacgtctg ggggcaaggg 360
accacugtca ccutctcctc a 381
210 SEQ ID NO 46
211 LENGTH 127
212 TYPE PRT
213 ORGANISN Artrfrc
220 FEATURE
223 OTHER INPORNATION
zal Sequence
Synthetzc
400 SEQUENCE 646
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Ly Ly Pro Gly Ala
I 5 10 1.5
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Net
35 40 45
Gly Trp Ile Sez Gly Tyz Asn Gly Lys Thz Asn Tyr Ala Gln Lys Leu
50 55 60
Gln Gly Arg Val Thr Net Thr Thr !\sp Thr Ser Thr Ser Thr !\Za Tyr
365
US 8,062,640 B2
-continued
366
65 70 80
Het Glu Leu Azg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ser Arg Asp Azg Leu Val Val Pzo Pro Ala Leu Tyr Tyr Ser Tyz Tyz
100 105 110
Val Het Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 647
211 LENGTH 336
212 TYPE DNA
213 ORGAEISH Artzfzczal Sequence
220 FEATURE:
223 oTHER INPORHATION Synthetzc
400. SEQUENCE 647
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 60
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg 120
tttcagcaga ggccaggcca atctccaagg cgcctaattt ataaggtttc taaccgggac 180
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc 240
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg 300
tacacttttg gccaggggac caagctggag atcaaa 336
210 SEQ ID NO 648
s211 LENGTH 112
212 TYPE PRT
213 ORGANIISN Artzfzczal Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 648
Asp Val Val Net Thr Gln Sez Pzo Leu Ser Leu Pzo Val Thz Leu Gly
I 5 10 15
Gln Pro Ala 6'er Ile Sez Cys Azg Sez Ser Gln Ser Leu Val Tyz Sez
20 25 30
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
35 40 45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ly. Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Net Gln Gly
85 90 95
Thr Hzs Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
210 SEQ ID NO 649
211 LEI'GTH 381
212 TYPE DNA
213 ORGANISE Artzfzc
220 PEATURE:
223 OTHER INFORHATION
zal sequence
Synthetzc
400 SEQUENCE 49
caggttcagc tggtgcagtc tggacctgag gtgaagaacc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc acctatcgta tcagttgggt acgacaggcc 120
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaacgat 180
367
US 8,062,640 B2
-continued
368
gcac.agaagt tccaggacag agtcgccatq acc.acagaca catccacgag c.acagcctac 240
atggagctga qgagcctgag atctgacgac acggccattt attactgttc gagagatcgt 300
ttagtagtac cacctgccct taattattac tactacgtta tggacgtctg gggccaaggg 360
accacggtca ccgtctcctc a 381
210 SEQ ID NO 650
211 LENGTH 127
212 TYPE PRT
213 ORGANISN Artzfzczal Sequence
220 FEATURE
223 OTHER INPORFZATION Synthetzc
400 SEQUENCE 650
Gln Val Gln Leu Val Gln ser Gly Pro Glu Val Lys Asn Pro Gly Ala
I 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Net
35 40 45
Gly Trp Ile Ser Gly Tyr Asn Gly Ly. Thr Asn Asp Ala Gln Lys Phe
50 55 60
Gln Asp Arg Val Ala Het Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Net Glu Leu Arg Ser Leu Arg Ser Asp Psp Thr Ala Ile Tyr Tyr Cys
85 90 95
Ser Arg Aep Arg Leu Val Val Pzo Pro Ala Leu A:n Tyr Tyr Tyr Tyz
100 105 110
Val Het Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 651
211 LEIIGTH 24
212 TYPE DNA
213 ORGANIS'N Artzfzczal Sequence
220. PEATURE.
223. OTHER INFORNATION Synthetzc
400 SEQURNCE 651
ggttacacct ttaccaccta tggt
210 SEQ ID NO 652
211 LENGTH 8
212 TYPE PRT
213 ORGANISE Artzfzczal Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 652
Gly Tyr Thr Phe Thr Thr Tyr Gly
5
210 SEO ID NO 653
211 LENGTH 24
212 TYPE DNA
213 ORGANISE .Artzfzctal Sequence
220 FEATURE
223 OTHER INPORKATION Synthetzc
400 SEQUENCE 653
atcagcggtt acaatggtaa aaca 24
369
US 8,062,640 B2
-continued
370
210 SEQ ID NO 54
211 LENGTH 8
212 TYPE PRT
213 ORGAEISN Artzfzczal Sequence
220 FEATURE
c223 OTHER INFORHATION Synthetzc
400 SEQUENCE 654
Ile Ser Gly Tyr Asn Gly Lys Thr
1 5
210 SEQ ID NO 655
211 LENGTH 0
212 TYPE DNA
213 ORGANISE Artzfzczal Sequence
220 PEATURE:
223 OTHER INPORNATION Synthetzc
400 SEQUENCE 55
tcgagagatc gtttagtagt accacctgcc cttaattatt actactacgt tatggacgtc 60
210 6'EQ ID NO 656
211 LENGTH 20
212 TYPE PRT
213 ORGANISE Artzfzczal Sequence
220 PEATURR.
223 OTHER INFORFIATION Synthetzc
400 SEQUENCE 656
Ser Arg Asp Prg Leu Val Val Pro Pro Ala Leu Asn Tyr Tyr Tyr Tyr
I 5 10 15
Val tset Asp Val
20
210 SEQ ID NO 657
211 LENGTH 336
212 TYPE DNA
213 ORGAEISH Artzfzczal Sequence
220 FEATURE.
223 OTHER INFOPHATION Synthetzc
400. SEQUENCE 657
gatgttgtaa tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg 12 0
tttcagcaga ggccaggtca atctccaagg cgcctaattt ataaggtttc taaccgggac 180
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg
240
300
tacacttttg gccaggggac caagctggag atcaaa 336
210 SEQ ID NO 658
211 LENGTH 112
212 TYPE PRT
213 ORGANIISH Artzfzc
220 FEATURE.
223 OTHER INFORffATION
zal Sequence
Synthetzc
400 SEQUENCE 658
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
10
Gln Pro Ala 5'er Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
35 40 45
371
US 8,062,640 B2
-continued
372
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu A p Val Gly Val Tyr Tyr Cys Het Gln Gly
85 90 95
Thr Hrs Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
210 SEQ ID NO 659
211 LEIIGTH 33
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
220 PEATURE:
223. OTHER INFORNATION Synthetrc
400 SEQUENCE 59
caaagcctcg tatacagtga tggaaacacc tac 33
210 SEQ ID NO 660
211 LENGTH 11
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORH'TION Synthetrc
400 SEQUENCE 660
Gln Ser Leu Val Tyr Ser I; p Gly 4 n Thr Tyr
I 5 10
210 SEQ ID No 661
211 LENGTH 9
212 TYPE DNA
213 ORGIINISH .Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 661
aaggtttct
210 SEQ ID NO 662
211 LENGTH 3
212 TYPE PPT
213 ORGIUIISN Artrfrcral Sequence
220 FEATURE:
223 OTHER IEFORHATION Synthetrc
400 SEQUENCE 62
Lys Val Ser
I
210 SEQ ID NO 663
211 LENGTH 27
212 TYPE DNA
213 ORGPIIISH Artrfrcral Sequence
220 FEATURE:
223 oTHER INFURNATIUN synthetrc
400 SEQUENCE 6 3
atgcaaggta cacactggcc gtacact
210 SEQ ID NO 664
211 LENGTH 9
212 TYPE PRT
213 ORGIINISH Artrfrcral Sequence
373
US 8,062,640 B2
-continued
374
220 PEATURR.
223 OTHER INFORN"PION Synthetrc
400 SEQUENCE 664
Net Gln Gly Tlr Hrs Trp Pro Tyr Thr
I 5
210 SEQ ID NO 665
211 LENGTH 381
212 TYPE DNA
213 ORGAEISN Artzfzczal Sequence
220 FEATURE
223 OTHER INPORFLATION Synthetzc
400 SEQUENCE 665
caggttcagc tggtgcagtc tggacctgag gtgaagaacc ctggggcctc agtgaaggtc
tcctgcaagg cttctggtta cacctttacc acctatggta tcagttgggt acgacaggcc 12 0
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaacgat 180
gcacagaagt tccaqgacag agtcgccatg accacaqaca catccacqag cacagcctac 240
atggaqctga ggagcctgag atctgacgac acggccattt attactgttc gagagatcgt 300
ttagtagtac cacctgccct taattattac tactacgtta t.ggacgtctg gggccaaggg 3 0
accacggtca ccgtctcctc a 381
210 SEQ ID NO 666
211 LENGTH 127
s212 TYPE PRT
213 ORGANHSH Art 1frctal Sequence
220 FEATURE:
223 OTHER INPORNATION: Synthet rc
400 SEQUENCE 66
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Asn Pro Gly Ala
I 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Net
35 40 45
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Asp Ala Gln Lys Phe
50 55 60
Gln Asp Arg Val Ala Het Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Net Glu Leu Arg Ser Leu Arg Ser .'-. p A p Tht Ala Ile Tyr Tyr Cys
85 90 95
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Asn Tyr Tyr Tyr Tyr
100 105 110
Val Het Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 667
211 LENGTH 336
212 TYPE DNA
213 ORGANISN Artrfrc
220 FEATURE
223 OTHER INFORHATION
tal Sequence
Synthetrc
400 SEQUENCE 667
gatqttgtga tgactcagtc tccactctcc ctqcccqtca cccttggaca gccggcctcc
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg 12 0
375
US 8,062,640 B2
-continued
376
tttc.agcaga ggccaggtca atctccaagg cgc.ctaattt ataaggtttc t.aacc.gggac 180
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc 240
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg
tacactt.ttg gccaggggac caagctggag atcaaa
300
336
210 SEQ ID NO 668
211 LENGTH 112
212 TYPE PRT
213 ORGAEISN Artzfrcral Sequence
220 FEATURE
223 OTHER INPORIAATION Synthetzc
400 SEQUENCE 668
4 p Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
I 5 10 15
Gln Pro fla Ser Zle Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Asn Tzp Phe Gln Gln Arg Pro Gly Gln Ser
35 40 45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Het Gln Gly
85 90 95
Thr Mze Tzp Pzo Tyr Thr Phe Gly Gln Gly Thr Ly Leu Glu Ile Lye
100 105 110
210 SEQ ID NO 69
211 LENGTH 381
212 TYPE DNI
213 ORGANISN Artzfzcral Sequence
220 FEATURE.
223 OTI'ER INFORFZATION Synthetzc
400. SEQUENCE 6 9
caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agt.gaaggtc
tcctgcaaqg cttctggtta cac«tttacc acctatggta tcagctgggt gcgacaggcc 12 0
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaactat 180
gcacaqaagc tccaggqcag agtcaccatg accacagaca catccacgag cacagcctac 240
atgqagctga qgagcctgag atctgacgac acqgccqtgt attactgttc gagagatcgt 300
ttagtagtac cacctgccct taattattac tactacgtta tggacgtctg ggggcaaggg 360
accacggtca ccgtctcctc a 381
210 SEQ ID NO 670
211 LENGTH 127
212 TYPE PRT
213 ORGPNISH Artrfrcral Sequence
220 FEATURE:
223 OTHER INPORHATION Synthetrc
400 SEQUENCE 670
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
I 5 10 15
Ser Val Lys Val Ser Cy- Lys Ala Ser Gly Tyt Thr Phe Thr Thz Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Net
377
US 8,062,640 B2
-continued
378
35 40
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Tyr Ala Gln Lys Leu
50 55 60
Gln Gly Azg Val Thr Net Thz Thz .'. p Thz Ser Thr Ser Thr Ala Tyz
65 70 75 80
Net Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Asn Tyr Tyr Tyr Tyr
100 105 110
Val Het Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 671
211s LENGTH 336
212 TYPE DNA
213 ORGANISE Artzfzczal Sequence
220 FEATUPE
223 OTHER INFORNTTION Synthetzc
400 6'EQUENCE 671
gatgt.tgtga tgactcagtc tccacrctcc ctgcccgt.ca cccttggaca gccggcctcc 60
atctcctgca ggtctagtca aagcctcgta tac.agtgatg gaaacaccta t.ttgaattgg 12 0
tttcagcaga ggccaggcca atctccaagg cgcctaattt ataaggtttc taaccgggac 180
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc 240
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg
tacacttttg gccaggggac caagctggag atcaaa
300
336
210 SEQ ID NO 72
211 LENGTH 112
212 TYPE PRT
213 ORGAHISN Artzfzc
220 FEATURE.
223 OTHER INFORFZATION
zal Sequence
Synthetzc
400. SEQUENCE 672
Asp Val Val Net Thr Gln Sez Pro Leu Ser Leu Pro Val Tlsr * au Gly
1 5 10 15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
Asp Gly Asn Thr Tyr Leu .Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
35 40 45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 0
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser lrg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Net Gln Gly
85 90 95
Thr Hz Trp Pro Tyr Thr Phe Gly Gln Gly Thr Ly Leu Glu Ile Ly
100 105 110
210 SEQ ID NO 673
211 LENGTH 381
212 TYPE DNA
213 ORGAEISN Artzfzc
220 FEATURE:
223 OTHER INFORNATION
zal Sequence
Synthetic
400 SEQUENCE 673
379
US 8,062,640 B2
-continued
380
caggttcagc tggtgcagtc tggacctgag gtgaagaacc ctggggcctc agt.gaaggtc 60
tcctgcaagg cttctggtta cacctttacc acctatggta tcagttgggt acgacaggcc 120
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaacgat 180
gcacagaagt tccaggacag agtcgccatg accacagaca catccacgag cacagcctac 240
atggagctua ggagcctgag atctgacgac acggccattt attactgttc gagagatcgt 300
ttagtagtac cacctgccct ttattattac tactacgtta tggacgtctg gggccaaggg 360
accacggtca ccgtctcctc a 381
210 SEQ ID NO 674
211 LENGTH 127
212 TYPE PRT
213 ORGWIISM Artzfzczal Sequence
220. FEATURE.
223 OTHER INFORN'ZION Synthetzc
400 SEQUENCE 674
Gln Val Gln Leu Val Gln Sez Gly Pro Glu Val Ly- Asn Pro Gly Ala
I 5 10 15
Ser Val Ly Val Ser Cy. Lys Ala Ser Gly Tyt Thr Phe Thr Thr Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Net
35 40 45
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Asp Ala Gln Lys Phe
50 55 60
Gln Aep rzg Val Ala Met Thr Thz 5 p Thz Ser Thr Ser Thr Ala Tyz
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Ile Tyr Tyr Cys
85 90 95
Ser Arg Asp Arg Leu Val Val Pro Pro
100 105
Ala Leu Tyr Tyr Tyr Tyr Tyr
110
Val lect Asp Val Trp Gly Gln Gly Thr
115 12 0
Thr Val Thr Val Ser Ser
125
210 SEQ ID NO 75
211 LENGTH 24
212 TYPE DNA
213 ORGANISN Artzfzczal Sequence
220 FEATURE
223 OTHER INFORM'TION Synthetzc
400 SEQUENCE 675
ggttacacct ttaccaccta tggt 24
210 SEQ ID NO 67
211 LENGTH 8
212 TYPE PRT
213 ORGANISN Artzfzczal Sequence
220 FEATURE
223 OTHER INPORMATION, Synthetzc
400 SEOUENCE 676
Gly Tyr Thr Phe Thr Thr Tyr Gly
I 5
210 SEQ ID NO 677
211 LENGTH 24
212 TYPE DNA
213 ORGANISM Aztzfzczal Sequence
220 FEATURE.
223 OTHER INFORMATION Synthetzc
381
US 8,062,640 B2
-continued
382
600 SEQUENCE 677
atcagcggtt acaatggtaa aaca
r210 SEQ ID NO 678
211 LEI'GTH 8
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORFIATION Synthetrc
600 SEQUENCE 678
Ile Ser Gly Tyr Asn Gly Lys Thr
I 5
210s SEQ ID NO 679
211 LEHGTH 60
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFORNATION Synthetzc
600 SEQUENCE 679
tcgagagatc gtttagtagt accacctgcc ctttattatt actactacgt t.atggacgtc
210 SEQ ID NO 680
211 LENGTH 20
212 TYPE PRT
213 ORGAEISN Artzfrcral Sequence
r220 FEATURE:
223 OTHER INFORNATION Synthetrc
600 SEQUENCE 680
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Tyr Tyr Tyr Tyr Tyr
I 5 10 15
Val Het Asp Val
20
210s SEQ ID NO 681
211s LENGTH 336
212 TYPE DNA
213 ORGANISbl Artrfrcral Sequence
220 FEATUPE
223 OTHER INPORNPTION Synthetrc
600 SEQUENCE 681
gatgt.tgtga tgactcagtc tccacrctcc ctgcccgt.ca cccttggaca gccggcctcc 60
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta c.ttgaattgg 12 0
tttcagcaua ggccaggtca atctccaagg cgcctaattt ataaggtttc taaccgggac 180
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc 260
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg 300
tacacttttg gccaggggac caagctggag atcaaa 336
210 SEQ ID I'10 682
211 LENGTH 112
212 TYPE PRT
213 ORGANISE Artrf
220 FETTURE
223 OTHER INFORFIATI
rcral Sequence
ON Synthetzc
600 SEQUENCE 682
Asp Val Val Net Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
I 5 10 15
383
US 8,062,640 B2
-continued
384
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
35 40 45
Pro Arg Zzg Leu Ile Tyr Lys Val Sez Aan Zzg Aap Ser Gly Val Pzo
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 .5 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly
85 90 95
Thr His Trp Pzo Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
210 SEQ ID NO 83
211 LENGTH 33
212 TYPE DNA
213 ORGANISN Artificial Sequence
220 FEATURE:
223 OTHER INPORNATION Syntlietic
400 SEQUENCE 683
caaagcctcg tatacagtga tggaaacacc tac. 33
210 SEQ ID NO 684
211 LENGTH 11
212 TYPE PRT
c213 ORGANIS14 Artificial Sequence
220 FEATURE:
223 OTHER INFORHATION. Synthetic
400 SEQUENCE 684
Gln Ser Leu Val Tyr Ser Asp Gly Asn Thr Tyr
I 5 10
210 SEQ ID NO 685
211 LENGTH 9
212a TYPE DNA
213a ORGMIISN ArtifiCial SequenCe
220 FEATURE:
223 OTHER INFORNATION Synthetic
400 SEQUENCE 685
aaggtttct
210 SEQ ID NO 686
211 LENGTH 3
212 TYPE PRT
213 ORGANISE Artificial Sequence
220 FEATURE
223 OTHER INPORKATION Synthetic
400 SEQUENCE 686
Ly- Val Ser
I
210 SEQ ID NO 687
211 LENGTH 27
212 TYPE DNA
213 ORGANISE Artificial Sequence
220 FEATURE.
223 OTHER INFOPHATION Synthetic
400 5'EQUENCE 687
at.gcaaggta cacactggcc gtacact 27
385
US 8,062,640 B2
-continued
386
210 SEQ ID NO 688
211 LENGTH 9
212 TYPE PRT
s213 ORGPAIISN AZtzfzCzal SequenCe
s220 FEATURE:
223 OTHER INFORNATION Synthetzc
400 SEQUENCE 688
Het Gln Gly Thr Hzs Trp Pro Tyr Thr
5
210 SEQ ID NO 689
211 LENGTH 381
212 TYPE DNA
213 ORGWIISN Artzfzczal Sequence
220. FEATURE.
223 OTHER INFORN'TION Synthetzc
400 SEQUENCE 689
cagqttcagc tggtucagtc tggacctgag gtqaagaacc ctguggcct- agtgaaggtc 60
tcctgcaagu cttctgutta cacctttacc acctatggta tcagttgggt acgacaggcc 120
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaat.ggtaa aacaaacgat 180
gcacagaagt tccaggacag agtcgccatg accacagaca catccacgag cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccattt attactgttc gagagatcgt 300
ttagtagtac cacctgccct ttattattac tactacgtta tggacgtctg gggccaaggg 360
accacggtca ccgtctcctc a 381
210 SEQ ID NO 690
211 LENGTH 127
212 TYPE PRT
213 ORGANISE .Brtzfzc
220 FEATURE.
223 OTHER INFORHATION
tal Sequence
Synthetzc
400 SEQUENCE 690
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Asn Pro Gly Ala
I 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Ser Gly Tyz .'. n Gly Ly. Thz Asn Asp Ala Gln Lya Phe
50 55 0
Gln Asp Arg Val Ala Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Het Glu Leu Pzg Ser Leu Arg Ser Asp Asp Thr Ala 'Ile Tyr Tyr Cys
85 90 95
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Tyr Tyr Tyr Tyr Tyr
100 105 110
Val Het Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 91
211 LENGTH 336
212 TYPE DNA
213 ORGANISN Artlflc
220 FEATURE:
223 OTHER INFORNATION
zal Sequence
Synthetzc
387
US 8,062,640 B2
-continued
388
400 SEQUENCE 91
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 60
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg 120
tttcagcaga ggccaggtca atctccaagg cgcctaattt ataaggtttc taaccgggac 180
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc 240
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg 300
tacacttttg gccaggggac caagctggag atcaaa 336
210 SEQ ID NO 692
211 LENGTH 112
212 TYPE PRT
213 ORGWIISN Artificial Sequence
220. FEATURE.
223 OTHER INFORN'TION Synthetic
400 SEQUENCE 692
Asp Val Val Net Thr Gln Sez Pzo Leu Ser Leu Pro Val Thr Leu Gly
I 5 10 15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
35 40 45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 60
Asp Arg Phe Sez Gly Ser Gly Sez Gly Thz Aep Phe Thr Leu Lye Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Net Gln Gly
85 90 95
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
210 SEQ ID NO 693
211a LENGTH 381
212a T'IPE DNA
213 ORGANISE Artificial Sequence
220 FEATURE:
223 OTHER INFORNATION Synthetic
400 SEQUENCE 693
caggttcagc tgqtgcagtc tggagctgag qtgaagaaqc ctgggqcctc agtgaaggtc
tcctgcaagg cttctggtta cacctttacc acct.atqgta tcagctgggt. gcgacaggcc
60
12 0
cctggacaag ggcttgagtg gatgggatgg atcagcggtt. acaatggtaa aacaaactat 180
gcacagaagc tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccgtgt attactgttc gagagatcgt 300
ttagtagtac cacctgccct ttattattac tactacgtta tggacgtctg ggggcaaggg 360
accacggtca ccgt.ctcctc a 381
210 SEQ ID NO 694
211 LENGTH 127
212 TYPE PRT
213 ORGANISE Artif
220 FEATURE.
223 OTHER INFORHATI
icial Sequence
ON Synthetic
400 6'EQUENCE 694
Gln Val Gln Leu Val Gln Ser Gly I\la Glu Val Lys Lys Pro Gly I\la
389
US 8,062,640 B2
-continued
390
10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30
Gly Ile Sez Tzp Val Azg Gln Ala Pro Gly Gln Gly Leu Glu Trp Het
35 40 45
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Tyr Ala Gln Lys Leu
50 55 60
Gln Gly Arg Val Thr Het Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Het Glu Leu Azg Ser Leu Arg Sez A p F.cp Thr Ala Val Tyz Tyz Cys
85 90 95
Sez Arg Asp Arg Leu Val Val Pro Pro Ala Leu Tyr Tyr Tyr Tyr Tyz
100 105 110
Val Het Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
12 0 125
210 SEQ ID NO 695
211 LENGTH 336
212 TYPE DNA
213 ORGPSHSH Artzfzczal Sequence
220 FEATURE.
223 OTHER INPORHATION Synthetzc
400 SEQUENCE 695
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc
at.ctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg
tttcagcaga ggccaggcca atctccaagg cgcctaattt ataaggtttc taaccgggac
12 0
180
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc 240
agcagggtcg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg 300
tacacttttg gccaggggac caagctggag atcaaa 336
210 SEQ ID NO 696
211s LENGTH 112
212s T'IPE PRT
213 ORGANISE Artzfzc
220 FEATURE:
223 OTHER INFORHATION
zal sequence
Synthetzc
400 SEQUENCE 696
Asp Val Val Net Thr Gln Ser Pro Leu Ser Leu Pzo Val Thr Leu Gly
I 5 10 15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Sez
20 25 30
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
35 40 45
Pro Irg Azg Leu Ile Tyr Lys Val Ser Asn Azg Asp Ser Gly Val Pzo
50 55 60
Asp Arg Phe Sez Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ' Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly
85 90 95
Thr Hzs Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
210 6'EQ ID NO 697
211 LENGTH 384
212 TYPE DNT
391
US 8,062,640 B2
-continued
392
213 ORGANISE Artificial Sequence
220 FEATURE
223 OTHER INFORH'TION Synthetic
400 SEQUENCE 697
caggtgcacc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt gaccactaca tgagctggat ccgccaggct 120
ccagggaagg ggctggagtg gatttcatac attagtaatg atggtggtac caaatactat 180
gtggactctg tggagggccg attcatcatt tccagggaca acgccaagaa ctcattgtat 240
ctacatatga acagcctcag agccgacgac acggccgtgt attactgtgc gagagatcag 300
ggatatattg gctacgactc gtatt.attac tattcctacg gtatggacgt ctggggccaa 360
gggaccacgg tcaccgtcgc crea 384
210 SEQ ID NO 98
211 LENGTH 128
212 TYPE PRT
213 ORGANISN Artificial Sequence
220 FEATURE:
223 OTHER INPORNATION Synthetic
400 SEQUENCE 698
Gln Val His Leu Val Glu Ser Gly Gly Gly Leu
5 10
Val Lvs Pro Gly Gly
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
20 25
Thr Phe Ser
30
Asp H18
Tyr Net ez Trp Ile Arg Gln Ala Pro Gly Ly Gly Leu Glu Trp Ile
35 40 45
Ser Tyr Ile Ser Asn Asp Gly Gly Thr Lys Tyr Tyr Val Asp Ser Val
50 55 0
Glu Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu His tfet Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gln Gly Tyr Ile Gly Tyr Asp Ser Tyr Tyr Tyr Tyr Ser
100 105 110
Tyr Gly Het Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ala Ser
115 12 0 125
210 SEQ ID NO 699
211 LENGTH 24
212 TYPE DNA
213 ORGANISE Artificial Sequence
220 FEATURE.
223 OTHER INFORNATION Synthetic
400 SEQUENCE 699
ggattcacct tcagtgacca ctac 24
210 SEQ ID NO 700
211 LENGTH 8
212 TYPE PRT
213 ORGANISN Artificial Sequence
220 FEATURE
223 OTHER INFORNATION Synthetic
400 SEQUENCE 700
Gly Phe Thr Phe Ser Asp His Tyr
I 5
393
US 8,062,640 B2
-continued
394
210 SEQ ID No 701
211 LENGTH 24
212 TYPE DNA
213 ORGAEISN Artrfrcral Sequence
220 FEATURE
s223 OTHER INFORHATION Synthetrc
400 SEQUENCE 701
attagtaatg atggtggtac casa
210 SEQ ID NO 702
211 LENGTH 8
212 TYPE PRT
213 ORGAEISH Artrfrcral Sequence
220 FEATURE:
223 OTHER INPORHATION Synthetrc
400. SEQUENCE 702
Ile Ser fsn fsp Gly Gly Thr Lys
I 5
210 6'EQ ID NO 703
211 LENGTH 63
212 TYPE DEA
213 ORGANISE Artrfrctal Sequence
220 PEATURR.
223 OTHER INFORSZATION Synthetrc
400 SEQUENCE 703
gcgagagatc agggatatat tggctacgac tcgtattatt actattccta cggtatggac
gtc 63
210 SEQ ID No 704
211 LENGTH 21
212 TYPE PRT
213 ORGANISE .Artrfrctal Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 704
Ala Arg Asp Gln Gly Tyr Ile Gly Tyr Asp Ser Tyr Tyr Tyr Tyr Ser
I 5 10 15
Tyr Gly Het Asp Val
20
210 SEQ ID NO 705
211 LENGTH 321
212 TYPE DNA
213 ORGANISE Artrfrcral Sequence
220 FEATURE.
223 OTHER INFOR6ZATION Synthetrc
400 SEQUENCE 05
aaaattgtgt tgacgcagtc tccaggcacc ctgcctttgt ttccagggga aagagccacc
ctctcctgta gggccagtca gagtgtr.aac aacaaar.tct tagccrggta ccagcagaaa
tctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca
12 0
180
gacaggttca gtggcagtgg gtctgggacc gacttcactc tcaccatcag cggactggag 240
cctgaagatt ttgaagtgta ttattgtcaa gtatatggta actcactcac tt.tcggcgga 300
gggaccaagg tggagatcaa g 321
210 6'EQ ID NO 706
211 LENGTH 107
212 TYPE PRT
395
US 8,062,640 B2
-continued
396
213 ORGANISE Artrfrc
220 FEATURE
223 OTHER INFORN'TION
ral Sequence
Synthetrc
400 SEQUENCE 06
Lya Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Pro Leu Phe Pro Gly
I 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Asn Lys
20 25 30
Phe Leu Ala Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ils Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phs Ser
50 55 60
Gly Ser Gly Ser Gly Thr Aap Phe Thr Leu Thr Ile Ser Gly Leu Glu
65 70 75 80
Pro Glu Isp Phe Glu Val Tyr Tyr Cys Gln Val Tyr Gly Asn Ser Leu
85 90 95
Thr Phe Gly Gly Gly Thr Ly- Val Glu Ile Ly-
100 105
210 SEQ ID NO 707
211 LENGTH 21
212 TYPE DNA
213 ORMEISN Artrfrc
220 FEATURE
223 OTHER INFORIBATION
ral Sequence
Synthetrc
s400 SEQUENCE 707
cagagtgtta acaacaaatt c 21
210 SEQ ID NO 708
211 LENGTH 7
212 TYPE PRT
213 ORGANISN Artrfrc
220 FEATURE.
223 OTI'ER INFORFZATION
ral Sequence
Synthetrc
400. SEQUENCE 708
Gln Ser Val Asn Asn Lys Phe
I 5
210 SEQ ID NO 709
211 LEIsGTH 9
212 TYPE DNA
213 ORGAIIISH Artrfrc
220 FEATURE;
223 OTHER INPORHATION
ral Sequence
Synthetrc
400 SEQUENCE 709
gg'tgca'tcc
210 SEQ ID NO 710
211 LEI'GTH 3
212 TYPE PRT
213 ORGANISE Artrfrc
220 PEATURE:
223 OTHER INFORNATION
ral sequence
Synthetrc
400 SEQUENCE 710
Gly Ala Ser
I
210 SEQ ID NO 711
211 LENGTH 24
397
US 8,062,640 B2
-continued
398
212 TYPE DNA
213 ORGANISE Artzfzczal Sequence
220 FEATURE
223 OTHER INFORNTTION Synthetzc
s400 SEQUENCE 711
caagt.at.atg gtaactcact cact
210 SEQ ID NO 712
211 LENGTH 8
212 TYPE PRT
213 ORGAEISN Artzfzczal Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetzc
400 SEQUENCE 712
Gln Val Tyr Gly Asn Ser Leu Thr
I 5
210 SEQ ID NO "13
211 LENGTH 384
212 TYPE DNA
213 ORGANISN Artzfzczal Sequence
220 FEATURE:
223 OTHER INFOPMATION Synthetzc
400 SEQUENCE 713
caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt gaccactaca tgagctggat ccgccaggct 120
ccagggaacg ggctggagtg gatttcatac attagtaatg atggtggtac caaat.actat 180
gtggactctg tggagggccg attcatcatt tccagggaca acgccaagaa ctcattgtat 240
ctacatatga acagcctcag agccgacgac acggccgtgt attactgtgc gagagatcag 300
ggatatattg gctacgactc gtattattac tattcctacg gtatggacgt ctggggccaa 360
gggaccacgg tcaccgtctc ctca 384
210s SEQ ID NO 714
211s LENGTH 128
212 TYPE PRT
213 ORGANISbl Artzfzc
220 FEATUPE
223 OTHER INPORN!TION
zal Sequence
Synthetzc
400 SEQUENCE 714
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Ly. Pzo Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Hz
20 25 30
Tyr Het Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Ser Tyr Ile Ser Asn Asp Gly Gly Thr Lys Tyr Tyr Val .Asp Ser Val
50 55 60
Glu Gly Arg Phe Ile Ile Ser Arg A p A n Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Hzs !4et ! sn Ser Leu !\rg !\Za !\sp Asp T!zr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gln Gly Tyr Ile Gly Tyr Asp Ser Tyr Tyr Tyr Tyr Ser
100 105 110
Tyr Gly Net Asp Val Tzp Gly Glr Gly Thr Thr Val Thr Val Sez Ser
115 12 0 125
399
US 8,062,640 B2
-continued
400
210 SEQ ID NO 715
211 LEI'GTH 321
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
a220 FEATURE;
a223 OTHER INPORfnATION. Synthetrc
400 SEQUENCE 715
gaaattgtgt tgacgcagtc tccaggcacc ctgcctttgt ttccagggga aagagccacc 60
ctctcctgta gggccagtca gagtgttaac aacaaattct tagcctggta ccagcagaaa 120
tctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca 180
gacaggttca gtggcagtgg gtctgggacc gacttcactc tcaccatcag cggactggag 240
cctgaagatt ttgaagtgta ttattgtcaa gtatatggta actcactcac t.ttcggcgga 300
gggaccaagg tggagatcaa a 321
210 SEQ ID NO "I
211 LENGTH 107
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE:
223 OTHER INFOPMATION Synthetrc
400 SEQUENCE 716
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Pro Leu Phe Pro Gly
5 10 15
Glu 'rg Ala Thr Leu Ser Cye Arg Ala Ser Gln Ser Val A n I; n Lya
20 25 30
Phe Leu Ala Trp Tyr Gln Gln 'a Ser Gly Gln Ala Pro Arg 'u 'u
35 40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Aap Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr .5 p Phe Thr Leu Thr Ile Ser Gly Leu Glu
65 70 75 80
Pro Glu Aep Phe Glu Val Tyr Tyr Cya Gln Val Tyr Gly Ann Ser Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lya Val Glu Ile Ly
100 105
210 SEQ ID NO 717
211 LENGTH 384
212 TYPE DEA
213 ORGPSIISN Artrfrcral Seque
220 PEATURR.
223 OTHER INFORFIATION Synthet
nce
10
400 SEQUENCE 717
caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt gaccactaca tgagctggat ccgccaggct 120
ccagggaaog ggctggagtg ggtttcatac attagtaatg atggtggtac caaatactac 180
gcagactctg tgaagggccg attcaccatc tccagggaca acgccaagaa ctcactgtat 240
ctgcaaatga acagcctgag agccgaggac acggccgtgt attactgtgc gagagatcag 300
ggatatattg gctacgactc gtattattac tattcctacg gtatggacgt ctgggggcaa 360
gggaccacgg tcaccgtctc ctca 384
210 SEQ ID NO 718
211 LENGTH 128
401
US 8,062,640 B2
-continued
402
212 TYPE PRT
213 ORGANISE Artzfzczal Sequence
220 FEATURE
223 OTHER INFORHPTION Synthetzc
c400 SEQUENCE 718
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
I 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Hzs
20 25 30
Tyr tset Ser Trp Ile Arg Gln Ala Pro Gly Ly Gly Leu Glu Tzp Val
35 40 45
Ser Tyr Ile Ser Asn Asp Gly Gly Thr Lys Tyr Tyr Ala A p Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Het Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala 'rg Asp Gln Gly Tyr Ile Gly Tyr Asp Ser Tyr Tyr Tyr Tyr Ser
100 105 110
Tyr Gly Het Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 719
211 LENGTH 321
212 TYPE DNA
c213 ORGANIS14 Artrfrc
220 FEATURE:
223 OTHER INFORHATION
ral Sequence
Synt.hetrc
400 SEQUENCE 719
gaaattgtat tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc
ctctcctgca gggccagtca gagtgttaac aacaaattct tagcctggta ccagcagaaa 12 0
cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca 180
gacaggttca gtggcagtgg gtctgggaca gacttcactc t.caccatcag cagactggag 240
cctgaagatt ttgcagtgta ttactgtcaa gtatatggta act.cactcac ttt.cggcgga 300
gggaccaaag tggagatcaa a 321
210 SEQ ID NO 720
211 LENGTH 107
212 TYPE PRT
213 ORG.SIISN AZtzfzC
220 PEATURR.
223 OTHER INFORSIATION
zal Sequence
Synthetrc
400 SEQUENCE 720
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
I 5 10 15
Glu Arg Ala Thr Leu Ser Cya Arg Ala Ser Gln Ser Val Asn Asn Lya
20 25 30
Phe Leu Ala Trp Tyr Gln Gln Ly- Pro Gly Gln Ala Pra Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser 9er Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly 6'er Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cy Gln Val Tyz Gly .4 n Ser Leu
85 90 95
403
US 8,062,640 B2
-continued
404
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
r210 SEQ ID NO 721
r211 LENGTH 378
212 TYPE Dl'IA
213 ORGANISE Artrfrcral Sequence
220 FEATURE
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 721
caaattctgc tggtgcaatc tggacctgag gtgaaggagc ctggggcctc agtgaaggtc 40
tcctgcaagg cttctggtta cacct.ttacc aactacgcta tcagctgggt gcgacaggtc 120
cctggacaag ggcttgagtg gatgggatgg gtcagcgctt. acaatggtca cacaaactat 180
gcacatgaag tccagggcag agtcaccatg accacagaca catccacgac cacagcctac 240
atggagctqa ggagcctgag atctgacgac acggccatgt attactgtgc gagagggggt
gtaqtcgtgc cagttgctcc ccacttctac aacggtatgg acgtctgqgg ccaagggacc
300
340
acggtcaccq tctcctca 378
210 SEQ ID NO 722
211 LENGTH 128
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INPORKATION Synthetrc
400 SEQUENCE 722
Gln Ile Leu Leu Val Gln Ser Gly Pro Glu Val Ly Glu Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Val Pro Gly Gln Gly Leu Glu Trp Net
35 40 45
Gly Trp Val Ser Ala Tyr Asn Gly Hre Thr Asn Tyr Ala His Glu Val
50 55 0
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Ala Tyr
70 75 80
Net Glu Leu Aug Ser Leu Arg Ser Asp Asp Thr Ala Net Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Val Val Val Pro Val Ala Pro Hr Phe Tyr .4 n Gly
100 105 110
Het Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 723
211 LENGTH 24
212 TYPE DNA
213 ORGANNSN Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 723
ggttacacct ttaccaacta cgct
210 SEQ ID NO 724
211 LENGTH 8
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE
405
US 8,062,640 B2
-continued
406
223 OTHER INPORHATION Synthetrc
400 SEQUENCE 724
Gly Tyr Thr Phe Thr Asn Tyr Ala
1 5
210 SEQ ID NO 725
211 LENGTH 24
212 TYPE DNA
213 ORGANISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFOPNP.TION Synthetrc
400 SEQUENCE 725
gtcagcgctt acaatggtca ceca 24
210 SEQ ID NO 726
211 LENGTH 8
212 TYPE PRT
213 ORGANISN Artrfrcral Sequence
220 FEATURE:
223 OTHER INPORNATION Synthetrc
400 SEQUENCE 726
Val Ser Ala Tyr Asn Gly Hrs Thr
I 5
210 SEQ ID NO 27
211 LENGTH 57
s212 TYPE DNA
213 ORGANHSN Artrfrcral Sequence
220 FEATURE:
223 OTHER INPORNATION: Synthet rc
400 SEQUENCE 727
gcgagagggg gtgtagtcgt gccagttgct ccccacttct acaacggtat ggacgtc 57
210 SEQ ID NO 728
211 LENGTH 19
212s TYPE PRT
213s ORGM4ISN ArtrfrCral SequenCe
220 FEATURE:
223 OTHER INFORNATION Synthetrc
400 SEQUENCE 28
Ala Arg Gly Gly Val Val Val Pro Val Ala Pro Hrs Phe Tyr Asn Gly
1 5 10 15
Net A p Val
210 SEQ ID NO 729
211 LENGTH 336
212 TYPE DNA
213 ORGAEISN Artrfrcral Sequence
220 FEATURE
223 OTHER INFOPNP.TION Synthetrc
400 SEQUENCE 729
gatattgtaa tgactcagtt. tccactctcc ctgcccgtca cccctggaga gccggcctcc
atctcctgca ggtctagtca gagcctcctg catattaatg aatacaacta tttggattgg 12 0
tacctaaaga agccagggca gtctccacag ctcctgatct atttgggttt taatcgggcc 180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240
agcagagtgg aggctgagga tgttggggtc tattactgca tgcaagctct tcaaactccg 300
tggacgttcg gccaagggac caaggtggaa atcaaa 336
407
US 8,062,640 B2
-continued
408
210 SEQ ID NO 730
211 LENGTH 112
212 TYPE PRT
c213 ORGANIISN Aztificial Sequence
c220 FEATURE:
223 OTHER INFORNATION Synthetic
400 SEQUENCE 730
Asp Ile Val fret Thr Gln Phe Pro Leu Ser Leu Pro Val Thr Pro Gly
5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ile
20 25 30
3 n Glu Tyr Asn Tyr Leu Asp Trp Tyr Leu Ly Ly- Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro
50 55 50
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
55 70 75 80
Ser Arg Val Glu Ala Glu .Aap Val Gly Val Tyz Tyr Cys Net Gln Ala
85 90 95
Leu Gln Thr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110
210 SEQ ID NO 31
211 LENGTH 33
c212 TYPE DNA
213 ORGANHSN Artificial Sequence
220 FEATURE:
223 OTHER INPORNATION: Synthetic
400 SEQUENCE 731
cagagcctcc tgcatattaa tgaatacaac tat 33
210 SEQ ID NO 732
211 LENGTH 11
212s TYPE PRT
213a ORGMIISN ArtifiCial SequenCe
220 FEATURE:
223 OTHER INFORNATION Synthetic
400 SEQUENCE 32
Gln Ser Leu Leu His Ile Asn Glu Tyr Asn Tyr
I 5 10
210 SEQ ID NO 733
211 LENGTH 9
212 TYPE DNA
213 ORGANISN Artificial Sequence
220 FEATURE
223 OTHER INPORKATION Synthetic
400 SEQUENCE 733
ttgggtttt
210 SEQ ID NO 734
211 LENGTH 3
212 TYPE PRT
213 ORGANISE Artificial Sequence
220 FEATURE.
223 OTHER INFOPHATION Synthetic
400 5'EQUENCE 734
Leu Gly Phe
409
US 8,062,640 B2
-continued
410
210 SEQ ID NO 735
211 LENGTH 27
r212 TYPE DNA
r213 ORGANIS14 Aztrfrcral Sequence
220 FEATURE:
223 OTHER INFORHATION Synthetrc
400 SEQUENCE 735
atgcaagctc ttcaaactcc gtggacg
210 SEQ ID NO 736
211 LENGTH 9
212 TYPE PRT
213 ORGWIISN Artrfrcral Sequence
220. FEATURE.
223 OTHER INFORN'TION Synthetzc
400 SEQUENCE 73
Net Gln Ala Leu Gln Thr Pro Tzp Thr
I 5
210 SEQ ID NO 737
211 LENGTH 378
212 TYPE DNA
213 ORG62IISN Artzfzczal Sequence
220 FEATURE
223 OTHER INFORFLATION Synthetzc
r400 SEQUENCE 737
caggt.tcagc tggtgcagtc t.ggaccrgag gtgaaggagc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc aactacgcta tcagctgggt gcgacaggtc 12 0
cctggacaag ggcttgagtg gatgggatgg gtcagcgctt acaatggtca cacaaactat 180
gcacatgaag tccagggcag agtcaccatg accacagaca catccacgac cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccatgt attactgtgc gagagggggt 300
gtagtcgtgc cagttgctcc ccact.tctac aacggtatgg acgtctgggg ccaagggacc 360
acggtcaccg tctcctca 3,8
210 SEQ ID NO 38
211 LENGTH 126
212 TYPE PRT
213 ORGANISN Artzfzc
220 FEATURE:
223 OTHER INFORNATION
zal Sequence
Synthetzc
400 SEQUENCE 738
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Glu Pro Gly Ala
5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Ala Ile ser Trp val Arg Gln val pro Gly Gln Gly Leu Glu Trp Net
35 40 45
Gly Trp Val Ser Ala Tyr Asn Gly Hzs Thr Asn Tyr Ala Hzs Glu Val
50 55 60
Gln Gly frg Val Thr Net Thr Thr Asp Thr Ser Thr Thr Thr Ala Tyr
65 70 75 80
Net Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Net Tyr Tyz Cya
85 90 95
Ala Arg Gly Gly Val Val Val Pro Val Ala Pro Hzs Phe Tyr Asn Gly
411
US 8,062,640 B2
-continued
412
100 105 110
Het Asp Val Tzp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
c210 SEQ ID NO 739
211 LEI'GTH 336
212 TYPE DNA
213 ORGANISE Artzfrczal Sequence
220 FEATURE.
223 OTHER INFORBIATION Synthetzc
400 SEQUENCE 739
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc
atctcctgca ggtcr.agtca gagcctcctg catattaatg aat.acaact.a r.ttggattgg
tacctaaaca agccagggca gtctccacag ctcctgatct atttgggttt taatcgggcc
12 0
180
tccggggtcc ctgacaggtt cagtggcagt ggatcagcca cagattttac actgaaaatc 240
agcagagtgg aggctgagga tgttggggtc tattactgca tgcaagctct tcaaactccg 300
tggacgttcg gccaagggac caaggtggaa atcaaa 336
210 SEQ ID NO 740
211 LENGTH 112
212 TYPE PRT
213 ORnaIIISH Aztzfzczal Sequence
220 FEATURE
223 OTHER INFORFIATION Synthetzc
c400 SEQUENCE 740
Asp Ile Val Net Thr Gln Ser Pro Leu Ser Leu Pzo Val Thr Pro Gly
I 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ile
20 25 30
Asn Glu Tyr Asn Tyr Leu Asp Tzp Tyr Leu Ly Ly Pro Gly Gln Sez
35 40 45
Pro Gln Leu Leu Ile Tyz Leu Gly Phe Asn Azg Ala Ser Gly Val Pzo
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu * ye Ile
65 70 ". 5 90
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Het Gln Ala
85 90 95
Leu Gln Thr Pzo Tzp Thr Phe Gly Gln Gly Thz Lys Val Glu Ile Ly
100 105 110
210 SEQ ID NO 741
211 LENGTH 378
212 TYPE DNA
213 ORGANISN Aztzfzczal Seque
220 FEATURE
223 OTHER INFORHATION Synthet
nce
10
400 SEQUENCE 743.
caggttcagc r.ggtgcagtc tggagct.gag gtgaagaagc ctggggcctc agtgaaggtc
tcctgcaacg cttctggtta cacctttacc aactacgcta tcagctgggt gcgacaggcc 12 0
cctggacaag ggcttgagtg gat.gggatgg gtcagcgctt acaatggtca cacaaactat 180
gcacagaagc tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240
atgqagctga qgagcctgag atctgacgac acqgccqtgt attactgtgc gagagggggt 300
gtagtcgtgc cagttgctcc ccacttctac aacggtatgg acgtctgggg gcaagggacc 360
413
US 8,062,640 B2
-continued
414
acggtcaccg tctcctca 378
210 SEQ ID NO 742
211 LENGTH 126
a212 TYPE PRT
a213 ORGANIS14 Aztzfzczal Sequence
220 FEATURE:
223 OTHER INFORMATION Synthetzc
400 SEQUENCE 742
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
5 10
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Net
35 40 45
Gly Trp Val Ser Ala Tyr Asn Gly Hzs Thr fsn Tyr Ala Gln Lys Leu
50 55 60
Gln Gly Azg Val Thr Met Thz Thr Asp Thr Set Thr Ser Thr Ala Tyr
65 70 75 80
Net Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Val Val Val Pro Val Ala Pro Hzs Phe Tyr Asn Gly
100 105 110
Net Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 12 0 125
210 SEQ ID NO 743
211 LENGTH 336
212 TYPE DNA
213 ORGANISN Artzfzczal Sequence
220 FEATURE
223 OTHER INFORMATION Synthetzc
400 SEQUENCE 743
gatattgtga tgactcagtc t«cactctcc ctgcccgtca cccctggaga gccggcctcc
atctcctgca ggtctagtca gagcctcctg catattaatg aatacaacta ttt.ggat.tgg 12 0
tacctgcaoa agccagggca gtctccacag ctcctgatct. atttgggttc t.aatcgggcc 180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240
agcagagtgg aggctgagga tgttggggtt tattactcca tgcaagctct tcaaactccg 300
tggacgttcg gccaagggac caaggtggaa atcaaa 336
210 SEQ ID NO 744
211 LENGTH 112
212 TYPE PRT
213 ORGAEISN Artzfzc
220 FEATURE
223 OTHER INFORMATION
zal Sequence
Synthetzc
400 SEQUENCE 744
A p Ile Val Met Thr Gln Ser Pro Leu
1 5
Ser Leu Pro Val Thr
10
Pro Gly
15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Hzs Ile
20 25 30
Asn Glu Tyr Asn Tyr Leu .Asp Tzp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn prg Ala Ser Gly Val pzo
55 6050
415
US 8,062,640 B2
-continued
416
8 p Arg Phe Ser Gly Ser Gly Ser Gly Thr Aep Phe Thr Leu Lye Ile
65 70 75 80
Ser Prg Val Glu Ala Glu Aep Val Gly Val Tyr Tyr Cya Met Gln Ala
85 80 95
Leu Gln Thr Pro Trp Thr Phe Gly Gln Gly Thr Ly Val Glu Ile Lye
100 105 110
210 SEQ ID NO 745
211 LENGTH 8
212 TYPE PRT
213 ORGAEISN Artrfrcral Sequence
220 FEATURE.
223 OTHER INFORHATION Synthetrc
220 FEATURE:
221 NAKE/KEY VARIANT
222 LOCATION (I! (8)
223. OTHER INFORHATION Xaa = Any amtno actd
400 SEQUENCE 745
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
I 5
210 SEQ ID EO 746
211 LENGTH 8
212 TYPE PRT
213 ORGANISb) Artrfrcral Sequence
220 FEATURE
223 OTHER INFORHPTION Synthetrc
220 FEATURE
221 NAHE/KEY VARIANT
e222 LOC..TION (ll ... (8)
223 OTHER INFORNATION Xaa — Any ammo acrd
400 SEQUENCE 746
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
I 5
210 SEQ ID NO 747
211 LENGTH 20
212 TYPE PRT
213. ORGWIISN Artrfrcral Sequence
220. FEATURE.
223 OTHER INFORI)ATION Synthetrc
220 FEATURE:
221 NAHE/KEY VARIANT
222 LOCATION (ll (20)
223 OTHER INFORH'TION Xaa = Any ammo actd
400 SEQUENCE 747
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
I 5 10 15
Xaa Xaa Xaa Xaa
20
210 SEQ ID NO 748
211 LENGTH 12
212 TYPE PRT
213 ORGANISE Artrfrcral Sequence
220 FEATURE:
223 OTHER INPORHATION Synthetrc
220 FEATURE
221 NA(4E/KEY VARIANT
222 LOCATION (I) (12)
223 OTHER INPORNATION Xaa = Any amtno actd
400 SEQUENCE 748
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
10
417
US 8,062,640 B2
-continued
210 SEQ ID NO 749
211 LEIsGTH 3
212 TYPE PRT
213 ORGANISN Artzfzczal Sequence
s220 FEATURE;
s223 OT('ER INPOR(44TION. Synthetzc
220 FEATURE:
221 NAHE/KEY VARIANT
222 LOCATION (Il (3l
223 OTHER INFORHATION Xaa = Any amtno aczd
400 SEQUENCE 749
Xaa Xaa Xaa
I
210 SEQ ID NO 750
211s LENGTH 9
212 TYPE PRT
213 ORGANISE Arttftctal Sequence
220 FEATUPE
223 OTHER INFORNITION Synthetzc
220 FEATURE:
221 NAHE/KEY VARIANT
222 LOCATION (I). (9(
223 OTHER IEFORHATION Xaa = Any amtno acid
400 SEQUENCE 750
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
I 5
s210 SEQ ID NO 751
211 LEI'GTH 330
212 TYPE PRT
213 ORGAI(ISH Artrf tc
220 FEATURE.
223 OTHER INFORHATION
tal Sequence
Synthetzc
400 SEQUENCE 751
Ala Ser Thr Ly Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
I 5 10 15
Ser Thz Ser Gly Gly Thr Ala Ala Leu Gly 0/0 Leu Val Lys A p Tyr
20 25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45
Gly Val Hzs Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Set Leu Gly Thr Gln Thr
65 70 75 80
Tyr Ile Cys Asn Val Asn Hts Ly Pro Ser Asn Thr Lys Val Asp Ly
85 90 95
Lys Val Glu Pro Lys Ser Cys Asp Lys Thr Hzs Thr Cys Pro Pro Cys
100 105 110
Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 12 0 125
Lys Pro Lys Asp Thr Leu Net Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140
Val Val Val fsp Val Ser Hts Glu !\sp Pro Glu Val Lys Phe !\sn Trp
145 150 I 5 160
Tyr Val Asp Gly Val Glu Val Hts Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175
Glu Gln Tyr Asn Ser Thr Tyz Azg Val Val Ser Val Leu Thr Val Leu
180 185 190
419
US 8,062,640 B2
-continued
420
His Gln Asp Tzp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg I; p Glu
225 230 235 240
Leu Thr Lys Asn Gln Val Ser Leu Thr
245
Cys Leu Val Lys
250
Gly Phe Tyr
255
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu A n
260 265 270
A n Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Sez Phe Phe
275 280 285
Leu Tyz Ser Ly Leu Thz Val A p Ly" Sez Arg Trp Gln Gln Gly Asn
290 295 300
Val Phe Ser Cys Ser Val Net Hrs Glu Ala Leu Hrs Asn Hts Tyr Thr
305 310 315 320
Gln Lys Sez Leu Ser Leu Sez Pzo Gly Lys
325 330
210 SEQ ID NO 752
211 LENGTH 327
212 TYPE PRT
213 ORGaZZISN Aztrftc
220 FEATURE
223 OTHER INFORFIATION
tal Sequence
Synthetrc
s400 SEQUENCE 752
Ala Ser Thr Ly Gly Pro Ser Val Phe Pro Leu Ala Pro Cy. Ser Arg
I 5 10 15
Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30
Phe Pro Glu Pzo Val Thz Val Sez Trp F.cn Ser Gly Ala Leu Thz Sez
35 40 45
Gly Val Hr ~ Thr Phe Pzo Ala Val Leu Gln Ser Ser Gly Leu Tyz Sez
50 55 60
Leu Sez Ser Val Val Thr Val Pro Ser Sez Ser Leu Gly Tlar * ys Thr
65 70 ". 5 80
Tyr Thr Cys Asn Val Asp Hts Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
Arg Val Glu Ser Lys Tyr Gly Pro Pro Cy. Pzo Ser Cys Pro Ala Pro
100 105 110
Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pzo Pro Lys Pro Lys
115 12 0 125
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
130 135 140
A p Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp
145 150 155 160
Gly Val Glu Val Ht Asn Ala ' Tlr Ly Pro Azg Glu Glu Gln Phe
165 170 1. 7 5
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu Hts Gln Asp
180 185 190
Trp Leu Zsn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu
195 200 205
Pro Sez Sez Ile Glu Ly- Thz Ile Sez Lys Ala Ly- Gly Gln Pro Azg
210 215 220
Glu Pro Gln Val Tyr Thr Leu Pzo Pro Ser Gln Glu Glu Net Thr Lys
421
US 8,062,640 B2
-continued
422
225 230 235 240
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
245 250 255
Ile Ala Val Glu Trp Glu Ser .'. n Gly Gln Pro Glu Asn A n Tyr Lys
260 265 270
Thr Thr Pro Pro Val Leu I\sp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
275 280 285
Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser
290 295 300
Cy Ser Val Met His Glu Ala Leu Hi F.cn Hi Tyr Thr Gln Lys Ser
305 310 315 320
Leu Ser Leu Ser Leu Gly Ly-
325
210 SEQ ID NO 753
211 LENGTH 327
212 TYPE PRT
213 ORGANISN Artific
220 FEATURE:
223 OTHER INFORMATION
ial Sequence
Synthetic
400 SEQUENCE 753
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
5 10
Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu 'Ial Lys Asp Tyr
20 25 30
Phe Pro Glu Pzo Val Thr Val Sez Trp Asn Ser Gly Ala Leu Thr Sez
35 40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 0
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr
65 70 75 80
Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val 4 p Lys
85 90 95
Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro
100 105 110
Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
115 12 0 125
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
130 135 140
.'. p Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val .'. p
145 150 155 I 0
Gly Val Glu Val His Asn I\la Lys Thr Lys Pro Arg Glu Glu Gln Phe
165 170 175
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
180 185 190
Trp Leu Asn Gly Ly. Glu Tyr Lys Cys Ly- Val Ser Asn Ly. Gly Leu
195 200 205
Pro Ser Ser Ile Glu Ly- Thr Ile Ser Ly Ala Ly Gly Gln Pro Arg
210 215 220
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys
225 230 235 240
Asn Gln Val 6'er Leu Thr Cys Leu Val Ly Gly Phe Tyr Pro Ser Asp
245 250 255
Ile Ala Val Glu Trp Glu Ser A n Gly Gln Pro Glu Asn .4 n Tyr Lys
260 2 5 270
423
US 8,062,640 B2
-continued
424
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
275 280 285
Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser
290 295 300
Cys Ser Val Net Hrs Glu Ala Leu Hrs Asn HI Tyr Thr Gln Lys Ser
305 310 315 320
Leu Ser Leu Ser Leu Gly Lys
325
210 SEQ ID NU 756
211 LEIIGTH 2076
212 TTPE ONA
213 ORGANISE Homo saprens
600. SEQUENCE 756
atgggcaccg tcagctccag gcggtcctgg tggccgctgc cactgctgct gctgctgctg 60
ctgctcctgg gtcccgcggg cgcccgtgcg caggaggacg aggacggcga ctacgaggag 120
ctggtgctag ccttgcgttc cgaggaggac ggcctggccg aagcacccga gcacggaacc 180
acagccacct tccaccgctg cgccaaggat ccgtggaggt tgcctggcac ctacgtggtg 260
gtgctgaagg aggagaccca cctct.cgcag tcagagcgca ctgcccgccg c.ctgc.aggcc 300
caggctgccc gccggggata cctcaccaag atcctgcatg tcttccatgg ccttcttcct 360
ggcttcctgg tgaagatgag tggcgacctg ctggagctgg ccttgaagtt gccccatgtc 620
gactacatcg aggaggactc ctctgtcttt gcccagagca tcccgtggaa cctggagcgg sso
attacccctc cacggtaccg ggcggatgaa taccagcccc ccgacggagg cagcctggtg 56O
gaggtgtatc tcctagacac cagcatacag agtgaccacc gggaaatcga gggcagggtc 600
atggtcaccg acttcgagaa tgtgcccgag gaggacggga cccgcttcca cagacaggcc 60
agcaagtgtg acagtcatgg cacccacctg gcaggggtgg tcagcggccg ggatgccggc 720
gtggccaagg gtgccagcat gcgcagcctg cgcgtgctca actgccaagg gaagggcacg 780
gttagcggca ccctcatagg cctggagttt attcggaaaa gccagctggt ccagcctgtg 860
gggccactgg tggtgctgct gcccctggcg ggtgggtaca gccgcgtcct caacgccgcc 9OO
tgccagcgcc tggcgagggc tggggtcgtg ctggtcaccg ctgccggcaa cttccgggac 960
gatgcctgcc tctactcccc agcctcagct cccgaggtca tcacagttgg ggccaccaat 1020
gcccaqgacc agccggtgac cctggggact ttggqgacca actttqgccg ctgtgtggac 1080
ctctttgccc caggqgagga catcattggt gcctccagcg actgcagcac ctgctttgtg 1160
tcacagagtg ggacatcaca ggctgctgcc cacgtggctg gcattgcagc catgatgctg 1200
tctgccgagc cggagctcac cctggccgag ttgaggcaga gactgatcca cttctctgcc 1260
aaagatgtca tcaatgaggc ctggttccct gaggaccagc gggtactgac ccccaacctg 1320
gtggccgccc tgccccccag cacccatggg gcaggttggc agctgttttg caggactgtg 1380
tggtcagcac actcggggcc t.acacggatg gccacagcca t.cgcccgctg cgccccagat 1660
gaggagctqc tgagctgctc cagtttctcc aggagtggga agcggcgggg cgagcgcatg 1500
gaggcccaag ggggcaagct ggtctgccgg gcccacaacg cttttggggg tgagggtgtc 1560
tacgccattg ccaggtgctg cctgctaccc caggccaact gcagcgtcca cacagctcca 1 20
ccagctgagg ccagcatggg gacccgtgtc cactgccacc aacagggcca cgtcctcaca 1680
ggctgcagct cccactggga ggtggaggac cttggcaccc acaagccgcc tgtgctgagg 1760
ccacgaggtc agcccaacca gtgcgtgggc cacagggagg ccagcatcca cgcttcctgc 1800
425
US 8,062,640 B2
-continued
426
tgccatgccc caggtctgga atgcaaagtc aaggagcatg gaatcccggc ccctcaggag 1860
caggtgaccg tggcctgcga ggagggctgg accctgactg gctgcagtgc cctccctggg 1920
acctcccacg tcctgggggc ctacgccgta gacaacacgt gtgtagtcag gagccgggac 1980
gtcagcacta caggcagcac cagcgaagag gccgtgacag ccgttgccat ctgctgccgg 2040
agccggcacc tggcgcaggc ctcccaggag ctccag 2076
755
2
210 SEQ ID NO
211 LENGTH 69
212 TYPE PRT
213 ORGANISN Homo apzens
400 SEQUENCE 755
Net Gly Thr Val Ser Ser Arg Arg Sez Trp Trp Pro Leu Pro Leu Leu
I 5 10 15
Leu Leu Leu Leu Leu Leu Leu Gly Pro Ala Gly Ala Arg Ala Gln Glu
20 25 30
A p Glu A p Gly A p Tyz Glu Glu Leu Val Leu Ala Leu Arg Ser Glu
35 40 45
Glu Asp Gly Leu Ala Glu Ala Pro Glu Hzs Gly Thr Thr Ala Tlcr Phe
50 55 0
Hzs Arg Cys Ala Lys Asp Pzo Trp Arg Leu Pzo Gly Thr Tyr Val Val
70 75 80
Val Leu Lys Glu Glu Thr Hzs Leu Ser Gln Ser Glu Azg Thr Ala Arg
85 90 95
Arg Leu Gln Ala Gln Ala Ala Arg Arg Gly Tyz Leu Thr Ly. Ile Leu
100 105 110
Hzs Val Phe Hzs Gly Leu Leu Pro Gly Phe Leu Val Lys Net Ser Gly
115 12 0 125
Asp Leu Leu Glu Leu Ala Leu Lys Leu Pro Hz Val Asp Tyz Ile Glu
13 0 135 140
Glu Asp Ser 5'er Val Phe Ala Gln Sez Ile Pzo Tzp Asn Leu Glu Azg
145 150 155 160
Ile Thz Pro Pro Arg Tyr Arg Ala Asp Glu Tyr Gln Pro Pro Asp Gly
165 170 175
Gly Ser Leu Val Glu yal Tyr Leu Leu Asp Thr Ser Zle Gln Ser Asp
180 185 190
H18 Arg Glu Ile Glu Gly Azg Val Net Val Thz Asp Phe Glu .4 n Val
195 200 205
Pro Glu Glu Asp Gly Thr Arg Phe Hzs Arg Gln Ala Ser Lys Cys Asp
210 215 220
Ser Hzs Gly Thr Hzs Leu Ala Gly Val Val Ser Gly Arg Asp Ala Gly
225 230 235 240
Val lla Lys Gly Ala Ser Net Azg Ser Leu Azg Val Leu Asn Cys Gln
245 250 255
Gly Ly Gly Thr Val Ser Gly Thr Leu Ile Gly Leu Glu Phe Ile .'. g
260 265 270
Lys Ser Gln Leu Val Gln Pro Val Gly Pro Leu Val Val Leu Leu Pro
275 280 285
Leu Ala Gly Gly Tyr Ser Arg Val Leu Asn Ila Ala Cys Gln Arg Leu
290 295 300
Ala Arg Ala Gly Val Val Leu Val Thz Ala Ala Gly Asn Phe Arg Asp
305 310 315 320
!\sp Ala Cys Leu Tyr Ser Pro !\Za Ser Ala Pro Glu Val Ile Thr Val
427
US 8,062,640 B2
-continued
428
325 330 335
Gly Ala Thr Asn Ala Gln Asp Gln Pro Val Thr Leu Gly Thr Leu Gly
340 345 350
Thr A n Phe Gly Arg Cy- Val .'. p Leu Phe Ala Pro Gly Glu .'. p Ile
355 360 365
Ile Gly Ala Ser Ser Asp Cys Ser Thr Cys Phe Val Ser Gln Ser Gly
370 375 380
Thr Ser Gln Ila Ala Ala Hzs Val Ala Gly Ile Ala Ala Met Net Leu
385 390 395 400
Ser Ala Glu Pro Glu Leu Thr Leu Ala Glu Leu Arg Gln Arg Leu Ile
405 410 415
Hi- Phe Ser Ala Ly. Asp Val Ile Asn Glu Ala Trp Phe Pto Glu Asp
420 425 430
Gln Arg Val Leu Thr Pro Asn Leu Val Ala Ala Leu Pro Pro Ser Thr
435 440 445
Hr.s Gly Ala Gly Trp Gln Leu Phe Cys Arg Thr Val Trp Ser Ala Hzs
450 455 460
Ser Gly Pzo Thr Arg Met Ala Thr Ala Ile Ala Arg Cys Ala Pro 4 p
4 5 470 475 480
Glu Glu Leu Leu Ser Cys Ser Ser Phe Ser Arg Ser Gly Lys Arg Arg
485 490 495
Gly Glu Arg Met Glu Ala Gln Gly Gly Lys Leu Val Cys Arg Ala Hzs
500 505 510
4 n Ala Phe Gly Gly Glu Gly Val Tyr Ala Ile Ala Azg Cy. Cys Leu
515 520 525
Leu Pro Gln Ala Asn Cy Ser Val Hz Thr Ala Pzo Pzo Ala Glu Ala
53 0 535 540
Ser Met Gly Thr Arg Val Hzs Cys Hzs Gln Gln Gly Hzs Val Leu Thr
545 550 555 560
Gly Cys Ser Ser Hzs Trp Glu Val Glu Asp Leu Gly Thr Hzs Lys Pro
565 570 575
Pro Val Leu Arg Pro Arg Gly Gln Pro Asn Gln Cys Val Gly His Arg
580 585 590
Glu Ala Ser Ile Hzs Ala Ser Cys Cys Hz" Ala Pro Gly Leu Glu Cys
595 600 605
Lys Val Lys Glu Hzs Gly Ile Pro Ala Pro Gln Glu Gln Val Thr Val
610 620
Ala Cy Glu Glu Gly Trp Thr Leu Thr Gly Cy Ser Ala Leu Pzo Gly
625 630 635 640
Thr Ser Hzs Val Leu Gly Ala Tyr Ala Val Asp Asn Thr Cys Val Val
645 50 655
Arg Ser Arg Asp 'Ial Ser Thr Thr Gly Ser Thr Ser Glu Glu Ala Val
660 665 670
Thr Ala Val Ala Zle Cys Cys Arg Ser Arg Hzs Leu Ala Gln Ala Ser
675 680 685
Gln Glu Leu Gln
690
756
2
210 SEQ ID NO
211 LENGTH 69
212 TYPE PRT
213 ORGANIS'N Macaca mulata
400 6'EQUENCE 756
Net Gly Thr Val Ser Ser !\rg !\rg Ser Trp Trp Pro Leu Pro Leu Pro
429
US 8,062,640 B2
-continued
430
10 15
Leu Leu Leu Leu Leu Leu Leu Gly
20
Pro Ala Gly Ala Arg Ala Gln Glu
25 30
.'. p Glu Asp Gly Asp Tyr Glu Glu Leu Val Leu Ala Leu Arg Ser Glu
35 40 45
Glu Asp Gly Leu Ala Asp Ala Pro Glu Hzs Gly Ala Thr Ala Thr Phe
50 55 60
Hts Arg Cys Zla Lys Asp Pro Trp Arg Leu Pro Gly Thr Tyr Val Val
65 70 75 80
Val Leu Ly Glu Glu Thr Hzs Arg Ser Gln Ser Glu Arg Thr Ala Arg
85 90 95
Arg Leu Gln Ala Gln Ala Ala Arg Arg Gly Tyr Leu Thr Ly. Ile Leu
100 105 110
Hts Val Phe Hzs Hzs Leu Leu Pro Gly Phe Leu Val Lys Met Ser Gly
12 0 125
Asp Leu Leu Glu Leu Ala Leu Lys Leu Pro Hzs Val Asp Tyr Ile Glu
13 0 135 140
Glu A p er Ser Val Phe Ala Gln Ser Ile Pro Trp A n Leu Glu Arg
145 150 155 160
Ile Thr Pro Ala Arg Tyr Arg Ala Asp Glu Tyr Gln Pro Pro Lys Gly
165 170 175
Gly Ser Leu Val Glu Val Tyr Leu Leu Asp Thr Ser Ile Gln Ser Asp
180 185 190
Mia 'rg Glu Ile Glu Gly Azg Val tact Val Thr Asp Phe Glu Ser Val
195 200 205
Pro Glu Glu Asp Gly Thr Szg Phe Hr Arg Gln Ala Ser Ly Cys 5 p
210 215 220
Ser Hzs Gly Thr Hzs Leu Ala Gly Val Val Ser Gly Arg Asp Ala Gly
225 230 235 240
Val Ala Lys Gly Ala Gly Leu Arg Ser Leu Arg Val Leu A n Cys Gln
245 250 255
Gly Lya Gly Thr Val Ser Gly Thr Leu Ile Gly Leu Glu Phe Ile Arg
260 265 270
Lys Ser Gln Leu Val Gln Pro Val Gly Pro Leu Val Val Leu Leu Pro
275 280 285
Leu Ala Gly Gly Tyr Ser Arg Val Phe Asn Ala Ala Cys Gln Arg Leu
290 295 300
Ala Arg Ala Gly Val Val Leu Val Thr Ala Ala Gly Asn Phe Arg .4 p
305 310 315 320
Asp Ala Cys Leu Tyr Ser Pro Ala Ser Ala Pro Glu Val Ile Thr Val
325 330 335
Gly Ala Thr Asn Ala Gln Asp Gln Pro Val Thr Leu Gly Thr Leu Gly
340 345 350
Thr Asn Phe Gly Arg 0'ys Val Asp Leu Phe Ala Pro Gly Glu Asp Ile
355 360 365
Ile Gly Ala Ser Ser Asp Cys Ser Thr Cys Phe Val Ser Arg Ser Gly
370 375 380
Thr Ser Gln Zla .Ala Ala Hts Val Ala Gly Ile Ala Ala Met Met Leu
385 3 90 395 400
Ser Ala Glu Pro Glu Leu Thr Leu Ala Glu Leu Arg Gln Arg Leu Ile
405 410 415
Hz- Phe Ser Ala Ly- A p Val Ile A n Glu Ala Tzp Phe Pro Glu .. p
420 425 430
431
US 8,062,640 B2
-continued
432
Gln Arg Val Leu Thr Pro A"n Leu Val ala Ala Leu Pro Pro Ser Thr
435 440 445
Hrs Arg Ala Gly Trp Gln Leu Phe Cys Arg Thr Val Trp Ser Ala Hzs
450 455 460
ser Gly pro Thr Arg sist Ala Thr ala val Ala Arg cy Ala Gln A p
465 4 70 475 480
Glu Glu Leu Leu Ser Cys Ser Ser Phe Ser Arg Ser Gly Lys Arg Arg
485 490 495
Gly Glu Arg Ile Glu Ala Gln Gly Gly Lys Arg Val Cys Arg Ala Hrs
500 505 510
A n Ala Phe Gly Gly Glu Gly Val Tyr Ala Ile Ala Arg Cys Cys Leu
515 520 525
Leu Pro Gln Val Asn Cys Ser Val Hza Thr Ala Pro Pro Ala Gly Ala
53 0 535 540
Ser Het Gly Thr Arg Val Hrs Cys Hzs Gln Gln Gly Hrs Val Leu Thr
545 550 555 560
Gly Cys Ser Ser Hrs Trp Glu Val Glu Asp Leu Gly Thr Hr- Lya Pzo
565 570 575
Pro Val Leu Arg Pro Arg Gly Gln Pro Asn Gln Cy Val Gly Hzs Arg
550 585 590
Glu Ala Ser Ile Hrs Ala Ser Cy Cys Hrs Ala Pro Gly Leu Glu Cy
595 600 605
Lys Val Lys Glu Hrs Gly Ile Pro Ala Pro Gln Glu Gln Val Ile Val
610 615 620
Ala Cy. Glu Aap Gly Trp Thr Leu Thr Gly Cy Ser Pro Leu Pro Gly
625 630 635 640
Thr Ser Hrs Val Leu Gly Ala Tyr Ala Val Asp Asn Thr Cys Val Val
45 650
!\rg Ser Arg Asp Val Ser Thr Thr Gly Ser Thr Ser Lys Glu !\Za Val
660 665 670
Ala Ala Val Ala Ile Cys Cys Arg Ser Arg Hrs Leu Val Gln Ala Ser
675 680 685
Gln Glu Leu Gln
690
210 SEQ IO NO 57
211 LENGTH 94
212 TYPE PRT
213 ORGANISN Nus muscular
400 SEQUENCE 757
Net Gly Thr Hrs Cys Ser Ala Trp Leu Arg Trp Pro Leu Leu Pro Leu
I 5 10 15
Leu Pro Pro Leu Leu Leu Leu Leu
20
Leu Leu Leu Cys
25
Pro Thr Gly Ala
30
Gly Ala Gln Asp Glu Asp Gly Asp Tyr Glu Glu Leu Met Leu Ala Leu
35 40 45
Pro Ser Gln Glu Asp Gly Leu Ala A p Glu Ala Ala Hrs Val Ala Thr
50 55 60
!\Za Thr Pire !rg .Arg Cys Ser Lys Glu Ala Trp Arg Leu Pro Gly Thr
65 70 7 80
Tyr Ile Val Val Leu Het Glu Glu Thr Gln Arg Leu Gln Ile Glu Gln
85 90 95
Thr Ala Hr Arg Leu Gln Thr ..zg Ala Ala Arg Arg Gly Tyr Val Ile
100 105 110
433
US 8,062,640 B2
-continued
434
Lys Val Leu Hz" Ile Phe Tyr Asp Leu Phe Pro Gly Phe Leu Val Lys
115 12 0 125
Net Ser Ser Asp Leu Leu Gly Leu Ala Leu Lys Leu Pro Hts Val Glu
13 0 135 140
Tyr Ile Glu Glu Asp Ser Phe Val Phe Ala Gln Ser Ile Pro Trp A n
145 150 155 160
Leu Glu Arg Ile Ile Pro Ala Trp Hzs Gln Thr Glu Glu Asp Arg Ser
165 170 I 5
Pro Asp Gly Ser Ser Gln Val Glu Val Tyr Leu Leu Asp Thr Sez Ile
180 185 190
Gln Gly Ala Hz Arg Glu Ils Glu Gly Arg Val Thr Ile Thz Asp Phs
195 200 205
4 n Sez Val Pro Glu Glu Asp Gly Thz Arg Phe Hts Arg Gln Ala Sez
210 215 220
Lys Cys Tsp Ser Hzs Gly Thr Hzs Leu Ala Gly Val Val Ser Gly Arg
225 230 235 240
Asp Ala Gly Val Ala Ly- Gly Thz Sez Leu Hz- Ser Leu Arg Val Leu
245 250 255
Asn Cy Gln Gly Ly. Gly Thr Val Sez Gly Tht Leu Ile Gly Leu Glu
260 265 270
Phe Ile Arg Lys Ser Gln Leu Ile Gln Pro Ser Gly Pzo Leu Val Val
275 280 285
Leu Leu Pzo Leu Ala Gly Gly Tyr Ser Arg Ile Leu Asn Ala Ala Cys
290 295 300
Arg Mzs Leu Ala Arg Thr Gly Val Val Leu Val Ala Ala Ala Gly Asn
305 310 315 320
Phe Arg Asp Asp Ala Cys Leu Tyr Ser Pro Ala Ser Ala Pro Glu Val
325 330 335
Ile Thr Val Gly .Ala Thr !\sn !\Za Gln Asp Gln Pro Val Thr Leu Gly
340 345 350
Thr Leu Gly Thr Asn Phe Gly Azg Cys Val Asp Leu Phe Ala Pro Gly
355 360 365
Lys Asp Ile Ile Gly Ala Sez Sez Asp Cys Ser Thr Cys Phe Met Sez
370 375 380
Gln Ser Gly Thr Ser Gln Ala Ala Ala Hzs Val Ala Gly Ile Val Ala
385 3 90 395 400
Arg Net Leu Ser Azg Glu Pro Thr Leu Thr Leu Ala Glu Leu Arg Gln
405 410 415
Arg Leu Ile Hz Phe Sez Thz Lys .'-. p Val Ile Asn Net Ala Trp Phe
420 425 430
Pro Glu Asp Gln Gln Val Leu Thz Pro Asn Leu Val Ala Thr Leu Pro
435 440 445
Pro Ser Thr Hzs Glu Thr Gly Gly Gln Leu Leu Cys Azg Thr Val Trp
450 455 460
Ser Ala Hr Ser Gly Pro Thz Arg Thr Ala Thr Ala Thr Ala Arg Cys
465 470 475 480
Ala Pro Glu Glu Glu Leu Leu Ser Cy. Sez Ser Phe Ser Atg Ser Gly
485 490 495
Arg Arg Arg Gly Asp Trp Ile Glu Ala Ile Gly Gly Gln Gln Val Cys
500 505 510
Lys Ala Leu Asn Ala Phe Gly Gly Glu Gly Val Tyr Ala Val Ala .Azg
515 520 525
Cy C. Leu Val Pro Azg Ala A n Cy Sez Ile Hz Asn Thz Pro Ala
530 535 540
435
US 8,062,640 B2
-continued
436
Ala Arg Ala Gly Leu Glu Thr Hzs Val Hzs Cys Hzs Gln Lys Asp Hzs
545 550 555 560
Val Leu Thr Gly Cys Ser Phe Hzs Trp Glu Val Glu Asp Leu Ser Val
565 570 575
Arg Arg Gln Pro Ala Leu Arg Ser Arg Arg Gln Pro Gly Gln Cya Val
580 585 590
Gly Hzs Gln Fla Ala Ser Val Tyr Ala Ser Cys Cys Hzs Ala Pro Gly
595 600 05
Leu Glu Cys Lys Ile Lys Glu Hzs Gly Ile Ser Gly Pro Ser Glu Gln
610 615 620
Val Thr Val Ala Cys Glu Ala Gly Trp Thr Leu Thr Gly Cys A n Val
625 630 635 640
Leu Pro Gly Ala Ser Leu Thr Leu Gly Ala Tyr Ser Val Asp Asn Leu
45 650 655
Cys Val Ala Arg Val Hrs Asp Thr Ala Arg Ala Asp Arg Thr Ser Gly
660 665 670
Glu Ala Thr Val Ala Ala Ala Ile Cy- C. Frg Ser Arg Pro Ser ..Ia
675 680 685
Lys Ala Ser Trp Val Gln
690
210 SEQ ID NO 758
211 LENGTH 53
212 TYPE PRT
.213 ORGANIS14 Homo sapzen
400 SEQUENCE 758
Glu Phe Arg Cys Hzs Asp Gly Lys Cys Ile Ser Arg Gln Phe Val Cys
I 5 10 15
!\sp Ser Asp Arg .Asp Cys Leu !\sp Gly Ser Asp Glu Ala Ser Cys Pro
20 25 30
Val Leu Thr Cy Gly Pro Ala Ser Phe Gln Cys Asn Sez Ser Thr Cys
35 40 45
Ile Pro Gln Leu Trp Ala Cys Asp Asn Asp Pro Asp Cys Glu Asp Gly
50 55 0
Ser Asp Glu Trp Pro Gln Arg Cys Arg Gly Leu Tyr Val Phe Gln Gly
70 75 80
Asp Ser Ser Pro Cys Ser Ala Phe Glu Phe Hzs Cys Leu Ser Gly Glu
85 90 95
Cy. Ile Hz Ser Ser Trp Arg Cys:-. p Gly Gly Pro Asp Cy- Lys .'. p
100 105 110
Lys Ser Asp Glu Glu Asn Cys I\la Val Ala Thr Cys Arg Pro I\sp Glu
115 12 0 125
Phe Gln Cys Ser Asp Gly Asn Cys Ile Hzs Gly Ser Arg Gln Cys Asp
130 135 140
Arg Glu Tyr Aap Cy. Ly. Asp Net Ser Asp Glu Val Gly Cy. Val Asn
145 150 155 160
Val Thr Leu Cy Glu Gly Pro Asn Ly. Phe Ly Cy- Hra Ser Gly Glu
165 170 175
Cys Ile Thr Leu Asp Lys Val Cys Asn Net Ala Arg Asp Cys Arg Asp
180 185 190
Trp Ser Asp Glu Pro Ile Lys Glu Cys Gly Thr Asn Glu Cys Leu Asp
195 200 205
Asn Arn Gly Gly Cys Ser Hzs Val Cy F.tn Asp Leu Lys Ile Gly Tyr
210 215 220
437
US 8,062,640 B2
-continued
438
Glu Cys Leu Cys Pro Asp Gly Phe Gln Leu Val Ala Gln Arg Arg Cys
225 230 235 240
Glu Asp Ile Asp Glu Cys Gln Asp Pro Asp Thr Cys Ser Gln Leu Cys
245 250 255
Val Asn Leu Glu Gly Gly Tyr Lys Cys Gln Cy Glu Glu Gly Phe Gln
260 2 5 270
Leu Asp Pro Hzs Thr Lys Ala Cys Lys Ala Val Gly Ser Ile Ala Tyr
275 280 285
Leu Phe Phe Thr Asn Arg Hzs Glu Val Arg Ly Met Thr Leu Asp Arg
290 295 300
Ser Glu Tyr Thr Ser Leu Ile Pro A n Leu Arg Asn Val Val Ala Leu
305 310 315 320
4 p Thr Glu Val Ala Ser Asn Arg Ile Tyr Trp Ser Asp Leu Ser Gln
325 330 335
Arg Net Ile Cys Ser Thr Gln Leu Asp Arg Ala Hzs Gly Val Ser Ser
340 345 350
Tyr A p Thr Val Ile Ser Arg .. p Ile Gln Ala Pro A p Gly Leu ..Ia
355 360 365
Val Asp Trp Ile Hzs Ser Asn Ile Tyr Trp Thr Asp Ser Val Leu Gly
370 375 380
Thr Val Ser Val Ala Asp Thr Lys Gly Val Lys Arg Lys Thr Leu Phe
385 390 395 400
Arg Glu Asn Gly Ser Lys Pro Arg Ala Ile Val Val Asp Pro Val Hzs
405 410 415
Gly Phe Net Tyr Trp Thr Asp Trp Gly Thr Pro Ala Ly. Ile Lys Lys
420 425 430
Gly Gly Leu Asn Gly Val Asp Ile Tyr Ser Leu Val Thr Glu Asn Ile
435 440 445
Gln Trp Pro Asn Gly Ile Thr Leu A p Leu Leu Ser Gly Arg Leu Tyr
450 455 460
Trp Val Asp 6'er Lys Leu Hzs Ser Ile Ser Ser Ile Asp Val Asn Gly
465 470 475 480
Gly Asn Arg Lys Thr Ile Leu Glu Asp Glu Lys Arg Leu Ala Hzs Pro
4 85 490 495
Phe Ser Leu Ala Val Phe Glu Asp Lys Val Phe Trp Thr Asp Ile Ile
500 505 510
Asn Glu Ala Ile Phe Ser Ala .4 n Arg Leu Tl.z Gly Ser A p Val 4 n
515 520 525
Leu Leu Ala Glu Asn Leu Leu Ser Pro Glu Asp Met Val Leu Phe Hzs
530 535 540
Asn Leu Thr Gln Pro Arg Gly Val Asn Trp Cys Glu Arg Tlsr Thr Leu
545 550 555 560
Ser lsn Gly Gly Cys Gln Tyr Leu Cys Leu Pro Ala Pro Gln Ile Asn
565 570 575
Pro Hz Ser Pzo Ly Phe Thr Cy Ala Cy Pro Asp Gly Met 'u 'u
580 585 590
Ala Arg Asp Net Arg Ser Cys Leu Thr Glu Ala Glu Ala Ala Val Ala
595 600 605
Thr Gln Glu Thr Ser Thr Val Arg Leu Lys Val Ser Ser Thr Ala Val
610 615 620
Arg Thr Gln Hzs Thr Thr Thz Azg Pro Val Pzo Asp Thr Ser Arg Leu
625 630 635 640
Pro Gly Ala Thr Pro Gly Leu Thr Thr Val Glu Ile Val
439
US 8,062,640 B2
-continued
440
45 650
210 SEQ ID NO 759
211 LENGTH 753
s212 TYPE PET
.213 ORGAHIS14 Homo sapzen
400 SEQUENCE 759
Net Glu Arg Arg Ala Trp Ser Leu Gln Cys Thr Ala Phe Val Leu Phe
I 5 10 15
Cys Ala Tzp Cys Ala Leu Asn Sez Ala Lys Ala Ly Arg Gln Phe Val
20 25 30
A n Glu Trp Ala Ala Glu Ile Pro Gly Gly Pro Glu Ala Ala Ser Ala
35 40 45
Ile Ala Glu Glu Leu Gly Tyz Asp Leu Leu Gly Gln lie Gly Sez Leu
50 55 60
Glu Asn Hzs Tyr Leu Phe Lys Hzs Lys Asn Hzs Pro Arg Arg Ser Arg
65 70 75 80
Azg Sez Ala Phe Hz- Ile Thr Ly- Arg Leu Ser A p A p A p Arg Val
85 90 95
Ile Trp Ala Glu Gln Gln Tyr Glu Lys Glu Arg Ser Lys Arg Ser Ala
100 105 110
Leu Arg Asp Ser Ala Leu Asn Leu Phe Asn Asp Pzo Net Trp Asn Gln
115 12 0 125
Gln Trp Tyr Leu Gln Asp Thz Arg Net Thr Ala Ala Leu Pro Lys Leu
13 0 135 140
Asp Leu Hz Val Ile Pzo Val Trp Gln Ly Gly Ile Thr Gly Lye Gly
145 150 155 160
Val Val Ile Thr Val Leu Asp Asp Gly Leu Glu Trp Asn Hzs Thr Asp
165 170 175
Ile Tyr Ala Asn Tyr Asp Pro Glu Ala Ser Tyr Asp Phe A n A p A n
180 185 190
Asp Hzs Asp Pzo Phe Pzo Arg Tyz Asp Pro Thr Asn Glu Asn Lys Hzs
195 200 205
Gly Thz Arg Cys Ala Gly Glu Ile Ala Net Gln Ala Asn Asn Hzs Lys
210 215 220
Cys Gly Val Gly Val Ala Tyr Asn Ser Lys Val Gly Gly Ile Arg Net
225 230 235 240
Leu Asp Gly Ile Val Thr .Asp Ala Ile Glu Ala Ser Ser Ile Gly Phe
245 250 255
A"n Pro Gly Hz" Val Asp Ile Tyz Ser Ala Ser Tzp Gly Pro Asn Asp
260 2 5 270
Asp Gly Lys Thr Val Glu Gly Pzo Gly Arg Leu Ala Gln Lys Ala Phe
275 280 285
Glu Tyr Gly Val Lys Gln Gly Azg Gln Gly Lys Gly Ser Ile Phe Val
290 295 300
Tzp s.la ser Gly Asn Gly Gly A g Gln Gly A p Asn cy A p cy Aep
305 310 315 320
Gly Tyr Thr Asp Ser Ile Tyr Thr Ile Ser Ile Ser Ser Ala Ser Gln
325 330 335
Gln Gly Leu Ser Pro Trp Tyr Ala Glu Lys Cys Ser Ser Thr Leu Ala
340 345 350
Thz Sez Tyz Sez Ser Gly Asp Tyz Thz Asp Gln Azg Ile Thr Sez Ala
355 360 365
!\sp Leu Hzs Asn Asp Cys Thr Glu Thr Hzs Thr Gly Thr Ser !\Ia Ser
441
US 8,062,640 B2
-continued
442
370 375 380
Ala Pro Leu Ala Ala Gly Ile Phe Ala Leu Ala Leu Glu Ala Asn Pro
385 390 395 400
.'. n Leu Thr Trp Arg Asp Net Gln Mz. Leu Valyal Trp Thr Ser Glu
405 410 415
Tyr Asp Pro Leu Ala Asn I\sn Pro Gly Trp Lys Lys A n Gly I\la Gly
420 425 430
Leu Net Val Isn Ser Arg Phe Gly Phe Gly Leu
435 440
Leu Asn Ala Lys Ala
445
Leu Val Asp Leu Ala Asp Pro Arg Thr Trp Arg Ser Val Pro Glu Lys
450 455 460
Ly. Glu Cy Val Val Ly. Asp Asn Asp Phe Glu Pro Arg Ala Leu Ly.
465 470 475 480
Ala Asn Gly Glu Val Ile Ile Glu Ile Pro Thr Arg Ala Cys Glu Gly
485 490 495
Gln Glu Asn Ala Ile Lys Ser Leu Glu Hzs Val Gln Phe Glu Ala Thr
500 505 510
Ile Glu Tyr Ser Arg Arg Gly 4 p Leu Hz Val Thr Leu Thr Ser Ala
515 520 525
Ala Gly Thr Ser Thr Val Leu Leu Ala Glu Arg Glu Arg Asp Thr Ser
530 535 540
Pro Asn Gly Phe Lys Asn Trp Asp Phe Net Ser Val Hzs Thr Trp Gly
545 550 555 560
Glu A n Pro Ile Gly Thr Tzp Thr Leu 'rg Ile Thr Asp Net Ser Gly
565 570 575
: rg Ile Gln Asn Glu Gly Szg Ile Val asn Trp Ly Leu lie 'u Hz.
580 585 590
Gly Thr Ser Ser Gln Pro Glu His Net Lys Gln Pro Arg Val Tyr Thr
595 600 605
Ser Tyr Asn Thr Val Gln .4 n Arp Arg Arg Gly Val Glu Lys Net Val
610 15 620
4 p Pro Gly Glu Glu Gin Pro Thr Gln Glu Asn Pro Lys Glu Asn Thr
625 630 35 640
Leu Val Ser Ly" Ser Pro Ser Ser Ser Ser Val Gly Gly Azg Izg Asp
645 50
Glu Leu Glu Glu Gly Ala Pro Ser Gln Ala Net Leu Arg Leu Leu Gln
60 665 70
Ser Ala Phe Ser Ly. Asn Ser Pro Pro Ly Gln Ser Pro Ly. Lys Ser
675 680 685
Pro Ser Ala Lys Leu Asn Ile Pro Tyr Glu Asn Phe Tyr Glu Ala Leu
90 695 "00
Glu L. s Leu Asn Lys Pro Ser Gln Leu L. s Asp Ser Glu Asp Ser Leu
705 710 715 720
Tyr Asn Asp Tyr Val Asp Val Phe Tyr Asn Thr Lys Pro Tyr Lys Hzs
725 730 735
arg A p Asp Azg Leu Leu Gin Ala Leu Val Asp Ile Leu A n Glu Glu
740 745 750
!\an
210 SEQ ID NO 760
211 LENGTH 785
212 TYPE PRT
213 ORGANISM Homo apzers
400 SEQUENCE 7 0
443
US 8,062,640 B2
-continued
444
Net Pro Lys Gly Arg Gln Lys Val Pro Hzs Leu Asp Ala Pro Leu Gly
5 10
Leu Pro Thr Cys Leu Trp Leu Glu Leu Ala Gly Leu
20 25
Phe Leu Leu Val
30
Pro Trp Val Net Gly Leu Ala Gly Thr Gly Gly Pzo Aep Gly Gln Gly
35 40 45
Thr Gly Gly Pro Ser Trp Ala Val Hzs Leu Glu Ser Leu Glu Gly Asp
50 55 0
Gly Glu Glu Glu Thr Leu Glu Gln Gln Ala Asp Ala Leu .Ala Gln Ala
65 70 75 80
Ala Gly Leu Val Asn Ala Gly Arg Ile Gly Glu Leu Gln Gly His Tyr
85 90 95
Leu Phe Val Gln Pro Ala Gly Hzs Arg Pro Ala Leu Glu Val Glu Ala
100 105 110
Ile Arg Gln Gln Val Glu Ala Val Leu Ala Gly Hrs Glu Ala Val Arg
115 12 0 125
Trp Hzs Ser Glu Gln Arg Leu Leu Arg 'rg Ala Ly- Arg Ser Val Hzs
130 135 140
Phe Asn Asp Pro Lys Tyr Pro Gln Gln Trp Hrs Leu Asn Asn Arg Arg
145 150 155 I 0
Ser Pro Gly Arg Asp Ile Asn Val Thr Gly Val Trp Glu Arg Asn Val
165 170 175
Thr Gly Arg Gly Val Thr Val Val Val Val Asp Asp Gly Val Glu Hzs
180 185 190
Thr Ile Gln Asp Ile Ala Pzo !\ n Tyr Ser Pro Glu Gly Ser Tyr !\ p
195 200 205
Leu Asn Ser Asn Asp Pro Asp Pro Net Pro Hrs Pro Asp Val Glu Asn
210 215 220
Gly Arn Hz Hz Gly Thr Arg Cys Ala Gly Glu Ile Ala Ala Val Pro
225 230 235 240
Asn Asn Ser Phe Cys Ala Val Gly Val Ala Tyr Gly Ser Arg Ile Ala
245 250 255
Gly Ile Arg Val Leu Asp Gly Pro Leu Thr Asp Ser Met Glu Ala Val
260 265 270
Ala Phe Asn Lys Hrs Tyr Gln Ile Asn Asp Ile Tyr Ser Cys Ser Trp
275 280 285
Gly Pro Asp Asp Aep Gly Ly. Thr Val Asp Gly Pro Hzs Gln Leu Gly
290 295 300
Lys Ala Ala Leu Gln Hrs Gly Val Ile Ala Gly Arg Gln Gly Phe Gly
305 310 315 320
Ser Ile Phe Val Val Ala Ser Gly Asn Gly Gly Gln Hrs Asn Asp Asn
325 330 335
Cys !sn Tyr Asp Gly Tyr Ala Asn Ser Ile Tyr Thr Val Thr Ile Gly
340 345 350
Ala Val Asp Glu Glu Gly Szg Mer. Pro Phe Tyr Ala Glu Glu Cy. Ala
355 360 365
Ser Net Leu Ala Val Thr Phe Ser Gly Gly Asp Lys Met Leu Arg Ser
370 375 380
Ile Val Thr Thr Asp Trp Asp Leu Gln Lys Gly Thr Gly Cys Thr Glu
385 390 395 400
Gly Hz- Thr Gly Thr Ser Ala Ala Ala Pro Leu Ala Ala Gly Net Ile
405 410 415
!\Ia Leu !4et Leu Gln Val !\rg Pro Cys Leu Thr Trp .Arg Asp Val Gln
445
US 8,062,640 B2
-continued
446
420 425 430
Hrs Ile Ile Val Phe Thr Ala Thr Arg Tyr Glu Asp Arg Arg Ala Glu
435 440 445
Trp Val Thz Asn Glu Ala Gly Phe Sez Mrs Ser Hrs Gln Hr- Gly Phe
450 455 460
Gly Leu Leu Asn Ala Trp I\rg Leu Val Asn Ala Ala Lys Ile Trp Thr
465 470 475 480
Ser Val Pro Tyr Leu Ala Ser Tyr Val Ser Pro Val Leu Lys Glu Asn
485 490 Bu5
Ly Ala Ile Pro Gln Ser Pro Arg Ser Leu Glu Val Leu Trp A n Val
500 505 510
Ser Arg Net Asp Leu Glu Net Ser Gly Leu Ly Thr Leu Glu Hi- Val
515 520 525
Ala Val Thr Val Ser Ile Thr Hzs Pro Arg Arg Gly Ser Leu Glu Leu
530 535 540
Lys Leu Phe Cys Pro Ser Gly Net Net Ser Leu Ile Gly Ala Pro Arg
545 550 555 560
Ser Net A p Ser Asp Pzo .Asn Gly Phe A n A p Trp Thr Phe Ser Thr
565 570 575
Val Arg Cy" Trp Gly Glu Arg Ala Arg Gly Thr Tyr Arg Leu Val Ile
580 585 590
Arg Asp Val Gly Asp Glu Ser Phe Gln Val Gly Ile Leu Arg Gln Trp
595 600 605
Gln Leu Thr Leu Tyr Gly Ser Val Trp Ser Ala Val Asp Ile 3;rg A p
610 615 620
Arg Gln Arg Leu Leu Glu ser Ala Net ser Gly Ly Tyr Leu Hi Asp
625 630 635 640
Asp Phe Ala Leu Pro Cys Pro Pro Gly Leu Lys Ile Pro Glu Glu Asp
645 650 655
Gly Tyr Thr Ile Thr Pro .5 n Thr Leu Lys Thr Leu Val Leu Val Gly
60 665 670
Cys Phe Thr Val Phe Trp Thr Val Tyr Tyr Net. Leu Glu Val Tyr Leu
675 680 85
Ser Gln Arg Asn Val Ala Ser Asn Gln Val Cy Arg Ser Gly Pro Cys
90 695 700
Hrs Trp Pro Hrs Arg Ser Arg Lys Ala Lys Glu Glu Gly Thr Glu Leu
705 710 715 720
Glu Ser Val Pro Leu Cy. Ser Ser Ly. Asp Pro Asp Glu Val Glu Thr
725 730 735
Glu Ser Arg Gly Pro Pro Thr Thr Ser Asp Leu Leu Ala Pro Asp Leu
740 745 750
Leu Glu Gln Gly Asp Trp Ser Leu Ser Gln Asn Lys Ser Ala Leu Asp
755 760 765
Cys Pro Hrs Gln Hrs Leu Asp Val Pro Hrs Gly Lys Glu Glu Gln Ile
770 775 780
Crs
785
761
2
210 SEQ ID NO
211 LENGTH 69
212 TYPE PRT
213 ORGANIS'N Macaca fascrcularrs
400 6'EQUENCE 761
Net Gly Thr Val Ser Ser !\rg !\rg Ser Trp Trp Pro Leu Pro Leu Pro
447
US 8,062,640 B2
-continued
448
10 15
Leu Leu Leu Leu Leu Leu Leu Gly
20
Pro Ala Gly Ala Arg Ala Gln Glu
25 30
.'. p Glu Asp Gly Asp Tyr Glu Glu Leu Val Leu Ala Leu Arg Ser Glu
35 40 45
Glu Asp Gly Leu Ala Asp Ala Pro Glu Hzs Gly Ala Thr Ala Thr Phe
50 55 60
Hts Arg Cys Zla Lys Asp Pro Trp Arg Leu Pro Gly Thr Tyr Val Val
65 70 75 80
Val Leu Ly Glu Glu Thr Hzs Arg Ser Gln Ser Glu Arg Thr Ala Arg
85 90 95
Arg Leu Gln Ala Gln Ala Ala Arg Arg Gly Tyr Leu Thr Ly. Ile Leu
100 105 110
Hts Val Phe Hzs Hzs Leu Leu Pro Gly Phe Leu Val Lys Met Ser Gly
12 0 125
Asp Leu Leu Glu Leu Ala Leu Lys Leu Pro Hzs Val Asp Tyr Ile Glu
13 0 135 140
Glu A p er Ser Val Phe Ala Gln Ser Ile Pro Trp A n Leu Glu Arg
145 150 155 160
Ile Thr Pro Ala Arg Tyr Arg Ala Asp Glu Tyr Gln Pro Pro Lys Gly
165 170 175
Gly Ser Leu Val Glu Val Tyr Leu Leu Asp Thr Ser Ile Gln Ser Asp
180 185 190
Mia 'rg Glu Ile Glu Gly Azg Val tact Val Thr Asp Phe Glu Ser Val
195 200 205
Pro Glu Glu Asp Gly Thr Szg Phe Hr Arg Gln Ala Ser Ly Cys 5 p
210 215 220
Ser Hzs Gly Thr Hzs Leu Ala Gly Val Val Ser Gly Arg Asp Ala Gly
225 230 235 240
Val Ala Lys Gly Ala Gly Leu Arg Ser Leu Arg Val Leu A n Cys Gln
245 250 255
Gly Lya Gly Thr Val Ser Gly Thr Leu Ile Gly Leu Glu Phe Ile Arg
260 265 270
Lys Ser Gln Leu Val Gln Pro Val Gly Pro Leu Val Val Leu Leu Pro
275 280 285
Leu Ala Gly Gly Tyr Ser Arg Val Phe Asn Ala Ala Cys Gln Arg Leu
290 295 300
Ala Arg Ala Gly Val Val Leu Val Thr Ala Ala Gly Asn Phe Arg .4 p
305 310 315 320
Asp Ala Cys Leu Tyr Ser Pro Ala Ser Ala Pro Glu Val Ile Thr Val
325 330 335
Gly Ala Thr Asn Ala Gln Asp Gln Pro Val Thr Leu Gly Thr Leu Gly
340 345 350
Thr Asn Phe Gly Arg 0'ys Val Asp Leu Phe Ala Pro Gly Glu Asp Ile
355 360 365
Ile Gly Ala Ser Ser Asp Cys Ser Thr Cys Phe Val Ser Arg Ser Gly
370 375 380
Thr Ser Gln Zla .Ala Ala Hts Val Ala Gly Ile Ala Ala Met Met Leu
385 3 90 395 400
Ser Ala Glu Pro Glu Leu Thr Leu Ala Glu Leu Arg Gln Arg Leu Ile
405 410 415
Hz- Phe Ser Ala Ly- A p Val Ile A n Glu Ala Tzp Phe Pro Glu .. p
420 425 430
449
US 8,062,640 B2
-continued
450
Gln Arg Val Leu Thr Pro A"n Leu Val ala Ala Leu Pro Pro Ser Thr
435 440 445
Hts Arg Ala Gly Trp Gln Leu Phe Cys Arg Thr Val Trp Ser Ala Hzs
450 455 460
ser Gly pro Thr Arg 9!et Ala Thr ala val Ala Arg cy Ala Gln A p
465 4 70 475 480
Glu Glu Leu Leu Ser Cys Ser Ser
485
Phe Ser Arg Ser Gly Lys Arg Arg
490 495
Gly Glu Arg Ile Glu Ala Gln Gly Gly Lys Arg Val Cys Arg Ala Hrs
500 505 510
A n Ala Phe Gly Gly Glu Gly Val Tyr Ala Ile Ala Arg Cys Cys Leu
515 520 525
Leu Pro Gln Val Asn Cys Ser Val Hze Thr Ala Pro Pro Ala Gly Ala
53 0 535 540
Ser Net Gly Thr Arg Val Hts Cys Hzs Gln Gln Gly Hrs Val Leu Thr
545 550 555 560
Gly Cys Ser Ser Hrs Trp Glu Val Glu Asp Leu Gly Thr Ht- Lys Pzo
565 570 575
Pro Val Leu Arg Pro Arg Gly Gln Pro Asn Gln Cy Val Gly Hts Arg
550 585 590
Glu Ala Ser Ile Hrs Ala Ser Cy Cys Hrs Ala Pro Gly Leu Glu Cy
595 600 605
Lys Val Lys Glu Hrs Gly Ile Pro Ala Pro Gln Glu Gln Val Ile Val
610 615 620
Ala Cy. Glu Aep Gly Trp Thr Leu Thr Gly Cy Ser Ala Leu Pro Gly
625 630 635 640
Thr Ser Hrs Val Leu Gly Ala Tyr Ala Val Asp Asn Thr Cys Val Val
45 650
!\rg Ser Arg Asp Val Ser Thr Thr Gly Ser Thr Ser Glu Glu !\Za Val
660 665 670
Ala Ala Val Ala Ile Cys Cys Arg Ser Arg Hrs Leu Val Gln Ala Ser
675 680 685
Gln Glu Leu Gln
690
2
8
210 SEQ IO NO
211 LENGTH 9
212 TYPE PRT
213 ORGANISN Nesoczrcetu auratu
400 SEQUENCE 762
Net Gly Thr Ser Cys Ser Ala Arg Pro Arg Trp Leu Leu Ser Pro Leu
I 5 10 15
Leu Leu Leu Leu Leu Leu Leu Arg
20
Tyr Net Gly Ala Ser Ala Gln Asp
25 30
Glu Asp Ala Glu Tyr Glu Glu Leu Net Leu Thr Leu Gln Ser Gln Asp
35 40 45
A p Gly Leu Ala Asp Glu Thr A p Glu Ala Pro Gln Gly Ala Thr Ala
50 55 60
!\Za Phe Hrs !rg Cys Pro Glu Glu !\Za Trp Arg Val Pro Gly Thr Tyr
65 70 7 80
Ile Val !set Leu Ala Glu Glu Ala Gln Trp Val Hrs Ile Glu Gln Thr
85 90 95
Net Hr Azg Leu Gln Thr Glr ..Za Ala 'rg Azg Gly Tyr Val Ile Ly-
100 105 110
451
US 8,062,640 B2
-continued
452
Ile Gln Hr" Ile Phe Tyr Asp Phe Leu Pro Ala Phe Val Val Lys Net
115 12 0 125
Ser Ser Asp Leu Leu Asp Leu Ala Leu Lys Leu Pro Hrs Val Lys Tyr
13 0 135 140
Ile Glu Glu Asp Ser Leu Val Phe Ala Gln Ser Ile Pzo Trp 3; n Leu
145 150 155 160
Asp Arg Ile Ile Pro Ala Gly Arg Gln Ala Gln Glu Tyr Ser Ser Ser
165 170 I 5
Arg Lys Val Pro Ser Gly Ser Gly Gln Val Glu Val Tyr Leu Leu A p
180 185 190
Thr Ser lie Gln Ser A p Hrs Arg Glu Ile Glu Gly Arg Val Thr Val
195 200 205
Thr Asp Phe Asn Ser Val Pro Glu Glu Asp Gly Thr Arg Phe His Arg
210 215 220
Gln Ala Ser Lys Cys Asp Ser Hzs Gly Thr Hrs Leu Ala Gly Val Val
225 230 235 240
Ser Gly Azg Asp Ala Gly Val Ala Ly- Gly Thr Ile Leu Hz- Gly Leu
245 250 255
Arg Val Leu Asn Cy. Gln Gly Lys Gly Ile Val Ser Gly Ile Leu Thr
260 265 270
Gly Leu Glu Phe Ile Trp Lys Ser Gln Leu Net. Gln Pro Ser Gly Pro
275 280 285
Gln Val Val Leu Leu Pro Leu Ala Gly Frg Tyr Ser Arg Val Leu Asn
290 295 300
Thz Ala Cy Gln Hrs Leu Ala Azg Thz Gly Val Val Leu Val Ala Ala
305 310 315 320
Ala Gly Asn Phe Arg Asp Asp Ala Cys Leu Tyr Ser Pro Ala Ser Ala
325 330 335
Pro Glu Val Ile Thr Val Gly Ala Thr Asp Val Gln Asp Gln Pro Val
340 345 350
Thr Leu Gly Thr Leu Gly Thr Asn Phe Gly Arg Cys Val .4 p Leu Phe
355 360 365
Ala pro Gly Ly Asp Ile Ile Gly Ala sez ser Asp cys ser Ala cys
370 375 380
Phe Net Ser Gln Ser Gly Thr Ser Gln Ala Ala Ala Hrs Val Ala Gly
385 3 90 395 400
Ile Val Ala Met Net Leu Thr Leu Glu Pro Glu Leu Thr Leu Thr Glu
405 410 415
Leu Arg Gln Azg Leu Ile Hrs Phe Sez Thz Ly- Asp Ala Ile .'. n Net
420 425 430
Ala Trp Phe Pro Glu Asp Gln I\rg Val Leu Thr Pro Asn Leu Val I\la
435 440 445
Thr Leu Pro Pro Ser Thr Hrs Gly Thr Gly Gly Gln Leu Leu Cys Arg
450 455 460
Thr Val Trp Ser Ala Hr. Ser Gly Pro Thr Arg Ala Ala Thr Ala Thr
465 470 475 480
Ala Arg Cy Ala Pro Gly Glu Glu Leu Leu Ser Cy Ser Ser Phe Ser
485 490 495
Arg Ser Gly Arg Arg Arg Gly Asp Arg Ile Glu Ala Ala Gly Thr Gln
500 505 510
Gln Val Cys Lys Ala Leu Asn Ala Phe Gly Gly Glu Gly Val Tyr Ala
515 520 525
Val Ala Arg Cy Cys Leu Leu Pro Arg F.la Asn Cy Ser Ile Hzs Trr
530 535 540
453
US 8,062,640 B2
-continued
454
Thr Pro Ala Ala Arg Thr Sez Leu Glu Thr Hzs Ala Hzs Cys Hzs Gln
545 550 555 560
Lys Asp Hzs Val Leu Thr Gly Cys Ser Leu Hzs Tzp Glu Val Glu Gly
565 570 575
Ile Gly Val Gln Pro Leu Ala Val Leu Arg Ser Azg Hza Gln Pro Gly
580 585 590
Gln Cys Thr Gly Hzs Arg Glu Ala Ser Val Hzs Ala Ser Cys Cys Hzs
595 600 05
Ala Pro Gly Leu Glu Cys Lys Ile Lys Glu Hz Gly Ile Sez Gly Pro
610 615 620
Ala Glu Gln Val Thr Val Ala Cys Glu Ala Gly Trp Thr Leu Thr Gly
625 630 635 640
Cys Asn Val Leu Pzo Gly Ala Phe Ile Thz Leu Gly Ala Tyr Ala Val
45 650 655
Asp Asn Thr Cys Val Ala Arg Ser Arg Val Thr Asp Thr Ala Gly Arg
660 665 670
Thz Gly Glu Glu Ala Thz Val ..Ia Ala Ala Ile Cy- Cy- Arg A r ..zg
675 680 685
Pro Ser Ala Ly" Ala Ser Trp Val Hzs Gln
690 695
763
I
210 SEQ ID HO
211 LENGTH 9
212 TYPE PRT
r213 ORGANIS14 Rattu. nozvegzcua
400 SEQUENCE 763
Net Gly Ile Azg Cys Ser Thr Trp Leu Arg Trp Pro Leu Ser Pro Gln
I 5 10 15
Leu Leu Leu Leu Leu Leu
20
Leu Cys Pro Thr Gly Ser Arg Ala Gln !\sp
25 30
Glu Asp Gly Asp Tyz Glu Glu Leu Net Leu Ala Leu Pzo Ser Gln Glu
35 40 45
4 p Sez Leu Val Asp Glu Ala Sez Hzs Val Ala Thr Ala Thr Phe Arg
50 55 0
Arg Cys Ser Lys Glu Ala Trp Arg Leu Pro Gly Thr Tyr Val Val Val
70 75 80
Leu Net Glu Glu Thr Gln Arg Leu Gln Val Glu Gln Thr Ala Hzs Arg
85 90 95
Leu Gln Thr Tzp Ala Ala Arg Azg Gly Tyr Val Ile Ly- Val Leu Hzs
100 105 110
Val Phe Tyr Asp Leu Phe Pro Gly Phe Leu Val Lys Met Ser Ser I\sp
115 12 0 125
Leu Leu Gly Leu Ala Leu Lys Leu Pro Hzs Val Glu Tyr Ile Glu Glu
130 135 140
Asp Ser Leu Val Phe Ala Gln Ser Ile Pro Trp Aan Leu Glu Arg Ile
145 150 155 160
Ile Pro Ala Trp Gln Gln Thr Glu Glu Asp Ser Ser Pro Asp Gly Sez
165 170 175
Ser Gln Val Glu Val Tyr Leu Leu Asp Thr Ser Ile Gln Ser Gly Hzs
180 185 190
Arg Glu Ile Glu Gly Azg Val Thz Ile Thz Asp Phe Asn Sez Val Pzo
195 200 205
Glu Glu Asp Gly Thz Azg Phe Hzs Azg Gln Ala Sez Lys Cys A p Sez
210 215 220
455
US 8,062,640 B2
-continued
456
Hzs Gly Thr Hzs Leu Ala Gly Val Val Ser Gly Arg Asp Ala Gly Val
225 230 235 240
Ala L. s Gly Thr Ser Leu Hzs Ser Leu Arg Val Leu Asn Cys Gln Gly
245 250 255
Lys Gly Thz Val Ser Gly Thr f,eu Ile Gly Leu Glu Phe Ile Arg Lys
260 2 5 270
Ser Gln Leu Ile Gln Pro Ser Gly Pro Leu Val Val Leu Leu Pro Leu
275 280 285
Ala Gly Gly Tyr Ser Arg Ile Leu Asn Thz Ala Cy Gln Arg Leu Ala
290 295 300
azg Thr Gly Val Val Leu Val Ala Ala Ala Gly Asn Phe Arg A p A p
305 310 315 320
Ala Cys Leu Tyz Ser Pzo Ala Sez Ala Pro Glu Val lie Thr Val Gly
325 330 335
Ala Thr Asn Ala Gln Asp Gln Pro Val Thr Leu Gly Thr Leu Gly Thr
340 345 350
A n Phe Gly Arg Cy- Val A p Leu Pffe Ala Pzo Gly Ly- A p Ile Ile
355 360 365
Gly Ala Ser Ser Asp Cys Ser Thz Cys Tyr Het Ser Gln Ser Gly Thz
370 375 380
Ser Gln Ala Ala Ala Hzs Val Ala Gly Ile Val Ala fiat Het Leu Asn
385 390 395 400
Arg Asp Pro Ala Leu Thr Leu Ala Glu Leu Arg Gln Azg Leu Ile Leu
405 410 415
Phe Ser Thr Ly Asp Val Ile I\ n feet Ala Tzp Phe Pro Glu A p Gln
420 425 430
Arg Val Leu Thr Pro Asn Arg Val Ala Thr Leu Pro
435 440
Pro Ser Thr Gln
445
Glu Thr Gly Gly Gln Leu Leu Cys Arg Thr Val Tzp Ser Ala Hzs Sez
450 455 460
Gly Pro Thr Azg Thr Ala Thz Ala Thz Ala Azg Cys Ala Pro Glu Glu
465 470 475 480
Glu Leu Leu Sez Cys Ser Sez Phe Ser Arg Ser Gly Arg Arg flrg Gly
4 85 490 495
Asp Arg Ile Glu Ala Ile Gly Gly Gln Gln Val Cys Lys Ala Leu Asn
500 505 510
Ala Phe Gly Gly Glu Gly Val Tyr Ala Val Ala Azg Cys Cys Leu Leu
515 520 525
Pro Arg Val Asn Cys Ser Ile Hzs Asn Thr Pro Ala Ala Arg Ala Gly
530 535 540
Pro Gln Thr Pro Val Hzs Cys Hzs Gln Lys Asp Hzs Val Leu Thr Gly
545 550 555 560
Cys Ser Phe Hzs Trp Glu Val Glu Asn Leu Azg Ala Gln Gln Gln Pzo
565 570 575
Leu Leu Arg Ser Azg Hz Gln Pro Gly Gln Cy Val Gly Hi Gln Glu
580 585 590
Ala Ser Val Hzs Ala Ser Cys Cys Hzs Ala Pro Gly Leu Glu Cys Lys
595 600 605
Ile Lys Glu Hzs Gly Ile Ala Gly Pro Ala Glu Gln Val Thr Val Ala
610 615 620
Cy- Glu Ala Gly Tzp Tlrz Leu Thz Gly Cy- Asn Val Leu Pro Gly Ala
625 630 635 640
Ser Leu Pro Leu Gly Ala Tyr Ser Val Asp Asn Val Cys Val Ala Arg
457
US 8,062,640 B2
-continued
458
45 650 655
I' Arg Asp Ala Gly Arg Ala Asp Arg Tnr Ser Glu Glu Ala Tur Val
60 670
..Ia Ala Ala Ile Cy- Cy- ..rg Ser ..rg Pro Ser Ala Lye Ala Ser Trp
675 660 655
Val urs Glu
600
Wc clean
1. An antibody or antigen binding fmgment of ml mltibody
thnt spccilically binds hPCSK9, comprising hmrvy and light
chain CI)R sequences from the H( I R and I.CVR seutuence
pair lmvins SFQ ID NOs 90/92
2. The antibody or antigen-binding fraynent of claim I
contprising hcavy and light chain (:DR sequences having
SRQ IDNOs: 76, 78, 80, 84. 86. and 88
3 The nntibody or nntigcn-bindins fmgment of claim 2
compnstn an IICVR havtn the amulo actd sequence. of
SL'Q ID NO: 90 and an LCVR having thc amino acid sequence
ol'SRQ ID NO 92.

